"Heading","CUI","Semantic Type", "Preferred Name"
"Room Temp.(25C)","C1547703|C0039476|C0279848","[spco]|[qnco]|[topp]","Room|Temperature|cisplatin/etoposide/mitoxantrone/tamoxifen protocol"
"Table 3 Established and Potential Drug Interactions: Use With Caution, Alteration in Dose or Regimen May Be Needed Due to Drug Interaction Established Drug Interactions: See Clinical Pharmacology (12.3), Table 4 for Magnitude of Interaction.","C0039224|C1706073|C1706074|C0443211|C1272684|C3840750|C0042153|C0457083|C1947944|C1515926|C0178602|C0869039|C1114758|C0040808|C3812381|C2945654|C0027552|C0686904|C0678798|C0687133|C0042789|C1947903|C0031332|C1555729|C0449286|C1704240|C1704675","[mnob]|[mnob]|[inpr]|[qlco]|[qlco]|[fndg]|[ftcn]|[ftcn]|[inpr]|[idcn]|[qnco]|[qnco]|[clna]|[topp]|[tmco]|[inpr]|[qlco]|[ftcn]|[fndg]|[moft]|[orgf]|[acty]|[bmod]|[prog]|[qnco]|[qnco]|[ftcn]","Table - furniture|Table Device Component|Data Table|Established|Accepted|Potential adverse drug interaction|utilization qualifier|Usage|Use - dosing instruction imperative|Alteration|Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Treatment Protocols|Month of May|Regimen - CHV concept|Needs|Patient need for (contextual qualifier)|Adverse drug interaction|Drug Interactions|Vision|See|Clinical pharmacology discipline|Allopathic & Osteopathic Physicians - Clinical Pharmacology|Degree or extent|Magnitude|Interaction"
"Table 1	Oral drugs that can be administered concomitantly with Velphoro","C0039224|C0029167|C0175795|C0304289|C1706073|C1706074|C1521801|C3696395","[mnob]|[bmod]|[topp]|[phsu]|[mnob]|[inpr]|[ftcn]|[phsu]","Table - furniture|Oral Medicine|oral medication|Oral drug preparation|Table Device Component|Data Table|Having administered|Velphoro"
"Table II. ","C0039224|C1706073|C1706074","[mnob]|[mnob]|[inpr]","Table - furniture|Table Device Component|Data Table"
"Table II. ","C0039224|C1706073|C1706074","[mnob]|[mnob]|[inpr]","Table - furniture|Table Device Component|Data Table""Clinically Significant Drug Interactions With Theophylline*","C0237881|C0687133|C0750502|C1546944|C0039771","[mnob]|[mnob]|[inpr][qnco]|[moft]|[idcn]|[qlco]|[bacs, orch, phsu]","Table - furniture|Table Device Component|Data TableStatistical Significance|Drug Interactions|Significant|Event Seriousness - Significant|Theophylline"
"Table III. ","C0039224|C0439070|C1705160|C1706073|C1706074","[mnob]|[inpr]|[qlco]|[mnob]|[inpr]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data Table"
"Table III. ","C0039224|C0439070|C1705160|C1706073|C1706074","[mnob]|[inpr]|[qlco]|[mnob]|[inpr]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data Table""Drugs That Have Been Documented Not to Interact With Theophylline or Drugs That Produce No Clinically Significant Interaction With Theophylline*","C0013227|C3687832|C1301725|C1609436|C1518422|C0040363|C0041260|C1883351|C0039771|C0237881|C1704675|C0750502|C1546944","[mnob]|[inpr]|[qlco]|[mnob]|[inpr][phsu]|[topp]|[hlca]|[inpr]|[ftcn]|[geoa]|[aapp, enzy]|[qlco]|[bacs, orch, phsu]|[qnco]|[ftcn]|[idcn]|[qlco]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data TablePharmaceutical Preparations|Drugs|Documented|Document completion status - Documented|Negation|Togo|Tryptophanase|To|Theophylline|Statistical Significance|Interaction|Significant|Event Seriousness - Significant"
"Parameter","C0549193|C1704769|C2350001","[spco]|[cnce]|[qnco]","Parameter Value|Programming Parameter|Population Parameter"
"\Atazanavir/RitonavirFor information regarding clinical recommendations, see \Drug Interactions (7)\.\, \Parallel group design; ","C1145759|C1533716|C0205210|C0034866|C0237412|C0497591|C1553058|C0042789|C1947903|C0687133|C2348042|C0441833|C1707689|C2983265|C0687744|C1257890|C1552516|C1705428|C1705429|C2826345","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[orgf]|[acty]|[moft]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Vision|See|Drug Interactions|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel Study"
"\Atazanavir/RitonavirFor information regarding clinical recommendations, see \Drug Interactions (7)\.\, \Parallel group design; ","C1145759|C1533716|C0205210|C0034866|C0237412|C0497591|C1553058|C0042789|C1947903|C0687133|C2348042|C0441833|C1707689|C2983265|C0687744|C1257890|C1552516|C1705428|C1705429|C2826345","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[orgf]|[acty]|[moft]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Vision|See|Drug Interactions|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel Study""n = 23 for atazanavir/ritonavir + nevirapine, n = 22 for atazanavir/ritonavir without nevirapine. ","C0369718|C0441922|C0450348|C1977391|C0132326","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[orgf]|[acty]|[moft]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa][aapp, imft]|[inpr]|[qnco]|[phsu]|[orch, phsu]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Vision|See|Drug Interactions|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel StudyN not otherwise specified Antibody|N+ (tumor staging)|23|Atazanavir+Ritonavir|Nevirapine"
"\Atazanavir/RitonavirFor information regarding clinical recommendations, see \Drug Interactions (7)\.\, \Parallel group design; ","C1145759|C1533716|C0205210|C0034866|C0237412|C0497591|C1553058|C0042789|C1947903|C0687133|C2348042|C0441833|C1707689|C2983265|C0687744|C1257890|C1552516|C1705428|C1705429|C2826345","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[orgf]|[acty]|[moft]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Vision|See|Drug Interactions|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel Study""n = 23 for atazanavir/ritonavir + nevirapine, n = 22 for atazanavir/ritonavir without nevirapine. ","C0369718|C0441922|C0450348|C1977391|C0132326","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[orgf]|[acty]|[moft]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa][aapp, imft]|[inpr]|[qnco]|[phsu]|[orch, phsu]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Vision|See|Drug Interactions|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel StudyN not otherwise specified Antibody|N+ (tumor staging)|23|Atazanavir+Ritonavir|Nevirapine""Changes in atazanavir PK are relative to atazanavir/ritonavir 300 mg/100 mg alone.","C0392747|C0443172|C1145759|C3875154|C1977391|C1319635|C3817553|C0205171|C0439044|C0679994","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[orgf]|[acty]|[moft]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa][aapp, imft]|[inpr]|[qnco]|[phsu]|[orch, phsu][ftcn]|[qnco]|[orch, phsu]|[idcn]|[phsu]|[qnco]|[qnco]|[qnco]|[fndg]|[grpa]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Vision|See|Drug Interactions|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel StudyN not otherwise specified Antibody|N+ (tumor staging)|23|Atazanavir+Ritonavir|NevirapineChanging|Changed status|Atazanavir|Relative to|Atazanavir+Ritonavir|mg/mg|100%|Singular|Living Alone|alone - group size"
"\Atazanavir/RitonavirFor information regarding clinical recommendations, seeDrug Interactions (7)\.\Parallel group design; ","C1145759|C1533716|C0205210|C0034866|C0237412|C0497591|C1553058|C1704675|C2348042|C0441833|C1707689|C2983265|C0687744|C1257890|C1552516|C1705428|C1705429|C2826345","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[ftcn]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Interaction|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel Study"
"\Atazanavir/RitonavirFor information regarding clinical recommendations, seeDrug Interactions (7)\.\Parallel group design; ","C1145759|C1533716|C0205210|C0034866|C0237412|C0497591|C1553058|C1704675|C2348042|C0441833|C1707689|C2983265|C0687744|C1257890|C1552516|C1705428|C1705429|C2826345","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[ftcn]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Interaction|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel Study""n = 23 for atazanavir/ritonavir + nevirapine, n = 22 for atazanavir/ritonavir without nevirapine. ","C0369718|C0441922|C0450348|C1977391|C0132326","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[ftcn]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa][aapp, imft]|[inpr]|[qnco]|[phsu]|[orch, phsu]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Interaction|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel StudyN not otherwise specified Antibody|N+ (tumor staging)|23|Atazanavir+Ritonavir|Nevirapine"
"\Atazanavir/RitonavirFor information regarding clinical recommendations, seeDrug Interactions (7)\.\Parallel group design; ","C1145759|C1533716|C0205210|C0034866|C0237412|C0497591|C1553058|C1704675|C2348042|C0441833|C1707689|C2983265|C0687744|C1257890|C1552516|C1705428|C1705429|C2826345","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[ftcn]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Interaction|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel Study""n = 23 for atazanavir/ritonavir + nevirapine, n = 22 for atazanavir/ritonavir without nevirapine. ","C0369718|C0441922|C0450348|C1977391|C0132326","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[ftcn]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa][aapp, imft]|[inpr]|[qnco]|[phsu]|[orch, phsu]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Interaction|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel StudyN not otherwise specified Antibody|N+ (tumor staging)|23|Atazanavir+Ritonavir|Nevirapine""Changes in atazanavir PK are relative to atazanavir/ritonavir 300 mg/100 mg alone.","C0392747|C0443172|C1145759|C3875154|C1977391|C1319635|C3817553|C0205171|C0439044|C0679994","[orch, phsu]|[idcn]|[qlco]|[idcn]|[prog]|[prog]|[prog]|[ftcn]|[qlco]|[idcn]|[acty]|[inpr]|[popg]|[popg]|[hcro]|[cnce]|[popg]|[resa][aapp, imft]|[inpr]|[qnco]|[phsu]|[orch, phsu][ftcn]|[qnco]|[orch, phsu]|[idcn]|[phsu]|[qnco]|[qnco]|[qnco]|[fndg]|[grpa]","Atazanavir|Information|Clinical|Recommendation|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Interaction|Parallel Lesion|Groups|Design|CDISC SEND Study Design Terminology|Social group|Population Group|Specialty Group|Group Object|User Group|Parallel StudyN not otherwise specified Antibody|N+ (tumor staging)|23|Atazanavir+Ritonavir|NevirapineChanging|Changed status|Atazanavir|Relative to|Atazanavir+Ritonavir|mg/mg|100%|Singular|Living Alone|alone - group size"
"\albuterol,\systemic and inhaled\amoxicillin\ampicillin,\with or without sulbactam\atenolol\azithromycin\caffeine,\dietary ingestion\cefaclor\co-trimoxazole\(trimethoprim and sulfamethoxazole)\diltiazem\dirithromycin\enflurane\famotidine\felodipine\finasteride\hydrocortisone\isoflurane\isoniazid\isradipine\influenza vaccine\ketoconazole\","C0001927|C0205373|C0004048|C0002645|C0002680|C0038665|C0004147|C0052796|C0006644|C0012155|C0232478|C0007537|C0041044|C2699635|C0041041|C0038689|C0012373|C0058445|C0014277|C0015620|C0015772|C0060389|C2928944|C0022180|C0022209|C0071304|C0021403|C0770694|C2708137","[orch, phsu]|[ftcn]|[orgf]|[antb, orch]|[antb, orch]|[antb, orch]|[orch, phsu]|[antb, orch]|[orch, phsu]|[food]|[biof]|[antb, orch]|[orch, phsu]|[ftcn]|[antb, orch]|[antb, orch]|[orch, phsu]|[antb, orch]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[imft, phsu]|[imft, orch, phsu]|[clna]","Albuterol|Systemic|Inspiration function|Amoxicillin|Ampicillin|Sulbactam|Atenolol|Azithromycin|Caffeine|Diet|Ingestion|Cefaclor|Trimethoprim-Sulfamethoxazole Combination|Dietary Route of Administration|Trimethoprim|Sulfamethoxazole|Diltiazem|dirithromycin|Enflurane|Famotidine|Felodipine|Finasteride|Hydrocortisone / Ketoconazole|Isoflurane|isoniazid|Isradipine|Influenza virus vaccine|trivalent influenza vaccine|Influenza vaccine:-:Point in time:^Patient:-"
"\albuterol,\ systemic and inhaled\amoxicillin\ampicillin,\ with or without sulbactam\atenolol\azithromycin\caffeine,\ dietary ingestion\cefaclor\co-trimoxazole\ (trimethoprim and sulfamethoxazole)\diltiazem\dirithromycin\enflurane\famotidine\felodipine\finasteride\hydrocortisone\isoflurane\isoniazid\isradipine\influenza vaccine\ketoconazole\","C0001927|C0205373|C0004048|C0002645|C0002680|C0038665|C0004147|C0052796|C0006644|C0012155|C0232478|C0007537|C0041044|C2699635|C0041041|C0038689|C0012373|C0058445|C0014277|C0015620|C0015772|C0060389|C2928944|C0022180|C0022209|C0071304|C0021403|C0770694|C2708137","[orch, phsu]|[ftcn]|[orgf]|[antb, orch]|[antb, orch]|[antb, orch]|[orch, phsu]|[antb, orch]|[orch, phsu]|[food]|[biof]|[antb, orch]|[orch, phsu]|[ftcn]|[antb, orch]|[antb, orch]|[orch, phsu]|[antb, orch]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[imft, phsu]|[imft, orch, phsu]|[clna]","Albuterol|Systemic|Inspiration function|Amoxicillin|Ampicillin|Sulbactam|Atenolol|Azithromycin|Caffeine|Diet|Ingestion|Cefaclor|Trimethoprim-Sulfamethoxazole Combination|Dietary Route of Administration|Trimethoprim|Sulfamethoxazole|Diltiazem|dirithromycin|Enflurane|Famotidine|Felodipine|Finasteride|Hydrocortisone / Ketoconazole|Isoflurane|isoniazid|Isradipine|Influenza virus vaccine|trivalent influenza vaccine|Influenza vaccine:-:Point in time:^Patient:-"
"\AminoglutethimideAmiodaroneIodide (including iodine-containing Radiographic contrast agents)LithiumMethimazolePropylthioracil (PTU)SulfonamidesTolbutamide\","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"\Amiodarone,amlodipine,ranolazine \","C0002598|C0051696|C0073633","[orch, phsu]|[orch, phsu]|[orch, phsu]","Amiodarone|Amlodipine|ranolazine"
"\AmiodaroneIodide (including iodine-containing Radiographic contrast agents)\","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"\Antibiotics\ciprofloxacingentamicintobramycintrimethoprim with sulfamethoxazolevancomycin","C0003232|C0003237|C3540704|C3540705|C3540706|C3540707|C3540708|C3540709|C3540710","[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]","Antibiotics|Antibiotics, Antitubercular|Antibiotics for systemic use|Antifungal Antibiotics, Topical|Antibiotic throat preparations|Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE|Antibiotics, Gynecological|antibiotics, intestinal|Antibiotics, ophthalmologic"
"\Dopamine/Dopamine AgonistsGlucocorticoidsOctreotide\","C0013030","[bacs, orch, phsu]","Dopamine"
"\Grapefruitjuice \","","",""
"\Lomitapide\","C2827241","[orch, phsu]","lomitapide"
"\Table 2: Drug  Thyroidal Axis Interactions\","C0039224|C1706073|C1706074|C0687133|C0040132|C0004457|C0999597|C1522496|C3540038","[mnob]|[mnob]|[inpr]|[moft]|[bpoc]|[bpoc]|[mamm]|[spco]|[irda]","Table - furniture|Table Device Component|Data Table|Drug Interactions|Thyroid Gland|Axis vertebra|Genus Axis|Axis|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS"
"\Table 2: Drug-Thyroidal Axis Interactions\","C0039224|C1706073|C1706074|C0687133|C0040132|C0004457|C0999597|C1522496|C3540038","[mnob]|[mnob]|[inpr]|[moft]|[bpoc]|[bpoc]|[mamm]|[spco]|[irda]","Table - furniture|Table Device Component|Data Table|Drug Interactions|Thyroid Gland|Axis vertebra|Genus Axis|Axis|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS"
"\Table III. ","C0039224|C0439070|C1705160|C1706073|C1706074","[mnob]|[inpr]|[qlco]|[mnob]|[inpr]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data Table"
"\Table III. ","C0039224|C0439070|C1705160|C1706073|C1706074","[mnob]|[inpr]|[qlco]|[mnob]|[inpr]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data Table""Clinically\significant drug interactions with\theophylline.\Refer to PRECAUTIONS, Drug Interactions for\further information regarding table.\","C0237881|C0687133|C0750502|C1546944|C0039771|C0205543|C1882442|C1517331|C1533716|C0039224|C1706073|C1706074","[mnob]|[inpr]|[qlco]|[mnob]|[inpr][qnco]|[moft]|[idcn]|[qlco]|[bacs, orch, phsu]|[ftcn]|[cnce]|[spco]|[idcn]|[mnob]|[mnob]|[inpr]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data TableStatistical Significance|Drug Interactions|Significant|Event Seriousness - Significant|Theophylline|Referring|Precaution|Further|Information|Table - furniture|Table Device Component|Data Table"
"\Table IV. ","C0039224|C0022326|C1706073|C1706074","[mnob]|[geoa]|[mnob]|[inpr]","Table - furniture|Ivory Coast|Table Device Component|Data Table"
"\Table IV. ","C0039224|C0022326|C1706073|C1706074","[mnob]|[geoa]|[mnob]|[inpr]","Table - furniture|Ivory Coast|Table Device Component|Data Table""Drugs that have\been documented not to interact with theophylline\or drugs that produce no clinically significant\interaction with theophylline.\Refer to PRECAUTIONS, Drug Interactions for\information regarding table.\","C0013227|C3687832|C1301725|C1609436|C1518422|C0040363|C0041260|C1883351|C0039771|C0237881|C1704675|C0750502|C1546944|C0205543|C1882442|C0687133|C1533716|C0039224|C1706073|C1706074","[mnob]|[geoa]|[mnob]|[inpr][phsu]|[topp]|[hlca]|[inpr]|[ftcn]|[geoa]|[aapp, enzy]|[qlco]|[bacs, orch, phsu]|[qnco]|[ftcn]|[idcn]|[qlco]|[ftcn]|[cnce]|[moft]|[idcn]|[mnob]|[mnob]|[inpr]","Table - furniture|Ivory Coast|Table Device Component|Data TablePharmaceutical Preparations|Drugs|Documented|Document completion status - Documented|Negation|Togo|Tryptophanase|To|Theophylline|Statistical Significance|Interaction|Significant|Event Seriousness - Significant|Referring|Precaution|Drug Interactions|Information|Table - furniture|Table Device Component|Data Table"
"\Verapamil,diltiazem,dronedarone \","C0042523|C0012373|C0766326","[orch, phsu]|[orch, phsu]|[orch, phsu]","Verapamil|Diltiazem|dronedarone"
"\* The interaction between nevirapine and the drug was evaluated in a clinical study. ","C1704675|C0132326|C0013227|C1254351|C0220825|C0008972","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical Research"
"\* The interaction between nevirapine and the drug was evaluated in a clinical study. ","C1704675|C0132326|C0013227|C1254351|C0220825|C0008972","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical Research""All other drug interactions shown are predicted.\","C0687133|C1547282|C0681842|C1882327","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa][moft]|[anim]|[idcn]|[qnco]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical ResearchDrug Interactions|Show|prediction|Percent of Predicted Value"
"\Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products)\","C0003138|C0038633|C0301532|C3714835|C1514468|C0332256|C2700400|C0007447|C0024467|C0304540|C2348270|C3540792|C3714621|C0032521|C4020599|C1707959|C0718050|C0768119|C0592249|C0012133|C0304290|C0006353|C0030755|C0032861|C1382110|C1521725|C0205250|C0013227|C3687832|C0006675|C0006726|C2936886|C3540037|C3714611|C0302583|C0376520|C1166521|C3714701|C0043481|C2348288|C3541396|C3714650|C0010947","[phsu]|[orch, phsu]|[orch, phsu, vita]|[phsu, vita]|[enty]|[ftcn]|[acty]|[chvs]|[elii]|[inch, phsu]|[elii]|[inch, phsu]|[phsu]|[bodm, chvs]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[nnon, phsu]|[nnon, phsu]|[bodm]|[irda, phsu]|[bmod]|[bodm]|[sbst]|[qlco]|[qlco]|[phsu]|[topp]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu, vita]|[phsu]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu]|[elii, phsu]|[elii]|[phsu]|[phsu]|[food]","Antacids|Sucralfate|Multivitamin preparation|Multivitamin Drug Class|product|Containing (qualifier)|Contain (action)|Cations|Magnesium|Aluminum-based antacid|Dietary Magnesium|Magnesium supplements|Magnesium Drug Class|Polymers|Phosphate Binders|Example|sevelamer|lanthanum carbonate|Videx|Didanosine|Chewable Tablet|Buffers|Pediatrics|Powder dose form|powder physical state|Pediatric|High|Pharmaceutical Preparations|Drugs|Calcium|Calcium, Dietary|Calcium [EPC]|CALCIUM SUPPLEMENTS|Calcium Drug Class|Iron|Dietary Iron|Ferrum metallicum, Homeopathic preparation|Iron Drug Class|Zinc|Dietary Zinc|Zinc Supplements|Zinc Drug Class|Dairy Products"
"\CiprofloxacinMycophenolate mofetil","","",""
"\Clozapine\","C0009079","[orch, phsu]","Clozapine"
"\DigoxinEnalaprilIronMetoprololWarfarin\","","",""
"\Duloxetine\","C0245561","[orch, phsu]","duloxetine"
"\I.Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:","C0021966|C0221138|C0679932|C0036075|C0036077|C0013227|C3687832|C1145667|C1167622|C0036773|C0728877|C0231290|C0687133|C0332282|C1709305|C2745955","[inch]|[aapp, imft]|[socb]|[orch, phsu]|[orch, phsu]|[phsu]|[topp]|[acty]|[moft]|[aapp]|[lbtr]|[tmco]|[moft]|[tmco]|[acty]|[tmco]","Iodides|Blood group antibody I|competition|salicylate|Salicylates|Pharmaceutical Preparations|Drugs|Binding action|Binding (Molecular Function)|Serum Albumin|Serum albumin level|Status post|Drug Interactions|Following|Occur (action)|Occurrence"
"\Phenytoin\","C0031507","[orch, phsu]","Phenytoin"
"\Probenecid\","C0033209","[orch, phsu]","Probenecid"
"\Ropinirole\","C0244821","[orch, phsu]","ropinirole"
"\Sildenafil\","C0529793","[orch, phsu]","sildenafil"
"\Table 1: Oral drugs that can be administered concomitantly with Auryxia\","C0039224|C1706073|C1706074|C0029167|C0175795|C0304289|C1521801|C3864953","[mnob]|[mnob]|[inpr]|[bmod]|[topp]|[phsu]|[ftcn]|[phsu]","Table - furniture|Table Device Component|Data Table|Oral Medicine|oral medication|Oral drug preparation|Having administered|Auryxia"
"\Table 2: Drug-Thyroidal Axis Interactions\","C0039224|C1706073|C1706074|C0687133|C0040132|C0004457|C0999597|C1522496|C3540038","[mnob]|[mnob]|[inpr]|[moft]|[bpoc]|[bpoc]|[mamm]|[spco]|[irda]","Table - furniture|Table Device Component|Data Table|Drug Interactions|Thyroid Gland|Axis vertebra|Genus Axis|Axis|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS"
"\Table 4 Drugs Tested in Binding or Drug Interaction Testing or With Post-Marketing Reports\In Vitro\In Vivo","C0039224|C0013227|C3687832|C1706073|C1706074|C0392366|C1145667|C1167622|C0038577|C1704675|C0678798|C0039593|C0687133|C0687676|C0024826|C1704687|C0684224|C0700287|C3273238|C3889645|C1515655|C1533691|C0021135|C2827718","[mnob]|[phsu]|[topp]|[mnob]|[inpr]|[inpr]|[acty]|[moft]|[lbpr]|[ftcn]|[fndg]|[ftcn]|[moft]|[tmco]|[ocac]|[mnob]|[inpr]|[hlca]|[inpr]|[inpr]|[spco]|[qlco]|[inpr]|[ftcn]","Table - furniture|Pharmaceutical Preparations|Drugs|Table Device Component|Data Table|Tests (qualifier value)|Binding action|Binding (Molecular Function)|Substance Abuse Detection|Interaction|Adverse drug interaction|Testing|Drug Interactions|Post|Marketing|Post Device Component|Report (document)|Reporting|Regulatory Report|Clinical Trial Final Report|in vivo|in vitro|In Vitro [Publication Type]|In Vitro Route of Administration"
"\Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports\","C0039224|C0013227|C3687832|C1706073|C1706074|C0392366|C0021135|C1145667|C1167622|C1533691|C2827718|C1515655|C0038577|C1704675|C0678798|C0039593|C0687133|C0687676|C0024826|C1704687|C0684224|C0700287|C3273238|C3889645","[mnob]|[phsu]|[topp]|[mnob]|[inpr]|[inpr]|[inpr]|[acty]|[moft]|[qlco]|[ftcn]|[spco]|[lbpr]|[ftcn]|[fndg]|[ftcn]|[moft]|[tmco]|[ocac]|[mnob]|[inpr]|[hlca]|[inpr]|[inpr]","Table - furniture|Pharmaceutical Preparations|Drugs|Table Device Component|Data Table|Tests (qualifier value)|In Vitro [Publication Type]|Binding action|Binding (Molecular Function)|in vitro|In Vitro Route of Administration|in vivo|Substance Abuse Detection|Interaction|Adverse drug interaction|Testing|Drug Interactions|Post|Marketing|Post Device Component|Report (document)|Reporting|Regulatory Report|Clinical Trial Final Report"
"\Theophylline\","C0039771","[bacs, orch, phsu]","Theophylline"
"\Tizanidine \","C0146011","[orch, phsu]","tizanidine"
"847","","",""
"* The interaction between nevirapine and the drug was evaluated in a clinical study. ","C1704675|C0132326|C0013227|C1254351|C0220825|C0008972","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical Research"
"* The interaction between nevirapine and the drug was evaluated in a clinical study. ","C1704675|C0132326|C0013227|C1254351|C0220825|C0008972","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical Research""All other drug interactions shown are predicted.\","C0687133|C1547282|C0681842|C1882327","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa][moft]|[anim]|[idcn]|[qnco]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical ResearchDrug Interactions|Show|prediction|Percent of Predicted Value"
"? levonorgestrel","C0023566","[horm, orch, phsu]","Levonorgestrel"
"Adenosine","C0001443","[bacs, nnon, phsu]","Adenosine"
"albuterol, systemic and\inhaled","C0001927|C0205373|C0004048","[orch, phsu]|[ftcn]|[orgf]","Albuterol|Systemic|Inspiration function"
"albuterol,  systemic and inhaled","C0001927|C0205373|C0004048","[orch, phsu]|[ftcn]|[orgf]","Albuterol|Systemic|Inspiration function"
"AminoglutethimideAmiodaroneIodide (including iodine-containing Radiographic contrast agents)LithiumMethimazolePropylthioracil (PTU)SulfonamidesTolbutamide","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"AminoglutethimideAmiodaroneIodide (including iodine-containing Radiographic contrast agents)LithiumMethimazolePropylthioracil (PTU)SulfonamidesTolbutamide","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"Aminoglutethimide Amiodarone Iodide (including iodine-containing Radiographic contrast agents) Lithium Methimazole Propylthioracil (PTU) Sulfonamides Tolbutamide","C0002555|C0002598|C0021966|C0332257|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749|C0023870|C0025644|C3540800|C0038760|C0040374|C0599503|C3539179|C3539184|C3541962|C3541963","[orch, phsu]|[orch, phsu]|[inch]|[ftcn]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]|[elii, phsu]|[orch, phsu]|[phsu]|[orch]|[orch, phsu]|[antb, orch]|[orch, phsu]|[orch]|[orch, phsu]|[orch, phsu]","Aminoglutethimide|Amiodarone|Iodides|Including (qualifier)|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media|Lithium|Methimazole|Lithium antipsychotics|Sulfonamides|Tolbutamide|Sulfonamide Anti-Infective Agents|Sulfonamides, Gynecological|Sulfonamides, topical|Sulfonamides, ophthalmologic antiinfectives|Sulfonamides, intestinal antiinfectives"
"AminoglutethimideAmiodaroneIodide (including iodine-containingRadiographic contrast agents)LithiumMethimazolePropylthiouracil (PTU)SulfonamidesTolbutamide","C0332257|C0021966|C0009924|C0021968|C0885449|C2348268","[ftcn]|[inch]|[irda]|[elii, phsu]|[phsu]|[elii]","Including (qualifier)|Iodides|Contrast Media|Iodine|Iodine, Homeopathic preparation|Dietary Iodine"
"AminoglutethimideAmiodaroneIodide (including iodine-containing Radiographic contrast agents)LithiumMethimazolePropylthioracil (PTU)SulfonamidesTolbutamide","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"AmiodaroneBeta-adrenergic antagonists- (e.g., Propranolol > 160 mg/day)Glucocorticoids-(e.g., Dexamethasone ? 4 mg/day)Propylthiouracil (PTU)","C0242889|C2757018|C0033497|C0439422|C0017710|C3540777|C3540778|C0985346|C0332173|C0439228|C0439505|C0033511","[phsu]|[moft]|[orch, phsu]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[clnd]|[tmco]|[tmco]|[tmco]|[nnon, phsu]","Adrenergic Antagonists|Adrenergic Antagonists [MoA]|Propranolol|milligram/day|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Dexamethasone 4 MG|Daily|day|per day|Propylthiouracil"
"AmiodaroneIodide (including iodine-containing Radiographic contrast agents)","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"AmiodaroneBeta-adrenergic antagonists- (e.g., Propranolol > 160 mg/day)Glucocorticoids-(e.g., Dexamethasone ? 4 mg/day)Propylthiouracil (PTU)","C0242889|C2757018|C0033497|C0439422|C0017710|C3540777|C3540778|C0985346|C0332173|C0439228|C0439505|C0033511","[phsu]|[moft]|[orch, phsu]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[clnd]|[tmco]|[tmco]|[tmco]|[nnon, phsu]","Adrenergic Antagonists|Adrenergic Antagonists [MoA]|Propranolol|milligram/day|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Dexamethasone 4 MG|Daily|day|per day|Propylthiouracil"
"AmiodaroneIodide (including iodine-containing Radiographic contrast agents)","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"Amiodarone Beta-adrenergic antagonists - (e.g., Propranolol > 160 mg/day) Glucocorticoids -(e.g., Dexamethasone ? 4 mg/day) Propylthiouracil (PTU)","C0002598|C0001645|C0178504|C2757061|C0033497|C0439422|C0017710|C3540777|C3540778|C0985346|C0332173|C0439228|C0439505|C0033511","[orch, phsu]|[phsu]|[phsu]|[moft]|[orch, phsu]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[clnd]|[tmco]|[tmco]|[tmco]|[nnon, phsu]","Amiodarone|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Propranolol|milligram/day|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Dexamethasone 4 MG|Daily|day|per day|Propylthiouracil"
"Amiodarone Iodide (including iodine-containing Radiographic contrast agents)","C0002598|C0021966|C0332257|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[orch, phsu]|[inch]|[ftcn]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Amiodarone|Iodides|Including (qualifier)|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"Amiodarone,amlodipine,ranolazine","C0002598|C0051696|C0073633","[orch, phsu]|[orch, phsu]|[orch, phsu]","Amiodarone|Amlodipine|ranolazine"
"AmiodaroneBeta-adrenergic antagonists- (e.g., Propranolol > 160 mg/day)Glucocorticoids- (e.g., Dexamethasone ? 4 mg/day)Propylthiouracil (PTU)","C0242889|C2757018|C0033497|C0439422|C0017710|C3540777|C3540778|C0985346|C0332173|C0439228|C0439505|C0033511","[phsu]|[moft]|[orch, phsu]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[clnd]|[tmco]|[tmco]|[tmco]|[nnon, phsu]","Adrenergic Antagonists|Adrenergic Antagonists [MoA]|Propranolol|milligram/day|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Dexamethasone 4 MG|Daily|day|per day|Propylthiouracil"
"AmiodaroneBeta-adrenergic antagonists- (e.g., Propranolol > 160 mg/day)Glucocorticoids-(e.g., Dexamethasone ? 4 mg/day)Propylthiouracil (PTU)","C0242889|C2757018|C0033497|C0439422|C0017710|C3540777|C3540778|C0985346|C0332173|C0439228|C0439505|C0033511","[phsu]|[moft]|[orch, phsu]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[clnd]|[tmco]|[tmco]|[tmco]|[nnon, phsu]","Adrenergic Antagonists|Adrenergic Antagonists [MoA]|Propranolol|milligram/day|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Dexamethasone 4 MG|Daily|day|per day|Propylthiouracil"
"AmiodaroneIodide (including iodine-containingRadiographic contrast agents)","C0332257|C0021966|C0009924|C0021968|C0885449|C2348268","[ftcn]|[inch]|[irda]|[elii, phsu]|[phsu]|[elii]","Including (qualifier)|Iodides|Contrast Media|Iodine|Iodine, Homeopathic preparation|Dietary Iodine"
"AmiodaroneIodide (including iodine-containing Radiographic contrast agents)","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"Amlodipine\									Aspirin\									Atorvastatin\									Calcitriol\									Clopidogrel\									Digoxin\									Diltiazem\									Doxercalciferol\									Enalapril\									Fluvastatin\									Glimepiride\									Levofloxacin\									Losartan\									Metoprolol\									Pravastatin\									Propranolol\									Sitagliptin\									Warfarin\","C1329978|C0004057|C0006674|C0070166|C0012265|C0717708|C0043668|C0082608|C0061323|C0282386|C0126174|C0025859|C0085542|C0033497|C1565750|C0043031|C3714610|C0051696|C1329980|C0286651","[orch, phsu]|[orch, phsu]|[horm, phsu, vita]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu, vita]|[orch, phsu]|[orch, phsu]|[antb, orch]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[hops, orch, phsu]|[phsu, vita]|[orch, phsu]|[orch, phsu]|[orch, phsu]","Amlodipine / atorvastatin|Aspirin|Calcitriol|clopidogrel|Digoxin|Diltiazem / Enalapril|Doxercalciferol|fluvastatin|glimepiride|Levofloxacin|Losartan|Metoprolol|Pravastatin|Propranolol|sitagliptin|Warfarin|Calcitriol Drug Class|Amlodipine|Aspirin / Pravastatin|atorvastatin"
"Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products)","C0003138|C0038633|C0301532|C3714835|C1514468|C0332256|C2700400|C0007447|C0024467|C0304540|C2348270|C3540792|C3714621|C0032521|C4020599|C1707959|C0718050|C0768119|C0592249|C0012133|C0304290|C0006353|C0030755|C0032861|C1382110|C1521725|C0205250|C0013227|C3687832|C0006675|C0006726|C2936886|C3540037|C3714611|C0302583|C0376520|C1166521|C3714701|C0043481|C2348288|C3541396|C3714650|C0010947","[phsu]|[orch, phsu]|[orch, phsu, vita]|[phsu, vita]|[enty]|[ftcn]|[acty]|[chvs]|[elii]|[inch, phsu]|[elii]|[inch, phsu]|[phsu]|[bodm, chvs]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[nnon, phsu]|[nnon, phsu]|[bodm]|[irda, phsu]|[bmod]|[bodm]|[sbst]|[qlco]|[qlco]|[phsu]|[topp]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu, vita]|[phsu]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu]|[elii, phsu]|[elii]|[phsu]|[phsu]|[food]","Antacids|Sucralfate|Multivitamin preparation|Multivitamin Drug Class|product|Containing (qualifier)|Contain (action)|Cations|Magnesium|Aluminum-based antacid|Dietary Magnesium|Magnesium supplements|Magnesium Drug Class|Polymers|Phosphate Binders|Example|sevelamer|lanthanum carbonate|Videx|Didanosine|Chewable Tablet|Buffers|Pediatrics|Powder dose form|powder physical state|Pediatric|High|Pharmaceutical Preparations|Drugs|Calcium|Calcium, Dietary|Calcium [EPC]|CALCIUM SUPPLEMENTS|Calcium Drug Class|Iron|Dietary Iron|Ferrum metallicum, Homeopathic preparation|Iron Drug Class|Zinc|Dietary Zinc|Zinc Supplements|Zinc Drug Class|Dairy Products"
"Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products)","C0003138|C0038633|C0301532|C3714835|C1514468|C0332256|C2700400|C0007447|C0024467|C0304540|C2348270|C3540792|C3714621|C0032521|C4020599|C1707959|C0718050|C0768119|C0592249|C0012133|C0304290|C0006353|C0030755|C0032861|C1382110|C1521725|C0205250|C0013227|C3687832|C0006675|C0006726|C2936886|C3540037|C3714611|C0302583|C0376520|C1166521|C3714701|C0043481|C2348288|C3541396|C3714650|C0010947","[phsu]|[orch, phsu]|[orch, phsu, vita]|[phsu, vita]|[enty]|[ftcn]|[acty]|[chvs]|[elii]|[inch, phsu]|[elii]|[inch, phsu]|[phsu]|[bodm, chvs]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[nnon, phsu]|[nnon, phsu]|[bodm]|[irda, phsu]|[bmod]|[bodm]|[sbst]|[qlco]|[qlco]|[phsu]|[topp]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu, vita]|[phsu]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu]|[elii, phsu]|[elii]|[phsu]|[phsu]|[food]","Antacids|Sucralfate|Multivitamin preparation|Multivitamin Drug Class|product|Containing (qualifier)|Contain (action)|Cations|Magnesium|Aluminum-based antacid|Dietary Magnesium|Magnesium supplements|Magnesium Drug Class|Polymers|Phosphate Binders|Example|sevelamer|lanthanum carbonate|Videx|Didanosine|Chewable Tablet|Buffers|Pediatrics|Powder dose form|powder physical state|Pediatric|High|Pharmaceutical Preparations|Drugs|Calcium|Calcium, Dietary|Calcium [EPC]|CALCIUM SUPPLEMENTS|Calcium Drug Class|Iron|Dietary Iron|Ferrum metallicum, Homeopathic preparation|Iron Drug Class|Zinc|Dietary Zinc|Zinc Supplements|Zinc Drug Class|Dairy Products"
"Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) \","C0003138|C0038633|C0301532|C3714835|C1514468|C0332256|C2700400|C0007447|C0024467|C0304540|C2348270|C3540792|C3714621|C0032521|C4020599|C1707959|C0718050|C0768119|C0592249|C0012133|C0304290|C0006353|C0030755|C0032861|C1382110|C1521725|C0205250|C0013227|C3687832|C0006675|C0006726|C2936886|C3540037|C3714611|C0302583|C0376520|C1166521|C3714701|C0043481|C2348288|C3541396|C3714650|C0010947","[phsu]|[orch, phsu]|[orch, phsu, vita]|[phsu, vita]|[enty]|[ftcn]|[acty]|[chvs]|[elii]|[inch, phsu]|[elii]|[inch, phsu]|[phsu]|[bodm, chvs]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[nnon, phsu]|[nnon, phsu]|[bodm]|[irda, phsu]|[bmod]|[bodm]|[sbst]|[qlco]|[qlco]|[phsu]|[topp]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu, vita]|[phsu]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu]|[elii, phsu]|[elii]|[phsu]|[phsu]|[food]","Antacids|Sucralfate|Multivitamin preparation|Multivitamin Drug Class|product|Containing (qualifier)|Contain (action)|Cations|Magnesium|Aluminum-based antacid|Dietary Magnesium|Magnesium supplements|Magnesium Drug Class|Polymers|Phosphate Binders|Example|sevelamer|lanthanum carbonate|Videx|Didanosine|Chewable Tablet|Buffers|Pediatrics|Powder dose form|powder physical state|Pediatric|High|Pharmaceutical Preparations|Drugs|Calcium|Calcium, Dietary|Calcium [EPC]|CALCIUM SUPPLEMENTS|Calcium Drug Class|Iron|Dietary Iron|Ferrum metallicum, Homeopathic preparation|Iron Drug Class|Zinc|Dietary Zinc|Zinc Supplements|Zinc Drug Class|Dairy Products"
"Anticonvulsants:Carbamazepine,clonazepam, ethosuximide\","C0003286|C0006949|C0682993|C0009011|C0015043","[phsu]|[orch, phsu]|[orch]|[orch, phsu]|[orch, phsu]","Anticonvulsants|Carbamazepine|carbamazepin|Clonazepam|Ethosuximide"
"Antidepressants- Tricyclics (e.g., Amitriptyline)- Tetracyclics (e.g., Maprotiline)- Selective Serotonin Reuptake Inhibitors (SSRIs; e.g., Sertraline)","C0003290|C0002600|C0024778|C0360105|C0074393","[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]","Tricyclic Antidepressive Agents|Amitriptyline|Maprotiline|Selective Serotonin Reuptake Inhibitors|Sertraline"
"Antidepressants- Tricyclics (e.g., Amitriptyline)- Tetracyclics (e.g., Maprotiline)- Selective Serotonin Reuptake Inhibitors (SSRIs; e.g., Sertraline)","C0003290|C0002600|C0024778|C0360105|C0074393","[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]","Tricyclic Antidepressive Agents|Amitriptyline|Maprotiline|Selective Serotonin Reuptake Inhibitors|Sertraline"
"Antidepressants - Tricyclics (e.g., Amitriptyline) - Tetracyclics (e.g., Maprotiline) - Selective Serotonin Reuptake Inhibitors (SSRIs; e.g., Sertraline)","C0003290|C0002600|C0024778|C0360105|C0074393","[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]","Tricyclic Antidepressive Agents|Amitriptyline|Maprotiline|Selective Serotonin Reuptake Inhibitors|Sertraline"
"Antidepressants- Tricyclics (e.g., Amitriptyline)- Tetracyclics (e.g., Maprotiline)- Selective Serotonin Reuptake Inhibitors (SSRIs; e.g., Sertraline)","C0003290|C0002600|C0024778|C0360105|C0074393","[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]","Tricyclic Antidepressive Agents|Amitriptyline|Maprotiline|Selective Serotonin Reuptake Inhibitors|Sertraline"
"Antidiabetic Agents- Biguanides- Meglitinides- Sulfonylureas- Thiazolidediones- Insulin","C0935929|C0005382|C0065880|C0038766|C0021641|C1533581|C1579433|C3714501|C3653359|C1579432|C0360396|C3540012","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]","Antidiabetics|Biguanides|Meglitinide|Sulfonylurea Compounds|Insulin|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Sulfonylureas for blood glucose lowering|Meglitinides|Biguanide antimalarial|biguanide blood glucose lower drugs"
"Antidiabetic Agents- Biguanides- Meglitinides- Sulfonylureas- Thiazolidediones- Insulin","C0935929|C0005382|C0065880|C0038766|C0021641|C1533581|C1579433|C3714501|C3653359|C1579432|C0360396|C3540012","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]","Antidiabetics|Biguanides|Meglitinide|Sulfonylurea Compounds|Insulin|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Sulfonylureas for blood glucose lowering|Meglitinides|Biguanide antimalarial|biguanide blood glucose lower drugs"
"Antidiabetic Agents - Biguanides - Meglitinides - Sulfonylureas - Thiazolidediones - Insulin","C0935929|C0005382|C0065880|C0038766|C0021641|C1533581|C1579433|C3714501|C3653359|C1579432|C0360396|C3540012","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]","Antidiabetics|Biguanides|Meglitinide|Sulfonylurea Compounds|Insulin|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Sulfonylureas for blood glucose lowering|Meglitinides|Biguanide antimalarial|biguanide blood glucose lower drugs"
"Antidiabetic Agents- Biguanides- Meglitinides- Sulfonylureas- Thiazolidediones- Insulin","C0935929|C0005382|C0065880|C0038766|C0021641|C1533581|C1579433|C3714501|C3653359|C1579432|C0360396|C3540012","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]","Antidiabetics|Biguanides|Meglitinide|Sulfonylurea Compounds|Insulin|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Sulfonylureas for blood glucose lowering|Meglitinides|Biguanide antimalarial|biguanide blood glucose lower drugs"
"Antidiabetic Agents- Biguanides- Meglitinides- Sulfonylureas- Thiazolidinediones- Insulin","C0935929|C0005382|C0065880|C0038766|C1257987|C0021641|C1533581|C1579433|C3714501|C3541957|C3653359|C1579432|C0360396|C3540012","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[orch, phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]","Antidiabetics|Biguanides|Meglitinide|Sulfonylurea Compounds|Thiazolidinediones|Insulin|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Thiazolidinediones, blood glucose lowering drugs|Sulfonylureas for blood glucose lowering|Meglitinides|Biguanide antimalarial|biguanide blood glucose lower drugs"
"Antifungals: Fluconazole*\","C0003308|C0016277","[phsu]|[orch, phsu]","Antifungal Agents|Fluconazole"
"Antithrombotics: Warfarin\","C0043031","[hops, orch, phsu]","Warfarin"
"Atazanavir/ Ritonavir*\","C1977391","[phsu]","Atazanavir+Ritonavir"
"Atazanavir/ritonavir","C1977391","[phsu]","Atazanavir+Ritonavir"
"Atazanavir/Ritonavir*\","C1977391","[phsu]","Atazanavir+Ritonavir"
"Boceprevir \","C1738934","[aapp, phsu]","boceprevir"
"Boceprevir\","C1738934","[aapp, phsu]","boceprevir"
"Calcitriol\										Ciprofloxacin\										Digoxin\										Enalapril\										Furosemide\										HMG-CoA reductase inhibitors\										Hydrochlorothiazide\										Losartan\										Metoprolol\										Nifedipine\										Omeprazole\										Quinidine\										Warfarin\","C0006674|C0008809|C0012265|C0717738|C0016860|C0360714|C0126174|C2929367|C0028978|C0034414|C0043031|C2756999|C3539119|C0014025|C0717825|C3714610","[horm, phsu, vita]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[hops, orch, phsu]|[moft]|[phsu]|[aapp, phsu]|[orch, phsu]|[phsu, vita]","Calcitriol|Ciprofloxacin|Digoxin|Enalapril / Hydrochlorothiazide|Furosemide|Hydroxymethylglutaryl-CoA Reductase Inhibitors|Losartan|Metoprolol / Nifedipine|Omeprazole|Quinidine|Warfarin|Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]|HMG CoA reductase inhibitors, plain lipid modifying drugs|Enalapril|Hydrochlorothiazide / Losartan|Calcitriol Drug Class"
"Calcium channel blockers: Diltiazem, nifedipine, verapamil\","C0006684|C0012373|C0028066|C0042523","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]","Calcium Channel Blockers|Diltiazem|Nifedipine|Verapamil"
"Cancer chemotherapy:Cyclophosphamide\","C0392920|C3665472|C0010583","[topp]|[topp]|[orch, phsu]","Chemotherapy Regimen|Chemotherapy|Cyclophosphamide"
"CarbamazepineHydantoinsPhenobarbitalRifampin","","",""
"CarbamazepineHydantoinsPhenobarbitalRifampin","","",""
"Carbamazepine \","C0006949|C0682993","[orch, phsu]|[orch]","Carbamazepine|carbamazepin"
"Carbamazepine","C0006949|C0682993","[orch, phsu]|[orch]","Carbamazepine|carbamazepin"
"Carbamazepine Hydantoins Phenobarbital Rifampin","C0006949|C0020209|C0031412|C0035608|C0682993","[orch, phsu]|[orch, phsu]|[orch, phsu]|[antb, orch]|[orch]","Carbamazepine|Hydantoins|Phenobarbital|Rifampin|carbamazepin"
"Carbamazepineand carbamazepine epoxide\","C0054640","[orch, phsu]","carbamazepine epoxide"
"CarbamazepineHydantoinsPhenobarbitalRifampin","","",""
"Carbamazepine","C0006949|C0682993","[orch, phsu]|[orch]","Carbamazepine|carbamazepin"
"Carbamazepine","C0006949|C0682993","[orch, phsu]|[orch]","Carbamazepine|carbamazepin"
"Carbamazepine","C0006949|C0682993","[orch, phsu]|[orch]","Carbamazepine|carbamazepin"
"Carbamazepine","C0006949|C0682993","[orch, phsu]|[orch]","Carbamazepine|carbamazepin"
"Chloral HydrateDiazepamEthionamideLovastatinMetoclopramide6-MercaptopurineNitroprussidePara-aminosalicylate sodiumPerphenazineResorcinol (excessive topical use)Thiazide Diuretics","C0077034|C0368663|C2825094|C0442802|C1522168|C0012802","[orch, phsu]|[orch, phsu]|[phsu]|[qlco]|[ftcn]|[orch, phsu]","trichloroacetaldehyde|aminosalicylate|Aminosalicylate [EPC]|Excessive|Topical Route of Drug Administration|Thiazide Diuretics"
"Chloral HydrateDiazepamEthionamideLovastatinMetoclopramide6-MercaptopurineNitroprussidePara-aminosalicylate sodiumPerphenazineResorcinol (excessive topical use)Thiazide Diuretics","C0077034|C0368663|C2825094|C0442802|C1522168|C0012802","[orch, phsu]|[orch, phsu]|[phsu]|[qlco]|[ftcn]|[orch, phsu]","trichloroacetaldehyde|aminosalicylate|Aminosalicylate [EPC]|Excessive|Topical Route of Drug Administration|Thiazide Diuretics"
"Chloral Hydrate Diazepam Ethionamide Lovastatin Metoclopramide 6-Mercaptopurine Nitroprusside Para-aminosalicylate sodium Perphenazine Resorcinol (excessive topical use) Thiazide Diuretics","C0008161|C0012010|C0015021|C1708744|C0025853|C0000618|C0028193|C0807286|C0031184|C0073085|C0024027|C0037533|C0442802|C1522168|C0012802","[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[nnon, phsu]|[inch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[qlco]|[ftcn]|[orch, phsu]","Chloral Hydrate|Diazepam|Ethionamide|Lovastatin Sodium|Metoclopramide|mercaptopurine|Nitroprusside|Para-aminosalicylate|Perphenazine|resorcinol|Lovastatin|Sodium Nitroprusside|Excessive|Topical Route of Drug Administration|Thiazide Diuretics"
"Chloral HydrateDiazepamEthionamideLovastatinMetoclopramide6-MercaptopurineNitroprussidePara-aminosalicylate sodiumPerphenazineResorcinol (excessive topical use)Thiazide Diuretics","C0077034|C0368663|C2825094|C0442802|C1522168|C0012802","[orch, phsu]|[orch, phsu]|[phsu]|[qlco]|[ftcn]|[orch, phsu]","trichloroacetaldehyde|aminosalicylate|Aminosalicylate [EPC]|Excessive|Topical Route of Drug Administration|Thiazide Diuretics"
"Cimetidine","C0008783","[orch, phsu]","Cimetidine"
"Cimetidine","C0008783","[orch, phsu]","Cimetidine"
"Cimetidine\","C0008783","[orch, phsu]","Cimetidine"
"ClofibrateEstrogen-containing oral contraceptivesEstrogens (oral)Heroin / Methadone5-FluorouracilMitotaneTamoxifen","C0332256|C2700400|C0442027|C0011892","[ftcn]|[acty]|[spco]|[hops, orch, phsu]","Containing (qualifier)|Contain (action)|Oral|Heroin"
"ClofibrateEstrogen-containing oral contraceptivesEstrogens (oral)Heroin / Methadone5-FluorouracilMitotaneTamoxifen","C0332256|C2700400|C0442027|C0011892","[ftcn]|[acty]|[spco]|[hops, orch, phsu]","Containing (qualifier)|Contain (action)|Oral|Heroin"
"Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin / Methadone 5-Fluorouracil Mitotane Tamoxifen","C0009002|C0014939|C0332256|C0009905|C3537250|C3541386|C3714615|C2700400|C2936882|C0442027|C0011892|C0025605|C0016360|C0026256|C0039286|C1552533","[orch, phsu]|[horm, orch, phsu]|[ftcn]|[phsu]|[horm, orch, phsu]|[horm, orch, phsu]|[phsu]|[acty]|[phsu]|[spco]|[hops, orch, phsu]|[orch, phsu]|[nnon, phsu]|[orch, phsu]|[orch, phsu]|[hcro, mnob]","Clofibrate|Estrogens|Containing (qualifier)|Contraceptives, Oral|ESTROGENS, SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM|Estrogens, endocrine therapy drugs|Estrogens Drug Class|Contain (action)|Estrogen [EPC]|Oral|Heroin|Methadone|Fluorouracil|Mitotane|Tamoxifen|Methadone Clinic/Center"
"ClofibrateEstrogen-containing oral contraceptivesEstrogens (oral)Heroin / Methadone5-FluorouracilMitotaneTamoxifen","C0332256|C2700400|C0442027|C0011892","[ftcn]|[acty]|[spco]|[hops, orch, phsu]","Containing (qualifier)|Contain (action)|Oral|Heroin"
"Clozapine","C0009079","[orch, phsu]","Clozapine"
"CYP1A2","C0207509|C1332826|C1620185","[aapp, enzy]|[gngm]|[aapp, enzy]","Cytochrome P-450 CYP1A2|CYP1A2 gene|CYP1A2 protein, human"
"CYP2C9","","",""
"Cytokines- Interferon-?- Interleukin-2","C0079189|C0021747|C0021756|C0879590|C1522405|C0733470|C3652465|C1524094","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft]|[gngm]|[aapp, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","cytokine|Interferons|Interleukin-2|IL2 gene|Recombinant Interleukin-2|human leukocyte interferon|Interferon|Recombinant Cytokines"
"Cytokines- Interferon-?- Interleukin-2","C0079189|C0021747|C0021756|C0879590|C1522405|C0733470|C3652465|C1524094","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft]|[gngm]|[aapp, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","cytokine|Interferons|Interleukin-2|IL2 gene|Recombinant Interleukin-2|human leukocyte interferon|Interferon|Recombinant Cytokines"
"Cytokines - Interferon-? ","C0079189|C0021747|C0733470|C3652465|C1524094","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","cytokine|Interferons|human leukocyte interferon|Interferon|Recombinant Cytokines"
"Cytokines - Interferon-? ","C0079189|C0021747|C0733470|C3652465|C1524094","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","cytokine|Interferons|human leukocyte interferon|Interferon|Recombinant Cytokines""- Interleukin-2","C0021756|C0879590|C1522405","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][aapp, imft]|[gngm]|[aapp, phsu]","cytokine|Interferons|human leukocyte interferon|Interferon|Recombinant CytokinesInterleukin-2|IL2 gene|Recombinant Interleukin-2"
"Cytokines- Interferon-?- Interleukin-2","C0079189|C0021747|C0021756|C0879590|C1522405|C0733470|C3652465|C1524094","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft]|[gngm]|[aapp, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","cytokine|Interferons|Interleukin-2|IL2 gene|Recombinant Interleukin-2|human leukocyte interferon|Interferon|Recombinant Cytokines"
"Delavirdine Etravirine Rilpivirine \","C0288165|C1456409|C1566826","[orch, phsu]|[orch, phsu]|[nnon, phsu]","Delavirdine|etravirine|Rilpivirine"
"didanosine","C0012133","[nnon, phsu]","Didanosine"
"DigoxinEnalapril Iron Metoprolol Warfarin","C0302583|C0025859|C0043031|C0376520|C1166521|C3714701","[bacs, elii, phsu]|[orch, phsu]|[hops, orch, phsu]|[inch]|[phsu]|[phsu]","Iron|Metoprolol|Warfarin|Dietary Iron|Ferrum metallicum, Homeopathic preparation|Iron Drug Class"
"DigoxinEnalaprilIronMetoprololWarfarin","","",""
"Dopamine / Dopamine AgonistsGlucocorticoidsOctreotide","C0013030","[bacs, orch, phsu]","Dopamine"
"Dopamine/Dopamine AgonistsGlucocorticoidsOctreotide","C0013030","[bacs, orch, phsu]","Dopamine"
"Dopamine/Dopamine AgonistsGlucocorticoidsOctreotide","C0013030","[bacs, orch, phsu]","Dopamine"
"Dopamine/Dopamine Agonists Glucocorticoids Octreotide","C0178601|C0017710|C0028833|C3540777|C3540778|C2757007","[phsu]|[horm, orch]|[aapp, horm, phsu]|[horm, orch, phsu]|[orch, phsu]|[moft]","Dopamine Agonists|Glucocorticoids|Octreotide|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Dopamine Agonists [MoA]"
"Dopamine/Dopamine AgonistsGlucocorticoidsOctreotide","C0013030","[bacs, orch, phsu]","Dopamine"
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.6, 5.1, 7, 12.3)","C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893","[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco]","Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5"
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis ( , , , )\2.6\5.1\7\12.3\","C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410","[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]","Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis"
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.6, 5.1, 7, 12.3)","C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893","[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco]","Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5"
"Duloxetine","C0245561","[orch, phsu]","duloxetine"
"Efavirenz* \","C0674428","[orch, phsu]","efavirenz"
"Efavirenz*DelavirdineEtravirineRilpivirine","C0674428","[orch, phsu]","efavirenz"
"Ergot alkaloids: Ergotamine\","C0014707|C3541393|C3541405|C3542459|C0014710","[bacs, orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]","Ergot Alkaloids|Ergot alkaloids, antimigraine|Ergot alkaloid peripheral vasodilators|Ergot alkaloid oxytocics|Ergotamine"
"Erythromycin","C0014806","[antb, orch]","Erythromycin"
"Erythromycin","C0014806","[antb, orch]","Erythromycin"
"Erythromycin","C0014806","[antb, orch]","Erythromycin"
"Erythromycin","C0014806","[antb, orch]","Erythromycin"
"Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel","C0014939|C0332256|C0009905|C2700400|C2936882|C3842588|C0439211|C0015011|C3463985|C0023566","[horm, orch, phsu]|[ftcn]|[phsu]|[acty]|[phsu]|[fndg]|[qnco]|[horm, orch, phsu]|[arch]|[horm, orch, phsu]","Estrogens|Containing (qualifier)|Contraceptives, Oral|Contain (action)|Estrogen [EPC]|30%|microgram|Ethinyl Estradiol|miscellaneous Crenarchaeota group|Levonorgestrel"
"Estrogen-containing oral contraceptivepreparation containing30 mcg ethinylestradioland 150 mcglevonorgestrel","C0014939|C0332256|C0442027|C0439211|C3463985|C2700400|C2936882","[horm, orch, phsu]|[ftcn]|[spco]|[qnco]|[arch]|[acty]|[phsu]","Estrogens|Containing (qualifier)|Oral|microgram|miscellaneous Crenarchaeota group|Contain (action)|Estrogen [EPC]"
"Estrogen-containing oralcontraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel","C0014939|C0332256|C2700400|C3842588|C0439211|C0015011|C3463985|C0023566","[horm, orch, phsu]|[ftcn]|[acty]|[fndg]|[qnco]|[horm, orch, phsu]|[arch]|[horm, orch, phsu]","Estrogens|Containing (qualifier)|Contain (action)|30%|microgram|Ethinyl Estradiol|miscellaneous Crenarchaeota group|Levonorgestrel"
"Fluoxetine","C0016365","[orch, phsu]","Fluoxetine"
"Fluoxetine","C0016365","[orch, phsu]","Fluoxetine"
"Fluoxetine","C0016365","[orch, phsu]","Fluoxetine"
"Fluoxetine","C0016365","[orch, phsu]","Fluoxetine"
"Fluoxetine","C0016365","[orch, phsu]","Fluoxetine"
"Fluoxetine\","C0016365","[orch, phsu]","Fluoxetine"
"Fosamprenavir* Fosamprenavir/Ritonavir* \","C1176315|C1979439","[orch, phsu]|[orch, phsu]","fosamprenavir|Fosamprenavir+Ritonavir"
"Fosamprenavir*\","C1176315","[orch, phsu]","fosamprenavir"
"Fosamprenavir/ Ritonavir*\","C1979439","[orch, phsu]","Fosamprenavir+Ritonavir"
"Furosemide ( > 80 mg IV)HeparinHydantoinsNon Steroidal Anti-lnflammatory Drugs- Fenamates- PhenylbutazoneSalicylates ( > 2 g/day)","C0016860|C3842583|C0026410|C0022326|C0439269|C1960952|C2346927|C0260264|C1955898|C3542931|C3843640|C0439267|C3843641|C0740116|C0439417|C2827735|C2981700|C3833492","[orch, phsu]|[fndg]|[geoa]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch]|[orch]|[orch, phsu]|[fndg]|[qnco]|[fndg]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Furosemide|80%|Mongolia|Ivory Coast|mg/dL|Milligram percent|Magnesium Cation|steroid drugs|Fenamates|Fenamates, antiinflammatory and antirheumatic drugs|> 2/day|Gram per Deciliter|2/day|+2|g/24h|2+ Score|2+ Score, WHO|2+"
"Furosemide ( > 80 mg IV)HeparinHydantoinsNon Steroidal Anti-lnflammatory Drugs- Fenamates- PhenylbutazoneSalicylates ( > 2 g/day)","C0016860|C3842583|C0026410|C0022326|C0439269|C1960952|C2346927|C0260264|C1955898|C3542931|C3843640|C0439267|C3843641|C0740116|C0439417|C2827735|C2981700|C3833492","[orch, phsu]|[fndg]|[geoa]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch]|[orch]|[orch, phsu]|[fndg]|[qnco]|[fndg]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Furosemide|80%|Mongolia|Ivory Coast|mg/dL|Milligram percent|Magnesium Cation|steroid drugs|Fenamates|Fenamates, antiinflammatory and antirheumatic drugs|> 2/day|Gram per Deciliter|2/day|+2|g/24h|2+ Score|2+ Score, WHO|2+"
"Furosemide ( > 80 mg IV) Heparin Hydantoins Non Steroidal Anti-lnflammatory Drugs - Fenamates - Phenylbutazone Salicylates ( > 2 g/day)","C0016860|C3842583|C0026410|C0022326|C0439269|C1960952|C2346927|C0019134|C0020209|C1518422|C0260264|C1955898|C0031463|C0036077|C3542931|C0770546|C3843640|C0439267|C3843641|C0740116|C0439417|C2827735|C2981700|C3833492","[orch, phsu]|[fndg]|[geoa]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[bacs, orch, phsu]|[orch, phsu]|[ftcn]|[orch]|[orch]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[bacs, orch, phsu]|[fndg]|[qnco]|[fndg]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Furosemide|80%|Mongolia|Ivory Coast|mg/dL|Milligram percent|Magnesium Cation|Heparin|Hydantoins|Negation|steroid drugs|Fenamates|Phenylbutazone|Salicylates|Fenamates, antiinflammatory and antirheumatic drugs|heparin, porcine|> 2/day|Gram per Deciliter|2/day|+2|g/24h|2+ Score|2+ Score, WHO|2+"
"Furosemide ( > 80 mg IV)HeparinHydantoinsNon Steroidal Anti-Inflammatory Drugs- Fenamates- PhenylbutazoneSalicylates ( > 2 g/day)","C0016860|C3842583|C0026410|C0022326|C0439269|C1960952|C2346927|C0003212|C1955898|C3542931|C3843640|C0439267|C3843641|C0740116|C0439417|C2827735|C2981700|C3833492","[orch, phsu]|[fndg]|[geoa]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch, phsu]|[orch]|[orch, phsu]|[fndg]|[qnco]|[fndg]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Furosemide|80%|Mongolia|Ivory Coast|mg/dL|Milligram percent|Magnesium Cation|steroidal anti-inflammatory drugs|Fenamates|Fenamates, antiinflammatory and antirheumatic drugs|> 2/day|Gram per Deciliter|2/day|+2|g/24h|2+ Score|2+ Score, WHO|2+"
"Furosemide ( > 80 mg IV)HeparinHydantoinsNon Steroidal Anti-lnflammatory Drugs- Fenamates- PhenylbutazoneSalicylates ( > 2 g/day)","C0016860|C3842583|C0026410|C0022326|C0439269|C1960952|C2346927|C0260264|C1955898|C3542931|C3843640|C0439267|C3843641|C0740116|C0439417|C2827735|C2981700|C3833492","[orch, phsu]|[fndg]|[geoa]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch]|[orch]|[orch, phsu]|[fndg]|[qnco]|[fndg]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Furosemide|80%|Mongolia|Ivory Coast|mg/dL|Milligram percent|Magnesium Cation|steroid drugs|Fenamates|Fenamates, antiinflammatory and antirheumatic drugs|> 2/day|Gram per Deciliter|2/day|+2|g/24h|2+ Score|2+ Score, WHO|2+"
"Grapefruitjuice","","",""
"Growth Hormones- Somatrem- Somatropin","C0037663|C0143083|C0169964|C0384570|C3714500","[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm]","Growth Hormone|somatrem|Somatropin|Recombinant Human Growth Hormone|Human Growth Hormone"
"Growth Hormones- Somatrem- Somatropin","C0037663|C0143083|C0169964|C0384570|C3714500","[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm]","Growth Hormone|somatrem|Somatropin|Recombinant Human Growth Hormone|Human Growth Hormone"
"Growth Hormones - Somatrem - Somatropin","C0037663|C0143083|C0169964|C0384570|C3714500","[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm]","Growth Hormone|somatrem|Somatropin|Recombinant Human Growth Hormone|Human Growth Hormone"
"Growth Hormones- Somatrem- Somatropin","C0037663|C0143083|C0169964|C0384570|C3714500","[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm]","Growth Hormone|somatrem|Somatropin|Recombinant Human Growth Hormone|Human Growth Hormone"
"Heparin","C0019134|C0770546","[bacs, orch, phsu]|[bacs, orch, phsu]","Heparin|heparin, porcine"
"I. ","C0021966|C0221138","[inch]|[aapp, imft]","Iodides|Blood group antibody I"
"I. ","C0021966|C0221138","[inch]|[aapp, imft]","Iodides|Blood group antibody I""Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:\","C0679932|C0036075|C0036077|C0013227|C3687832|C1145667|C1167622|C0036773|C0728877|C0231290|C0687133|C0332282|C1709305|C2745955","[inch]|[aapp, imft][socb]|[orch, phsu]|[orch, phsu]|[phsu]|[topp]|[acty]|[moft]|[aapp]|[lbtr]|[tmco]|[moft]|[tmco]|[acty]|[tmco]","Iodides|Blood group antibody Icompetition|salicylate|Salicylates|Pharmaceutical Preparations|Drugs|Binding action|Binding (Molecular Function)|Serum Albumin|Serum albumin level|Status post|Drug Interactions|Following|Occur (action)|Occurrence"
"Immunosuppressants: Cyclosporine, tacrolimus, sirolimus\","C0021081|C0010592|C0010594|C0085149|C0072980","[imft, phsu]|[aapp, phsu]|[imft, phsu]|[orch, phsu]|[antb, orch]","Immunosuppressive Agents|Cyclosporine|Cyclosporins|Tacrolimus|Sirolimus"
"Increased Risk of Myopathy/Rhabdomyolysis (2, 5.1, 7, 12.3)","C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893","[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco]","Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5"
"Indinavir* \","C0376637","[orch, phsu]","Indinavir"
"Indinavir* \","C0376637","[orch, phsu]","Indinavir"
"Itraconazole\","C0064113","[orch, phsu]","Itraconazole"
"Ketamine","C0022614","[orch, phsu]","Ketamine"
"Ketoconazole*\","C0022625","[orch, phsu]","Ketoconazole"
"Lomitapide","C2827241","[orch, phsu]","lomitapide"
"Lopinavir/ritonavir","C0939237","[orch, phsu]","lopinavir / Ritonavir"
"Lopinavir/Ritonavir*\","C0939237","[orch, phsu]","lopinavir / Ritonavir"
"Lopinavir/Ritonavir* \","C0939237","[orch, phsu]","lopinavir / Ritonavir"
"Methylxanthine Bronchodilators- (e.g., Theophylline)","C0066447|C0006280|C3536939|C0039771","[orch, phsu]|[phsu]|[phsu]|[bacs, orch, phsu]","methylxanthine|Bronchodilator Agents|Methylxanthine [EPC]|Theophylline"
"Methylxanthine Bronchodilators- (e.g., Theophylline)","C0066447|C0006280|C3536939|C0039771","[orch, phsu]|[phsu]|[phsu]|[bacs, orch, phsu]","methylxanthine|Bronchodilator Agents|Methylxanthine [EPC]|Theophylline"
"Methylxanthine Bronchodilators - (e.g., Theophylline)","C0066447|C0006280|C3536939|C0039771","[orch, phsu]|[phsu]|[phsu]|[bacs, orch, phsu]","methylxanthine|Bronchodilator Agents|Methylxanthine [EPC]|Theophylline"
"Methylxanthine Bronchodilators- (e.g., Theophylline)","C0066447|C0006280|C3536939|C0039771","[orch, phsu]|[phsu]|[phsu]|[bacs, orch, phsu]","methylxanthine|Bronchodilator Agents|Methylxanthine [EPC]|Theophylline"
"Motility agents: Cisapride\","C0007608|C0450442|C1254351|C1521826|C0678835|C1510470|C0072916","[orgf]|[chvf]|[phsu]|[inpr]|[lbtr]|[orgf]|[orch, phsu]","cell motility|Agent|Pharmacologic Substance|Protocol Agent|Motility result|Motility|Cisapride"
"nafcillin","C0027324","[antb, orch]","Nafcillin"
"Nelfinavir*\","C0525005","[orch, phsu]","Nelfinavir"
"Nelfinavir* \","C0525005","[orch, phsu]","Nelfinavir"
"Opiate agonists: Fentanyl\","C0242402|C0015846","[hops, orch, phsu]|[orch, phsu]","Opioids|Fentanyl"
"Oral contraceptives: Ethinyl estradiol and Norethindrone*\","C0009905|C0015011|C0028356","[phsu]|[horm, orch, phsu]|[horm, orch, phsu]","Contraceptives, Oral|Ethinyl Estradiol|Norethindrone"
"Paroxetine","C0070122","[orch, phsu]","Paroxetine"
"Paroxetine","C0070122","[orch, phsu]","Paroxetine"
"Paroxetine","C0070122","[orch, phsu]","Paroxetine"
"Paroxetine","C0070122","[orch, phsu]","Paroxetine"
"Paroxetine","C0070122","[orch, phsu]","Paroxetine"
"Paroxetine\","C0070122","[orch, phsu]","Paroxetine"
"Phenobarbital\","C0031412","[orch, phsu]","Phenobarbital"
"Phenobarbital","C0031412","[orch, phsu]","Phenobarbital"
"Phenytoin \","C0031507","[orch, phsu]","Phenytoin"
"Phenytoin","C0031507","[orch, phsu]","Phenytoin"
"Probenecid","C0033209","[orch, phsu]","Probenecid"
"Probenecid","C0033209","[orch, phsu]","Probenecid"
"Probenecid \","C0033209","[orch, phsu]","Probenecid"
"Protease inhibitor:atazanavir","C0033607|C3536890|C1145759","[bacs, phsu]|[phsu]|[orch, phsu]","Protease Inhibitors|Protease Inhibitor [EPC]|Atazanavir"
"Ranitidine","C0034665","[orch, phsu]","Ranitidine"
"Ranitidine","C0034665","[orch, phsu]","Ranitidine"
"Ranitidine\","C0034665","[orch, phsu]","Ranitidine"
"Rifabutin*\","C0140575","[antb, orch]","Rifabutin"
"Rifampin*\","C0035608","[antb, orch]","Rifampin"
"Ropinirole","C0244821","[orch, phsu]","ropinirole"
"Saquinavir/ritonavir\","C1977397","[antb, orch]","Saquinavir+Ritonavir"
"Saquinavir/Ritonavir \","C1977397","[antb, orch]","Saquinavir+Ritonavir"
"Sildenafil","C0529793","[orch, phsu]","sildenafil"
"Telaprevir\","C1876229","[aapp, phsu]","telaprevir"
"Theophylline","C0039771","[bacs, orch, phsu]","Theophylline"
"Tizanidine","C0146011","[orch, phsu]","tizanidine"
"Tolbutamide; ","C0040374","[orch, phsu]","Tolbutamide"
"Tolbutamide; ","C0040374","[orch, phsu]","Tolbutamide""Sulfonylureas","C0038766|C3653359","[orch, phsu][orch, phsu]|[phsu]","TolbutamideSulfonylurea Compounds|Sulfonylureas for blood glucose lowering"
"Valproic acid \","C0042291","[orch, phsu]","Valproic Acid"
"Verapamil,diltiazem,dronedarone","C0042523|C0012373|C0766326","[orch, phsu]|[orch, phsu]|[orch, phsu]","Verapamil|Diltiazem|dronedarone"
"Ibuprofen and anticoagulants such as warfarin have a synergistic effect on bleeding.","C0020740|C0003280|C0043031|C2986495|C1280500|C2348382|C0019080","[orch, phsu]|[phsu]|[hops, orch, phsu]|[qlco]|[qlco]|[qlco]|[patf]","Ibuprofen|Anticoagulants|Warfarin|Synergistic|Effect|Effect, Appearance|Hemorrhage"
"The concomitant use of ibuprofen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.","C0521115|C0042153|C0457083|C1947944|C0020740|C0003280|C0205217|C0035647|C0442805|C0205404|C0019080|C1707455|C3844638|C0013227|C1254351|C0205171|C0439044|C0679994","[tmco]|[ftcn]|[ftcn]|[inpr]|[orch, phsu]|[phsu]|[qnco]|[idcn]|[ftcn]|[qlco]|[patf]|[acty]|[fndg]|[phsu]|[phsu]|[qnco]|[fndg]|[grpa]","Simultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Ibuprofen|Anticoagulants|Increased|Risk|Increase|Serious|Hemorrhage|Comparison|Either|Pharmaceutical Preparations|Pharmacologic Substance|Singular|Living Alone|alone - group size"
"Serotonin release by platelets plays an important role in hemostasis.","C1979804|C0005821|C1963076|C0032214|C0600138|C3898777|C0035820|C1705810|C0019116|C0740166","[celf]|[cell]|[fndg]|[dora]|[fndg]|[qlco]|[socb]|[cnce]|[ortf]|[topp]","serotonin release|Blood Platelets|Platelets Adverse Event|Play|Does play|Important|Social Role|Generic Role|Hemostatic function|Hemostasis procedure"
"Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.","C0872128|C0009247|C0014507|C0599755|C0002783|C1547282|C0521115|C0042153|C0457083|C1947944|C0013227|C3687832|C0521102|C0036751|C0599702|C0003211|C3536840|C0035647|C0019080|C0205171|C0439044|C0679994","[hlca]|[qnco]|[bmod]|[popg]|[resa]|[anim]|[tmco]|[ftcn]|[ftcn]|[inpr]|[phsu]|[topp]|[ftcn]|[bacs, orch]|[celf]|[phsu]|[phsu]|[idcn]|[patf]|[qnco]|[fndg]|[grpa]","case control|Cohort Studies|Epidemiology|cohort|Epidemiologic Studies|Show|Simultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Pharmaceutical Preparations|Drugs|Interferes with|Serotonin|reuptake|Anti-Inflammatory Agents, Non-Steroidal|Nonsteroidal Anti-inflammatory Drug [EPC]|Risk|Hemorrhage|Singular|Living Alone|alone - group size"
"Refrigerated(4C)","C2347927|C0450376","[qlco]|[inpr]","Refrigerated Specimen|4c serotype"
"Storage","C0337174|C1698986|C1753314","[spco]|[ftcn]|[celc]","Storage area|Storage|cellular entity storage"
"Table 3 Established and Potential Drug Interactions: Use With Caution, Alteration in Dose or Regimen May Be Needed Due to Drug Interaction Established Drug Interactions: See Clinical Pharmacology (12.3), Table 4 for Magnitude of Interaction.","C0039224|C1706073|C1706074|C0443211|C1272684|C3840750|C0042153|C0457083|C1947944|C1515926|C0178602|C0869039|C1114758|C0040808|C3812381|C2945654|C0027552|C0686904|C0678798|C0687133|C0042789|C1947903|C0031332|C1555729|C0449286|C1704240|C1704675","[mnob]|[mnob]|[inpr]|[qlco]|[qlco]|[fndg]|[ftcn]|[ftcn]|[inpr]|[idcn]|[qnco]|[qnco]|[clna]|[topp]|[tmco]|[inpr]|[qlco]|[ftcn]|[fndg]|[moft]|[orgf]|[acty]|[bmod]|[prog]|[qnco]|[qnco]|[ftcn]","Table - furniture|Table Device Component|Data Table|Established|Accepted|Potential adverse drug interaction|utilization qualifier|Usage|Use - dosing instruction imperative|Alteration|Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Treatment Protocols|Month of May|Regimen - CHV concept|Needs|Patient need for (contextual qualifier)|Adverse drug interaction|Drug Interactions|Vision|See|Clinical pharmacology discipline|Allopathic & Osteopathic Physicians - Clinical Pharmacology|Degree or extent|Magnitude|Interaction"
"Table 1	Oral drugs that can be administered concomitantly with Velphoro","C0039224|C0029167|C0175795|C0304289|C1706073|C1706074|C1521801|C3696395","[mnob]|[bmod]|[topp]|[phsu]|[mnob]|[inpr]|[ftcn]|[phsu]","Table - furniture|Oral Medicine|oral medication|Oral drug preparation|Table Device Component|Data Table|Having administered|Velphoro"
"Table II. ","C0039224|C1706073|C1706074","[mnob]|[mnob]|[inpr]","Table - furniture|Table Device Component|Data Table"
"Table II. ","C0039224|C1706073|C1706074","[mnob]|[mnob]|[inpr]","Table - furniture|Table Device Component|Data Table""Clinically Significant Drug Interactions With Theophylline*","C0237881|C0687133|C0750502|C1546944|C0039771","[mnob]|[mnob]|[inpr][qnco]|[moft]|[idcn]|[qlco]|[bacs, orch, phsu]","Table - furniture|Table Device Component|Data TableStatistical Significance|Drug Interactions|Significant|Event Seriousness - Significant|Theophylline"
"Table III. ","C0039224|C0439070|C1705160|C1706073|C1706074","[mnob]|[inpr]|[qlco]|[mnob]|[inpr]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data Table"
"Table III. ","C0039224|C0439070|C1705160|C1706073|C1706074","[mnob]|[inpr]|[qlco]|[mnob]|[inpr]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data Table""Drugs That Have Been Documented Not to Interact With Theophylline or Drugs That Produce No Clinically Significant Interaction With Theophylline*","C0013227|C3687832|C1301725|C1609436|C1518422|C0040363|C0041260|C1883351|C0039771|C0237881|C1704675|C0750502|C1546944","[mnob]|[inpr]|[qlco]|[mnob]|[inpr][phsu]|[topp]|[hlca]|[inpr]|[ftcn]|[geoa]|[aapp, enzy]|[qlco]|[bacs, orch, phsu]|[qnco]|[ftcn]|[idcn]|[qlco]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data TablePharmaceutical Preparations|Drugs|Documented|Document completion status - Documented|Negation|Togo|Tryptophanase|To|Theophylline|Statistical Significance|Interaction|Significant|Event Seriousness - Significant"
"% Change of CoadministeredDrug Pharmacokinetic Parameters\The 90% confidence intervals for the percent change in the pharmacokinetic parameter are displayed.\All studies conducted in healthy volunteers at least 60 kg with creatinine clearance of at least 60 mL/min.","C0392747|C0443172|C1705241|C1705911|C0439083|C0009667|C0439087|C3842582|C0439165|C0201734|C0549193|C1704769|C2350001|C0870432|C0947630|C0004927|C1708335|C0439092|C3842585|C0022718|C0439209|C0547044|C0812399|C0439445","[ftcn]|[qnco]|[qnco]|[idcn]|[qnco]|[qnco]|[qnco]|[fndg]|[qnco]|[resa]|[spco]|[cnce]|[qnco]|[ftcn]|[lbpr]|[inbe]|[popg]|[qnco]|[fndg]|[geoa]|[qnco]|[qlco]|[fndg]|[qnco]","Changing|Changed status|Delta (difference)|Pharmacokinetic Parameters Domain|>90|Confidence Intervals|<90|90%|Percent (qualifier value)|Pharmacokinetic study|Parameter Value|Programming Parameter|Population Parameter|Display - arrangement|Scientific Study|Behavior|Healthy Volunteers|Less Than|60%|Kyrgyzstan|Kilogram|Smaller|Creatinine clearance|mL/min"
"% Change of Coadministered DrugPharmacokinetic Parameters\The 95% confidence intervals for the percent change in the pharmacokinetic parameter are displayed.","C0392747|C0443172|C1705241|C0449381|C0009667|C0439165|C0201734|C0549193|C1704769|C2350001|C0870432","[ftcn]|[qnco]|[qnco]|[fndg]|[qnco]|[qnco]|[resa]|[spco]|[cnce]|[qnco]|[ftcn]","Changing|Changed status|Delta (difference)|Observation parameter|Confidence Intervals|Percent (qualifier value)|Pharmacokinetic study|Parameter Value|Programming Parameter|Population Parameter|Display - arrangement"
"% Change of Didanosine Pharmacokeinetic Parameters\The 95% confidence intervals for the percent change in the pharmacokinetic parameter are displayed.","C0392747|C0443172|C1705241|C0012133|C0449381|C0009667|C0439165|C0201734|C0549193|C1704769|C2350001|C0870432","[ftcn]|[qnco]|[qnco]|[nnon, phsu]|[fndg]|[qnco]|[qnco]|[resa]|[spco]|[cnce]|[qnco]|[ftcn]","Changing|Changed status|Delta (difference)|Didanosine|Observation parameter|Confidence Intervals|Percent (qualifier value)|Pharmacokinetic study|Parameter Value|Programming Parameter|Population Parameter|Display - arrangement"
"% Change of Didanosine Pharmacokinetic Parameters\The 90% confidence intervals for the percent change in the pharmacokinetic parameter are displayed.","C0392747|C0443172|C1705241|C0012133|C1705911|C0439083|C0009667|C0439087|C3842582|C0439165|C0201734|C0549193|C1704769|C2350001|C0870432","[ftcn]|[qnco]|[qnco]|[nnon, phsu]|[idcn]|[qnco]|[qnco]|[qnco]|[fndg]|[qnco]|[resa]|[spco]|[cnce]|[qnco]|[ftcn]","Changing|Changed status|Delta (difference)|Didanosine|Pharmacokinetic Parameters Domain|>90|Confidence Intervals|<90|90%|Percent (qualifier value)|Pharmacokinetic study|Parameter Value|Programming Parameter|Population Parameter|Display - arrangement"
"12 to 18 years(n=6)","C0439234|C0369718|C0441922","[tmco]|[aapp, imft]|[inpr]","year|N not otherwise specified Antibody|N+ (tumor staging)"
"2 to <6\years(n=12)","C0740116|C2827735|C2981700|C3833492|C0439234|C0369718|C0441922","[qnco]|[qnco]|[clas]|[fndg]|[tmco]|[aapp, imft]|[inpr]","+2|2+ Score|2+ Score, WHO|2+|year|N not otherwise specified Antibody|N+ (tumor staging)"
"6 to <12\years(n=8)","C0439234|C0369718|C0441922","[tmco]|[aapp, imft]|[inpr]","year|N not otherwise specified Antibody|N+ (tumor staging)"
"Atazanavir 300 mg/100 mg?28 (?40 to ?14)","C1812845|C3817553|C0439509|C3842587","[clnd]|[qnco]|[tmco]|[qnco]","Atazanavir 300 MG|100%|/40|40%"
"Atazanavir 300 mg/100 mg?42 (?52 to ?29)","C1812845|C3817553|C3843708","[clnd]|[qnco]|[fndg]","Atazanavir 300 MG|100%|29+"
"Atazanavir 300 mg/100 mg?72 (?80 to ?60)","C1812845|C3817553|C3842583|C3842585","[clnd]|[qnco]|[fndg]|[fndg]","Atazanavir 300 MG|100%|80%|60%"
"Atazanavir 300 mg/100 mg?28 (?40 to ?14)","C1812845|C3817553|C0439509|C3842587","[clnd]|[qnco]|[tmco]|[qnco]","Atazanavir 300 MG|100%|/40|40%"
"Atazanavir 300 mg/100 mg?42 (?52 to ?29)","C1812845|C3817553|C3843708","[clnd]|[qnco]|[fndg]","Atazanavir 300 MG|100%|29+"
"Atazanavir 300 mg/100 mg?72 (?80 to ?60)","C1812845|C3817553|C3842583|C3842585","[clnd]|[qnco]|[fndg]|[fndg]","Atazanavir 300 MG|100%|80%|60%"
"200 mg BID day 1 to 23. ","C0439422|C0450348","[qnco]|[qnco]","milligram/day|23"
"200 mg BID day 1 to 23. ","C0439422|C0450348","[qnco]|[qnco]","milligram/day|23""Subjects were treated with nevirapine prior to trial entry.","C0681850|C1550501|C1706203|C2349001|C2697811|C1522326|C0132326|C0008976|C1705654","[qnco]|[qnco][grup]|[idcn]|[idcn]|[humn]|[ftcn]|[ftcn]|[orch, phsu]|[resa]|[inpr]","milligram/day|23Study Subject|Subject -direct target|Subject - topic|Human Study Subject|Investigative Subject|Treating|Nevirapine|Clinical Trials|Entry (data)"
"23","C0450348","[qnco]","23"
"300 mg/100 mg QD day 4 to 13, then 400 mg/100 mg QD, day 14 to 23","C1319635|C3817553|C0309985|C0332173|C0439228|C0439505|C3840892|C1883708|C0450348","[qnco]|[qnco]|[phsu]|[tmco]|[tmco]|[tmco]|[fndg]|[tmco]|[qnco]","mg/mg|100%|QD-4|Daily|day|per day|Day 4|Then|23"
"-","","",""
"3-Hydroxydesloratadine","C1436173","[orch]","3-hydroxydesloratadine"
"Anti-Inflammatory Drugs\azapropazoncolchicinediclofenacnaproxensulindac","C0003209","[phsu]","Anti-Inflammatory Agents"
"Antineoplastic\melphalan\Antifungals\amphotericin Bketoconazole","C0003392|C0025241|C0003308|C0002679|C0085795","[orch, phsu]|[aapp, phsu]|[phsu]|[antb, orch]|[antb, orch]","Antineoplastic Agents|Melphalan|Antifungal Agents|Amphotericin B|Amphotericin"
"Avoidgrapefruitjuice","","",""
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. ","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism"
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. ","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism""Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. ","C0006681|C0348078|C0376315|C1522492|C0040165|C1881373|C0060282|C0332148|C0750492|C2346593|C0439855|C1704241","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)"
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. ","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism""Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. ","C0006681|C0348078|C0376315|C1522492|C0040165|C1881373|C0060282|C0332148|C0750492|C2346593|C0439855|C1704241","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)""Administer levothyroxine at least 4 hours apart from these agents. ","C1621583|C0040165|C1881373|C0439092|C0439227|C0547044|C0450442|C1254351|C1521826","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs][ftcn]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[tmco]|[qlco]|[chvf]|[phsu]|[inpr]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)Administer|Thyroxine|Synthetic Levothyroxine|Less Than|Hour|Smaller|Agent|Pharmacologic Substance|Protocol Agent"
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. ","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism""Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. ","C0006681|C0348078|C0376315|C1522492|C0040165|C1881373|C0060282|C0332148|C0750492|C2346593|C0439855|C1704241","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)""Administer levothyroxine at least 4 hours apart from these agents. ","C1621583|C0040165|C1881373|C0439092|C0439227|C0547044|C0450442|C1254351|C1521826","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs][ftcn]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[tmco]|[qlco]|[chvf]|[phsu]|[inpr]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)Administer|Thyroxine|Synthetic Levothyroxine|Less Than|Hour|Smaller|Agent|Pharmacologic Substance|Protocol Agent""Patients treated concomitantly with orlistat and levothyroxine should be monitored for changes in thyroid function.","C0030705|C1522326|C0076275|C0040165|C1881373|C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0392747|C0443172|C2242456","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs][ftcn]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[tmco]|[qlco]|[chvf]|[phsu]|[inpr][podg]|[ftcn]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[ftcn]|[qnco]|[phsf]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)Administer|Thyroxine|Synthetic Levothyroxine|Less Than|Hour|Smaller|Agent|Pharmacologic Substance|Protocol AgentPatients|Treating|orlistat|Thyroxine|Synthetic Levothyroxine|Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Changing|Changed status|thyroid function"
"Contraindicatedwithsimvastatin","","",""
"Desloratadine","C0908935","[orch, phsu]","desloratadine"
"Donotexceed10mgsimvastatindaily","","",""
"Donotexceed20mgsimvastatindaily","","",""
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.6, 5.1, 7, 12.3)","C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893","[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco]","Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5"
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.2, 4, 5.2, 7.1, 7.2, 7.3, 7.4, 12.3)","C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893","[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco]","Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5"
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.6, 5.1, 7, 12.3)","C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893","[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco]","Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5"
"Effect\Average effect on steady-state theophylline\concentration or other clinical effect for\pharmacologic interactions. ","C1280500|C1510992|C2825518|C2348382|C0678587|C0039771|C0004268|C0086045|C1446561|C0205210|C0237412|C0497591|C1553058|C0031330|C1704675|C0205464","[qlco]|[qnco]|[qnco]|[qlco]|[npop]|[bacs, orch, phsu]|[menp]|[menp]|[qnco]|[qlco]|[prog]|[prog]|[prog]|[bmod]|[ftcn]|[ftcn]","Effect|Average|Average of Value Derivation Technique|Effect, Appearance|steady state|Theophylline|Attention|Mental concentration|Concentration measurement|Clinical|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Pharmacology|Interaction|pharmacological"
"Effect\Average effect on steady-state theophylline\concentration or other clinical effect for\pharmacologic interactions. ","C1280500|C1510992|C2825518|C2348382|C0678587|C0039771|C0004268|C0086045|C1446561|C0205210|C0237412|C0497591|C1553058|C0031330|C1704675|C0205464","[qlco]|[qnco]|[qnco]|[qlco]|[npop]|[bacs, orch, phsu]|[menp]|[menp]|[qnco]|[qlco]|[prog]|[prog]|[prog]|[bmod]|[ftcn]|[ftcn]","Effect|Average|Average of Value Derivation Technique|Effect, Appearance|steady state|Theophylline|Attention|Mental concentration|Concentration measurement|Clinical|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Pharmacology|Interaction|pharmacological""Individual patients\may experience larger changes in serum\theophylline concentration than the value\listed.","C0027361|C0030705|C0237401|C0237607|C0596545|C0549177|C0392747|C0443172|C1704243|C0683149|C0039771|C1522609|C0745732|C3272378","[qlco]|[qnco]|[qnco]|[qlco]|[npop]|[bacs, orch, phsu]|[menp]|[menp]|[qnco]|[qlco]|[prog]|[prog]|[prog]|[bmod]|[ftcn]|[ftcn][popg]|[podg]|[humn]|[menp]|[menp]|[qnco]|[ftcn]|[qnco]|[qnco]|[qnco]|[bacs, orch, phsu]|[qnco]|[cnce]|[inpr]","Effect|Average|Average of Value Derivation Technique|Effect, Appearance|steady state|Theophylline|Attention|Mental concentration|Concentration measurement|Clinical|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Pharmacology|Interaction|pharmacologicalPersons|Patients|Individual|Practice Experience|Experience|Large|Changing|Changed status|Greater|serum concentration|Theophylline|Numerical value|List|Sequence Data Type"
"For patients with HoFH, do not exceed 20 mg simvastatin daily*","C0030705|C1518422|C3842589|C0026410|C0074554|C0332173|C0439269|C1960952|C2346927","[podg]|[ftcn]|[fndg]|[geoa]|[orch, phsu]|[tmco]|[qnco]|[qnco]|[elii, phsu]","Patients|Negation|20%|Mongolia|Simvastatin|Daily|mg/dL|Milligram percent|Magnesium Cation"
"Gastrointestinal Agents\cimetidineranitidine\Immunosuppressives\tacrolimus\Other Drugs\fibric acid derivatives(e.g., bezafibrate, fenofibrate)","C0017173|C0021081|C0085149|C0013227|C2936462|C3687832|C0005330|C0033228","[phsu]|[imft, phsu]|[orch, phsu]|[phsu]|[orch]|[topp]|[orch, phsu]|[orch, phsu]","Gastrointestinal Agents|Immunosuppressive Agents|Tacrolimus|Pharmaceutical Preparations|Fibric Acids|Drugs|Bezafibrate|Fenofibrate"
"Iodide and drugs that contain pharmacologic amounts of iodide may cause hyperthyroidism in euthyroid patients with Grave's disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular goiter or hyper functioning thyroid adenoma). ","C0021966|C0013227|C3687832|C0332256|C2700400|C0031330|C1265611|C0205464|C0015127|C1524003|C0020550|C0117002|C0030705|C0018213|C1522326|C0040125|C0040132|C0085862|C3540038|C0342208|C0424295|C0205245|C0151468|C0542341","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|Function"
"Iodide and drugs that contain pharmacologic amounts of iodide may cause hyperthyroidism in euthyroid patients with Grave's disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular goiter or hyper functioning thyroid adenoma). ","C0021966|C0013227|C3687832|C0332256|C2700400|C0031330|C1265611|C0205464|C0015127|C1524003|C0020550|C0117002|C0030705|C0018213|C1522326|C0040125|C0040132|C0085862|C3540038|C0342208|C0424295|C0205245|C0151468|C0542341","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|Function""Hyperthyroidism may develop over several weeks and may persist for several months after therapy discontinuation. ","C0020550|C0205136|C0439230|C0347984|C0439064|C0439231|C0443302|C0039798|C0457454|C1444662|C0087111|C1363945","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn][dsyn]|[spco]|[tmco]|[tmco]|[qnco]|[tmco]|[qnco]|[ftcn]|[hlca]|[fndg]|[topp]|[fndg]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|FunctionHyperthyroidism|Over (spatial)|week|During|Numerous|month|Several|therapeutic aspects|Discontinuation (procedure)|Discontinued|Therapeutic procedure|Therapy Object (animal model)"
"Iodide and drugs that contain pharmacologic amounts of iodide may cause hyperthyroidism in euthyroid patients with Grave's disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular goiter or hyper functioning thyroid adenoma). ","C0021966|C0013227|C3687832|C0332256|C2700400|C0031330|C1265611|C0205464|C0015127|C1524003|C0020550|C0117002|C0030705|C0018213|C1522326|C0040125|C0040132|C0085862|C3540038|C0342208|C0424295|C0205245|C0151468|C0542341","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|Function""Hyperthyroidism may develop over several weeks and may persist for several months after therapy discontinuation. ","C0020550|C0205136|C0439230|C0347984|C0439064|C0439231|C0443302|C0039798|C0457454|C1444662|C0087111|C1363945","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn][dsyn]|[spco]|[tmco]|[tmco]|[qnco]|[tmco]|[qnco]|[ftcn]|[hlca]|[fndg]|[topp]|[fndg]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|FunctionHyperthyroidism|Over (spatial)|week|During|Numerous|month|Several|therapeutic aspects|Discontinuation (procedure)|Discontinued|Therapeutic procedure|Therapy Object (animal model)""Amiodarone may induce hyperthyroidism by causing thyroiditis.","C0002598|C0205263|C0020550|C0678227|C0040147","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn][dsyn]|[spco]|[tmco]|[tmco]|[qnco]|[tmco]|[qnco]|[ftcn]|[hlca]|[fndg]|[topp]|[fndg][orch, phsu]|[ftcn]|[dsyn]|[ftcn]|[dsyn]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|FunctionHyperthyroidism|Over (spatial)|week|During|Numerous|month|Several|therapeutic aspects|Discontinuation (procedure)|Discontinued|Therapeutic procedure|Therapy Object (animal model)Amiodarone|Induce (action)|Hyperthyroidism|Causing|Thyroiditis"
"lomefloxacin\mebendazole\medroxyprogesterone\methylprednisolone\metronidazole\metoprolol\nadolol\nifedipine\nizatidine\norfloxacin\ofloxacin\omeprazole\prednisone, prednisolone\ranitidine\rifabutin\roxithromycin\sorbitol\(purgative doses do not inhibit\theophylline absorption)\sucralfate\terbutaline, systemic\terfenadine\tetracycline\tocainide","C0065162|C0025023|C0025147|C0025815|C0025872|C2929367|C0027302|C0085154|C0028365|C0028902|C0028978|C0032952|C0032950|C0034665|C0140575|C0035891|C0037688|C0007422|C0178602|C1518422|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C0039771|C0000854|C2347023|C2347080|C2698776|C2825050|C0038633|C0039542|C0205373|C0085173|C0039644|C0085237|C1744619","[orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[horm, orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[antb, orch]|[orch, phsu]|[horm, orch, phsu]|[orch, phsu]|[orch, phsu]|[antb, orch]|[antb, orch]|[orch, phsu]|[phsu]|[qnco]|[ftcn]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[bacs, orch, phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[orch, phsu]|[orch, phsu]|[ftcn]|[orch, phsu]|[antb, orch]|[orch, phsu]|[antb, orch]","lomefloxacin|Mebendazole|Medroxyprogesterone|Methylprednisolone|Metronidazole|Metoprolol / Nifedipine|Nadolol|Nizatidine|Norfloxacin|Ofloxacin|Omeprazole|Prednisone|prednisolone|Ranitidine|Rifabutin|Roxithromycin|Sorbitol|Cathartics|Dosage|Negation|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Theophylline|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Sucralfate|Terbutaline|Systemic|Terfenadine|Tetracycline|Tocainide|Tetracycline Antibiotics"
"lomefloxacin\mebendazole\medroxyprogesterone\methylprednisolone\metronidazole\metoprolol\nadolol\nifedipine\nizatidine\norfloxacin\ofloxacin\omeprazole\prednisone, prednisolone\ranitidine\rifabutin\roxithromycin\sorbitol\ (purgative doses do not inhibit\ theophylline absorption)\sucralfate\terbutaline, systemic\terfenadine\tetracycline\tocainide","C0065162|C0025023|C0025147|C0025815|C0025872|C2929367|C0027302|C0085154|C0028365|C0028902|C0028978|C0032952|C0032950|C0034665|C0140575|C0035891|C0037688|C0007422|C0178602|C1518422|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C0039771|C0000854|C2347023|C2347080|C2698776|C2825050|C0038633|C0039542|C0205373|C0085173|C0039644|C0085237|C1744619","[orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[horm, orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[antb, orch]|[orch, phsu]|[horm, orch, phsu]|[orch, phsu]|[orch, phsu]|[antb, orch]|[antb, orch]|[orch, phsu]|[phsu]|[qnco]|[ftcn]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[bacs, orch, phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[orch, phsu]|[orch, phsu]|[ftcn]|[orch, phsu]|[antb, orch]|[orch, phsu]|[antb, orch]","lomefloxacin|Mebendazole|Medroxyprogesterone|Methylprednisolone|Metronidazole|Metoprolol / Nifedipine|Nadolol|Nizatidine|Norfloxacin|Ofloxacin|Omeprazole|Prednisone|prednisolone|Ranitidine|Rifabutin|Roxithromycin|Sorbitol|Cathartics|Dosage|Negation|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Theophylline|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Sucralfate|Terbutaline|Systemic|Terfenadine|Tetracycline|Tocainide|Tetracycline Antibiotics"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents. ","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents. ","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media""Long-term amino-glu-tethimide therapy may minimally decrease T4 and T3 levels and increase TSH, although all values remain within normal limits in most patients.","C0443252|C0061472|C0039798|C0087111|C1363945|C0220839|C0392756|C0547047|C0446421|C0442805|C0042295|C0442816|C0030705","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda][tmco]|[aapp, bacs, phsu]|[ftcn]|[topp]|[fndg]|[aapp, bacs]|[qlco]|[qnco]|[blor]|[ftcn]|[qlco]|[qnco]|[podg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast mediaLong-term|Glutamic Acid|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Glutamate|Reduced|Decrease|Level of the third thoracic vertebra|Increase|Values|Normal limits|Patients"
"Risperidone","C0073393","[orch, phsu]","Risperidone"
"Table 2: Drug  Thyroidal Axis Interactions","C0039224|C1706073|C1706074|C0687133|C0040132|C0004457|C0999597|C1522496|C3540038","[mnob]|[mnob]|[inpr]|[moft]|[bpoc]|[bpoc]|[mamm]|[spco]|[irda]","Table - furniture|Table Device Component|Data Table|Drug Interactions|Thyroid Gland|Axis vertebra|Genus Axis|Axis|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS"
"Table 2: Drug-Thyroidal Axis Interactions","C0039224|C1706073|C1706074|C0687133|C0040132|C0004457|C0999597|C1522496|C3540038","[mnob]|[mnob]|[inpr]|[moft]|[bpoc]|[bpoc]|[mamm]|[spco]|[irda]","Table - furniture|Table Device Component|Data Table|Drug Interactions|Thyroid Gland|Axis vertebra|Genus Axis|Axis|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS"
"Table III. ","C0039224|C0439070|C1705160|C1706073|C1706074","[mnob]|[inpr]|[qlco]|[mnob]|[inpr]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data Table"
"Table III. ","C0039224|C0439070|C1705160|C1706073|C1706074","[mnob]|[inpr]|[qlco]|[mnob]|[inpr]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data Table""Clinically\significant drug interactions with\theophylline.\Refer to PRECAUTIONS, Drug Interactions for\further information regarding table.","C0237881|C0687133|C0750502|C1546944|C0039771|C0205543|C1882442|C1517331|C1533716|C0039224|C1706073|C1706074","[mnob]|[inpr]|[qlco]|[mnob]|[inpr][qnco]|[moft]|[idcn]|[qlco]|[bacs, orch, phsu]|[ftcn]|[cnce]|[spco]|[idcn]|[mnob]|[mnob]|[inpr]","Table - furniture|Roman Numeral III|III (suffix)|Table Device Component|Data TableStatistical Significance|Drug Interactions|Significant|Event Seriousness - Significant|Theophylline|Referring|Precaution|Further|Information|Table - furniture|Table Device Component|Data Table"
"Table IV. ","C0039224|C0022326|C1706073|C1706074","[mnob]|[geoa]|[mnob]|[inpr]","Table - furniture|Ivory Coast|Table Device Component|Data Table"
"Table IV. ","C0039224|C0022326|C1706073|C1706074","[mnob]|[geoa]|[mnob]|[inpr]","Table - furniture|Ivory Coast|Table Device Component|Data Table""Drugs that have\been documented not to interact with theophylline\or drugs that produce no clinically significant\interaction with theophylline.\Refer to PRECAUTIONS, Drug Interactions for\information regarding table.","C0013227|C3687832|C1301725|C1609436|C1518422|C0040363|C0041260|C1883351|C0039771|C0237881|C1704675|C0750502|C1546944|C0205543|C1882442|C0687133|C1533716|C0039224|C1706073|C1706074","[mnob]|[geoa]|[mnob]|[inpr][phsu]|[topp]|[hlca]|[inpr]|[ftcn]|[geoa]|[aapp, enzy]|[qlco]|[bacs, orch, phsu]|[qnco]|[ftcn]|[idcn]|[qlco]|[ftcn]|[cnce]|[moft]|[idcn]|[mnob]|[mnob]|[inpr]","Table - furniture|Ivory Coast|Table Device Component|Data TablePharmaceutical Preparations|Drugs|Documented|Document completion status - Documented|Negation|Togo|Tryptophanase|To|Theophylline|Statistical Significance|Interaction|Significant|Event Seriousness - Significant|Referring|Precaution|Drug Interactions|Information|Table - furniture|Table Device Component|Data Table"
"Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: dopamine ( ? 1 mcg/kg/min); ","C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C1274040|C1546471|C2825142|C0040704|C0301630|C0392756|C0441610|C0205374|C2611225|C1521801|C0231290|C0178602|C0332282|C0013030|C2827734|C1300567|C2981698|C3816745","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+"
"Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: dopamine ( ? 1 mcg/kg/min); ","C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C1274040|C1546471|C2825142|C0040704|C0301630|C0392756|C0441610|C0205374|C2611225|C1521801|C0231290|C0178602|C0332282|C0013030|C2827734|C1300567|C2981698|C3816745","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+""Glucocorticoids (hydrocortisone ? 100 mg/day or equivalent); ","C0017710|C3540777|C3540778|C0020268|C3817553|C0439422|C0205163|C0439185","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg][horm, orch]|[horm, orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[qnco]|[qnco]|[qlco]|[qnco]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Hydrocortisone|100%|milligram/day|Equal|Equivalent Weight"
"Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: dopamine ( ? 1 mcg/kg/min); ","C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C1274040|C1546471|C2825142|C0040704|C0301630|C0392756|C0441610|C0205374|C2611225|C1521801|C0231290|C0178602|C0332282|C0013030|C2827734|C1300567|C2981698|C3816745","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+""Glucocorticoids (hydrocortisone ? 100 mg/day or equivalent); ","C0017710|C3540777|C3540778|C0020268|C3817553|C0439422|C0205163|C0439185","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg][horm, orch]|[horm, orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[qnco]|[qnco]|[qlco]|[qnco]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Hydrocortisone|100%|milligram/day|Equal|Equivalent Weight""Octreotide ( > 100 mcg/day).","C0028833|C3817553|C0439426","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg][horm, orch]|[horm, orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[qnco]|[qnco]|[qlco]|[qnco][aapp, horm, phsu]|[qnco]|[qnco]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Hydrocortisone|100%|milligram/day|Equal|Equivalent WeightOctreotide|100%|Microgram per Day"
"The concomitant use of ADDYI with alcohol increased the risk of hypotension, syncope, and CNS depression compared to the use of ADDYI alone or alcohol alone [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)].","C0521115|C0042153|C0457083|C1947944|C0001962|C0001975|C0205217|C0442805|C0035647|C0020649|C3163620|C0039070|C3541349|C0151559|C1707455|C0205171|C0439044|C0679994|C0042789|C1947903|C0871599|C1882442|C0439084|C0728893|C0031332|C1555729","[tmco]|[ftcn]|[ftcn]|[inpr]|[orch, phsu]|[orch, phsu]|[qnco]|[ftcn]|[idcn]|[fndg]|[patf]|[sosy]|[amph]|[dsyn]|[acty]|[qnco]|[fndg]|[grpa]|[orgf]|[acty]|[gora]|[cnce]|[qnco]|[qnco]|[bmod]|[prog]","Simultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Ethanol|Alcohols|Increased|Increase|Risk|Hypotension|Hypotension Adverse Event|Syncope|Syncope (amphibian)|Central nervous system depression (disorder)|Comparison|Singular|Living Alone|alone - group size|Vision|See|Cautionary Warning|Precaution|>5|+5|Clinical pharmacology discipline|Allopathic & Osteopathic Physicians - Clinical Pharmacology"
"* The interaction between nevirapine and the drug was evaluated in a clinical study. ","C1704675|C0132326|C0013227|C1254351|C0220825|C0008972","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical Research"
"* The interaction between nevirapine and the drug was evaluated in a clinical study. ","C1704675|C0132326|C0013227|C1254351|C0220825|C0008972","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical Research""All other drug interactions shown are predicted.","C0687133|C1547282|C0681842|C1882327","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa][moft]|[anim]|[idcn]|[qnco]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical ResearchDrug Interactions|Show|prediction|Percent of Predicted Value"
"-","","",""
"Analgesics:\Methadone*","C0002771|C0025605|C1552533","[phsu]|[orch, phsu]|[hcro, mnob]","Analgesics|Methadone|Methadone Clinic/Center"
"Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products)","C0003138|C0038633|C0301532|C3714835|C1514468|C0332256|C2700400|C0007447|C0024467|C0304540|C2348270|C3540792|C3714621|C0032521|C4020599|C1707959|C0718050|C0768119|C0592249|C0012133|C0304290|C0006353|C0030755|C0032861|C1382110|C1521725|C0205250|C0013227|C3687832|C0006675|C0006726|C2936886|C3540037|C3714611|C0302583|C0376520|C1166521|C3714701|C0043481|C2348288|C3541396|C3714650|C0010947","[phsu]|[orch, phsu]|[orch, phsu, vita]|[phsu, vita]|[enty]|[ftcn]|[acty]|[chvs]|[elii]|[inch, phsu]|[elii]|[inch, phsu]|[phsu]|[bodm, chvs]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[nnon, phsu]|[nnon, phsu]|[bodm]|[irda, phsu]|[bmod]|[bodm]|[sbst]|[qlco]|[qlco]|[phsu]|[topp]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu, vita]|[phsu]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu]|[elii, phsu]|[elii]|[phsu]|[phsu]|[food]","Antacids|Sucralfate|Multivitamin preparation|Multivitamin Drug Class|product|Containing (qualifier)|Contain (action)|Cations|Magnesium|Aluminum-based antacid|Dietary Magnesium|Magnesium supplements|Magnesium Drug Class|Polymers|Phosphate Binders|Example|sevelamer|lanthanum carbonate|Videx|Didanosine|Chewable Tablet|Buffers|Pediatrics|Powder dose form|powder physical state|Pediatric|High|Pharmaceutical Preparations|Drugs|Calcium|Calcium, Dietary|Calcium [EPC]|CALCIUM SUPPLEMENTS|Calcium Drug Class|Iron|Dietary Iron|Ferrum metallicum, Homeopathic preparation|Iron Drug Class|Zinc|Dietary Zinc|Zinc Supplements|Zinc Drug Class|Dairy Products"
"Antiarrhythmics:\Amiodarone, disopyramide,lidocaine","C0003195|C0002598|C0012702|C0023660","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]","Anti-Arrhythmia Agents|Amiodarone|Disopyramide|Lidocaine"
"Antibiotics:\Clarithromycin*","C0003232|C0003237|C3540704|C3540705|C3540706|C3540707|C3540708|C3540709|C3540710|C0055856","[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb, orch]","Antibiotics|Antibiotics, Antitubercular|Antibiotics for systemic use|Antifungal Antibiotics, Topical|Antibiotic throat preparations|Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE|Antibiotics, Gynecological|antibiotics, intestinal|Antibiotics, ophthalmologic|Clarithromycin"
"AUCSS(012h)(Extent of systemic \exposure)","C0439792|C0205373|C0274281|C0332157","[spco]|[ftcn]|[inpo]|[clna]","Extent|Systemic|Injury due to exposure to external cause|Exposure to"
"Avoid Use\(Plasma Exposure Likely to be Increased and Prolonged)","C0042153|C0457083|C1947944|C0032105|C0274281|C0332157|C1550098|C0332148|C0750492|C0040363|C0041260|C1883351|C0205217|C0442805|C0439590","[ftcn]|[ftcn]|[inpr]|[bdsu]|[inpo]|[clna]|[bdsu]|[qlco]|[idcn]|[geoa]|[aapp, enzy]|[qlco]|[qnco]|[ftcn]|[tmco]","utilization qualifier|Usage|Use - dosing instruction imperative|Plasma|Injury due to exposure to external cause|Exposure to|Plasma, NOS (not otherwise specified)|Probable diagnosis|Probably|Togo|Tryptophanase|To|Increased|Increase|Prolonged"
"Avoid Use\Five-fold increase in duloxetine exposure","C0042153|C0205451|C0332462|C0442805|C1880834|C0457083|C1947944|C0245561|C0274281|C0332157","[ftcn]|[qnco]|[spco]|[ftcn]|[phpr]|[ftcn]|[inpr]|[orch, phsu]|[inpo]|[clna]","utilization qualifier|Five|Folded structure|Increase|Fold in Medical Device Material|Usage|Use - dosing instruction imperative|duloxetine|Injury due to exposure to external cause|Exposure to"
"Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with CIPRO XR are advised.","C1947933|C0150369|C1283169|C1516647|C0009079|C0332281|C0559546|C1548787|C0376209|C0456081|C0683269|C0178602|C0814472|C1170167","[acty]|[hlca]|[hlca]|[resa]|[orch, phsu]|[qlco]|[patf]|[qlco]|[inbe]|[ftcn]|[inbe]|[qnco]|[hlca]|[orch, phsu]","care activity|Preventive monitoring|Monitoring - action|Clinical Trials, Monitoring|Clozapine|Associated with|Adverse reactions|Appropriate|Individual Adjustment|Adjustment Action|Psychological adjustment|Dosage|co-treatment|Cipro XR"
"CIPRO XR inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products). ","C1170167|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C0220781|C0439634|C1522492|C0044060|C0006644|C0001554|C1533734|C0030899|C0332256|C1514468|C2700400","[orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[biof]|[spco]|[ftcn]|[orch]|[orch, phsu]|[ocac]|[topp]|[orch, phsu]|[ftcn]|[enty]|[acty]","Cipro XR|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Anabolism|Formations|Formation|1,7-dimethylxanthine|Caffeine|Administration occupational activities|Administration procedure|Pentoxifylline|Containing (qualifier)|product|Contain (action)"
"CIPRO XR inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products). ","C1170167|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C0220781|C0439634|C1522492|C0044060|C0006644|C0001554|C1533734|C0030899|C0332256|C1514468|C2700400","[orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[biof]|[spco]|[ftcn]|[orch]|[orch, phsu]|[ocac]|[topp]|[orch, phsu]|[ftcn]|[enty]|[acty]","Cipro XR|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Anabolism|Formations|Formation|1,7-dimethylxanthine|Caffeine|Administration occupational activities|Administration procedure|Pentoxifylline|Containing (qualifier)|product|Contain (action)""Monitor for xanthine toxicity and adjust dose as necessary.","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0043314|C0040539|C0600688|C0043318|C0178602|C0869039|C1114758","[orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[biof]|[spco]|[ftcn]|[orch]|[orch, phsu]|[ocac]|[topp]|[orch, phsu]|[ftcn]|[enty]|[acty][hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, nnon]|[qlco]|[inpo]|[bacs, nnon]|[qnco]|[qnco]|[clna]","Cipro XR|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Anabolism|Formations|Formation|1,7-dimethylxanthine|Caffeine|Administration occupational activities|Administration procedure|Pentoxifylline|Containing (qualifier)|product|Contain (action)Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|xanthine|Toxicity aspects|Toxic effect|Xanthines|Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative"
"Cipro XR may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) [see Warnings and Precautions (5.10) and Use in Specific Populations (8.5)].","C1170167|C1517331|C0429028|C0488414|C0030705|C1514756|C0013227|C3687832|C0205309|C0040363|C0041260|C1883351|C1707959|C0456387|C1947960|C1705943|C0439070|C0003195|C1705160|C0003290|C0430087|C0003240|C0282563|C0040615|C0042789|C1947903|C0871599|C1882442|C0439084|C3842590|C0728893|C0042153|C0457083|C1947944|C0205369|C0032659|C1257890|C1552740","[orch, phsu]|[spco]|[clna]|[clna]|[podg]|[qlco]|[phsu]|[topp]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[cnce]|[inpr]|[mamm]|[clas]|[inpr]|[phsu]|[qlco]|[phsu]|[lbpr]|[antb, orch]|[orch, phsu]|[phsu]|[orgf]|[acty]|[gora]|[cnce]|[qnco]|[fndg]|[qnco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[qnco]|[popg]|[inpr]","Cipro XR|Further|QT interval feature (observable entity)|QT interval:Time:Point in time:Heart:Quantitative:EKG|Patients|Receive|Pharmaceutical Preparations|Drugs|Known|Togo|Tryptophanase|To|Example|Class|Ia <mammal>|Class (taxonomic)|Roman Numeral III|Anti-Arrhythmia Agents|III (suffix)|Tricyclic Antidepressive Agents|Tricyclic antidepressant measurement|Macrolide Antibiotics|Macrolides|Antipsychotic Agents|Vision|See|Cautionary Warning|Precaution|>5|10%|+5|utilization qualifier|Usage|Use - dosing instruction imperative|Specific qualifier value|geographic population|Population Group|Entity Determiner - specific"
"CIPRO XR should be taken at least two hours before or six hours after Multivalent cation-containing products administration. ","C1170167|C1883727|C0439092|C0205448|C0439227|C0547044|C0205452|C0007447|C0332256|C1514468|C0001554|C1533734|C2700400","[orch, phsu]|[cnce]|[qnco]|[qnco]|[tmco]|[qlco]|[qnco]|[chvs]|[ftcn]|[enty]|[ocac]|[topp]|[acty]","Cipro XR|Taken|Less Than|Two|Hour|Smaller|Six|Cations|Containing (qualifier)|product|Administration occupational activities|Administration procedure|Contain (action)"
"CIPRO XR should be taken at least two hours before or six hours after Multivalent cation-containing products administration. ","C1170167|C1883727|C0439092|C0205448|C0439227|C0547044|C0205452|C0007447|C0332256|C1514468|C0001554|C1533734|C2700400","[orch, phsu]|[cnce]|[qnco]|[qnco]|[tmco]|[qlco]|[qnco]|[chvs]|[ftcn]|[enty]|[ocac]|[topp]|[acty]","Cipro XR|Taken|Less Than|Two|Hour|Smaller|Six|Cations|Containing (qualifier)|product|Administration occupational activities|Administration procedure|Contain (action)""[See Dosage and Administration (2).]","C0042789|C1947903|C0178602|C0001554|C1533734|C0740116|C2827735|C2981700|C3833492","[orch, phsu]|[cnce]|[qnco]|[qnco]|[tmco]|[qlco]|[qnco]|[chvs]|[ftcn]|[enty]|[ocac]|[topp]|[acty][orgf]|[acty]|[qnco]|[ocac]|[topp]|[qnco]|[qnco]|[clas]|[fndg]","Cipro XR|Taken|Less Than|Two|Hour|Smaller|Six|Cations|Containing (qualifier)|product|Administration occupational activities|Administration procedure|Contain (action)Vision|See|Dosage|Administration occupational activities|Administration procedure|+2|2+ Score|2+ Score, WHO|2+"
"Concomitant administration of tizanidine and CIPRO XR is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications (4.2)].","C0521115|C0001554|C1533734|C0146011|C1170167|C1444657|C0279023|C0857353|C3179159|C0042789|C1947903|C0079164|C3838679","[tmco]|[ocac]|[topp]|[orch, phsu]|[orch, phsu]|[fndg]|[topp]|[patf]|[phsf]|[orgf]|[acty]|[qlco]|[fndg]","Simultaneous|Administration occupational activities|Administration procedure|tizanidine|Cipro XR|Contraindicated|chemosensitization/potentiation|Hypotensive|Sedative Effect|Vision|See|contraindications aspect|4+ Answer to question"
"Concurrent administration of CIPRO XR with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. ","C0205420|C0001554|C1533734|C1170167|C0039771|C1274040|C1546471|C2825142|C0205217|C0035647|C0442805|C0030705|C2360836|C2360838|C2360840|C1269563|C3540014|C3714787|C0559546","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf]","Concurrent|Administration occupational activities|Administration procedure|Cipro XR|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactions"
"Concurrent administration of CIPRO XR with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. ","C0205420|C0001554|C1533734|C1170167|C0039771|C1274040|C1546471|C2825142|C0205217|C0035647|C0442805|C0030705|C2360836|C2360838|C2360840|C1269563|C3540014|C3714787|C0559546","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf]","Concurrent|Administration occupational activities|Administration procedure|Cipro XR|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactions""If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate. ","C0521115|C0042153|C0457083|C1947944|C0030695|C0229671|C0441889|C1546774|C1550100|C0150369|C0181904|C0596972|C1521743|C1704646|C0039771|C0178602|C1548787","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf][tmco]|[ftcn]|[ftcn]|[inpr]|[hlca]|[bdsu]|[qlco]|[inpr]|[bdsu]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, orch, phsu]|[qnco]|[qlco]","Concurrent|Administration occupational activities|Administration procedure|Cipro XR|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactionsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Patient Monitoring|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Theophylline|Dosage|Appropriate"
"Concurrent administration of CIPRO XR with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. ","C0205420|C0001554|C1533734|C1170167|C0039771|C1274040|C1546471|C2825142|C0205217|C0035647|C0442805|C0030705|C2360836|C2360838|C2360840|C1269563|C3540014|C3714787|C0559546","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf]","Concurrent|Administration occupational activities|Administration procedure|Cipro XR|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactions""If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate. ","C0521115|C0042153|C0457083|C1947944|C0030695|C0229671|C0441889|C1546774|C1550100|C0150369|C0181904|C0596972|C1521743|C1704646|C0039771|C0178602|C1548787","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf][tmco]|[ftcn]|[ftcn]|[inpr]|[hlca]|[bdsu]|[qlco]|[inpr]|[bdsu]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, orch, phsu]|[qnco]|[qlco]","Concurrent|Administration occupational activities|Administration procedure|Cipro XR|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactionsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Patient Monitoring|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Theophylline|Dosage|Appropriate""[See Warnings and Precautions (5.6).]","C0042789|C1947903|C0871599|C1882442|C0442749|C3843715","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf][tmco]|[ftcn]|[ftcn]|[inpr]|[hlca]|[bdsu]|[qlco]|[inpr]|[bdsu]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, orch, phsu]|[qnco]|[qlco][orgf]|[acty]|[gora]|[cnce]|[fndg]|[fndg]","Concurrent|Administration occupational activities|Administration procedure|Cipro XR|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactionsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Patient Monitoring|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Theophylline|Dosage|AppropriateVision|See|Cautionary Warning|Precaution|6/5|5-6"
"Decrease CIPRO XR absorption, resulting in lower serum and urine levels considerably lower than desired for concurrent administration of these agents with CIPRO XR","C0392756|C1170167|C0000854|C2347023|C2347080|C2698776|C2825050|C0547047|C0678226|C0441994|C0229671|C1546774|C1550100|C1548802|C2003888|C0428152|C1318110|C0871633|C0205420|C0001554|C1533734|C0450442|C1254351|C1521826","[qlco]|[orch, phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[qnco]|[ftcn]|[spco]|[bdsu]|[inpr]|[bdsu]|[blor]|[acty]|[lbpr]|[lbtr]|[menp]|[tmco]|[ocac]|[topp]|[chvf]|[phsu]|[inpr]","Reduced|Cipro XR|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Decrease|Due to|Lower - spatial qualifier|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Body Site Modifier - Lower|Lower (action)|Urine level measurement|Urine levels result|desire|Concurrent|Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent"
"DigoxinEnalaprilIronMetoprololWarfarin","","",""
"Dosing Recommendations\Take at least 2 hours before or 6 hours after sevelamerTake at least 2 hours before sevelamer","C0178602|C0034866|C0869039|C1114758|C1515187|C0439092|C0439227|C0547044|C1292428|C0718050","[qnco]|[idcn]|[qnco]|[clna]|[hlca]|[qnco]|[tmco]|[qlco]|[tmco]|[orch, phsu]","Dosage|Recommendation|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Take|Less Than|Hour|Smaller|6 Hours|sevelamer"
"Hypoglycemia sometimes severe has been reported when CIPRO XR and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C1170167|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Cipro XR|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action"
"Hypoglycemia sometimes severe has been reported when CIPRO XR and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C1170167|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Cipro XR|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Cipro XR|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting"
"Hypoglycemia sometimes severe has been reported when CIPRO XR and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C1170167|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Cipro XR|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Cipro XR|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting""Monitor blood glucose when CIPRO XR is co-administered with oral antidiabetic drugs. ","C1820407|C1170167|C3245499|C1521801|C0029167|C0935929|C0175795|C0304289|C0442027","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Cipro XR|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Cipro XR|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|Oral"
"Hypoglycemia sometimes severe has been reported when CIPRO XR and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C1170167|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Cipro XR|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Cipro XR|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting""Monitor blood glucose when CIPRO XR is co-administered with oral antidiabetic drugs. ","C1820407|C1170167|C3245499|C1521801|C0029167|C0935929|C0175795|C0304289|C0442027","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Cipro XR|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Cipro XR|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|Oral""[See Adverse Reactions (6.1).]","C0042789|C1947903|C0559546","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco][orgf]|[acty]|[patf]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Cipro XR|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Cipro XR|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|OralVision|See|Adverse reactions"
"I.Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:","C0021966|C0221138|C0679932|C0036075|C0036077|C0013227|C3687832|C1145667|C1167622|C0036773|C0728877|C0231290|C0687133|C0332282|C1709305|C2745955","[inch]|[aapp, imft]|[socb]|[orch, phsu]|[orch, phsu]|[phsu]|[topp]|[acty]|[moft]|[aapp]|[lbtr]|[tmco]|[moft]|[tmco]|[acty]|[tmco]","Iodides|Blood group antibody I|competition|salicylate|Salicylates|Pharmaceutical Preparations|Drugs|Binding action|Binding (Molecular Function)|Serum Albumin|Serum albumin level|Status post|Drug Interactions|Following|Occur (action)|Occurrence"
"If unavoidable monitor, for duloxetine toxicity","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0245561|C0040539|C0600688","[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[orch, phsu]|[qlco]|[inpo]","Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|duloxetine|Toxicity aspects|Toxic effect"
"Monitor for sildenafil toxicity [see Pharmacokinetics (12.3\)].","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0529793|C0040539|C0600688|C0042789|C1947903|C0031327|C0031328","[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[orch, phsu]|[qlco]|[inpo]|[orgf]|[acty]|[phsf]|[ftcn]","Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|sildenafil|Toxicity aspects|Toxic effect|Vision|See|Drug Kinetics|Pharmacokinetic aspects"
"Monitor renal function (in particular serum creatinine) when CIPRO XR is co-administered with cyclosporine.","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0232804|C0201976|C0600061|C1170167|C3245499|C1521801|C0010592|C0010594","[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[ortf]|[lbpr]|[fndg]|[orch, phsu]|[geoa]|[ftcn]|[aapp, phsu]|[imft, phsu]","Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Renal function|Creatinine measurement, serum (procedure)|Serum creatinine level|Cipro XR|Colombia|Having administered|Cyclosporine|Cyclosporins"
"Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with CIPRO XR [see Warnings and Precautions (5.15)].","C0150369|C1283169|C1516647|C0244821|C0439849|C0559546|C0445223|C1548787|C2826232|C0034866|C0814472|C1170167|C0042789|C1947903|C0871599|C1882442|C0439084|C0728893","[hlca]|[hlca]|[resa]|[orch, phsu]|[qlco]|[patf]|[fndg]|[qlco]|[hlca]|[idcn]|[hlca]|[orch, phsu]|[orgf]|[acty]|[gora]|[cnce]|[qnco]|[qnco]","Preventive monitoring|Monitoring - action|Clinical Trials, Monitoring|ropinirole|Relationships|Adverse reactions|Related personal status|Appropriate|Dose Adjustment|Recommendation|co-treatment|Cipro XR|Vision|See|Cautionary Warning|Precaution|>5|+5"
"Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing.","C0003211|C1518422|C0004057|C0205195|C1947911|C3811910|C0442804|C0178602|C0034428|C1533693|C1547282|C0040363|C0041260|C1883351|C0036572|C1709630|C0947630|C0332152|C0008972|C0740175|C2257086|C3669034","[phsu]|[ftcn]|[orch, phsu]|[qlco]|[phob]|[fndg]|[fndg]|[qnco]|[orch]|[orch, phsu]|[anim]|[geoa]|[aapp, enzy]|[qlco]|[sosy]|[qlco]|[lbpr]|[tmco]|[resa]|[qlco]|[genf]|[mamm]","Anti-Inflammatory Agents, Non-Steroidal|Negation|Aspirin|Combined|combination of objects|combination - answer to question|Very high|Dosage|Quinolones|Quinolone Antibacterial Agents|Show|Togo|Tryptophanase|To|Seizures|Preclinical|Scientific Study|Before|Clinical Research|Before values|photoreactivating enzyme activity|Pure Spanish horse breed (organism)"
"Potential increase in the risk of methotrexate associated toxic reactions. ","C3245505|C0442805|C0035647|C0025677|C0332281|C0542243","[qlco]|[ftcn]|[idcn]|[orch, phsu]|[qlco]|[fndg]","potential|Increase|Risk|Methotrexate|Associated with|toxic reaction (non-specific)"
"Potential increase in the risk of methotrexate associated toxic reactions. ","C3245505|C0442805|C0035647|C0025677|C0332281|C0542243","[qlco]|[ftcn]|[idcn]|[orch, phsu]|[qlco]|[fndg]","potential|Increase|Risk|Methotrexate|Associated with|toxic reaction (non-specific)""Therefore, carefully monitor patients under methotrexate therapy when concomitant CIPRO XR therapy is indicated.","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0030705|C0025677|C0039798|C0087111|C1363945|C1707479|C1170167|C1444656","[qlco]|[ftcn]|[idcn]|[orch, phsu]|[qlco]|[fndg][hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[podg]|[orch, phsu]|[ftcn]|[topp]|[fndg]|[topp]|[orch, phsu]|[fndg]","potential|Increase|Risk|Methotrexate|Associated with|toxic reaction (non-specific)Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Patients|Methotrexate|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Concomitant Therapy|Cipro XR|Indicated"
"Potentiation of CIPRO XR toxicity may occur.","C0279023|C1170167|C0040539|C0600688|C1709305|C2745955","[topp]|[orch, phsu]|[qlco]|[inpo]|[acty]|[tmco]","chemosensitization/potentiation|Cipro XR|Toxicity aspects|Toxic effect|Occur (action)|Occurrence"
"Probenecid","C0033209","[orch, phsu]","Probenecid"
"Table 1: Oral drugs that can be administered concomitantly with Auryxia","C0039224|C1706073|C1706074|C0029167|C0175795|C0304289|C1521801|C3864953","[mnob]|[mnob]|[inpr]|[bmod]|[topp]|[phsu]|[ftcn]|[phsu]","Table - furniture|Table Device Component|Data Table|Oral Medicine|oral medication|Oral drug preparation|Having administered|Auryxia"
"Table 4 Drugs Tested in Binding or Drug Interaction Testing or With Post-Marketing Reports\In Vitro\In Vivo","C0039224|C0013227|C3687832|C1706073|C1706074|C0392366|C1145667|C1167622|C0038577|C1704675|C0678798|C0039593|C0687133|C0687676|C0024826|C1704687|C0684224|C0700287|C3273238|C3889645|C1515655|C1533691|C0021135|C2827718","[mnob]|[phsu]|[topp]|[mnob]|[inpr]|[inpr]|[acty]|[moft]|[lbpr]|[ftcn]|[fndg]|[ftcn]|[moft]|[tmco]|[ocac]|[mnob]|[inpr]|[hlca]|[inpr]|[inpr]|[spco]|[qlco]|[inpr]|[ftcn]","Table - furniture|Pharmaceutical Preparations|Drugs|Table Device Component|Data Table|Tests (qualifier value)|Binding action|Binding (Molecular Function)|Substance Abuse Detection|Interaction|Adverse drug interaction|Testing|Drug Interactions|Post|Marketing|Post Device Component|Report (document)|Reporting|Regulatory Report|Clinical Trial Final Report|in vivo|in vitro|In Vitro [Publication Type]|In Vitro Route of Administration"
"Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports","C0039224|C0013227|C3687832|C1706073|C1706074|C0392366|C0021135|C1145667|C1167622|C1533691|C2827718|C1515655|C0038577|C1704675|C0678798|C0039593|C0687133|C0687676|C0024826|C1704687|C0684224|C0700287|C3273238|C3889645","[mnob]|[phsu]|[topp]|[mnob]|[inpr]|[inpr]|[inpr]|[acty]|[moft]|[qlco]|[ftcn]|[spco]|[lbpr]|[ftcn]|[fndg]|[ftcn]|[moft]|[tmco]|[ocac]|[mnob]|[inpr]|[hlca]|[inpr]|[inpr]","Table - furniture|Pharmaceutical Preparations|Drugs|Table Device Component|Data Table|Tests (qualifier value)|In Vitro [Publication Type]|Binding action|Binding (Molecular Function)|in vitro|In Vitro Route of Administration|in vivo|Substance Abuse Detection|Interaction|Adverse drug interaction|Testing|Drug Interactions|Post|Marketing|Post Device Component|Report (document)|Reporting|Regulatory Report|Clinical Trial Final Report"
"The concomitant use of CNS depressants can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.","C0521115|C0042153|C0457083|C1947944|C0007681|C0442805|C0035647|C0020649|C3163620|C0235063|C0439808|C0235195|C0344106|C0009421|C0543874|C3146279|C0011065|C1306577","[tmco]|[ftcn]|[ftcn]|[inpr]|[phsu]|[ftcn]|[idcn]|[fndg]|[patf]|[patf]|[qlco]|[fndg]|[topp]|[dsyn]|[cgab]|[fngs]|[orgf]|[fndg]","Simultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Central Nervous System Depressants|Increase|Risk|Hypotension|Hypotension Adverse Event|Respiratory Depression|Profound|Sedated state|Sedation procedure|Comatose|Apraxia, oculomotor, Cogan type|Coma (genus)|Cessation of life|Death (finding)"
"The risk may vary with the underlying infection, age and general status of the patient so that the contribution of CIPRO XR to the increase in INR (international normalized ratio) is difficult to assess. ","C0035647|C0749769|C0001779|C0947124|C0030705|C2360836|C2360838|C2360840|C0037640|C1880177|C1170167|C0442805|C0525032|C1704538|C0332218|C1299586|C0040363|C0041260|C1883351|C1516048","[idcn]|[dsyn]|[orga]|[fndg]|[podg]|[clna]|[clna]|[clna]|[geoa]|[acty]|[orch, phsu]|[ftcn]|[lbpr]|[topp]|[qlco]|[fndg]|[geoa]|[aapp, enzy]|[qlco]|[acty]","Risk|underlying infection|Age|General status|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Somalia|Contribution|Cipro XR|Increase|International Normalized Ratio|Integrated Neuromusculoskeletal Release|Difficult (qualifier value)|Has difficulty doing (qualifier value)|Togo|Tryptophanase|To|Assessed"
"The risk may vary with the underlying infection, age and general status of the patient so that the contribution of CIPRO XR to the increase in INR (international normalized ratio) is difficult to assess. ","C0035647|C0749769|C0001779|C0947124|C0030705|C2360836|C2360838|C2360840|C0037640|C1880177|C1170167|C0442805|C0525032|C1704538|C0332218|C1299586|C0040363|C0041260|C1883351|C1516048","[idcn]|[dsyn]|[orga]|[fndg]|[podg]|[clna]|[clna]|[clna]|[geoa]|[acty]|[orch, phsu]|[ftcn]|[lbpr]|[topp]|[qlco]|[fndg]|[geoa]|[aapp, enzy]|[qlco]|[acty]","Risk|underlying infection|Age|General status|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Somalia|Contribution|Cipro XR|Increase|International Normalized Ratio|Integrated Neuromusculoskeletal Release|Difficult (qualifier value)|Has difficulty doing (qualifier value)|Togo|Tryptophanase|To|Assessed""Monitor prothrombin time and INR frequently during and shortly after co-administration of CIPRO XR with an oral anti-coagulant (for example, warfarin).","C0030695|C0033707|C0482694|C0150369|C0181904|C0596972|C1521743|C1704646|C0525032|C0332183|C1704538|C0814472|C1170167|C0442027|C0848112|C3536711|C1707959|C0043031","[idcn]|[dsyn]|[orga]|[fndg]|[podg]|[clna]|[clna]|[clna]|[geoa]|[acty]|[orch, phsu]|[ftcn]|[lbpr]|[topp]|[qlco]|[fndg]|[geoa]|[aapp, enzy]|[qlco]|[acty][hlca]|[lbpr]|[clna]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[lbpr]|[tmco]|[topp]|[hlca]|[orch, phsu]|[spco]|[topp]|[phsu]|[cnce]|[hops, orch, phsu]","Risk|underlying infection|Age|General status|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Somalia|Contribution|Cipro XR|Increase|International Normalized Ratio|Integrated Neuromusculoskeletal Release|Difficult (qualifier value)|Has difficulty doing (qualifier value)|Togo|Tryptophanase|To|AssessedPatient Monitoring|Prothrombin time assay|Coagulation tissue factor induced:Time:Pt:PPP:Qn:Coag|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|International Normalized Ratio|Frequent|Integrated Neuromusculoskeletal Release|co-treatment|Cipro XR|Oral|on anti-coagulants|Anti-coagulant [EPC]|Example|Warfarin"
"There have been a number of reports regarding coma and death associated with the misuse and abuse of the combination of buprenorphine and benzodiazepines. ","C0237753|C0449788|C0684224|C0700287|C3889645|C0009421|C0543874|C3146279|C0011065|C1306577|C0332281|C0549649|C1546940|C0013146|C0562381|C0205195|C1947911|C3811910|C0006405|C0005064","[qnco]|[qnco]|[inpr]|[hlca]|[inpr]|[dsyn]|[cgab]|[fngs]|[orgf]|[fndg]|[qlco]|[fndg]|[idcn]|[mobd]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]|[orch, phsu]","Numbers|Count of entities|Report (document)|Reporting|Clinical Trial Final Report|Comatose|Apraxia, oculomotor, Cogan type|Coma (genus)|Cessation of life|Death (finding)|Associated with|MISUSE|Event Qualification - Misuse|Drug abuse|Victim of abuse finding|Combined|combination of objects|combination - answer to question|Buprenorphine|Benzodiazepines"
"There have been a number of reports regarding coma and death associated with the misuse and abuse of the combination of buprenorphine and benzodiazepines. ","C0237753|C0449788|C0684224|C0700287|C3889645|C0009421|C0543874|C3146279|C0011065|C1306577|C0332281|C0549649|C1546940|C0013146|C0562381|C0205195|C1947911|C3811910|C0006405|C0005064","[qnco]|[qnco]|[inpr]|[hlca]|[inpr]|[dsyn]|[cgab]|[fngs]|[orgf]|[fndg]|[qlco]|[fndg]|[idcn]|[mobd]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]|[orch, phsu]","Numbers|Count of entities|Report (document)|Reporting|Clinical Trial Final Report|Comatose|Apraxia, oculomotor, Cogan type|Coma (genus)|Cessation of life|Death (finding)|Associated with|MISUSE|Event Qualification - Misuse|Drug abuse|Victim of abuse finding|Combined|combination of objects|combination - answer to question|Buprenorphine|Benzodiazepines""In many, but not all of these cases, buprenorphine was misused by self-injection of crushed buprenorphine tablets. ","C1518422|C0868928|C1533148|C0006405|C0549649|C1546940|C0036588|C0021485|C1272883|C1533685|C1828121|C1551994|C0185060|C0039225|C0332679","[qnco]|[qnco]|[inpr]|[hlca]|[inpr]|[dsyn]|[cgab]|[fngs]|[orgf]|[fndg]|[qlco]|[fndg]|[idcn]|[mobd]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]|[orch, phsu][ftcn]|[ftcn]|[qnco]|[orch, phsu]|[fndg]|[idcn]|[idcn]|[topp]|[bodm]|[topp]|[ftcn]|[inpr]|[topp]|[bodm]|[inpo]","Numbers|Count of entities|Report (document)|Reporting|Clinical Trial Final Report|Comatose|Apraxia, oculomotor, Cogan type|Coma (genus)|Cessation of life|Death (finding)|Associated with|MISUSE|Event Qualification - Misuse|Drug abuse|Victim of abuse finding|Combined|combination of objects|combination - answer to question|Buprenorphine|BenzodiazepinesNegation|Case (situation)|Case unit dose|Buprenorphine|MISUSE|Event Qualification - Misuse|Self|Injection of therapeutic agent|Injection product|Injection procedure|Injection Route of Drug Administration|subscriber - self|Crushing procedure|Tablet Dosage Form|Crushing injury"
"There have been a number of reports regarding coma and death associated with the misuse and abuse of the combination of buprenorphine and benzodiazepines. ","C0237753|C0449788|C0684224|C0700287|C3889645|C0009421|C0543874|C3146279|C0011065|C1306577|C0332281|C0549649|C1546940|C0013146|C0562381|C0205195|C1947911|C3811910|C0006405|C0005064","[qnco]|[qnco]|[inpr]|[hlca]|[inpr]|[dsyn]|[cgab]|[fngs]|[orgf]|[fndg]|[qlco]|[fndg]|[idcn]|[mobd]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]|[orch, phsu]","Numbers|Count of entities|Report (document)|Reporting|Clinical Trial Final Report|Comatose|Apraxia, oculomotor, Cogan type|Coma (genus)|Cessation of life|Death (finding)|Associated with|MISUSE|Event Qualification - Misuse|Drug abuse|Victim of abuse finding|Combined|combination of objects|combination - answer to question|Buprenorphine|Benzodiazepines""In many, but not all of these cases, buprenorphine was misused by self-injection of crushed buprenorphine tablets. ","C1518422|C0868928|C1533148|C0006405|C0549649|C1546940|C0036588|C0021485|C1272883|C1533685|C1828121|C1551994|C0185060|C0039225|C0332679","[qnco]|[qnco]|[inpr]|[hlca]|[inpr]|[dsyn]|[cgab]|[fngs]|[orgf]|[fndg]|[qlco]|[fndg]|[idcn]|[mobd]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]|[orch, phsu][ftcn]|[ftcn]|[qnco]|[orch, phsu]|[fndg]|[idcn]|[idcn]|[topp]|[bodm]|[topp]|[ftcn]|[inpr]|[topp]|[bodm]|[inpo]","Numbers|Count of entities|Report (document)|Reporting|Clinical Trial Final Report|Comatose|Apraxia, oculomotor, Cogan type|Coma (genus)|Cessation of life|Death (finding)|Associated with|MISUSE|Event Qualification - Misuse|Drug abuse|Victim of abuse finding|Combined|combination of objects|combination - answer to question|Buprenorphine|BenzodiazepinesNegation|Case (situation)|Case unit dose|Buprenorphine|MISUSE|Event Qualification - Misuse|Self|Injection of therapeutic agent|Injection product|Injection procedure|Injection Route of Drug Administration|subscriber - self|Crushing procedure|Tablet Dosage Form|Crushing injury""Preclinical studies have shown that the combination of benzodiazepines and buprenorphine altered the usual ceiling effect on buprenorphine-induced respiratory depression, making the respiratory effects of buprenorphine appear similar to those of full opioid agonists.","C1709631|C1547282|C0205195|C1947911|C3811910|C0005064|C0006405|C0392747|C3538928|C1516322|C0205263|C0235063|C1881534|C0521346|C1280500|C1546767|C0700364|C2348205|C2917221|C3850134","[qnco]|[qnco]|[inpr]|[hlca]|[inpr]|[dsyn]|[cgab]|[fngs]|[orgf]|[fndg]|[qlco]|[fndg]|[idcn]|[mobd]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]|[orch, phsu][ftcn]|[ftcn]|[qnco]|[orch, phsu]|[fndg]|[idcn]|[idcn]|[topp]|[bodm]|[topp]|[ftcn]|[inpr]|[topp]|[bodm]|[inpo][resa]|[anim]|[qlco]|[phob]|[fndg]|[orch, phsu]|[orch, phsu]|[ftcn]|[qlco]|[idcn]|[ftcn]|[patf]|[ftcn]|[ftcn]|[qlco]|[inpr]|[qlco]|[qlco]|[moft]|[phsu]","Numbers|Count of entities|Report (document)|Reporting|Clinical Trial Final Report|Comatose|Apraxia, oculomotor, Cogan type|Coma (genus)|Cessation of life|Death (finding)|Associated with|MISUSE|Event Qualification - Misuse|Drug abuse|Victim of abuse finding|Combined|combination of objects|combination - answer to question|Buprenorphine|BenzodiazepinesNegation|Case (situation)|Case unit dose|Buprenorphine|MISUSE|Event Qualification - Misuse|Self|Injection of therapeutic agent|Injection product|Injection procedure|Injection Route of Drug Administration|subscriber - self|Crushing procedure|Tablet Dosage Form|Crushing injuryNonclinical Study|Show|Combined|combination of objects|combination - answer to question|Benzodiazepines|Buprenorphine|Changing|Usual|Ceiling Effect|Induce (action)|Respiratory Depression|Make - Instruction Imperative|respiratory|Effect|Specimen Source Codes - Respiratory|Appearance|Similarity|Full Opioid Agonists [MoA]|Full Opioid Agonists"
"To avoid the loss of seizure control associated with decreased phenytoin levels and to prevent phenytoin overdose-related adverse reactions upon CIPRO XR discontinuation in patients receiving both agents, monitor phenytoin therapy, including phenytoin serum concentration during and shortly after co-administration of CIPRO XR with phenytoin.","C0040363|C0041260|C1883351|C1517945|C0036572|C0243148|C1550141|C1882979|C2587213|C3274648|C1959629|C0332281|C0205216|C0702177|C0392756|C0442797|C0309872|C0413741|C0029944|C0439849|C0445223|C1546941|C4018909|C1170167|C0457454|C1444662|C0030705|C1514756|C0450442|C1254351|C1521826|C0030695|C0031507|C0039798|C0087111|C1363945|C0150369|C0181904|C0596972|C1521743|C1704646|C0332257|C0683149|C0814472","[geoa]|[aapp, enzy]|[qlco]|[qnco]|[sosy]|[qlco]|[sbst]|[cnce]|[ftcn]|[qlco]|[fndg]|[qlco]|[qnco]|[lbtr]|[qlco]|[qlco]|[phsu]|[inpo]|[inpo]|[qlco]|[fndg]|[idcn]|[fndg]|[orch, phsu]|[hlca]|[fndg]|[podg]|[qlco]|[chvf]|[phsu]|[inpr]|[hlca]|[orch, phsu]|[ftcn]|[topp]|[fndg]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[ftcn]|[qnco]|[hlca]","Togo|Tryptophanase|To|Loss|Seizures|control aspects|control substance|Scientific Control|Control function|True Control Status|Seizure Adverse Event|Associated with|Decreased|Phenytoin level - finding|Reduced|Decreasing|PREVENT (product)|Phenytoin adverse reaction|Drug Overdose|Relationships|Related personal status|Event Qualification - Overdose|Overdose|Cipro XR|Discontinuation (procedure)|Discontinued|Patients|Receive|Agent|Pharmacologic Substance|Protocol Agent|Patient Monitoring|Phenytoin|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Including (qualifier)|serum concentration|co-treatment"
"Use with caution\(Increase in anticoagulant effect)","C0042153|C0457083|C1947944|C0442805|C0520996","[ftcn]|[ftcn]|[inpr]|[ftcn]|[ortf]","utilization qualifier|Usage|Use - dosing instruction imperative|Increase|Anticoagulant effect"
"Use with caution\(interferes with renal tubular secretion of CIPRO XR and increases CIPRO XR serum levels)","C0042153|C0457083|C1947944|C0521102|C0678876|C1170167|C0205217|C0442805|C0229671|C0441889|C1546774|C1550100","[ftcn]|[ftcn]|[inpr]|[ftcn]|[ortf]|[orch, phsu]|[qnco]|[ftcn]|[bdsu]|[qlco]|[inpr]|[bdsu]","utilization qualifier|Usage|Use - dosing instruction imperative|Interferes with|renal tubular secretion|Cipro XR|Increased|Increase|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum"
"Use with caution\(transient elevations in serum creatinine)","C0042153|C0457083|C1947944|C0040704|C0702240|C0205374|C0201976|C0600061","[ftcn]|[ftcn]|[inpr]|[popg]|[spco]|[tmco]|[lbpr]|[fndg]","utilization qualifier|Usage|Use - dosing instruction imperative|Transient Population Group|Elevation|Transitory|Creatinine measurement, serum (procedure)|Serum creatinine level"
"Use with caution\Altered serum levels of phenytoin (increased and decreased)","C0042153|C0457083|C1947944|C0392747|C0229671|C0441889|C1546774|C1550100|C0031507|C0205217|C0442805|C0205216|C0392756|C0442797","[ftcn]|[ftcn]|[inpr]|[ftcn]|[bdsu]|[qlco]|[inpr]|[bdsu]|[orch, phsu]|[qnco]|[ftcn]|[qnco]|[qlco]|[qlco]","utilization qualifier|Usage|Use - dosing instruction imperative|Changing|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Phenytoin|Increased|Increase|Decreased|Reduced|Decreasing"
"Use with caution\Glucose-lowering effect potentiated","C0042153|C0457083|C1947944|C1158774|C0441994|C2003888","[ftcn]|[ftcn]|[inpr]|[genf]|[spco]|[acty]","utilization qualifier|Usage|Use - dosing instruction imperative|negative regulation of transcription by glucose|Lower - spatial qualifier|Lower (action)"
"Use with caution\Inhibition of methotrexate renal tubular transport potentially leading to increased methotrexate plasma levels","C0042153|C0457083|C1947944|C0021467|C0021469|C1628982|C3463820|C0025677|C0597373|C0332152|C1522538|C0205217|C0202421|C0032105|C1550098|C0442805","[ftcn]|[ftcn]|[inpr]|[menp]|[moft]|[qnco]|[acty]|[orch, phsu]|[ortf]|[tmco]|[ftcn]|[qnco]|[lbpr]|[bdsu]|[bdsu]|[ftcn]","utilization qualifier|Usage|Use - dosing instruction imperative|Psychological inhibition|Metabolic Inhibition|Percent inhibition|Inhibition|Methotrexate|renal tubular transport|Before|Leading|Increased|Methotrexate measurement|Plasma|Plasma, NOS (not otherwise specified)|Increase"
"Use with caution\Reduced clearance resulting in elevated levels and prolongation of serum half-life","C0042153|C0457083|C1947944|C0392756|C0449297|C1382187|C2825073|C0678226|C0205250|C0441889|C3163633|C0229671|C0018517|C1546774|C1550100","[ftcn]|[ftcn]|[inpr]|[qlco]|[qlco]|[clna]|[npop]|[ftcn]|[qlco]|[qlco]|[qlco]|[bdsu]|[tmco]|[inpr]|[bdsu]","utilization qualifier|Usage|Use - dosing instruction imperative|Reduced|Clearance|Clearance of substance|Clearance [PK]|Due to|High|Levels (qualifier value)|Elevated|Serum|Half-Life|Specimen Source Codes - Serum|Specimen Type - Serum"
"Use with caution\Two-fold increase in exposure","C0042153|C0457083|C1947944|C0205448|C0332462|C0442805|C1880834|C0274281|C0332157","[ftcn]|[ftcn]|[inpr]|[qnco]|[spco]|[ftcn]|[phpr]|[inpo]|[clna]","utilization qualifier|Usage|Use - dosing instruction imperative|Two|Folded structure|Increase|Fold in Medical Device Material|Injury due to exposure to external cause|Exposure to"
"na","C0597484|C1272460","[elii]|[qlco]","Sodium Cation|Not Applicable"
"826","","",""
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.6, 5.1, 7, 12.3)","C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893","[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco]","Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5"
"* The interaction between nevirapine and the drug was evaluated in a clinical study. ","C1704675|C0132326|C0013227|C1254351|C0220825|C0008972","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical Research"
"* The interaction between nevirapine and the drug was evaluated in a clinical study. ","C1704675|C0132326|C0013227|C1254351|C0220825|C0008972","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical Research""All other drug interactions shown are predicted.","C0687133|C1547282|C0681842|C1882327","[ftcn]|[orch, phsu]|[phsu]|[phsu]|[hlca]|[resa][moft]|[anim]|[idcn]|[qnco]","Interaction|Nevirapine|Pharmaceutical Preparations|Pharmacologic Substance|Evaluation|Clinical ResearchDrug Interactions|Show|prediction|Percent of Predicted Value"
"-","","",""
"0.51","C3842591","[fndg]","0%"
"0.51","C3842591","[fndg]","0%"
"0.51","C3842591","[fndg]","0%"
"0.51","C3842591","[fndg]","0%"
"0.55","C3842591|C0450382","[fndg]|[inpr]","0%|55"
"0.55","C3842591|C0450382","[fndg]|[inpr]","0%|55"
"0.55","C3842591|C0450382","[fndg]|[inpr]","0%|55"
"0.55","C3842591|C0450382","[fndg]|[inpr]","0%|55"
"0.94","C3842591","[fndg]","0%"
"0.94","C3842591","[fndg]","0%"
"0.94","C3842591","[fndg]","0%"
"0.94","C3842591","[fndg]","0%"
"1.1","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.1","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.1","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.1","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.2","C0580272|C1519043|C3843716","[inpr]|[resa]|[fndg]","1/2|Phase I/II Trial|1-2"
"1.2","C0580272|C1519043|C3843716","[inpr]|[resa]|[fndg]","1/2|Phase I/II Trial|1-2"
"1.2","C0580272|C1519043|C3843716","[inpr]|[resa]|[fndg]","1/2|Phase I/II Trial|1-2"
"1.2","C0580272|C1519043|C3843716","[inpr]|[resa]|[fndg]","1/2|Phase I/II Trial|1-2"
"1.3","C3843504","[fndg]","1 - 3"
"1.3","C3843504","[fndg]","1 - 3"
"1.3","C3843504","[fndg]","1 - 3"
"1.3","C3843504","[fndg]","1 - 3"
"1.3","C3843504","[fndg]","1 - 3"
"1.4","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.4","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.4","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.4","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.4","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.4","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.4","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.4","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.4","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.5","C0450316","[qnco]","1/5"
"1.5","C0450316","[qnco]","1/5"
"1.5","C0450316","[qnco]","1/5"
"1.5","C0450316","[qnco]","1/5"
"1.5","C0450316","[qnco]","1/5"
"1.6","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.6","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.6","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.6","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.8","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.8","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.8","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"1.8","C2827734|C2981698|C3816745","[qnco]|[clas]|[fndg]","1+ Score|1+ Score, WHO|1+"
"10mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"10mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"10mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"10mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"10mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"150mgtwicedaily","","",""
"150mgtwicedaily","","",""
"150mgtwicedaily","","",""
"150mgtwicedaily","","",""
"1mgsingledose","","",""
"1mgsingledose","","",""
"1mgsingledose","","",""
"1mgsingledose","","",""
"20mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"20mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"20mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"20mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"20mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"2or3mgtwicedaily","","",""
"2or3mgtwice daily","C0332173","[tmco]","Daily"
"2or3mgtwicedaily","","",""
"2or3mgtwicedaily","","",""
"2or3mgtwicedaily","","",""
"3mgtwicedaily","","",""
"3mgtwicedaily","","",""
"3mgtwicedaily","","",""
"3mgtwicedaily","","",""
"400mgtwicedaily","","",""
"400mgtwicedaily","","",""
"400mgtwicedaily","","",""
"400mgtwicedaily","","",""
"40mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"40mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"40mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"40mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"4mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"4mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"4mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"4mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"4mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"5-Fluorouracil","C0016360","[nnon, phsu]","Fluorouracil"
"500mgfourtimesdaily","","",""
"500mgfourtimes daily","C0332173","[tmco]","Daily"
"500mgfourtimesdaily","","",""
"500mgfourtimesdaily","","",""
"573168mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"573168mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"573168mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"573168mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"? Atazanavir? ","C1145759","[orch, phsu]","Atazanavir"
"? Atazanavir? ","C1145759","[orch, phsu]","Atazanavir""Nevirapine","C0132326","[orch, phsu][orch, phsu]","AtazanavirNevirapine"
"? Indinavir","C0376637","[orch, phsu]","Indinavir"
"? lamotrigine","C0064636|C0524166","[orch, phsu]|[lbpr]","lamotrigine|Lamotrigine measurement"
"? lamotrigine? carbamazepine epoxide","C0064636|C0054640|C0524166","[orch, phsu]|[orch, phsu]|[lbpr]","lamotrigine|carbamazepine epoxide|Lamotrigine measurement"
"? lamotrigine? levonorgestrel","C0064636|C0023566|C0524166","[orch, phsu]|[horm, orch, phsu]|[lbpr]","lamotrigine|Levonorgestrel|Lamotrigine measurement"
"? Lopinavir","C0674432","[orch, phsu]","lopinavir"
"?Amprenavir ?Nevirapine ?Amprenavir ?Nevirapine","C0754188|C0132326","[orch, phsu]|[orch, phsu]","Amprenavir|Nevirapine"
"?Efavirenz","C0674428","[orch, phsu]","efavirenz"
"?Nelfinavir M8 Metabolite?","C1370173|C0870883","[orch, phsu]|[bacs]","M8-nelfinavir|Metabolite"
"?Nelfinavir M8 Metabolite?","C1370173|C0870883","[orch, phsu]|[bacs]","M8-nelfinavir|Metabolite""Nelfinavir Cmin","C0525005|C2827771","[orch, phsu]|[bacs][orch, phsu]|[qnco]","M8-nelfinavir|MetaboliteNelfinavir|Cmin"
"Addition of carbamazepine decreases lamotrigine concentration approximately 40%.May increase carbamazepine epoxide levels.","C0332287|C1883712|C0006949|C0682993|C0392756|C0442797|C0547047|C0064636|C0004268|C0332232|C0439509|C3842587|C0086045|C1446561|C0524166|C0442805|C0054640|C0441889","[qlco]|[ftcn]|[orch, phsu]|[orch]|[qlco]|[qlco]|[qnco]|[orch, phsu]|[menp]|[qlco]|[tmco]|[qnco]|[menp]|[qnco]|[lbpr]|[ftcn]|[orch, phsu]|[qlco]","In addition to|Add - instruction imperative|Carbamazepine|carbamazepin|Reduced|Decreasing|Decrease|lamotrigine|Attention|Approximate|/40|40%|Mental concentration|Concentration measurement|Lamotrigine measurement|Increase|carbamazepine epoxide|Levels (qualifier value)"
"Addition of levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements.","C0332287|C1883712|C0040165|C1881373|C0935929|C0021641|C0039798|C0087111|C1363945|C1533581|C1579433|C3714501|C1274040|C1546471|C2825142|C0205217|C0442805|C1514873|C3889426","[qlco]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[aapp, horm, phsu]|[ftcn]|[topp]|[fndg]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[ftcn]|[ftcn]|[ftcn]","In addition to|Add - instruction imperative|Thyroxine|Synthetic Levothyroxine|Antidiabetics|Insulin|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Result|What subject filter - Result|Experimental Result|Increased|Increase|Requirement|Content Type Requirement"
"Addition of levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements.","C0332287|C1883712|C0040165|C1881373|C0935929|C0021641|C0039798|C0087111|C1363945|C1533581|C1579433|C3714501|C1274040|C1546471|C2825142|C0205217|C0442805|C1514873|C3889426","[qlco]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[aapp, horm, phsu]|[ftcn]|[topp]|[fndg]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[ftcn]|[ftcn]|[ftcn]","In addition to|Add - instruction imperative|Thyroxine|Synthetic Levothyroxine|Antidiabetics|Insulin|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Result|What subject filter - Result|Experimental Result|Increased|Increase|Requirement|Content Type Requirement""Careful monitoring of diabetic control is recommended, especially when thyroid therapy is started, changed, or discontinued.","C1947933|C0150369|C1283169|C1516647|C0241863|C0243148|C1550141|C1882979|C2587213|C3274648|C0034866|C1696944|C3540775|C1272689|C0392747|C0443172|C1444662","[qlco]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[aapp, horm, phsu]|[ftcn]|[topp]|[fndg]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[ftcn]|[ftcn]|[ftcn][acty]|[hlca]|[hlca]|[resa]|[fndg]|[qlco]|[sbst]|[cnce]|[ftcn]|[qlco]|[idcn]|[topp]|[phsu]|[qlco]|[ftcn]|[qnco]|[fndg]","In addition to|Add - instruction imperative|Thyroxine|Synthetic Levothyroxine|Antidiabetics|Insulin|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Result|What subject filter - Result|Experimental Result|Increased|Increase|Requirement|Content Type Requirementcare activity|Preventive monitoring|Monitoring - action|Clinical Trials, Monitoring|diabetic|control aspects|control substance|Scientific Control|Control function|True Control Status|Recommendation|Thyroid therapy|THYROID THERAPY DRUGS|Started|Changing|Changed status|Discontinued"
"Addition of levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements. ","C0332287|C1883712|C0040165|C1881373|C0935929|C0021641|C0039798|C0087111|C1363945|C1533581|C1579433|C3714501|C1274040|C1546471|C2825142|C0205217|C0442805|C1514873|C3889426","[qlco]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[aapp, horm, phsu]|[ftcn]|[topp]|[fndg]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[ftcn]|[ftcn]|[ftcn]","In addition to|Add - instruction imperative|Thyroxine|Synthetic Levothyroxine|Antidiabetics|Insulin|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Result|What subject filter - Result|Experimental Result|Increased|Increase|Requirement|Content Type Requirement"
"Addition of levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements. ","C0332287|C1883712|C0040165|C1881373|C0935929|C0021641|C0039798|C0087111|C1363945|C1533581|C1579433|C3714501|C1274040|C1546471|C2825142|C0205217|C0442805|C1514873|C3889426","[qlco]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[aapp, horm, phsu]|[ftcn]|[topp]|[fndg]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[ftcn]|[ftcn]|[ftcn]","In addition to|Add - instruction imperative|Thyroxine|Synthetic Levothyroxine|Antidiabetics|Insulin|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Result|What subject filter - Result|Experimental Result|Increased|Increase|Requirement|Content Type Requirement""Careful monitoring of diabetic control is recommended, especially when thyroid therapy is started, changed, or discontinued.","C1947933|C0150369|C1283169|C1516647|C0241863|C0243148|C1550141|C1882979|C2587213|C3274648|C0034866|C1696944|C3540775|C1272689|C0392747|C0443172|C1444662","[qlco]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[aapp, horm, phsu]|[ftcn]|[topp]|[fndg]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[ftcn]|[ftcn]|[ftcn][acty]|[hlca]|[hlca]|[resa]|[fndg]|[qlco]|[sbst]|[cnce]|[ftcn]|[qlco]|[idcn]|[topp]|[phsu]|[qlco]|[ftcn]|[qnco]|[fndg]","In addition to|Add - instruction imperative|Thyroxine|Synthetic Levothyroxine|Antidiabetics|Insulin|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Result|What subject filter - Result|Experimental Result|Increased|Increase|Requirement|Content Type Requirementcare activity|Preventive monitoring|Monitoring - action|Clinical Trials, Monitoring|diabetic|control aspects|control substance|Scientific Control|Control function|True Control Status|Recommendation|Thyroid therapy|THYROID THERAPY DRUGS|Started|Changing|Changed status|Discontinued"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage""Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0549178|C0001554|C1533734|C1274040|C1546471|C2825142|C0392756|C0547047|C0036833|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage""Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0549178|C0001554|C1533734|C1274040|C1546471|C2825142|C0392756|C0547047|C0036833|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)""Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. ","C0036077|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C1145667|C1167622|C3814864|C0032923|C0337441|C1421224","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[gngm]|[aapp, bacs]|[lbpr]|[gngm]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR gene"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage""Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0549178|C0001554|C1533734|C1274040|C1546471|C2825142|C0392756|C0547047|C0036833|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)""Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. ","C0036077|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C1145667|C1167622|C3814864|C0032923|C0337441|C1421224","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[gngm]|[aapp, bacs]|[lbpr]|[gngm]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR gene""An initial increase in serum FT4, is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total-T4 levels may decrease by as much as 30%.","C0205265|C0442805|C1279901|C1555582|C1705685|C0229671|C1546774|C1550100|C0332283|C0332156|C0205307|C0441889|C0439166|C2347086|C0443318|C0087111|C0683149|C0036075|C0036077|C0302350|C1281902|C0392756|C0547047|C0205393|C3842588","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[gngm]|[aapp, bacs]|[lbpr]|[gngm][tmco]|[ftcn]|[qlco]|[idcn]|[ftcn]|[bdsu]|[inpr]|[bdsu]|[tmco]|[qlco]|[qlco]|[qlco]|[qnco]|[qnco]|[ftcn]|[topp]|[qnco]|[orch, phsu]|[orch, phsu]|[ftcn]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR geneInitially|Increase|Firstly|Initial (abbreviation)|Initial Usage|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Followed by|Return to (contextual qualifier) (qualifier value)|Normal|Levels (qualifier value)|Percent normal|Mean Percent of Normal|Sustained|Therapeutic procedure|serum concentration|salicylate|Salicylates|Therapeutic|Total Thyroxine Measurement|Reduced|Decrease|Most|30%"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage""Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0549178|C0001554|C1533734|C1274040|C1546471|C2825142|C0392756|C0547047|C0036833|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage""Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0549178|C0001554|C1533734|C1274040|C1546471|C2825142|C0392756|C0547047|C0036833|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)""Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. ","C0036077|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C1145667|C1167622|C3814864|C0032923|C0337441|C1421224","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[gngm]|[aapp, bacs]|[lbpr]|[gngm]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR gene"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage""Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0549178|C0001554|C1533734|C1274040|C1546471|C2825142|C0392756|C0547047|C0036833|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)""Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. ","C0036077|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C1145667|C1167622|C3814864|C0032923|C0337441|C1421224","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[gngm]|[aapp, bacs]|[lbpr]|[gngm]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR gene""An initial increase in serum FT4, is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total-T4 levels may decrease by as much as 30%.","C0205265|C0442805|C1279901|C1555582|C1705685|C0229671|C1546774|C1550100|C0332283|C0332156|C0205307|C0441889|C0439166|C2347086|C0443318|C0087111|C0683149|C0036075|C0036077|C0302350|C1281902|C0392756|C0547047|C0205393|C3842588","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[gngm]|[aapp, bacs]|[lbpr]|[gngm][tmco]|[ftcn]|[qlco]|[idcn]|[ftcn]|[bdsu]|[inpr]|[bdsu]|[tmco]|[qlco]|[qlco]|[qlco]|[qnco]|[qnco]|[ftcn]|[topp]|[qnco]|[orch, phsu]|[orch, phsu]|[ftcn]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR geneInitially|Increase|Firstly|Initial (abbreviation)|Initial Usage|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Followed by|Return to (contextual qualifier) (qualifier value)|Normal|Levels (qualifier value)|Percent normal|Mean Percent of Normal|Sustained|Therapeutic procedure|serum concentration|salicylate|Salicylates|Therapeutic|Total Thyroxine Measurement|Reduced|Decrease|Most|30%"
"Administration of these agents with levothyroxine results in an initial transient increase in FT . Continued administration results in a decrease in serum T and normal FT and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685|C1881534|C0549178|C3890579|C0392756|C0547047|C0229671|C1546774|C1550100|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]|[ftcn]|[idcn]|[idcn]|[qlco]|[qnco]|[bdsu]|[inpr]|[bdsu]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage|Make - Instruction Imperative|Continuous|Functional Tests Domain|Reduced|Decrease|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)"
"Administration of these agents with levothyroxine results in an initial transient increase in FT . Continued administration results in a decrease in serum T and normal FT and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685|C1881534|C0549178|C3890579|C0392756|C0547047|C0229671|C1546774|C1550100|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]|[ftcn]|[idcn]|[idcn]|[qlco]|[qnco]|[bdsu]|[inpr]|[bdsu]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage|Make - Instruction Imperative|Continuous|Functional Tests Domain|Reduced|Decrease|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)""Salicylates inhibit binding of T and T to TBG and transthyretin. ","C0036077|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C1145667|C1167622|C2603360|C3814864|C0032923|C0337441|C1421224","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]|[ftcn]|[idcn]|[idcn]|[qlco]|[qnco]|[bdsu]|[inpr]|[bdsu]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[clna]|[gngm]|[aapp, bacs]|[lbpr]|[gngm]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage|Make - Instruction Imperative|Continuous|Functional Tests Domain|Reduced|Decrease|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|T prime|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR gene"
"Administration of these agents with levothyroxine results in an initial transient increase in FT . Continued administration results in a decrease in serum T and normal FT and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685|C1881534|C0549178|C3890579|C0392756|C0547047|C0229671|C1546774|C1550100|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]|[ftcn]|[idcn]|[idcn]|[qlco]|[qnco]|[bdsu]|[inpr]|[bdsu]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage|Make - Instruction Imperative|Continuous|Functional Tests Domain|Reduced|Decrease|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)""Salicylates inhibit binding of T and T to TBG and transthyretin. ","C0036077|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C1145667|C1167622|C2603360|C3814864|C0032923|C0337441|C1421224","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]|[ftcn]|[idcn]|[idcn]|[qlco]|[qnco]|[bdsu]|[inpr]|[bdsu]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[clna]|[gngm]|[aapp, bacs]|[lbpr]|[gngm]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage|Make - Instruction Imperative|Continuous|Functional Tests Domain|Reduced|Decrease|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|T prime|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR gene""An initial increase in serum FT , is followed by return of FT to normal levels with sustained therapeutic serum salicylate concentrations, although total-T levels may decrease by as much as 30%.\4\4\4\4\3\4\4\4","C0205265|C0442805|C1279901|C1555582|C1705685|C0229671|C1881534|C3890579|C1546774|C1550100|C0332283|C0332156|C0205307|C0441889|C0439166|C2347086|C0443318|C0087111|C0683149|C0036075|C0036077|C0302350|C0439175|C0439810|C0392756|C0547047|C0205393|C3842588","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]|[ftcn]|[idcn]|[idcn]|[qlco]|[qnco]|[bdsu]|[inpr]|[bdsu]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[clna]|[gngm]|[aapp, bacs]|[lbpr]|[gngm][tmco]|[ftcn]|[qlco]|[idcn]|[ftcn]|[bdsu]|[ftcn]|[idcn]|[inpr]|[bdsu]|[tmco]|[qlco]|[qlco]|[qlco]|[qnco]|[qnco]|[ftcn]|[topp]|[qnco]|[orch, phsu]|[orch, phsu]|[ftcn]|[qnco]|[qlco]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage|Make - Instruction Imperative|Continuous|Functional Tests Domain|Reduced|Decrease|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|T prime|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR geneInitially|Increase|Firstly|Initial (abbreviation)|Initial Usage|Serum|Make - Instruction Imperative|Functional Tests Domain|Specimen Source Codes - Serum|Specimen Type - Serum|Followed by|Return to (contextual qualifier) (qualifier value)|Normal|Levels (qualifier value)|Percent normal|Mean Percent of Normal|Sustained|Therapeutic procedure|serum concentration|salicylate|Salicylates|Therapeutic|% of total|Total|Reduced|Decrease|Most|30%"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4.","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4.","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage""Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid.","C0549178|C0001554|C1533734|C1274040|C1546471|C2825142|C0392756|C0547047|C0036833|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4.","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage""Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid.","C0549178|C0001554|C1533734|C1274040|C1546471|C2825142|C0392756|C0547047|C0036833|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)""Salicylates inhibit binding of T4 and T3 to TBG and transthyretin.An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total-T4 levels may decrease by as much as 30%.","C0036077|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C1145667|C1167622|C3814864|C0032923|C0337441|C1421224|C0205265|C0442805|C1279901|C1555582|C1705685|C0229671|C1546774|C1550100|C0332283|C0332156|C0205307|C0441889|C0439166|C2347086|C0443318|C0087111|C0683149|C0036075|C0302350|C1281902|C0392756|C0547047|C0205393|C3842588","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[gngm]|[aapp, bacs]|[lbpr]|[gngm]|[tmco]|[ftcn]|[qlco]|[idcn]|[ftcn]|[bdsu]|[inpr]|[bdsu]|[tmco]|[qlco]|[qlco]|[qlco]|[qnco]|[qnco]|[ftcn]|[topp]|[qnco]|[orch, phsu]|[ftcn]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR gene|Initially|Increase|Firstly|Initial (abbreviation)|Initial Usage|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Followed by|Return to (contextual qualifier) (qualifier value)|Normal|Levels (qualifier value)|Percent normal|Mean Percent of Normal|Sustained|Therapeutic procedure|serum concentration|salicylate|Therapeutic|Total Thyroxine Measurement|Reduced|Decrease|Most|30%"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage""Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0549178|C0001554|C1533734|C1274040|C1546471|C2825142|C0392756|C0547047|C0036833|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage""Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0549178|C0001554|C1533734|C1274040|C1546471|C2825142|C0392756|C0547047|C0036833|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)""Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. ","C0036077|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C1145667|C1167622|C3814864|C0032923|C0337441|C1421224","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[gngm]|[aapp, bacs]|[lbpr]|[gngm]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR gene"
"Administration of these agents with levothyroxine results in an initial transient increase in FT4. ","C0001554|C1533734|C0450442|C1254351|C1521826|C0040165|C1274040|C1546471|C2825142|C1881373|C0205265|C0040704|C0442805|C0205374|C1279901|C1555582|C1705685","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial Usage""Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations and, therefore, patients are clinically euthyroid. ","C0549178|C0001554|C1533734|C1274040|C1546471|C2825142|C0392756|C0547047|C0036833|C0205307|C0439166|C2347086|C0086045|C0030705|C0117002","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)""Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. ","C0036077|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C1145667|C1167622|C3814864|C0032923|C0337441|C1421224","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[gngm]|[aapp, bacs]|[lbpr]|[gngm]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR gene""An initial increase in serum FT4, is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total-T4 levels may decrease by as much as 30%.","C0205265|C0442805|C1279901|C1555582|C1705685|C0229671|C1546774|C1550100|C0332283|C0332156|C0205307|C0441889|C0439166|C2347086|C0443318|C0087111|C0683149|C0036075|C0036077|C0302350|C1281902|C0392756|C0547047|C0205393|C3842588","[ocac]|[topp]|[chvf]|[phsu]|[inpr]|[aapp, horm, phsu]|[ftcn]|[idcn]|[fndg]|[orch, phsu]|[tmco]|[popg]|[ftcn]|[tmco]|[qlco]|[idcn]|[ftcn][idcn]|[ocac]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[lbpr]|[qlco]|[qnco]|[qnco]|[menp]|[podg]|[fndg][orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[acty]|[moft]|[gngm]|[aapp, bacs]|[lbpr]|[gngm][tmco]|[ftcn]|[qlco]|[idcn]|[ftcn]|[bdsu]|[inpr]|[bdsu]|[tmco]|[qlco]|[qlco]|[qlco]|[qnco]|[qnco]|[ftcn]|[topp]|[qnco]|[orch, phsu]|[orch, phsu]|[ftcn]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Agent|Pharmacologic Substance|Protocol Agent|Thyroxine|Result|What subject filter - Result|Experimental Result|Synthetic Levothyroxine|Initially|Transient Population Group|Increase|Transitory|Firstly|Initial (abbreviation)|Initial UsageContinuous|Administration occupational activities|Administration procedure|Result|What subject filter - Result|Experimental Result|Reduced|Decrease|serum t4|Normal|Percent normal|Mean Percent of Normal|Mental concentration|Patients|Euthyroid (finding)Salicylates|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Binding action|Binding (Molecular Function)|SERPINA7 wt Allele|Prealbumin|Prealbumin measurement|TTR geneInitially|Increase|Firstly|Initial (abbreviation)|Initial Usage|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Followed by|Return to (contextual qualifier) (qualifier value)|Normal|Levels (qualifier value)|Percent normal|Mean Percent of Normal|Sustained|Therapeutic procedure|serum concentration|salicylate|Salicylates|Therapeutic|Total Thyroxine Measurement|Reduced|Decrease|Most|30%"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0428417","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurement"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0428417","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurement""However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (see above).","C0443252|C0744425|C1274040|C1546471|C2825142|C0750482|C0205216|C0392756|C0442797|C2937276|C0505385|C3814864|C0033268|C0042789|C1947903|C1282910|C1552828","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr][tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[qlco]|[qlco]|[qlco]|[blor]|[gngm]|[ocac]|[orgf]|[acty]|[spco]|[idcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurementLong-term|glucocorticoid therapy|Result|What subject filter - Result|Experimental Result|Slightly (qualifier value)|Decreased|Reduced|Decreasing|Slight (qualifier value)|Level of the fourth thoracic vertebra|SERPINA7 wt Allele|production|Vision|See|Upper|Table Frame - above"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0428417","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurement"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0428417","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurement""However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (see above).","C0443252|C0744425|C1274040|C1546471|C2825142|C0750482|C0205216|C0392756|C0442797|C2937276|C0505385|C3814864|C0033268|C0042789|C1947903|C1282910|C1552828","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr][tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[qlco]|[qlco]|[qlco]|[blor]|[gngm]|[ocac]|[orgf]|[acty]|[spco]|[idcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurementLong-term|glucocorticoid therapy|Result|What subject filter - Result|Experimental Result|Slightly (qualifier value)|Decreased|Reduced|Decreasing|Slight (qualifier value)|Level of the fourth thoracic vertebra|SERPINA7 wt Allele|production|Vision|See|Upper|Table Frame - above"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , Ieading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|Decreasing"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , Ieading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|Decreasing""However, serum T levels are usually normal but may occasionally be slightly increased. ","C0229671|C0441889|C1546774|C1550100|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , Ieading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|Decreasing""However, serum T levels are usually normal but may occasionally be slightly increased. ","C0229671|C0441889|C1546774|C1550100|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T and T levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C2603360|C0441889|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , Ieading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|Decreasing""However, serum T levels are usually normal but may occasionally be slightly increased. ","C0229671|C0441889|C1546774|C1550100|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T and T levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C2603360|C0441889|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , Ieading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|Decreasing""However, serum T levels are usually normal but may occasionally be slightly increased. ","C0229671|C0441889|C1546774|C1550100|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T and T levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C2603360|C0441889|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T concentrations by 30% with minimal change in serum T levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0229671|C0441889|C1546774|C1550100","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[bdsu]|[qlco]|[inpr]|[bdsu]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , Ieading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|Decreasing""However, serum T levels are usually normal but may occasionally be slightly increased. ","C0229671|C0441889|C1546774|C1550100|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T and T levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C2603360|C0441889|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T concentrations by 30% with minimal change in serum T levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0229671|C0441889|C1546774|C1550100","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[bdsu]|[qlco]|[inpr]|[bdsu]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum""However, long-term glucocorticoid therapy may result in slightly decreased T and T levels due to decreased TBG production (see above).\4\3\3\4\3\4\3\4\3\4","C0443252|C0744425|C1274040|C1546471|C2825142|C0750482|C0205216|C0392756|C0442797|C2937276|C0441889|C3814864|C0033268|C0042789|C1947903|C1282910|C1552828","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[bdsu]|[qlco]|[inpr]|[bdsu][tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[qlco]|[qlco]|[qlco]|[qlco]|[gngm]|[ocac]|[orgf]|[acty]|[spco]|[idcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - SerumLong-term|glucocorticoid therapy|Result|What subject filter - Result|Experimental Result|Slightly (qualifier value)|Decreased|Reduced|Decreasing|Slight (qualifier value)|Levels (qualifier value)|SERPINA7 wt Allele|production|Vision|See|Upper|Table Frame - above"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , leading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0332152|C1522538|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|Decreasing"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , leading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0332152|C1522538|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|Decreasing""However, serum T levels are usually normal but may occasionally be slightly increased. ","C0229671|C0441889|C1546774|C1550100|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , leading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0332152|C1522538|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|Decreasing""However, serum T levels are usually normal but may occasionally be slightly increased. ","C0229671|C0441889|C1546774|C1550100|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T and T levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C2603360|C0441889|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , leading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0332152|C1522538|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|Decreasing""However, serum T levels are usually normal but may occasionally be slightly increased. ","C0229671|C0441889|C1546774|C1550100|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T and T levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C2603360|C0441889|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , leading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0332152|C1522538|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|Decreasing""However, serum T levels are usually normal but may occasionally be slightly increased. ","C0229671|C0441889|C1546774|C1550100|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T and T levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C2603360|C0441889|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T concentrations by 30% with minimal change in serum T levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0229671|C0441889|C1546774|C1550100","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[bdsu]|[qlco]|[inpr]|[bdsu]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T to T , leading to decreased T levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C2603360|C0332152|C1522538|C0205216|C0441889|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|Decreasing""However, serum T levels are usually normal but may occasionally be slightly increased. ","C0229671|C0441889|C1546774|C1550100|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T and T levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C2603360|C0441889|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T concentrations by 30% with minimal change in serum T levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0229671|C0441889|C1546774|C1550100","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[bdsu]|[qlco]|[inpr]|[bdsu]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum""However, long-term glucocorticoid therapy may result in slightly decreased T and T levels due to decreased TBG production (see above).\4\3\3\4\3\4\3\4\3\4","C0443252|C0744425|C1274040|C1546471|C2825142|C0750482|C0205216|C0392756|C0442797|C2937276|C0441889|C3814864|C0033268|C0042789|C1947903|C1282910|C1552828","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[clna]|[tmco]|[ftcn]|[qnco]|[qlco]|[qlco][bdsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[clna]|[qlco]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[bdsu]|[qlco]|[inpr]|[bdsu][tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[qlco]|[qlco]|[qlco]|[qlco]|[gngm]|[ocac]|[orgf]|[acty]|[spco]|[idcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|T prime|Before|Leading|Decreased|Levels (qualifier value)|DecreasingSerum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|T prime|Levels (qualifier value)|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - SerumLong-term|glucocorticoid therapy|Result|What subject filter - Result|Experimental Result|Slightly (qualifier value)|Decreased|Reduced|Decreasing|Slight (qualifier value)|Levels (qualifier value)|SERPINA7 wt Allele|production|Vision|See|Upper|Table Frame - above"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, Ieading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|Decreasing"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, Ieading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, Ieading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, Ieading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, Ieading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0428417","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurement"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, Ieading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0428417","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurement""However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (see above).","C0443252|C0744425|C1274040|C1546471|C2825142|C0750482|C0205216|C0392756|C0442797|C2937276|C0505385|C3814864|C0033268|C0042789|C1947903|C1282910|C1552828","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr][tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[qlco]|[qlco]|[qlco]|[blor]|[gngm]|[ocac]|[orgf]|[acty]|[spco]|[idcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurementLong-term|glucocorticoid therapy|Result|What subject filter - Result|Experimental Result|Slightly (qualifier value)|Decreased|Reduced|Decreasing|Slight (qualifier value)|Level of the fourth thoracic vertebra|SERPINA7 wt Allele|production|Vision|See|Upper|Table Frame - above"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0428417","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurement"
"Administration of these enzyme inhibitors decrease the peripheral conversion of T4 to T3, leading to decreased T3 levels. ","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421|C0442797","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|Decreasing""However, serum T4 levels are usually normal but may occasionally be slightly increased. ","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase""In patients treated with large doses of propranolol ( > 160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. ","C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0505385|C0392747|C0443172|C1705241|C0750482|C2937276|C0202230|C0205307|C0439166|C2347086|C0117002","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)""It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. ","C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. ","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0428417","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurement""However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (see above).","C0443252|C0744425|C1274040|C1546471|C2825142|C0750482|C0205216|C0392756|C0442797|C2937276|C0505385|C3814864|C0033268|C0042789|C1947903|C1282910|C1552828","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]|[qlco][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn][podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[blor]|[ftcn]|[qnco]|[qnco]|[qlco]|[qlco]|[lbpr]|[qlco]|[qnco]|[qnco]|[fndg][clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr][tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[qlco]|[qlco]|[qlco]|[blor]|[gngm]|[ocac]|[orgf]|[acty]|[spco]|[idcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra|DecreasingSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|IncreasePatients|Treating|Large|Dosage|Propranolol|milligram/day|Level of the fourth thoracic vertebra|Changing|Changed status|Delta (difference)|Slightly (qualifier value)|Slight (qualifier value)|Thyroid stimulating hormone measurement|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurementLong-term|glucocorticoid therapy|Result|What subject filter - Result|Experimental Result|Slightly (qualifier value)|Decreased|Reduced|Decreasing|Slight (qualifier value)|Level of the fourth thoracic vertebra|SERPINA7 wt Allele|production|Vision|See|Upper|Table Frame - above"
"Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels.","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0442797|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decreasing|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra"
"Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels.","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0442797|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decreasing|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra""However, serum T4 levels are usually normal but may occasionally be slightly increased.In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4levels change slightly, TSH levels remain normal, and patients are clinically euthyroid.It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state.","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805|C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0392747|C0443172|C1705241|C0202230|C0117002|C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C2360836|C2360838|C2360840|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]|[podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[ftcn]|[qnco]|[qnco]|[lbpr]|[fndg]|[clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[clna]|[clna]|[clna]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decreasing|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebraSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase|Patients|Treating|Large|Dosage|Propranolol|milligram/day|Changing|Changed status|Delta (difference)|Thyroid stimulating hormone measurement|Euthyroid (finding)|Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Geographic state|State|US State"
"Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels.","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0442797|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decreasing|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra""However, serum T4 levels are usually normal but may occasionally be slightly increased.In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4levels change slightly, TSH levels remain normal, and patients are clinically euthyroid.It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state.","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805|C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0392747|C0443172|C1705241|C0202230|C0117002|C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C2360836|C2360838|C2360840|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]|[podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[ftcn]|[qnco]|[qnco]|[lbpr]|[fndg]|[clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[clna]|[clna]|[clna]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decreasing|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebraSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase|Patients|Treating|Large|Dosage|Propranolol|milligram/day|Changing|Changed status|Delta (difference)|Thyroid stimulating hormone measurement|Euthyroid (finding)|Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels.","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0428417","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]|[podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[ftcn]|[qnco]|[qnco]|[lbpr]|[fndg]|[clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[clna]|[clna]|[clna]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decreasing|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebraSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase|Patients|Treating|Large|Dosage|Propranolol|milligram/day|Changing|Changed status|Delta (difference)|Thyroid stimulating hormone measurement|Euthyroid (finding)|Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurement"
"Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels.","C0001554|C1533734|C0014432|C1152555|C2756995|C0392756|C0442797|C0547047|C0205100|C0439836|C0332152|C1522538|C0205216|C0446421","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decreasing|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebra""However, serum T4 levels are usually normal but may occasionally be slightly increased.In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4levels change slightly, TSH levels remain normal, and patients are clinically euthyroid.It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state.","C0428417|C3538928|C0205307|C0439166|C2347086|C3888388|C1998882|C0750482|C2937276|C0205217|C0442805|C0030705|C1522326|C0549177|C0178602|C0033497|C0439422|C0392747|C0443172|C1705241|C0202230|C0117002|C1316572|C1317574|C0441472|C0001645|C0178504|C2757061|C0221099|C0020676|C2360836|C2360838|C2360840|C1301808|C1442792|C3148680","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]|[podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[ftcn]|[qnco]|[qnco]|[lbpr]|[fndg]|[clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[clna]|[clna]|[clna]|[geoa]|[ftcn]|[geoa]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decreasing|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebraSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase|Patients|Treating|Large|Dosage|Propranolol|milligram/day|Changing|Changed status|Delta (difference)|Thyroid stimulating hormone measurement|Euthyroid (finding)|Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Geographic state|State|US State""Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels.","C0443303|C0001554|C1533734|C0549177|C0178602|C0017710|C3540777|C3540778|C0392756|C0547047|C0683149|C3842588|C3845594|C0428417","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]|[podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[ftcn]|[qnco]|[qnco]|[lbpr]|[fndg]|[clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[clna]|[clna]|[clna]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decreasing|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebraSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase|Patients|Treating|Large|Dosage|Propranolol|milligram/day|Changing|Changed status|Delta (difference)|Thyroid stimulating hormone measurement|Euthyroid (finding)|Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurement""However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (see above).","C0443252|C0744425|C1274040|C1546471|C2825142|C0750482|C0205216|C0392756|C0442797|C2937276|C0505385|C3814864|C0033268|C0042789|C1947903|C1282910|C1552828","[ocac]|[topp]|[phsu]|[moft]|[moft]|[qlco]|[qlco]|[qnco]|[spco]|[ftcn]|[tmco]|[ftcn]|[qnco]|[blor][lbpr]|[qlco]|[qlco]|[qnco]|[qnco]|[inpr]|[tmco]|[qlco]|[qlco]|[qnco]|[ftcn]|[podg]|[ftcn]|[qnco]|[qnco]|[orch, phsu]|[qnco]|[ftcn]|[qnco]|[qnco]|[lbpr]|[fndg]|[clna]|[inpr]|[ftcn]|[phsu]|[phsu]|[moft]|[ftcn]|[dsyn]|[clna]|[clna]|[clna]|[geoa]|[ftcn]|[geoa][tmco]|[ocac]|[topp]|[qnco]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[qlco]|[qnco]|[qnco]|[fndg]|[fndg]|[lbpr][tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[qlco]|[qnco]|[qlco]|[qlco]|[qlco]|[blor]|[gngm]|[ocac]|[orgf]|[acty]|[spco]|[idcn]","Administration occupational activities|Administration procedure|Enzyme Inhibitors|enzyme inhibitor activity|Enzyme Inhibitors [MoA]|Reduced|Decreasing|Decrease|Peripheral|Conversions|Before|Leading|Decreased|Level of the third thoracic vertebraSerum T4 measurement|Usual|Normal|Percent normal|Mean Percent of Normal|Usually|Sometimes|Slightly (qualifier value)|Slight (qualifier value)|Increased|Increase|Patients|Treating|Large|Dosage|Propranolol|milligram/day|Changing|Changed status|Delta (difference)|Thyroid stimulating hormone measurement|Euthyroid (finding)|Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}|Note (document)|Clinical action|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Impaired|Hypothyroidism|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Geographic state|State|US Stateshort-term|Administration occupational activities|Administration procedure|Large|Dosage|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Reduced|Decrease|serum concentration|30%|Slight change|Serum T4 measurementLong-term|glucocorticoid therapy|Result|What subject filter - Result|Experimental Result|Slightly (qualifier value)|Decreased|Reduced|Decreasing|Slight (qualifier value)|Level of the fourth thoracic vertebra|SERPINA7 wt Allele|production|Vision|See|Upper|Table Frame - above"
"AminoglutethimideAmiodaroneIodide (including iodine-containing Radiographic contrast agents)LithiumMethimazolePropylthioracil (PTU)SulfonamidesTolbutamide","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"AminoglutethimideAmiodaroneIodide (including iodine-containing Radiographic contrast agents)LithiumMethimazolePropylthioracil (PTU)SulfonamidesTolbutamide","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"Aminoglutethimide Amiodarone Iodide (including iodine-  containing radiographic  contrast agents) Lithium Methimazole Propylthioracil (PTU) Sulfonamides Tolbutamide","C0002555|C0002598|C0021966|C0332257|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749|C0023870|C0025644|C3540800|C0038760|C0040374|C0599503|C3539179|C3539184|C3541962|C3541963","[orch, phsu]|[orch, phsu]|[inch]|[ftcn]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]|[elii, phsu]|[orch, phsu]|[phsu]|[orch]|[orch, phsu]|[antb, orch]|[orch, phsu]|[orch]|[orch, phsu]|[orch, phsu]","Aminoglutethimide|Amiodarone|Iodides|Including (qualifier)|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media|Lithium|Methimazole|Lithium antipsychotics|Sulfonamides|Tolbutamide|Sulfonamide Anti-Infective Agents|Sulfonamides, Gynecological|Sulfonamides, topical|Sulfonamides, ophthalmologic antiinfectives|Sulfonamides, intestinal antiinfectives"
"Aminoglutethimide Amiodarone Iodide (including iodine-containing Radiographic contrast agents) Lithium Methimazole Propylthioracil (PTU) Sulfonamides Tolbutamide","C0002555|C0002598|C0021966|C0332257|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749|C0023870|C0025644|C3540800|C0038760|C0040374|C0599503|C3539179|C3539184|C3541962|C3541963","[orch, phsu]|[orch, phsu]|[inch]|[ftcn]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]|[elii, phsu]|[orch, phsu]|[phsu]|[orch]|[orch, phsu]|[antb, orch]|[orch, phsu]|[orch]|[orch, phsu]|[orch, phsu]","Aminoglutethimide|Amiodarone|Iodides|Including (qualifier)|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media|Lithium|Methimazole|Lithium antipsychotics|Sulfonamides|Tolbutamide|Sulfonamide Anti-Infective Agents|Sulfonamides, Gynecological|Sulfonamides, topical|Sulfonamides, ophthalmologic antiinfectives|Sulfonamides, intestinal antiinfectives"
"AminoglutethimideAmiodaroneIodide (including iodine-containing Radiographic contrast agents)LithiumMethimazolePropylthioracil (PTU)SulfonamidesTolbutamide","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"AminoglutethimideAmiodaroneIodide (including iodine- containing radiographic contrast agents)LithiumMethimazolePropylthioracil (PTU)SulfonamidesTolbutamide","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"AmiodaroneBeta-adrenergic antagonists- (e.g., Propranolol > 160 mg/day)Glucocorticoids-(e.g., Dexamethasone ? 4 mg/day)Propylthiouracil (PTU)","C0242889|C2757018|C0033497|C0439422|C0017710|C3540777|C3540778|C0985346|C0332173|C0439228|C0439505|C0033511","[phsu]|[moft]|[orch, phsu]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[clnd]|[tmco]|[tmco]|[tmco]|[nnon, phsu]","Adrenergic Antagonists|Adrenergic Antagonists [MoA]|Propranolol|milligram/day|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Dexamethasone 4 MG|Daily|day|per day|Propylthiouracil"
"AmiodaroneIodide (including iodine-containing Radiographic contrast agents)","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"AmiodaroneBeta-adrenergic antagonists- (e.g., Propranolol > 160 mg/day)Glucocorticoids-(e.g., Dexamethasone ? 4 mg/day)Propylthiouracil (PTU)","C0242889|C2757018|C0033497|C0439422|C0017710|C3540777|C3540778|C0985346|C0332173|C0439228|C0439505|C0033511","[phsu]|[moft]|[orch, phsu]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[clnd]|[tmco]|[tmco]|[tmco]|[nnon, phsu]","Adrenergic Antagonists|Adrenergic Antagonists [MoA]|Propranolol|milligram/day|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Dexamethasone 4 MG|Daily|day|per day|Propylthiouracil"
"AmiodaroneIodide (including iodine-containing Radiographic contrast agents)","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"Amiodarone Beta-adrenergic antagonists - (e.g., Propranolol > 160 mg/day) Glucocorticoids -(e.g., Dexamethasone ? 4 mg/day) Propylthiouracil (PTU)","C0002598|C0001645|C0178504|C2757061|C0033497|C0439422|C0017710|C3540777|C3540778|C0985346|C0332173|C0439228|C0439505|C0033511","[orch, phsu]|[phsu]|[phsu]|[moft]|[orch, phsu]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[clnd]|[tmco]|[tmco]|[tmco]|[nnon, phsu]","Amiodarone|Adrenergic beta-Antagonists|beta antiadrenergic agent|Adrenergic beta-Antagonists [MoA]|Propranolol|milligram/day|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Dexamethasone 4 MG|Daily|day|per day|Propylthiouracil"
"Amiodarone Iodide (including iodine- containing Radiographic contrast agents)","C0002598|C0021966|C0332257|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[orch, phsu]|[inch]|[ftcn]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Amiodarone|Iodides|Including (qualifier)|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"Amiodarone Iodide (including iodine-containing Radiographic contrast agents)","C0002598|C0021966|C0332257|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[orch, phsu]|[inch]|[ftcn]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Amiodarone|Iodides|Including (qualifier)|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"AmiodaroneBeta-adrenergic antagonists- (e.g., Propranolol > 160 mg/day)Glucocorticoids-(e.g., Dexamethasone ? 4 mg/day)Propylthiouracil (PTU)","C0242889|C2757018|C0033497|C0439422|C0017710|C3540777|C3540778|C0985346|C0332173|C0439228|C0439505|C0033511","[phsu]|[moft]|[orch, phsu]|[qnco]|[horm, orch]|[horm, orch, phsu]|[orch, phsu]|[clnd]|[tmco]|[tmco]|[tmco]|[nnon, phsu]","Adrenergic Antagonists|Adrenergic Antagonists [MoA]|Propranolol|milligram/day|Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Dexamethasone 4 MG|Daily|day|per day|Propylthiouracil"
"AmiodaroneIodide (including iodine-containing Radiographic contrast agents)","C0332257|C0021966|C0021968|C0885449|C2348268|C0332256|C2700400|C2930749","[ftcn]|[inch]|[elii, phsu]|[phsu]|[elii]|[ftcn]|[acty]|[irda]","Including (qualifier)|Iodides|Iodine|Iodine, Homeopathic preparation|Dietary Iodine|Containing (qualifier)|Contain (action)|Radiographic contrast media"
"AmiodaroneIodide (including iodine-containing Radiographiccontrast agents)","C0332257|C0021966|C0332256|C0450442|C1254351|C1521826|C2700400|C0021968|C0885449|C2348268","[ftcn]|[inch]|[ftcn]|[chvf]|[phsu]|[inpr]|[acty]|[elii, phsu]|[phsu]|[elii]","Including (qualifier)|Iodides|Containing (qualifier)|Agent|Pharmacologic Substance|Protocol Agent|Contain (action)|Iodine|Iodine, Homeopathic preparation|Dietary Iodine"
"Amlodipine\									Aspirin\									Atorvastatin\									Calcitriol\									Clopidogrel\									Digoxin\									Diltiazem\									Doxercalciferol\									Enalapril\									Fluvastatin\									Glimepiride\									Levofloxacin\									Losartan\									Metoprolol\									Pravastatin\									Propranolol\									Sitagliptin\									Warfarin","C1329978|C0004057|C0006674|C0070166|C0012265|C0717708|C0043668|C0082608|C0061323|C0282386|C0126174|C0025859|C0085542|C0033497|C1565750|C0043031|C3714610|C0051696|C1329980|C0286651","[orch, phsu]|[orch, phsu]|[horm, phsu, vita]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu, vita]|[orch, phsu]|[orch, phsu]|[antb, orch]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[hops, orch, phsu]|[phsu, vita]|[orch, phsu]|[orch, phsu]|[orch, phsu]","Amlodipine / atorvastatin|Aspirin|Calcitriol|clopidogrel|Digoxin|Diltiazem / Enalapril|Doxercalciferol|fluvastatin|glimepiride|Levofloxacin|Losartan|Metoprolol|Pravastatin|Propranolol|sitagliptin|Warfarin|Calcitriol Drug Class|Amlodipine|Aspirin / Pravastatin|atorvastatin"
"Androgens / Anabolic SteroidsAsparaginaseGlucocorticoidsSlow-Release Nicotinic Acid","C0002844|C0002744|C0030685|C0391871|C0439180|C0680255|C1283071|C1963578|C0027996|C0028049|C3536880|C3714626","[horm, phsu]|[orch, phsu]|[hlca]|[ftcn]|[qnco]|[hlca]|[ftcn]|[topp]|[orch, phsu, vita]|[orch, phsu, vita]|[phsu]|[phsu, vita]","Androgens|Anabolic steroids|Patient Discharge|Released (action)|% release (qualifier value)|Discharge (release)|Release - action (qualifier value)|Release (procedure)|Niacin|Nicotinic Acids|Nicotinic Acid [EPC]|Nicotinic Acid Drug Class"
"Androgens / Anabolic SteroidsAsparaginaseGlucocorticoidsSlow-Release Nicotinic Acid","C0002844|C0002744|C0030685|C0391871|C0439180|C0680255|C1283071|C1963578|C0027996|C0028049|C3536880|C3714626","[horm, phsu]|[orch, phsu]|[hlca]|[ftcn]|[qnco]|[hlca]|[ftcn]|[topp]|[orch, phsu, vita]|[orch, phsu, vita]|[phsu]|[phsu, vita]","Androgens|Anabolic steroids|Patient Discharge|Released (action)|% release (qualifier value)|Discharge (release)|Release - action (qualifier value)|Release (procedure)|Niacin|Nicotinic Acids|Nicotinic Acid [EPC]|Nicotinic Acid Drug Class"
"Androgens / Anabolic Steroids","C0351241","[phsu]","Androgens+anabolic steroids"
"Androgens / Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid","C0351241|C0003993|C0017710|C0439834|C0030685|C0027996|C0028049|C3536880|C3714626|C0391871|C0439180|C0680255|C1283071|C1963578|C3540777|C3540778|C2681123","[phsu]|[aapp, enzy, phsu]|[horm, orch]|[qlco]|[hlca]|[orch, phsu, vita]|[orch, phsu, vita]|[phsu]|[phsu, vita]|[ftcn]|[qnco]|[hlca]|[ftcn]|[topp]|[horm, orch, phsu]|[orch, phsu]|[gngm]","Androgens+anabolic steroids|ASPARAGINASE|Glucocorticoids|Slow|Patient Discharge|Niacin|Nicotinic Acids|Nicotinic Acid [EPC]|Nicotinic Acid Drug Class|Released (action)|% release (qualifier value)|Discharge (release)|Release - action (qualifier value)|Release (procedure)|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|ASPG gene"
"Androgens / Anabolic SteroidsAsparaginaseGlucocorticoidsSlow-Release Nicotinic Acid","C0002844|C0002744|C0030685|C0391871|C0439180|C0680255|C1283071|C1963578|C0027996|C0028049|C3536880|C3714626","[horm, phsu]|[orch, phsu]|[hlca]|[ftcn]|[qnco]|[hlca]|[ftcn]|[topp]|[orch, phsu, vita]|[orch, phsu, vita]|[phsu]|[phsu, vita]","Androgens|Anabolic steroids|Patient Discharge|Released (action)|% release (qualifier value)|Discharge (release)|Release - action (qualifier value)|Release (procedure)|Niacin|Nicotinic Acids|Nicotinic Acid [EPC]|Nicotinic Acid Drug Class"
"Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products)","C0003138|C0038633|C0301532|C3714835|C1514468|C0332256|C2700400|C0007447|C0024467|C0304540|C2348270|C3540792|C3714621|C0032521|C4020599|C1707959|C0718050|C0768119|C0592249|C0012133|C0304290|C0006353|C0030755|C0032861|C1382110|C1521725|C0205250|C0013227|C3687832|C0006675|C0006726|C2936886|C3540037|C3714611|C0302583|C0376520|C1166521|C3714701|C0043481|C2348288|C3541396|C3714650|C0010947","[phsu]|[orch, phsu]|[orch, phsu, vita]|[phsu, vita]|[enty]|[ftcn]|[acty]|[chvs]|[elii]|[inch, phsu]|[elii]|[inch, phsu]|[phsu]|[bodm, chvs]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[nnon, phsu]|[nnon, phsu]|[bodm]|[irda, phsu]|[bmod]|[bodm]|[sbst]|[qlco]|[qlco]|[phsu]|[topp]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu, vita]|[phsu]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu]|[elii, phsu]|[elii]|[phsu]|[phsu]|[food]","Antacids|Sucralfate|Multivitamin preparation|Multivitamin Drug Class|product|Containing (qualifier)|Contain (action)|Cations|Magnesium|Aluminum-based antacid|Dietary Magnesium|Magnesium supplements|Magnesium Drug Class|Polymers|Phosphate Binders|Example|sevelamer|lanthanum carbonate|Videx|Didanosine|Chewable Tablet|Buffers|Pediatrics|Powder dose form|powder physical state|Pediatric|High|Pharmaceutical Preparations|Drugs|Calcium|Calcium, Dietary|Calcium [EPC]|CALCIUM SUPPLEMENTS|Calcium Drug Class|Iron|Dietary Iron|Ferrum metallicum, Homeopathic preparation|Iron Drug Class|Zinc|Dietary Zinc|Zinc Supplements|Zinc Drug Class|Dairy Products"
"Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products)","C0003138|C0038633|C0301532|C3714835|C1514468|C0332256|C2700400|C0007447|C0024467|C0304540|C2348270|C3540792|C3714621|C0032521|C4020599|C1707959|C0718050|C0768119|C0592249|C0012133|C0304290|C0006353|C0030755|C0032861|C1382110|C1521725|C0205250|C0013227|C3687832|C0006675|C0006726|C2936886|C3540037|C3714611|C0302583|C0376520|C1166521|C3714701|C0043481|C2348288|C3541396|C3714650|C0010947","[phsu]|[orch, phsu]|[orch, phsu, vita]|[phsu, vita]|[enty]|[ftcn]|[acty]|[chvs]|[elii]|[inch, phsu]|[elii]|[inch, phsu]|[phsu]|[bodm, chvs]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[nnon, phsu]|[nnon, phsu]|[bodm]|[irda, phsu]|[bmod]|[bodm]|[sbst]|[qlco]|[qlco]|[phsu]|[topp]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu, vita]|[phsu]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu]|[elii, phsu]|[elii]|[phsu]|[phsu]|[food]","Antacids|Sucralfate|Multivitamin preparation|Multivitamin Drug Class|product|Containing (qualifier)|Contain (action)|Cations|Magnesium|Aluminum-based antacid|Dietary Magnesium|Magnesium supplements|Magnesium Drug Class|Polymers|Phosphate Binders|Example|sevelamer|lanthanum carbonate|Videx|Didanosine|Chewable Tablet|Buffers|Pediatrics|Powder dose form|powder physical state|Pediatric|High|Pharmaceutical Preparations|Drugs|Calcium|Calcium, Dietary|Calcium [EPC]|CALCIUM SUPPLEMENTS|Calcium Drug Class|Iron|Dietary Iron|Ferrum metallicum, Homeopathic preparation|Iron Drug Class|Zinc|Dietary Zinc|Zinc Supplements|Zinc Drug Class|Dairy Products"
"Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products)","C0003138|C0038633|C0301532|C3714835|C1514468|C0332256|C2700400|C0007447|C0024467|C0304540|C2348270|C3540792|C3714621|C0032521|C4020599|C1707959|C0718050|C0768119|C0592249|C0012133|C0304290|C0006353|C0030755|C0032861|C1382110|C1521725|C0205250|C0013227|C3687832|C0006675|C0006726|C2936886|C3540037|C3714611|C0302583|C0376520|C1166521|C3714701|C0043481|C2348288|C3541396|C3714650|C0010947","[phsu]|[orch, phsu]|[orch, phsu, vita]|[phsu, vita]|[enty]|[ftcn]|[acty]|[chvs]|[elii]|[inch, phsu]|[elii]|[inch, phsu]|[phsu]|[bodm, chvs]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[nnon, phsu]|[nnon, phsu]|[bodm]|[irda, phsu]|[bmod]|[bodm]|[sbst]|[qlco]|[qlco]|[phsu]|[topp]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu, vita]|[phsu]|[bacs, elii, phsu]|[inch]|[phsu]|[phsu]|[elii, phsu]|[elii]|[phsu]|[phsu]|[food]","Antacids|Sucralfate|Multivitamin preparation|Multivitamin Drug Class|product|Containing (qualifier)|Contain (action)|Cations|Magnesium|Aluminum-based antacid|Dietary Magnesium|Magnesium supplements|Magnesium Drug Class|Polymers|Phosphate Binders|Example|sevelamer|lanthanum carbonate|Videx|Didanosine|Chewable Tablet|Buffers|Pediatrics|Powder dose form|powder physical state|Pediatric|High|Pharmaceutical Preparations|Drugs|Calcium|Calcium, Dietary|Calcium [EPC]|CALCIUM SUPPLEMENTS|Calcium Drug Class|Iron|Dietary Iron|Ferrum metallicum, Homeopathic preparation|Iron Drug Class|Zinc|Dietary Zinc|Zinc Supplements|Zinc Drug Class|Dairy Products"
"Antacids- Aluminum & MagnesiumHydroxides- SimethiconeBile Acid Sequestrants- Cholestyramine- ColestipolCalcium CarbonateCation Exchange Resins- KayexalateFerrous SulfateOrlistatSucralfate","C0003138|C0002367|C0001128|C0008402|C0678640|C4019011|C0202406|C2348254","[phsu]|[elii]|[chem]|[orch, phsu]|[socb]|[clna]|[lbpr]|[inch]","Antacids|Aluminum|Acids|Cholestyramine Resin|degree of relationship - exchange|Exchange (clinical)|Lysergic acid diethylamide measurement|Dietary Aluminum"
"Anticoagulants (oral)- Coumarin Derivatives- Indandione Derivatives","C0003280|C0442027|C0010207","[phsu]|[spco]|[orch, phsu]","Anticoagulants|Oral|Coumarins"
"Anticoagulants (oral)- Coumarin Derivatives- Indandione Derivatives","C0003280|C0442027|C0010207","[phsu]|[spco]|[orch, phsu]","Anticoagulants|Oral|Coumarins"
"Anticoagulants (oral) - Coumarin Derivatives - Indandione Derivatives","C0003280|C0442027|C0010207","[phsu]|[spco]|[orch, phsu]","Anticoagulants|Oral|Coumarins"
"Anticoagulants (oral)- Coumarin Derivatives- Indandione Derivatives","C0003280|C0442027|C0010207","[phsu]|[spco]|[orch, phsu]","Anticoagulants|Oral|Coumarins"
"Anticonvulsants:Carbamazepine,clonazepam, ethosuximide","C0003286|C0006949|C0682993|C0009011|C0015043","[phsu]|[orch, phsu]|[orch]|[orch, phsu]|[orch, phsu]","Anticonvulsants|Carbamazepine|carbamazepin|Clonazepam|Ethosuximide"
"Antidepressants- Tricyclics (e.g., Amitriptyline)- Tetracyclics (e.g., Maprotiline)- Selective Serotonin Reuptake Inhibitors (SSRIs; e.g., Sertraline)","C0003290|C0002600|C0024778|C0360105|C0074393","[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]","Tricyclic Antidepressive Agents|Amitriptyline|Maprotiline|Selective Serotonin Reuptake Inhibitors|Sertraline"
"Antidepressants- Tricyclics (e.g., Amitriptyline)- Tetracyclics (e.g., Maprotiline)- Selective Serotonin Reuptake Inhibitors (SSRIs; e.g., Sertraline)","C0003290|C0002600|C0024778|C0360105|C0074393","[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]","Tricyclic Antidepressive Agents|Amitriptyline|Maprotiline|Selective Serotonin Reuptake Inhibitors|Sertraline"
"Antidepressants - Tricyclics (e.g., Amitriptyline) - Tetracyclics (e.g., Maprotiline) - Selective Serotonin Reuptake Inhibitors (SSRIs; e.g., Sertraline)","C0003290|C0002600|C0024778|C0360105|C0074393","[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]","Tricyclic Antidepressive Agents|Amitriptyline|Maprotiline|Selective Serotonin Reuptake Inhibitors|Sertraline"
"Antidepressants - Tricyclics (e.g., Amitriptyline) - Tetracyclics (e.g., Maprotiline) - Selective Serotonin Reuptake Inhibitors (SSRIs; e.g., Sertraline)","C0003290|C0002600|C0024778|C0360105|C0074393","[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]","Tricyclic Antidepressive Agents|Amitriptyline|Maprotiline|Selective Serotonin Reuptake Inhibitors|Sertraline"
"Antidepressants- Tricyclics (e.g., Amitriptyline)- Tetracyclics (e.g., Maprotiline)- Selective Serotonin Reuptake Inhibitors (SSRIs; e.g., Sertraline)","C0003290|C0002600|C0024778|C0360105|C0074393","[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]","Tricyclic Antidepressive Agents|Amitriptyline|Maprotiline|Selective Serotonin Reuptake Inhibitors|Sertraline"
"Antidepressants- Tricyclics (e.g., Amitriptyline)- Tetracyclics (e.g., Maprotiline)- Selective Serotonin ReuptakeInhibitors (SSRIs; e.g., Sertraline)","C0003290|C0002600|C0024778|C0036751|C0360105|C0074393","[phsu]|[orch, phsu]|[orch, phsu]|[bacs, orch]|[phsu]|[orch, phsu]","Tricyclic Antidepressive Agents|Amitriptyline|Maprotiline|Serotonin|Selective Serotonin Reuptake Inhibitors|Sertraline"
"Antidiabetic Agents- Biguanides- Meglitinides- Sulfonylureas- Thiazolidediones- Insulin","C0935929|C0005382|C0065880|C0038766|C0021641|C1533581|C1579433|C3714501|C3653359|C1579432|C0360396|C3540012","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]","Antidiabetics|Biguanides|Meglitinide|Sulfonylurea Compounds|Insulin|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Sulfonylureas for blood glucose lowering|Meglitinides|Biguanide antimalarial|biguanide blood glucose lower drugs"
"Antidiabetic Agents- Biguanides- Meglitinides- Sulfonylureas- Thiazolidediones- Insulin","C0935929|C0005382|C0065880|C0038766|C0021641|C1533581|C1579433|C3714501|C3653359|C1579432|C0360396|C3540012","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]","Antidiabetics|Biguanides|Meglitinide|Sulfonylurea Compounds|Insulin|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Sulfonylureas for blood glucose lowering|Meglitinides|Biguanide antimalarial|biguanide blood glucose lower drugs"
"Antidiabetic Agents - Biguanides - Meglitinides - Sulfonylureas - Thiazolidediones - Insulin","C0935929|C0005382|C0065880|C0038766|C0021641|C1533581|C1579433|C3714501|C3653359|C1579432|C0360396|C3540012","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]","Antidiabetics|Biguanides|Meglitinide|Sulfonylurea Compounds|Insulin|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Sulfonylureas for blood glucose lowering|Meglitinides|Biguanide antimalarial|biguanide blood glucose lower drugs"
"Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.","C0935929|C0003015|C0003011|C0233660|C0450442|C1254351|C1521826|C0332206|C0012702|C1449704|C3540783|C0016365|C0026457|C2756978|C0030899|C0537551|C0033493|C1880235|C0036077|C0732165|C3536825|C0028833|C0038760|C0003232|C0003237|C3540704|C3540705|C3540706|C3540707|C3540708|C3540709|C3540710|C0599503|C3536763","[phsu]|[phsu]|[aapp, rcpt]|[mobd]|[chvf]|[phsu]|[inpr]|[ftcn]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[moft]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[phsu]|[aapp, horm, phsu]|[orch]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb, orch]|[phsu]","Antidiabetics|Angiotensin-Converting Enzyme Inhibitors|Receptor, Angiotensin II|Mental blocking|Agent|Pharmacologic Substance|Protocol Agent|Blocking|Disopyramide|Fibrates|Fibrates, lipid modifying drugs, plain|Fluoxetine|Monoamine Oxidase Inhibitors|Monoamine Oxidase Inhibitors [MoA]|Pentoxifylline|Pramlintide|Propoxyphene|Propoxyphene, (+/-)-|Salicylates|Somatostatin analog|Somatostatin Analog [EPC]|Octreotide|Sulfonamides|Antibiotics|Antibiotics, Antitubercular|Antibiotics for systemic use|Antifungal Antibiotics, Topical|Antibiotic throat preparations|Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE|Antibiotics, Gynecological|antibiotics, intestinal|Antibiotics, ophthalmologic|Sulfonamide Anti-Infective Agents|Sulfonamide [EPC]"
"Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.","C0935929|C0003015|C0003011|C0233660|C0450442|C1254351|C1521826|C0332206|C0012702|C1449704|C3540783|C0016365|C0026457|C2756978|C0030899|C0537551|C0033493|C1880235|C0036077|C0732165|C3536825|C0028833|C0038760|C0003232|C0003237|C3540704|C3540705|C3540706|C3540707|C3540708|C3540709|C3540710|C0599503|C3536763","[phsu]|[phsu]|[aapp, rcpt]|[mobd]|[chvf]|[phsu]|[inpr]|[ftcn]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[moft]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[phsu]|[aapp, horm, phsu]|[orch]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb]|[antb, orch]|[phsu]","Antidiabetics|Angiotensin-Converting Enzyme Inhibitors|Receptor, Angiotensin II|Mental blocking|Agent|Pharmacologic Substance|Protocol Agent|Blocking|Disopyramide|Fibrates|Fibrates, lipid modifying drugs, plain|Fluoxetine|Monoamine Oxidase Inhibitors|Monoamine Oxidase Inhibitors [MoA]|Pentoxifylline|Pramlintide|Propoxyphene|Propoxyphene, (+/-)-|Salicylates|Somatostatin analog|Somatostatin Analog [EPC]|Octreotide|Sulfonamides|Antibiotics|Antibiotics, Antitubercular|Antibiotics for systemic use|Antifungal Antibiotics, Topical|Antibiotic throat preparations|Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE|Antibiotics, Gynecological|antibiotics, intestinal|Antibiotics, ophthalmologic|Sulfonamide Anti-Infective Agents|Sulfonamide [EPC]"
"Antidiabetic Agents- Biguanides- Meglitinides- Sulfonylureas- Thiazolidediones- Insulin","C0935929|C0005382|C0065880|C0038766|C0021641|C1533581|C1579433|C3714501|C3653359|C1579432|C0360396|C3540012","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[phsu]|[horm, phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]","Antidiabetics|Biguanides|Meglitinide|Sulfonylurea Compounds|Insulin|Recombinant Insulin|Insulin [EPC]|Insulin Drug Class|Sulfonylureas for blood glucose lowering|Meglitinides|Biguanide antimalarial|biguanide blood glucose lower drugs"
"Antifungals: Fluconazole*","C0003308|C0016277","[phsu]|[orch, phsu]","Antifungal Agents|Fluconazole"
"Antithrombotics: Warfarin","C0043031","[hops, orch, phsu]","Warfarin"
"Appropriate doses for these combinations have not been established.","C1548787|C0178602|C0453882|C3539181|C3539182|C3539954|C3539955|C3539956|C3539957|C3539958|C3539959|C3539960|C3539961|C3539962|C3539963|C3539964|C3539965|C3539966|C3539967|C3539968|C3539969|C3539970|C3539971|C3539972|C3539973|C3539974|C3539975|C3539976|C3539977|C3539978|C3539979|C3540026|C3540027|C3540028|C3540030|C3540031|C3540719|C3540720|C3540721|C3540722|C3540723|C3540724|C3540740|C3854036|C1518422|C0443211|C1272684","[qlco]|[qnco]|[mnob]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[phsu]|[ftcn]|[qlco]|[qlco]","Appropriate|Dosage|Combinations (Undergarment)|Short-acting sulfonamide combinations|Salt solution combinations|topical antibiotic combinations|lung surfactant combinations|Magnesium antacid compound combinations|opium alkaloids and derivative combination cough suppressants|Imidazole and triazole derivative topical antifungal combinations|Long-acting sulfonamide combinations|Other intestinal adsorbent combinations in ATC|Platelet aggregation inhibitor combinations excl. heparin|vitamin D and analog combinations|Amide local anesthetic combinations|local opthalmologic anesthetic combinations|Local hemostatic combinations|insulins and analogs for injection combinations, long-acting|Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations|Enema combinations|Specific immunoglobulin combinations|combination drugs used in erectile dysfunction|otologic analgesic and anesthetic combinations|Combination solutions for parenteral nutrition|Other antifungal combinations for topical use in ATC|Insulins and analogs for injection, intermediate-acting combinations|Aluminium antacid compound combinations|Penicillins with extended spectrum combinations|Calcium antacid compound combinations|expectorant combinations excluding combinations with cough suppressants|Antiinfective irrigating solution combinations|Hepatitis vaccine combinations|Adrenergic and dopaminergic agents combinations|Other irrigating solution combinations in ATC|other cough suppressant combinations in ATC|gonadotropin combinations|Intermediate-acting sulfonamide combinations|Caries prophylactic agent combinations|other nasal preparation combinations in ATC|Beta-lactamase sensitive penicillin combinations|Insulins and analogs for injection, fast-acting combinations|expectorant combinations, excl. combinations with cough suppressants|Potassium supplement combinations|Other anti-dementia drug combinations in ATC|Negation|Established|Accepted"
"Appropriate doses for this combination have not been established.","C1548787|C0178602|C0205195|C1947911|C3811910|C1518422|C0443211|C1272684","[qlco]|[qnco]|[qlco]|[phob]|[fndg]|[ftcn]|[qlco]|[qlco]","Appropriate|Dosage|Combined|combination of objects|combination - answer to question|Negation|Established|Accepted"
"Asparaginase","C0003993|C2681123","[aapp, enzy, phsu]|[gngm]","ASPARAGINASE|ASPG gene"
"Atazanavir/ Ritonavir*","C1977391","[phsu]","Atazanavir+Ritonavir"
"AUC024 hrs","","",""
"Avoid Use(Plasma Exposure Likely to be Increased and Prolonged)","C0042153|C0457083|C1947944|C0032105|C0274281|C0332157|C1550098|C0332148|C0750492|C0040363|C0041260|C1883351|C0205217|C0442805|C0439590","[ftcn]|[ftcn]|[inpr]|[bdsu]|[inpo]|[clna]|[bdsu]|[qlco]|[idcn]|[geoa]|[aapp, enzy]|[qlco]|[qnco]|[ftcn]|[tmco]","utilization qualifier|Usage|Use - dosing instruction imperative|Plasma|Injury due to exposure to external cause|Exposure to|Plasma, NOS (not otherwise specified)|Probable diagnosis|Probably|Togo|Tryptophanase|To|Increased|Increase|Prolonged"
"Avoid Use Five-fold increase in duloxetine exposure","C0042153|C0205451|C0332462|C0442805|C1880834|C0457083|C1947944|C0245561|C0274281|C0332157","[ftcn]|[qnco]|[spco]|[ftcn]|[phpr]|[ftcn]|[inpr]|[orch, phsu]|[inpo]|[clna]","utilization qualifier|Five|Folded structure|Increase|Fold in Medical Device Material|Usage|Use - dosing instruction imperative|duloxetine|Injury due to exposure to external cause|Exposure to"
"Avoid Use","C0042153|C0457083|C1947944","[ftcn]|[ftcn]|[inpr]","utilization qualifier|Usage|Use - dosing instruction imperative"
"Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)","C0042153|C0457083|C1947944|C0032105|C0274281|C0332157|C1550098|C0332148|C0750492|C0040363|C0041260|C1883351|C0205217|C0442805|C0439590","[ftcn]|[ftcn]|[inpr]|[bdsu]|[inpo]|[clna]|[bdsu]|[qlco]|[idcn]|[geoa]|[aapp, enzy]|[qlco]|[qnco]|[ftcn]|[tmco]","utilization qualifier|Usage|Use - dosing instruction imperative|Plasma|Injury due to exposure to external cause|Exposure to|Plasma, NOS (not otherwise specified)|Probable diagnosis|Probably|Togo|Tryptophanase|To|Increased|Increase|Prolonged"
"Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)","C0042153|C0457083|C1947944|C0032105|C0274281|C0332157|C1550098|C0332148|C0750492|C0040363|C0041260|C1883351|C0205217|C0442805|C0439590","[ftcn]|[ftcn]|[inpr]|[bdsu]|[inpo]|[clna]|[bdsu]|[qlco]|[idcn]|[geoa]|[aapp, enzy]|[qlco]|[qnco]|[ftcn]|[tmco]","utilization qualifier|Usage|Use - dosing instruction imperative|Plasma|Injury due to exposure to external cause|Exposure to|Plasma, NOS (not otherwise specified)|Probable diagnosis|Probably|Togo|Tryptophanase|To|Increased|Increase|Prolonged"
"Avoid Use Five-fold increase in duloxetine exposure","C0042153|C0205451|C0332462|C0442805|C1880834|C0457083|C1947944|C0245561|C0274281|C0332157","[ftcn]|[qnco]|[spco]|[ftcn]|[phpr]|[ftcn]|[inpr]|[orch, phsu]|[inpo]|[clna]","utilization qualifier|Five|Folded structure|Increase|Fold in Medical Device Material|Usage|Use - dosing instruction imperative|duloxetine|Injury due to exposure to external cause|Exposure to"
"Avoid Use Five-fold increase in duloxetine exposure","C0042153|C0205451|C0332462|C0442805|C1880834|C0457083|C1947944|C0245561|C0274281|C0332157","[ftcn]|[qnco]|[spco]|[ftcn]|[phpr]|[ftcn]|[inpr]|[orch, phsu]|[inpo]|[clna]","utilization qualifier|Five|Folded structure|Increase|Fold in Medical Device Material|Usage|Use - dosing instruction imperative|duloxetine|Injury due to exposure to external cause|Exposure to"
"Avoidgrapefruitjuice","","",""
"Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events.","C0035647|C0205217|C0274281|C0332157|C0442805|C0132326|C1273517|C0521115|C0001554|C1533734|C0030705|C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0332281|C0877248|C1705413","[idcn]|[qnco]|[inpo]|[clna]|[ftcn]|[orch, phsu]|[fndg]|[tmco]|[ocac]|[topp]|[podg]|[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[qlco]|[patf]|[inpr]","Risk|Increased|Injury due to exposure to external cause|Exposure to|Increase|Nevirapine|Used by|Simultaneous|Administration occupational activities|Administration procedure|Patients|Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Associated with|Adverse event|Adverse Event Domain"
"Boceprevir","C1738934","[aapp, phsu]","boceprevir"
"bosentan","C0252643","[orch, phsu]","bosentan"
"Calcitriol\										Ciprofloxacin\										Digoxin\										Enalapril\										Furosemide\										HMG-CoA reductase inhibitors\										Hydrochlorothiazide\										Losartan\										Metoprolol\										Nifedipine\										Omeprazole\										Quinidine\										Warfarin","C0006674|C0008809|C0012265|C0717738|C0016860|C0360714|C0126174|C2929367|C0028978|C0034414|C0043031|C2756999|C3539119|C0014025|C0717825|C3714610","[horm, phsu, vita]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[hops, orch, phsu]|[moft]|[phsu]|[aapp, phsu]|[orch, phsu]|[phsu, vita]","Calcitriol|Ciprofloxacin|Digoxin|Enalapril / Hydrochlorothiazide|Furosemide|Hydroxymethylglutaryl-CoA Reductase Inhibitors|Losartan|Metoprolol / Nifedipine|Omeprazole|Quinidine|Warfarin|Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]|HMG CoA reductase inhibitors, plain lipid modifying drugs|Enalapril|Hydrochlorothiazide / Losartan|Calcitriol Drug Class"
"Calcium channel blockers: Diltiazem, nifedipine, verapamil","C0006684|C0012373|C0028066|C0042523","[phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]","Calcium Channel Blockers|Diltiazem|Nifedipine|Verapamil"
"Cancer chemotherapy:Cyclophosphamide","C0392920|C3665472|C0010583","[topp]|[topp]|[orch, phsu]","Chemotherapy Regimen|Chemotherapy|Cyclophosphamide"
"CarbamazepineHydantoinsPhenobarbitalRifampin","","",""
"CarbamazepineHydantoinsPhenobarbitalRifampin","","",""
"carbamazepine","C0006949|C0682993","[orch, phsu]|[orch]","Carbamazepine|carbamazepin"
"Carbamazepine Hydantoins Phenobarbital Rifampin","C0006949|C0020209|C0031412|C0035608|C0682993","[orch, phsu]|[orch, phsu]|[orch, phsu]|[antb, orch]|[orch]","Carbamazepine|Hydantoins|Phenobarbital|Rifampin|carbamazepin"
"CarbamazepineHydantoinsPhenobarbitalRifampin","","",""
"carbamazepine","C0006949|C0682993","[orch, phsu]|[orch]","Carbamazepine|carbamazepin"
"Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised.","C1947933|C0150369|C1283169|C1516647|C0009079|C0332281|C0559546|C1548787|C0376209|C0456081|C0683269|C0178602|C0814472|C0008809","[acty]|[hlca]|[hlca]|[resa]|[orch, phsu]|[qlco]|[patf]|[qlco]|[inbe]|[ftcn]|[inbe]|[qnco]|[hlca]|[orch, phsu]","care activity|Preventive monitoring|Monitoring - action|Clinical Trials, Monitoring|Clozapine|Associated with|Adverse reactions|Appropriate|Individual Adjustment|Adjustment Action|Psychological adjustment|Dosage|co-treatment|Ciprofloxacin"
"Change in the Concentration of Ganciclovir or Concomitant Drug","C0392747|C0443172|C1705241|C0004268|C0086045|C1446561|C0017066|C0521115|C0013227|C1254351","[ftcn]|[qnco]|[qnco]|[menp]|[menp]|[qnco]|[nnon, phsu]|[tmco]|[phsu]|[phsu]","Changing|Changed status|Delta (difference)|Attention|Mental concentration|Concentration measurement|Ganciclovir|Simultaneous|Pharmaceutical Preparations|Pharmacologic Substance"
"Chloral HydrateDiazepamEthionamideLovastatinMetoclopramide6-MercaptopurineNitroprussidePara-aminosalicylate sodiumPerphenazineResorcinol (excessive topical use)Thiazide Diuretics","C0077034|C0368663|C2825094|C0442802|C1522168|C0012802","[orch, phsu]|[orch, phsu]|[phsu]|[qlco]|[ftcn]|[orch, phsu]","trichloroacetaldehyde|aminosalicylate|Aminosalicylate [EPC]|Excessive|Topical Route of Drug Administration|Thiazide Diuretics"
"Chloral HydrateDiazepamEthionamideLovastatinMetoclopramide6-MercaptopurineNitroprussidePara-aminosalicylate sodiumPerphenazineResorcinol (excessive topical use)Thiazide Diuretics","C0077034|C0368663|C2825094|C0442802|C1522168|C0012802","[orch, phsu]|[orch, phsu]|[phsu]|[qlco]|[ftcn]|[orch, phsu]","trichloroacetaldehyde|aminosalicylate|Aminosalicylate [EPC]|Excessive|Topical Route of Drug Administration|Thiazide Diuretics"
"Chloral Hydrate Diazepam Ethionamide Lovastatin Metoclopramide 6-Mercaptopurine Nitroprusside Para-aminosalicylate sodium Perphenazine Resorcinol (excessive topical use) Thiazide Diuretics","C0008161|C0012010|C0015021|C1708744|C0025853|C0000618|C0028193|C0807286|C0031184|C0073085|C0024027|C0037533|C0442802|C1522168|C0012802","[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[nnon, phsu]|[inch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[qlco]|[ftcn]|[orch, phsu]","Chloral Hydrate|Diazepam|Ethionamide|Lovastatin Sodium|Metoclopramide|mercaptopurine|Nitroprusside|Para-aminosalicylate|Perphenazine|resorcinol|Lovastatin|Sodium Nitroprusside|Excessive|Topical Route of Drug Administration|Thiazide Diuretics"
"Chloral Hydrate Diazepam Ethionamide Lovastatin Metoclopramide 6-Mercaptopurine NITROPRUSSIDE Para-aminosalicylate sodium Perphenazine Resorcinol (excessive topical use) Thiazide Diuretics","C0008161|C0012010|C0015021|C1708744|C0025853|C0000618|C0028193|C0807286|C0031184|C0073085|C0024027|C0037533|C0442802|C1522168|C0012802","[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[nnon, phsu]|[inch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[qlco]|[ftcn]|[orch, phsu]","Chloral Hydrate|Diazepam|Ethionamide|Lovastatin Sodium|Metoclopramide|mercaptopurine|Nitroprusside|Para-aminosalicylate|Perphenazine|resorcinol|Lovastatin|Sodium Nitroprusside|Excessive|Topical Route of Drug Administration|Thiazide Diuretics"
"Chloral HydrateDiazepamEthionamideLovastatinMetoclopramide6-MercaptopurineNitroprussidePara-aminosalicylate sodiumPerphenazineResorcinol (excessive topical use)Thiazide Diuretics","C0077034|C0368663|C2825094|C0442802|C1522168|C0012802","[orch, phsu]|[orch, phsu]|[phsu]|[qlco]|[ftcn]|[orch, phsu]","trichloroacetaldehyde|aminosalicylate|Aminosalicylate [EPC]|Excessive|Topical Route of Drug Administration|Thiazide Diuretics"
"Chloral HydrateDiazepamEthionamideLovastatinMetoclopramide6-MercaptopurineNITROPRUSSIDEPara-aminosalicylate sodiumPerphenazineResorcinol(excessive topical use)Thiazide Diuretics","C0077034|C0368663|C2825094|C0442802|C1522168|C0012802","[orch, phsu]|[orch, phsu]|[phsu]|[qlco]|[ftcn]|[orch, phsu]","trichloroacetaldehyde|aminosalicylate|Aminosalicylate [EPC]|Excessive|Topical Route of Drug Administration|Thiazide Diuretics"
"Ciprofloxacin inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products). ","C0008809|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C0220781|C0439634|C1522492|C0044060|C0006644|C0001554|C1533734|C0030899|C0332256|C1514468|C2700400","[orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[biof]|[spco]|[ftcn]|[orch]|[orch, phsu]|[ocac]|[topp]|[orch, phsu]|[ftcn]|[enty]|[acty]","Ciprofloxacin|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Anabolism|Formations|Formation|1,7-dimethylxanthine|Caffeine|Administration occupational activities|Administration procedure|Pentoxifylline|Containing (qualifier)|product|Contain (action)"
"Ciprofloxacin inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products). ","C0008809|C0018790|C0028778|C0233660|C0237477|C0332206|C0392351|C0521111|C1533157|C1706084|C2828370|C3811660|C0220781|C0439634|C1522492|C0044060|C0006644|C0001554|C1533734|C0030899|C0332256|C1514468|C2700400","[orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[biof]|[spco]|[ftcn]|[orch]|[orch, phsu]|[ocac]|[topp]|[orch, phsu]|[ftcn]|[enty]|[acty]","Ciprofloxacin|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Anabolism|Formations|Formation|1,7-dimethylxanthine|Caffeine|Administration occupational activities|Administration procedure|Pentoxifylline|Containing (qualifier)|product|Contain (action)""Monitor for xanthine toxicity and adjust dose as necessary.","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0043314|C0040539|C0600688|C0043318|C0178602|C0869039|C1114758","[orch, phsu]|[dsyn]|[patf]|[mobd]|[tmco]|[ftcn]|[gora]|[qlco]|[sbst]|[geoa]|[qnco]|[qnco]|[biof]|[spco]|[ftcn]|[orch]|[orch, phsu]|[ocac]|[topp]|[orch, phsu]|[ftcn]|[enty]|[acty][hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, nnon]|[qlco]|[inpo]|[bacs, nnon]|[qnco]|[qnco]|[clna]","Ciprofloxacin|Cardiac Arrest|Obstruction|Mental blocking|Arrested progression|Blocking|Law enforcement arrest|Retarded|Block Specimens|(City) Block|Block (unit of measure)|Block Unit of Distance|Anabolism|Formations|Formation|1,7-dimethylxanthine|Caffeine|Administration occupational activities|Administration procedure|Pentoxifylline|Containing (qualifier)|product|Contain (action)Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|xanthine|Toxicity aspects|Toxic effect|Xanthines|Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative"
"Ciprofloxacin may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics)\[see Warnings and Precautions (5.10) and Use inSpecific Populations (8.5)].","C0008809|C1517331|C0429028|C0488414|C0030705|C1514756|C0013227|C3687832|C0205309|C0040363|C0041260|C1883351|C1707959|C0456387|C1947960|C1705943|C0439070|C0003195|C1705160|C0003290|C0430087|C0003240|C0282563|C0040615|C0042789|C1947903|C0871599|C1882442|C0439084|C3842590|C0728893|C0042153|C0032659|C1257890|C0457083|C1947944","[orch, phsu]|[spco]|[clna]|[clna]|[podg]|[qlco]|[phsu]|[topp]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[cnce]|[inpr]|[mamm]|[clas]|[inpr]|[phsu]|[qlco]|[phsu]|[lbpr]|[antb, orch]|[orch, phsu]|[phsu]|[orgf]|[acty]|[gora]|[cnce]|[qnco]|[fndg]|[qnco]|[ftcn]|[qnco]|[popg]|[ftcn]|[inpr]","Ciprofloxacin|Further|QT interval feature (observable entity)|QT interval:Time:Point in time:Heart:Quantitative:EKG|Patients|Receive|Pharmaceutical Preparations|Drugs|Known|Togo|Tryptophanase|To|Example|Class|Ia <mammal>|Class (taxonomic)|Roman Numeral III|Anti-Arrhythmia Agents|III (suffix)|Tricyclic Antidepressive Agents|Tricyclic antidepressant measurement|Macrolide Antibiotics|Macrolides|Antipsychotic Agents|Vision|See|Cautionary Warning|Precaution|>5|10%|+5|utilization qualifier|geographic population|Population Group|Usage|Use - dosing instruction imperative"
"Ciprofloxacin may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) [see Warnings and Precautions (5.10) and Use in Specific Populations (8.5)].","C0008809|C1517331|C0429028|C0488414|C0030705|C1514756|C0013227|C3687832|C0205309|C0040363|C0041260|C1883351|C1707959|C0456387|C1947960|C1705943|C0439070|C0003195|C1705160|C0003290|C0430087|C0003240|C0282563|C0040615|C0042789|C1947903|C0871599|C1882442|C0439084|C3842590|C0728893|C0042153|C0457083|C1947944|C0205369|C0032659|C1257890|C1552740","[orch, phsu]|[spco]|[clna]|[clna]|[podg]|[qlco]|[phsu]|[topp]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[cnce]|[inpr]|[mamm]|[clas]|[inpr]|[phsu]|[qlco]|[phsu]|[lbpr]|[antb, orch]|[orch, phsu]|[phsu]|[orgf]|[acty]|[gora]|[cnce]|[qnco]|[fndg]|[qnco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[qnco]|[popg]|[inpr]","Ciprofloxacin|Further|QT interval feature (observable entity)|QT interval:Time:Point in time:Heart:Quantitative:EKG|Patients|Receive|Pharmaceutical Preparations|Drugs|Known|Togo|Tryptophanase|To|Example|Class|Ia <mammal>|Class (taxonomic)|Roman Numeral III|Anti-Arrhythmia Agents|III (suffix)|Tricyclic Antidepressive Agents|Tricyclic antidepressant measurement|Macrolide Antibiotics|Macrolides|Antipsychotic Agents|Vision|See|Cautionary Warning|Precaution|>5|10%|+5|utilization qualifier|Usage|Use - dosing instruction imperative|Specific qualifier value|geographic population|Population Group|Entity Determiner - specific"
"Ciprofloxacin may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) [see Warnings and Precautions (5.10) and Use in Specific Populations (8.5)].","C0008809|C1517331|C0429028|C0488414|C0030705|C1514756|C0013227|C3687832|C0205309|C0040363|C0041260|C1883351|C1707959|C0456387|C1947960|C1705943|C0439070|C0003195|C1705160|C0003290|C0430087|C0003240|C0282563|C0040615|C0042789|C1947903|C0871599|C1882442|C0439084|C3842590|C0728893|C0042153|C0457083|C1947944|C0205369|C0032659|C1257890|C1552740","[orch, phsu]|[spco]|[clna]|[clna]|[podg]|[qlco]|[phsu]|[topp]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[cnce]|[inpr]|[mamm]|[clas]|[inpr]|[phsu]|[qlco]|[phsu]|[lbpr]|[antb, orch]|[orch, phsu]|[phsu]|[orgf]|[acty]|[gora]|[cnce]|[qnco]|[fndg]|[qnco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[qnco]|[popg]|[inpr]","Ciprofloxacin|Further|QT interval feature (observable entity)|QT interval:Time:Point in time:Heart:Quantitative:EKG|Patients|Receive|Pharmaceutical Preparations|Drugs|Known|Togo|Tryptophanase|To|Example|Class|Ia <mammal>|Class (taxonomic)|Roman Numeral III|Anti-Arrhythmia Agents|III (suffix)|Tricyclic Antidepressive Agents|Tricyclic antidepressant measurement|Macrolide Antibiotics|Macrolides|Antipsychotic Agents|Vision|See|Cautionary Warning|Precaution|>5|10%|+5|utilization qualifier|Usage|Use - dosing instruction imperative|Specific qualifier value|geographic population|Population Group|Entity Determiner - specific"
"Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration. (2)].","C0008809|C1883727|C0439092|C0205448|C0439227|C0547044|C0205452|C0007447|C0332256|C1514468|C0001554|C1533734|C2700400|C0042789|C1947903|C0178602|C0740116|C2827735|C2981700|C3833492","[orch, phsu]|[cnce]|[qnco]|[qnco]|[tmco]|[qlco]|[qnco]|[chvs]|[ftcn]|[enty]|[ocac]|[topp]|[acty]|[orgf]|[acty]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Ciprofloxacin|Taken|Less Than|Two|Hour|Smaller|Six|Cations|Containing (qualifier)|product|Administration occupational activities|Administration procedure|Contain (action)|Vision|See|Dosage|+2|2+ Score|2+ Score, WHO|2+"
"Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration .\[see Dosage and Administration\(2)].","C0008809|C1883727|C0439092|C0205448|C0439227|C0547044|C0205452|C0007447|C0332256|C1514468|C0001554|C1533734|C2700400|C0042789|C1947903|C0178602|C0740116|C2827735|C2981700|C3833492","[orch, phsu]|[cnce]|[qnco]|[qnco]|[tmco]|[qlco]|[qnco]|[chvs]|[ftcn]|[enty]|[ocac]|[topp]|[acty]|[orgf]|[acty]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Ciprofloxacin|Taken|Less Than|Two|Hour|Smaller|Six|Cations|Containing (qualifier)|product|Administration occupational activities|Administration procedure|Contain (action)|Vision|See|Dosage|+2|2+ Score|2+ Score, WHO|2+"
"Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration. (2)].","C0008809|C1883727|C0439092|C0205448|C0439227|C0547044|C0205452|C0007447|C0332256|C1514468|C0001554|C1533734|C2700400|C0042789|C1947903|C0178602|C0740116|C2827735|C2981700|C3833492","[orch, phsu]|[cnce]|[qnco]|[qnco]|[tmco]|[qlco]|[qnco]|[chvs]|[ftcn]|[enty]|[ocac]|[topp]|[acty]|[orgf]|[acty]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Ciprofloxacin|Taken|Less Than|Two|Hour|Smaller|Six|Cations|Containing (qualifier)|product|Administration occupational activities|Administration procedure|Contain (action)|Vision|See|Dosage|+2|2+ Score|2+ Score, WHO|2+"
"Clarithromycin exposure was significantly decreased by nevirapine; ","C0055856|C0274281|C0332157|C0205216|C0392756|C0442797|C0132326","[antb, orch]|[inpo]|[clna]|[qnco]|[qlco]|[qlco]|[orch, phsu]","Clarithromycin|Injury due to exposure to external cause|Exposure to|Decreased|Reduced|Decreasing|Nevirapine"
"Clarithromycin exposure was significantly decreased by nevirapine; ","C0055856|C0274281|C0332157|C0205216|C0392756|C0442797|C0132326","[antb, orch]|[inpo]|[clna]|[qnco]|[qlco]|[qlco]|[orch, phsu]","Clarithromycin|Injury due to exposure to external cause|Exposure to|Decreased|Reduced|Decreasing|Nevirapine""however, 14-OH metabolite concentrations were increased. ","C0220853|C0870883|C0086045|C0205217|C0442805","[antb, orch]|[inpo]|[clna]|[qnco]|[qlco]|[qlco]|[orch, phsu][elii]|[bacs]|[menp]|[qnco]|[ftcn]","Clarithromycin|Injury due to exposure to external cause|Exposure to|Decreased|Reduced|Decreasing|NevirapineHydroxide Ion|Metabolite|Mental concentration|Increased|Increase"
"Clarithromycin exposure was significantly decreased by nevirapine; ","C0055856|C0274281|C0332157|C0205216|C0392756|C0442797|C0132326","[antb, orch]|[inpo]|[clna]|[qnco]|[qlco]|[qlco]|[orch, phsu]","Clarithromycin|Injury due to exposure to external cause|Exposure to|Decreased|Reduced|Decreasing|Nevirapine""however, 14-OH metabolite concentrations were increased. ","C0220853|C0870883|C0086045|C0205217|C0442805","[antb, orch]|[inpo]|[clna]|[qnco]|[qlco]|[qlco]|[orch, phsu][elii]|[bacs]|[menp]|[qnco]|[ftcn]","Clarithromycin|Injury due to exposure to external cause|Exposure to|Decreased|Reduced|Decreasing|NevirapineHydroxide Ion|Metabolite|Mental concentration|Increased|Increase""Because clarithromycin active metabolite has reduced activity against Mycobacterium aviumintracellulare complex, overall activity against this pathogen may be altered. ","C0055856|C0205177|C0870883|C3853793|C3888249|C0392756|C0439167|C0441655|C1561536|C3668946|C1032649|C0282416|C1561607|C0450254|C0392747","[antb, orch]|[inpo]|[clna]|[qnco]|[qlco]|[qlco]|[orch, phsu][elii]|[bacs]|[menp]|[qnco]|[ftcn][antb, orch]|[ftcn]|[bacs]|[idcn]|[qlco]|[qlco]|[qnco]|[acty]|[idcn]|[fndg]|[bact]|[inpr]|[qlco]|[orgm]|[ftcn]","Clarithromycin|Injury due to exposure to external cause|Exposure to|Decreased|Reduced|Decreasing|NevirapineHydroxide Ion|Metabolite|Mental concentration|Increased|IncreaseClarithromycin|Active|Metabolite|active (HL7 RoleLink)|Active License|Reduced|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Mycobacterium tuberculosis complex|Overall Publication Type|Overall|Pathogenic organism|Changing"
"Clarithromycin exposure was significantly decreased by nevirapine; ","C0055856|C0274281|C0332157|C0205216|C0392756|C0442797|C0132326","[antb, orch]|[inpo]|[clna]|[qnco]|[qlco]|[qlco]|[orch, phsu]","Clarithromycin|Injury due to exposure to external cause|Exposure to|Decreased|Reduced|Decreasing|Nevirapine""however, 14-OH metabolite concentrations were increased. ","C0220853|C0870883|C0086045|C0205217|C0442805","[antb, orch]|[inpo]|[clna]|[qnco]|[qlco]|[qlco]|[orch, phsu][elii]|[bacs]|[menp]|[qnco]|[ftcn]","Clarithromycin|Injury due to exposure to external cause|Exposure to|Decreased|Reduced|Decreasing|NevirapineHydroxide Ion|Metabolite|Mental concentration|Increased|Increase""Because clarithromycin active metabolite has reduced activity against Mycobacterium aviumintracellulare complex, overall activity against this pathogen may be altered. ","C0055856|C0205177|C0870883|C3853793|C3888249|C0392756|C0439167|C0441655|C1561536|C3668946|C1032649|C0282416|C1561607|C0450254|C0392747","[antb, orch]|[inpo]|[clna]|[qnco]|[qlco]|[qlco]|[orch, phsu][elii]|[bacs]|[menp]|[qnco]|[ftcn][antb, orch]|[ftcn]|[bacs]|[idcn]|[qlco]|[qlco]|[qnco]|[acty]|[idcn]|[fndg]|[bact]|[inpr]|[qlco]|[orgm]|[ftcn]","Clarithromycin|Injury due to exposure to external cause|Exposure to|Decreased|Reduced|Decreasing|NevirapineHydroxide Ion|Metabolite|Mental concentration|Increased|IncreaseClarithromycin|Active|Metabolite|active (HL7 RoleLink)|Active License|Reduced|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Mycobacterium tuberculosis complex|Overall Publication Type|Overall|Pathogenic organism|Changing""Alternatives to clarithromycin, such as azithromycin, should be considered.","C1523987|C0055856|C0052796|C0750591","[antb, orch]|[inpo]|[clna]|[qnco]|[qlco]|[qlco]|[orch, phsu][elii]|[bacs]|[menp]|[qnco]|[ftcn][antb, orch]|[ftcn]|[bacs]|[idcn]|[qlco]|[qlco]|[qnco]|[acty]|[idcn]|[fndg]|[bact]|[inpr]|[qlco]|[orgm]|[ftcn][cnce]|[antb, orch]|[antb, orch]|[idcn]","Clarithromycin|Injury due to exposure to external cause|Exposure to|Decreased|Reduced|Decreasing|NevirapineHydroxide Ion|Metabolite|Mental concentration|Increased|IncreaseClarithromycin|Active|Metabolite|active (HL7 RoleLink)|Active License|Reduced|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Mycobacterium tuberculosis complex|Overall Publication Type|Overall|Pathogenic organism|ChangingAlternative|Clarithromycin|Azithromycin|consider"
"ClofibrateEstrogen-containing oral contraceptivesEstrogens (oral)Heroin / Methadone5-FluorouracilMitotaneTamoxifen","C0332256|C2700400|C0442027|C0011892","[ftcn]|[acty]|[spco]|[hops, orch, phsu]","Containing (qualifier)|Contain (action)|Oral|Heroin"
"ClofibrateEstrogen-containing oral contraceptivesEstrogens (oral)Heroin / Methadone5-FluorouracilMitotaneTamoxifen","C0332256|C2700400|C0442027|C0011892","[ftcn]|[acty]|[spco]|[hops, orch, phsu]","Containing (qualifier)|Contain (action)|Oral|Heroin"
"Clofibrate","C0009002","[orch, phsu]","Clofibrate"
"Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin / Methadone 5-Fluorouracil Mitotane Tamoxifen","C0009002|C0014939|C0332256|C0009905|C3537250|C3541386|C3714615|C2700400|C2936882|C0442027|C0011892|C0025605|C0016360|C0026256|C0039286|C1552533","[orch, phsu]|[horm, orch, phsu]|[ftcn]|[phsu]|[horm, orch, phsu]|[horm, orch, phsu]|[phsu]|[acty]|[phsu]|[spco]|[hops, orch, phsu]|[orch, phsu]|[nnon, phsu]|[orch, phsu]|[orch, phsu]|[hcro, mnob]","Clofibrate|Estrogens|Containing (qualifier)|Contraceptives, Oral|ESTROGENS, SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM|Estrogens, endocrine therapy drugs|Estrogens Drug Class|Contain (action)|Estrogen [EPC]|Oral|Heroin|Methadone|Fluorouracil|Mitotane|Tamoxifen|Methadone Clinic/Center"
"ClofibrateEstrogen-containing oral contraceptivesEstrogens (oral)Heroin / Methadone5-FluorouracilMitotaneTamoxifen","C0332256|C2700400|C0442027|C0011892","[ftcn]|[acty]|[spco]|[hops, orch, phsu]","Containing (qualifier)|Contain (action)|Oral|Heroin"
"Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended.","C0814472|C0132326|C1176315|C0292818|C1518422|C0034866","[hlca]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[ftcn]|[idcn]","co-treatment|Nevirapine|fosamprenavir|Ritonavir|Negation|Recommendation"
"Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. ","C0814472|C0132326|C1176315|C0292818|C1518422|C0034866","[hlca]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[ftcn]|[idcn]","co-treatment|Nevirapine|fosamprenavir|Ritonavir|Negation|Recommendation"
"Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. ","C0814472|C0132326|C1176315|C0292818|C1518422|C0034866","[hlca]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[ftcn]|[idcn]","co-treatment|Nevirapine|fosamprenavir|Ritonavir|Negation|Recommendation""No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily. ","C2826232|C1514873|C0132326|C3245499|C1521801|C3817553|C0026410|C0439269|C1960952|C2346927|C1979439|C0585361","[hlca]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[ftcn]|[idcn][hlca]|[ftcn]|[orch, phsu]|[geoa]|[ftcn]|[qnco]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch, phsu]|[tmco]","co-treatment|Nevirapine|fosamprenavir|Ritonavir|Negation|RecommendationDose Adjustment|Requirement|Nevirapine|Colombia|Having administered|100%|Mongolia|mg/dL|Milligram percent|Magnesium Cation|Fosamprenavir+Ritonavir|Twice a day"
"Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended. ","C0814472|C0132326|C1176315|C0292818|C1518422|C0034866","[hlca]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[ftcn]|[idcn]","co-treatment|Nevirapine|fosamprenavir|Ritonavir|Negation|Recommendation""No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily. ","C2826232|C1514873|C0132326|C3245499|C1521801|C3817553|C0026410|C0439269|C1960952|C2346927|C1979439|C0585361","[hlca]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[ftcn]|[idcn][hlca]|[ftcn]|[orch, phsu]|[geoa]|[ftcn]|[qnco]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch, phsu]|[tmco]","co-treatment|Nevirapine|fosamprenavir|Ritonavir|Negation|RecommendationDose Adjustment|Requirement|Nevirapine|Colombia|Having administered|100%|Mongolia|mg/dL|Milligram percent|Magnesium Cation|Fosamprenavir+Ritonavir|Twice a day""The combination of nevirapine administered with fosamprenavir/ritonavir once daily has not been studied.","C0205195|C1947911|C3811910|C0132326|C1521801|C1979439|C0332173|C1518422|C0557651|C2603343","[hlca]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[ftcn]|[idcn][hlca]|[ftcn]|[orch, phsu]|[geoa]|[ftcn]|[qnco]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch, phsu]|[tmco][qlco]|[phob]|[fndg]|[orch, phsu]|[ftcn]|[orch, phsu]|[tmco]|[ftcn]|[mnob]|[resa]","co-treatment|Nevirapine|fosamprenavir|Ritonavir|Negation|RecommendationDose Adjustment|Requirement|Nevirapine|Colombia|Having administered|100%|Mongolia|mg/dL|Milligram percent|Magnesium Cation|Fosamprenavir+Ritonavir|Twice a dayCombined|combination of objects|combination - answer to question|Nevirapine|Having administered|Fosamprenavir+Ritonavir|Daily|Negation|Room of building - Study|Study"
"Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications (4.2)]","C0521115|C0001554|C1533734|C0146011|C0008809|C1444657|C0279023|C0857353|C3179159|C0042789|C1947903|C0079164|C3838679","[tmco]|[ocac]|[topp]|[orch, phsu]|[orch, phsu]|[fndg]|[topp]|[patf]|[phsf]|[orgf]|[acty]|[qlco]|[fndg]","Simultaneous|Administration occupational activities|Administration procedure|tizanidine|Ciprofloxacin|Contraindicated|chemosensitization/potentiation|Hypotensive|Sedative Effect|Vision|See|contraindications aspect|4+ Answer to question"
"Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [ ]\see Contraindications (4.2)","C0521115|C0001554|C1533734|C0146011|C0008809|C1444657|C0279023|C0857353|C3179159|C0042789|C1947903|C0079164|C3838679","[tmco]|[ocac]|[topp]|[orch, phsu]|[orch, phsu]|[fndg]|[topp]|[patf]|[phsf]|[orgf]|[acty]|[qlco]|[fndg]","Simultaneous|Administration occupational activities|Administration procedure|tizanidine|Ciprofloxacin|Contraindicated|chemosensitization/potentiation|Hypotensive|Sedative Effect|Vision|See|contraindications aspect|4+ Answer to question"
"Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications (4.2)]","C0521115|C0001554|C1533734|C0146011|C0008809|C1444657|C0279023|C0857353|C3179159|C0042789|C1947903|C0079164|C3838679","[tmco]|[ocac]|[topp]|[orch, phsu]|[orch, phsu]|[fndg]|[topp]|[patf]|[phsf]|[orgf]|[acty]|[qlco]|[fndg]","Simultaneous|Administration occupational activities|Administration procedure|tizanidine|Ciprofloxacin|Contraindicated|chemosensitization/potentiation|Hypotensive|Sedative Effect|Vision|See|contraindications aspect|4+ Answer to question"
"Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. ","C0205420|C0001554|C1533734|C0008809|C0039771|C1274040|C1546471|C2825142|C0205217|C0035647|C0442805|C0030705|C2360836|C2360838|C2360840|C1269563|C3540014|C3714787|C0559546","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactions"
"Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. ","C0205420|C0001554|C1533734|C0008809|C0039771|C1274040|C1546471|C2825142|C0205217|C0035647|C0442805|C0030705|C2360836|C2360838|C2360840|C1269563|C3540014|C3714787|C0559546","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactions""If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate.\[See Warnings and Precautions (5.6).]","C0521115|C0042153|C0457083|C1947944|C0030695|C0229671|C0441889|C1546774|C1550100|C0150369|C0181904|C0596972|C1521743|C1704646|C0039771|C0178602|C1548787|C0042789|C1947903|C0871599|C1882442|C0442749|C3843715","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf][tmco]|[ftcn]|[ftcn]|[inpr]|[hlca]|[bdsu]|[qlco]|[inpr]|[bdsu]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, orch, phsu]|[qnco]|[qlco]|[orgf]|[acty]|[gora]|[cnce]|[fndg]|[fndg]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactionsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Patient Monitoring|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Theophylline|Dosage|Appropriate|Vision|See|Cautionary Warning|Precaution|6/5|5-6"
"Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. ","C0205420|C0001554|C1533734|C0008809|C0039771|C1274040|C1546471|C2825142|C0205217|C0035647|C0442805|C0030705|C2360836|C2360838|C2360840|C1269563|C3540014|C3714787|C0559546","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactions"
"Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. ","C0205420|C0001554|C1533734|C0008809|C0039771|C1274040|C1546471|C2825142|C0205217|C0035647|C0442805|C0030705|C2360836|C2360838|C2360840|C1269563|C3540014|C3714787|C0559546","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactions""If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate. ","C0521115|C0042153|C0457083|C1947944|C0030695|C0229671|C0441889|C1546774|C1550100|C0150369|C0181904|C0596972|C1521743|C1704646|C0039771|C0178602|C1548787","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf][tmco]|[ftcn]|[ftcn]|[inpr]|[hlca]|[bdsu]|[qlco]|[inpr]|[bdsu]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, orch, phsu]|[qnco]|[qlco]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactionsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Patient Monitoring|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Theophylline|Dosage|Appropriate"
"Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. ","C0205420|C0001554|C1533734|C0008809|C0039771|C1274040|C1546471|C2825142|C0205217|C0035647|C0442805|C0030705|C2360836|C2360838|C2360840|C1269563|C3540014|C3714787|C0559546","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactions""If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate. ","C0521115|C0042153|C0457083|C1947944|C0030695|C0229671|C0441889|C1546774|C1550100|C0150369|C0181904|C0596972|C1521743|C1704646|C0039771|C0178602|C1548787","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf][tmco]|[ftcn]|[ftcn]|[inpr]|[hlca]|[bdsu]|[qlco]|[inpr]|[bdsu]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, orch, phsu]|[qnco]|[qlco]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactionsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Patient Monitoring|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Theophylline|Dosage|Appropriate""[See Warnings and Precautions (5.6).]","C0042789|C1947903|C0871599|C1882442|C0442749|C3843715","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf][tmco]|[ftcn]|[ftcn]|[inpr]|[hlca]|[bdsu]|[qlco]|[inpr]|[bdsu]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, orch, phsu]|[qnco]|[qlco][orgf]|[acty]|[gora]|[cnce]|[fndg]|[fndg]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactionsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Patient Monitoring|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Theophylline|Dosage|AppropriateVision|See|Cautionary Warning|Precaution|6/5|5-6"
"Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. ","C0205420|C0001554|C1533734|C0008809|C0039771|C1274040|C1546471|C2825142|C0205217|C0035647|C0442805|C0030705|C2360836|C2360838|C2360840|C1269563|C3540014|C3714787|C0559546","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactions"
"Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. ","C0205420|C0001554|C1533734|C0008809|C0039771|C1274040|C1546471|C2825142|C0205217|C0035647|C0442805|C0030705|C2360836|C2360838|C2360840|C1269563|C3540014|C3714787|C0559546","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactions""If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate. ","C0521115|C0042153|C0457083|C1947944|C0030695|C0229671|C0441889|C1546774|C1550100|C0150369|C0181904|C0596972|C1521743|C1704646|C0039771|C0178602|C1548787","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf][tmco]|[ftcn]|[ftcn]|[inpr]|[hlca]|[bdsu]|[qlco]|[inpr]|[bdsu]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, orch, phsu]|[qnco]|[qlco]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactionsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Patient Monitoring|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Theophylline|Dosage|Appropriate"
"Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. ","C0205420|C0001554|C1533734|C0008809|C0039771|C1274040|C1546471|C2825142|C0205217|C0035647|C0442805|C0030705|C2360836|C2360838|C2360840|C1269563|C3540014|C3714787|C0559546","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactions""If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate. ","C0521115|C0042153|C0457083|C1947944|C0030695|C0229671|C0441889|C1546774|C1550100|C0150369|C0181904|C0596972|C1521743|C1704646|C0039771|C0178602|C1548787","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf][tmco]|[ftcn]|[ftcn]|[inpr]|[hlca]|[bdsu]|[qlco]|[inpr]|[bdsu]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, orch, phsu]|[qnco]|[qlco]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactionsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Patient Monitoring|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Theophylline|Dosage|Appropriate""[See Warnings and Precautions (5.6).]","C0042789|C1947903|C0871599|C1882442|C0442749|C3843715","[tmco]|[ocac]|[topp]|[orch, phsu]|[bacs, orch, phsu]|[ftcn]|[idcn]|[fndg]|[qnco]|[idcn]|[ftcn]|[podg]|[clna]|[clna]|[clna]|[bdsy]|[irda]|[bdsy]|[patf][tmco]|[ftcn]|[ftcn]|[inpr]|[hlca]|[bdsu]|[qlco]|[inpr]|[bdsu]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[bacs, orch, phsu]|[qnco]|[qlco][orgf]|[acty]|[gora]|[cnce]|[fndg]|[fndg]","Concurrent|Administration occupational activities|Administration procedure|Ciprofloxacin|Theophylline|Result|What subject filter - Result|Experimental Result|Increased|Risk|Increase|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Entire central nervous system|CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS|Central Nervous System|Adverse reactionsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Patient Monitoring|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Theophylline|Dosage|AppropriateVision|See|Cautionary Warning|Precaution|6/5|5-6"
"Concurrent use may increase the effects of sympathomimetics or thyroid hormone.","C0205420|C0042153|C0457083|C1947944|C0442805|C1280500|C0039052|C0040135","[tmco]|[ftcn]|[ftcn]|[inpr]|[ftcn]|[qlco]|[phsu]|[aapp, horm]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Increase|Effect|Sympathomimetics|Thyroid Hormones"
"Concurrent use may increase the effects of sympathomimetics or thyroid hormone.","C0205420|C0042153|C0457083|C1947944|C0442805|C1280500|C0039052|C0040135","[tmco]|[ftcn]|[ftcn]|[inpr]|[ftcn]|[qlco]|[phsu]|[aapp, horm]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Increase|Effect|Sympathomimetics|Thyroid Hormones""Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.","C0040135|C0442805|C0035647|C0542052|C0039052|C1521801|C0030705|C0010054|C0010068|C1956346","[tmco]|[ftcn]|[ftcn]|[inpr]|[ftcn]|[qlco]|[phsu]|[aapp, horm][aapp, horm]|[ftcn]|[idcn]|[dsyn]|[phsu]|[ftcn]|[podg]|[dsyn]|[dsyn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Increase|Effect|Sympathomimetics|Thyroid HormonesThyroid Hormones|Increase|Risk|coronary artery insufficiency|Sympathomimetics|Having administered|Patients|Coronary Arteriosclerosis|Coronary heart disease|Coronary Artery Disease"
"Concurrent use may increase the effects of sympathomimetics or thyroid hormone. ","C0205420|C0042153|C0457083|C1947944|C0442805|C1280500|C0039052|C0040135","[tmco]|[ftcn]|[ftcn]|[inpr]|[ftcn]|[qlco]|[phsu]|[aapp, horm]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Increase|Effect|Sympathomimetics|Thyroid Hormones"
"Concurrent use may increase the effects of sympathomimetics or thyroid hormone. ","C0205420|C0042153|C0457083|C1947944|C0442805|C1280500|C0039052|C0040135","[tmco]|[ftcn]|[ftcn]|[inpr]|[ftcn]|[qlco]|[phsu]|[aapp, horm]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Increase|Effect|Sympathomimetics|Thyroid Hormones""Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.","C0040135|C0442805|C0035647|C0542052|C0039052|C1521801|C0030705|C0010054|C0010068|C1956346","[tmco]|[ftcn]|[ftcn]|[inpr]|[ftcn]|[qlco]|[phsu]|[aapp, horm][aapp, horm]|[ftcn]|[idcn]|[dsyn]|[phsu]|[ftcn]|[podg]|[dsyn]|[dsyn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Increase|Effect|Sympathomimetics|Thyroid HormonesThyroid Hormones|Increase|Risk|coronary artery insufficiency|Sympathomimetics|Having administered|Patients|Coronary Arteriosclerosis|Coronary heart disease|Coronary Artery Disease"
"Concurrent use may produce marked hypertension and tachycardia; ","C0205420|C0042153|C0457083|C1947944|C0522501|C0020538|C1963138|C1706089|C0039231|C3827868","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[dsyn]|[fndg]|[qlco]|[fndg]|[fndg]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Massive|Hypertensive disease|Hypertension Adverse Event|Marked|Tachycardia|Tachycardia by ECG Finding"
"Concurrent use may produce marked hypertension and tachycardia; ","C0205420|C0042153|C0457083|C1947944|C0522501|C0020538|C1963138|C1706089|C0039231|C3827868","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[dsyn]|[fndg]|[qlco]|[fndg]|[fndg]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Massive|Hypertensive disease|Hypertension Adverse Event|Marked|Tachycardia|Tachycardia by ECG Finding""cautious administration to patients receiving thyroid hormone therapy is recommended.","C0001554|C1533734|C0030705|C1514756|C1696944|C0019932|C3540775|C0040135|C0039798|C0087111|C1363945|C0040132|C0279025|C3540038|C0034866","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[dsyn]|[fndg]|[qlco]|[fndg]|[fndg][ocac]|[topp]|[podg]|[qlco]|[topp]|[horm]|[phsu]|[aapp, horm]|[ftcn]|[topp]|[fndg]|[bpoc]|[topp]|[irda]|[idcn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Massive|Hypertensive disease|Hypertension Adverse Event|Marked|Tachycardia|Tachycardia by ECG FindingAdministration occupational activities|Administration procedure|Patients|Receive|Thyroid therapy|Hormones|THYROID THERAPY DRUGS|Thyroid Hormones|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Thyroid Gland|Hormone Therapy|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Recommendation"
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism"
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism""Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex.","C0006681|C0348078|C0376315|C1522492|C0040165|C1881373|C0060282|C0332148|C0750492|C2346593|C0439855|C1704241","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)"
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism""Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex.","C0006681|C0348078|C0376315|C1522492|C0040165|C1881373|C0060282|C0332148|C0750492|C2346593|C0439855|C1704241","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)""Administer levothyroxine at least 4 hours apart from these agents. ","C1621583|C0040165|C1881373|C0439092|C0439227|C0547044|C0450442|C1254351|C1521826","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs][ftcn]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[tmco]|[qlco]|[chvf]|[phsu]|[inpr]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)Administer|Thyroxine|Synthetic Levothyroxine|Less Than|Hour|Smaller|Agent|Pharmacologic Substance|Protocol Agent"
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism""Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex.","C0006681|C0348078|C0376315|C1522492|C0040165|C1881373|C0060282|C0332148|C0750492|C2346593|C0439855|C1704241","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)""Administer levothyroxine at least 4 hours apart from these agents. ","C1621583|C0040165|C1881373|C0439092|C0439227|C0547044|C0450442|C1254351|C1521826","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs][ftcn]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[tmco]|[qlco]|[chvf]|[phsu]|[inpr]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)Administer|Thyroxine|Synthetic Levothyroxine|Less Than|Hour|Smaller|Agent|Pharmacologic Substance|Protocol Agent""Patients treated concomitantly with orlistat and levothyroxine should be monitored for changes in thyroid function.","C0030705|C1522326|C0076275|C0040165|C1881373|C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0392747|C0443172|C2242456","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs][ftcn]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[tmco]|[qlco]|[chvf]|[phsu]|[inpr][podg]|[ftcn]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[ftcn]|[qnco]|[phsf]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)Administer|Thyroxine|Synthetic Levothyroxine|Less Than|Hour|Smaller|Agent|Pharmacologic Substance|Protocol AgentPatients|Treating|orlistat|Thyroxine|Synthetic Levothyroxine|Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Changing|Changed status|thyroid function"
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. ","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism"
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. ","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism""Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. ","C0006681|C0348078|C0376315|C1522492|C0040165|C1881373|C0060282|C0332148|C0750492|C2346593|C0439855|C1704241","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)"
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. ","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism""Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. ","C0006681|C0348078|C0376315|C1522492|C0040165|C1881373|C0060282|C0332148|C0750492|C2346593|C0439855|C1704241","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)""Administer levothyroxine at least 4 hours apart from these agents. ","C1621583|C0040165|C1881373|C0439092|C0439227|C0547044|C0450442|C1254351|C1521826","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs][ftcn]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[tmco]|[qlco]|[chvf]|[phsu]|[inpr]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)Administer|Thyroxine|Synthetic Levothyroxine|Less Than|Hour|Smaller|Agent|Pharmacologic Substance|Protocol Agent"
"Concurrent use may reduce the efficacy of levothyroxine by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. ","C0205420|C0042153|C0457083|C1947944|C1280519|C1707887|C0040165|C1881373|C1145667|C1167622|C0205421|C0309872|C0000854|C2347023|C2347080|C2698776|C2825050|C0678226|C0020676","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|Hypothyroidism""Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. ","C0006681|C0348078|C0376315|C1522492|C0040165|C1881373|C0060282|C0332148|C0750492|C2346593|C0439855|C1704241","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)""Administer levothyroxine at least 4 hours apart from these agents. ","C1621583|C0040165|C1881373|C0439092|C0439227|C0547044|C0450442|C1254351|C1521826","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs][ftcn]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[tmco]|[qlco]|[chvf]|[phsu]|[inpr]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)Administer|Thyroxine|Synthetic Levothyroxine|Less Than|Hour|Smaller|Agent|Pharmacologic Substance|Protocol Agent""Patients treated concomitantly with orlistat and levothyroxine should be monitored for changes in thyroid function.","C0030705|C1522326|C0076275|C0040165|C1881373|C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0392747|C0443172|C2242456","[tmco]|[ftcn]|[ftcn]|[inpr]|[qlco]|[resa]|[aapp, horm, phsu]|[orch, phsu]|[acty]|[moft]|[tmco]|[phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[ftcn]|[dsyn][inch, phsu]|[qlco]|[mnob]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[inch, phsu]|[qlco]|[idcn]|[elii]|[qlco]|[chvs][ftcn]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[tmco]|[qlco]|[chvf]|[phsu]|[inpr][podg]|[ftcn]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[ftcn]|[qnco]|[phsf]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|Effectiveness|Efficacy Study|Thyroxine|Synthetic Levothyroxine|Binding action|Binding (Molecular Function)|Deferred|PREVENT (product)|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Due to|HypothyroidismCalcium Carbonate|Qualitative form|Manufactured form|Formation|Thyroxine|Synthetic Levothyroxine|ferrous sulfate|Probable diagnosis|Probably|Ferric|Complex|complex (molecular entity)Administer|Thyroxine|Synthetic Levothyroxine|Less Than|Hour|Smaller|Agent|Pharmacologic Substance|Protocol AgentPatients|Treating|orlistat|Thyroxine|Synthetic Levothyroxine|Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Changing|Changed status|thyroid function"
"Concurrent use of tri/tetracyclic antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines.","C0205420|C0042153|C0457083|C1947944|C0814229|C0360108|C0040165|C1881373|C0442805|C0087111|C0302350|C0600688|C0013227|C3687832|C2362652|C1881189|C0597357|C2346484|C0205217|C0597362|C0007412","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|Catecholamines"
"Concurrent use of tri/tetracyclic antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines.","C0205420|C0042153|C0457083|C1947944|C0814229|C0360108|C0040165|C1881373|C0442805|C0087111|C0302350|C0600688|C0013227|C3687832|C2362652|C1881189|C0597357|C2346484|C0205217|C0597362|C0007412","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|Catecholamines""Toxic effects may include increased risk of cardiac arrhythmias and CNS stimulation; ","C0600688|C0332257|C1552866|C2700399|C0205217|C0035647|C0442805|C0003811|C0151560|C2919013","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)"
"Concurrent use of tri/tetracyclic antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines.","C0205420|C0042153|C0457083|C1947944|C0814229|C0360108|C0040165|C1881373|C0442805|C0087111|C0302350|C0600688|C0013227|C3687832|C2362652|C1881189|C0597357|C2346484|C0205217|C0597362|C0007412","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|Catecholamines""Toxic effects may include increased risk of cardiac arrhythmias and CNS stimulation; ","C0600688|C0332257|C1552866|C2700399|C0205217|C0035647|C0442805|C0003811|C0151560|C2919013","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)""onset of action oftricyclics may be accelerated.","C0206132|C0332162|C0441472|C3266814|C0521110","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg][qnco]|[qlco]|[ftcn]|[acty]|[ftcn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)Age of Onset|Onset of (contextual qualifier)|Clinical action|Action|Accelerated"
"Concurrent use of tri/tetracyclic antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines.","C0205420|C0042153|C0457083|C1947944|C0814229|C0360108|C0040165|C1881373|C0442805|C0087111|C0302350|C0600688|C0013227|C3687832|C2362652|C1881189|C0597357|C2346484|C0205217|C0597362|C0007412","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|Catecholamines""Toxic effects may include increased risk of cardiac arrhythmias and CNS stimulation; ","C0600688|C0332257|C1552866|C2700399|C0205217|C0035647|C0442805|C0003811|C0151560|C2919013","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)""onset of action oftricyclics may be accelerated.","C0206132|C0332162|C0441472|C3266814|C0521110","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg][qnco]|[qlco]|[ftcn]|[acty]|[ftcn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)Age of Onset|Onset of (contextual qualifier)|Clinical action|Action|Accelerated""Administration of sertraline in patients stabilized on levothyroxine may result in increased levothyroxine requirements.","C0001554|C1533734|C0074393|C0030705|C0184512|C0040165|C1881373|C1274040|C1546471|C2825142|C0520917","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg][qnco]|[qlco]|[ftcn]|[acty]|[ftcn][ocac]|[topp]|[orch, phsu]|[podg]|[qlco]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[idcn]|[fndg]|[patf]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)Age of Onset|Onset of (contextual qualifier)|Clinical action|Action|AcceleratedAdministration occupational activities|Administration procedure|Sertraline|Patients|Stabilized (qualifier value)|Thyroxine|Synthetic Levothyroxine|Result|What subject filter - Result|Experimental Result|Increased metabolic requirement"
"Concurrent use of tri/tetracyclic antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines.","C0205420|C0042153|C0457083|C1947944|C0814229|C0360108|C0040165|C1881373|C0442805|C0087111|C0302350|C0600688|C0013227|C3687832|C2362652|C1881189|C0597357|C2346484|C0205217|C0597362|C0007412","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|Catecholamines"
"Concurrent use of tri/tetracyclic antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines.","C0205420|C0042153|C0457083|C1947944|C0814229|C0360108|C0040165|C1881373|C0442805|C0087111|C0302350|C0600688|C0013227|C3687832|C2362652|C1881189|C0597357|C2346484|C0205217|C0597362|C0007412","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|Catecholamines""Toxic effects may include increased risk of cardiac arrhythmias and CNS stimulation; ","C0600688|C0332257|C1552866|C2700399|C0205217|C0035647|C0442805|C0003811|C0151560|C2919013","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)"
"Concurrent use of tri/tetracyclic antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines.","C0205420|C0042153|C0457083|C1947944|C0814229|C0360108|C0040165|C1881373|C0442805|C0087111|C0302350|C0600688|C0013227|C3687832|C2362652|C1881189|C0597357|C2346484|C0205217|C0597362|C0007412","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|Catecholamines""Toxic effects may include increased risk of cardiac arrhythmias and CNS stimulation; ","C0600688|C0332257|C1552866|C2700399|C0205217|C0035647|C0442805|C0003811|C0151560|C2919013","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)""onset of action of tricyclics may be accelerated. ","C0206132|C0332162|C0441472|C3266814|C0003290|C0521110","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg][qnco]|[qlco]|[ftcn]|[acty]|[phsu]|[ftcn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)Age of Onset|Onset of (contextual qualifier)|Clinical action|Action|Tricyclic Antidepressive Agents|Accelerated"
"Concurrent use of tri/tetracyclic antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines.","C0205420|C0042153|C0457083|C1947944|C0814229|C0360108|C0040165|C1881373|C0442805|C0087111|C0302350|C0600688|C0013227|C3687832|C2362652|C1881189|C0597357|C2346484|C0205217|C0597362|C0007412","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|Catecholamines""Toxic effects may include increased risk of cardiac arrhythmias and CNS stimulation; ","C0600688|C0332257|C1552866|C2700399|C0205217|C0035647|C0442805|C0003811|C0151560|C2919013","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)""onset of action of tricyclics may be accelerated. ","C0206132|C0332162|C0441472|C3266814|C0003290|C0521110","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg][qnco]|[qlco]|[ftcn]|[acty]|[phsu]|[ftcn]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)Age of Onset|Onset of (contextual qualifier)|Clinical action|Action|Tricyclic Antidepressive Agents|Accelerated""Administration of sertraline in patients stabilized on levothyroxine may result in increased levothyroxine requirements.","C0001554|C1533734|C0074393|C0030705|C0184512|C0040165|C1881373|C1274040|C1546471|C2825142|C0520917","[tmco]|[ftcn]|[ftcn]|[inpr]|[inpr]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[topp]|[ftcn]|[inpo]|[phsu]|[topp]|[qlco]|[phpr]|[aapp, rcpt]|[phpr]|[qnco]|[ftcn]|[bacs, phsu][inpo]|[ftcn]|[idcn]|[acty]|[qnco]|[idcn]|[ftcn]|[fndg]|[topp]|[fndg][qnco]|[qlco]|[ftcn]|[acty]|[phsu]|[ftcn][ocac]|[topp]|[orch, phsu]|[podg]|[qlco]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[idcn]|[fndg]|[patf]","Concurrent|utilization qualifier|Usage|Use - dosing instruction imperative|temptation and restraint inventory (TRI)|Tetracyclic antidepressant|Thyroxine|Synthetic Levothyroxine|Increase|Therapeutic procedure|Therapeutic|Toxic effect|Pharmaceutical Preparations|Drugs|Possible diagnosis|Increased Device Sensitivity|receptor|Increased Sensitivy|Increased|receptor sensitivity|CatecholaminesToxic effect|Including (qualifier)|include - SetOperator|Include (action)|Increased|Risk|Increase|Cardiac Arrhythmia|Central nervous system stimulation (procedure)|CNS STIMULATION (finding)Age of Onset|Onset of (contextual qualifier)|Clinical action|Action|Tricyclic Antidepressive Agents|AcceleratedAdministration occupational activities|Administration procedure|Sertraline|Patients|Stabilized (qualifier value)|Thyroxine|Synthetic Levothyroxine|Result|What subject filter - Result|Experimental Result|Increased metabolic requirement"
"Contraindicated","C1444657","[fndg]","Contraindicated"
"cyclosporine , glimepiride , glipizide , glyburide , levothyroxine , olmesartan medoxomil , and oral contraceptives containing ethinyl estradiol and norethindrone\c\a\a\aa\aa","C0010592|C0010594|C0061323|C0017642|C0017628|C0040165|C1881373|C0386393|C0009905|C0332256|C2700400|C0015011|C0028356|C0282379|C1235746|C1882141","[aapp, phsu]|[imft, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[aapp, horm, phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[ftcn]|[acty]|[horm, orch, phsu]|[horm, orch, phsu]|[geoa]|[plnt]|[qlco]","Cyclosporine|Cyclosporins|glimepiride|Glipizide|Glyburide|Thyroxine|Synthetic Levothyroxine|Olmesartan medoxomil|Contraceptives, Oral|Containing (qualifier)|Contain (action)|Ethinyl Estradiol|Norethindrone|Aruba|Aa (Plant)|Of Each"
"cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea","C0386393|C1098320|C0332256|C0015011|C2700400","[orch, phsu]|[orch, phsu]|[ftcn]|[horm, orch, phsu]|[acty]","Olmesartan medoxomil|olmesartan|Containing (qualifier)|Ethinyl Estradiol|Contain (action)"
"Cytokines- Interferon-?- Interleukin-2","C0079189|C0021747|C0021756|C0879590|C1522405|C0733470|C3652465|C1524094","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft]|[gngm]|[aapp, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","cytokine|Interferons|Interleukin-2|IL2 gene|Recombinant Interleukin-2|human leukocyte interferon|Interferon|Recombinant Cytokines"
"Cytokines- Interferon-?- Interleukin-2","C0079189|C0021747|C0021756|C0879590|C1522405|C0733470|C3652465|C1524094","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft]|[gngm]|[aapp, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","cytokine|Interferons|Interleukin-2|IL2 gene|Recombinant Interleukin-2|human leukocyte interferon|Interferon|Recombinant Cytokines"
"Cytokines - Interferon-? ","C0079189|C0021747|C0733470|C3652465|C1524094","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","cytokine|Interferons|human leukocyte interferon|Interferon|Recombinant Cytokines"
"Cytokines - Interferon-? ","C0079189|C0021747|C0733470|C3652465|C1524094","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","cytokine|Interferons|human leukocyte interferon|Interferon|Recombinant Cytokines""- Interleukin-2","C0021756|C0879590|C1522405","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][aapp, imft]|[gngm]|[aapp, phsu]","cytokine|Interferons|human leukocyte interferon|Interferon|Recombinant CytokinesInterleukin-2|IL2 gene|Recombinant Interleukin-2"
"Cytokines- Interferon-?- Interleukin-2","C0079189|C0021747|C0021756|C0879590|C1522405|C0733470|C3652465|C1524094","[aapp, imft]|[aapp, imft, phsu]|[aapp, imft]|[gngm]|[aapp, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","cytokine|Interferons|Interleukin-2|IL2 gene|Recombinant Interleukin-2|human leukocyte interferon|Interferon|Recombinant Cytokines"
"Decrease ciprofloxacin absorption, resulting in lower serum and urine levels","C0392756|C0008809|C0000854|C2347023|C2347080|C2698776|C2825050|C0547047|C0678226|C0441994|C0229671|C1546774|C1550100|C1548802|C2003888|C0428152|C1318110","[qlco]|[orch, phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[qnco]|[ftcn]|[spco]|[bdsu]|[inpr]|[bdsu]|[blor]|[acty]|[lbpr]|[lbtr]","Reduced|Ciprofloxacin|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Decrease|Due to|Lower - spatial qualifier|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Body Site Modifier - Lower|Lower (action)|Urine level measurement|Urine levels result"
"Decrease ciprofloxacin absorption, resulting in lower serum and urine levels","C0392756|C0008809|C0000854|C2347023|C2347080|C2698776|C2825050|C0547047|C0678226|C0441994|C0229671|C1546774|C1550100|C1548802|C2003888|C0428152|C1318110","[qlco]|[orch, phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[qnco]|[ftcn]|[spco]|[bdsu]|[inpr]|[bdsu]|[blor]|[acty]|[lbpr]|[lbtr]","Reduced|Ciprofloxacin|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Decrease|Due to|Lower - spatial qualifier|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Body Site Modifier - Lower|Lower (action)|Urine level measurement|Urine levels result"
"Decrease ciprofloxacin absorption, resulting in lower serum and urine levels","C0392756|C0008809|C0000854|C2347023|C2347080|C2698776|C2825050|C0547047|C0678226|C0441994|C0229671|C1546774|C1550100|C1548802|C2003888|C0428152|C1318110","[qlco]|[orch, phsu]|[npop]|[phpr]|[phpr]|[bmod]|[phpr]|[qnco]|[ftcn]|[spco]|[bdsu]|[inpr]|[bdsu]|[blor]|[acty]|[lbpr]|[lbtr]","Reduced|Ciprofloxacin|Process of absorption|Biological Absorption|Material Absorption|Pharmacokinetics: Absorption|Energy Absorption|Decrease|Due to|Lower - spatial qualifier|Serum|Specimen Source Codes - Serum|Specimen Type - Serum|Body Site Modifier - Lower|Lower (action)|Urine level measurement|Urine levels result"
"Decreased lamotrigine AUCapproximately 32%.","C0205216|C0064636|C0524166|C0392756|C0442797","[qnco]|[orch, phsu]|[lbpr]|[qlco]|[qlco]","Decreased|lamotrigine|Lamotrigine measurement|Reduced|Decreasing"
"Decreased lamotrigine concentrationapproximately 50%.","C0205216|C0064636|C3842586|C3843766|C0524166|C0392756|C0442797","[qnco]|[orch, phsu]|[fndg]|[fndg]|[lbpr]|[qlco]|[qlco]","Decreased|lamotrigine|50%|<50|Lamotrigine measurement|Reduced|Decreasing"
"Decreased lamotrigine concentrationsapproximately 50%.","C0205216|C0064636|C3842586|C3843766|C0524166|C0392756|C0442797","[qnco]|[orch, phsu]|[fndg]|[fndg]|[lbpr]|[qlco]|[qlco]","Decreased|lamotrigine|50%|<50|Lamotrigine measurement|Reduced|Decreasing"
"Decreased lamotrigine concentrationsapproximately 50%.","C0205216|C0064636|C3842586|C3843766|C0524166|C0392756|C0442797","[qnco]|[orch, phsu]|[fndg]|[fndg]|[lbpr]|[qlco]|[qlco]","Decreased|lamotrigine|50%|<50|Lamotrigine measurement|Reduced|Decreasing""Decrease in levonorgestrel component by 19%.","C0392756|C0547047|C0023566|C0449432|C1705248","[qnco]|[orch, phsu]|[fndg]|[fndg]|[lbpr]|[qlco]|[qlco][qlco]|[qnco]|[horm, orch, phsu]|[mnob]|[cnce]","Decreased|lamotrigine|50%|<50|Lamotrigine measurement|Reduced|DecreasingReduced|Decrease|Levonorgestrel|Component object|Component (part)"
"Decreased theophylline clearance may occur in hypothyroid patients; ","C0205216|C0039771|C0449297|C1382187|C2825073|C0392756|C0442797|C1709305|C2745955|C0020676|C0030705","[qnco]|[bacs, orch, phsu]|[qlco]|[clna]|[npop]|[qlco]|[qlco]|[acty]|[tmco]|[dsyn]|[podg]","Decreased|Theophylline|Clearance|Clearance of substance|Clearance [PK]|Reduced|Decreasing|Occur (action)|Occurrence|Hypothyroidism|Patients"
"Decreased theophylline clearance may occur in hypothyroid patients; ","C0205216|C0039771|C0449297|C1382187|C2825073|C0392756|C0442797|C1709305|C2745955|C0020676|C0030705","[qnco]|[bacs, orch, phsu]|[qlco]|[clna]|[npop]|[qlco]|[qlco]|[acty]|[tmco]|[dsyn]|[podg]","Decreased|Theophylline|Clearance|Clearance of substance|Clearance [PK]|Reduced|Decreasing|Occur (action)|Occurrence|Hypothyroidism|Patients""clearance returns to normal when the euthyroid state is achieved.","C0449297|C0332156|C1382187|C2825073|C0205307|C0439166|C2347086|C0117002|C1301808|C1442792|C3148680","[qnco]|[bacs, orch, phsu]|[qlco]|[clna]|[npop]|[qlco]|[qlco]|[acty]|[tmco]|[dsyn]|[podg][qlco]|[qlco]|[clna]|[npop]|[qlco]|[qnco]|[qnco]|[fndg]|[geoa]|[ftcn]|[geoa]","Decreased|Theophylline|Clearance|Clearance of substance|Clearance [PK]|Reduced|Decreasing|Occur (action)|Occurrence|Hypothyroidism|PatientsClearance|Return to (contextual qualifier) (qualifier value)|Clearance of substance|Clearance [PK]|Normal|Percent normal|Mean Percent of Normal|Euthyroid (finding)|Geographic state|State|US State"
"Decreases tubular reabsorption; ","C0392756|C0442797|C0547047|C0232816","[qlco]|[qlco]|[qnco]|[ortf]","Reduced|Decreasing|Decrease|Tubular reabsorption"
"Decreases tubular reabsorption; ","C0392756|C0442797|C0547047|C0232816","[qlco]|[qlco]|[qnco]|[ortf]","Reduced|Decreasing|Decrease|Tubular reabsorption""clinical toxicity from methotrexate can result.","C0205210|C0040539|C0600688|C0237412|C0497591|C1553058|C0025677|C1274040|C1546471|C2825142","[qlco]|[qlco]|[qnco]|[ortf][qlco]|[qlco]|[inpo]|[prog]|[prog]|[prog]|[orch, phsu]|[ftcn]|[idcn]|[fndg]","Reduced|Decreasing|Decrease|Tubular reabsorptionClinical|Toxicity aspects|Toxic effect|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Methotrexate|Result|What subject filter - Result|Experimental Result"
"diarrhea elevated temperature hepatic disorders infectious hepatitis jaundice","C0011991|C1963091|C0205250|C3163633|C0005903|C0023895|C0241954|C0019158|C0019159|C0795623|C0022346|C0039476","[sosy]|[fndg]|[qlco]|[qlco]|[orga]|[dsyn]|[dsyn]|[dsyn]|[dsyn]|[imft, phsu]|[patf]|[qnco]","Diarrhea|Diarrhea Adverse Event|High|Elevated|Body Temperature|Liver diseases|Canine leptospirosis|Hepatitis|Hepatitis A|Hepatitis A Vaccine, Inactivated|Icterus|Temperature"
"diarrheaelevated temperaturehepatic disorders infectious hepatitis jaundice","C0012634|C0241954|C0019158|C0019159|C0795623|C0022346","[dsyn]|[dsyn]|[dsyn]|[dsyn]|[imft, phsu]|[patf]","Disease|Canine leptospirosis|Hepatitis|Hepatitis A|Hepatitis A Vaccine, Inactivated|Icterus"
"diarrheaelevated temperaturehepatic disordersinfectious hepatitisjaundice","","",""
"DigoxinEnalapril Iron Metoprolol Warfarin","C0302583|C0025859|C0043031|C0376520|C1166521|C3714701","[bacs, elii, phsu]|[orch, phsu]|[hops, orch, phsu]|[inch]|[phsu]|[phsu]","Iron|Metoprolol|Warfarin|Dietary Iron|Ferrum metallicum, Homeopathic preparation|Iron Drug Class"
"DigoxinEnalaprilIronMetoprololWarfarin","","",""
"diltiazem","C0012373","[orch, phsu]","Diltiazem"
"Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure and there is a potential risk for nevirapine-associated toxicity due to increased nevirapine exposures.","C1518422|C3245499|C1621583|C0132326|C1145759|C0392756|C0442797|C0547047|C0274281|C0332157|C3245505|C0035647|C0332281|C0040539|C0600688|C0205217|C0728853|C0442805","[ftcn]|[geoa]|[ftcn]|[orch, phsu]|[orch, phsu]|[qlco]|[qlco]|[qnco]|[inpo]|[clna]|[qlco]|[idcn]|[qlco]|[qlco]|[inpo]|[qnco]|[phpr]|[ftcn]","Negation|Colombia|Administer|Nevirapine|Atazanavir|Reduced|Decreasing|Decrease|Injury due to exposure to external cause|Exposure to|potential|Risk|Associated with|Toxicity aspects|Toxic effect|Increased|Accident due to exposure to weather conditions|Increase"
"Dopamine/Dopamine AgonistsGlucocorticoidsOctreotide","C0013030","[bacs, orch, phsu]","Dopamine"
"Dopamine/Dopamine AgonistsGlucocorticoidsOctreotide","C0013030","[bacs, orch, phsu]","Dopamine"
"Dopamine/Dopamine Agonists Glucocorticoids Octreotide","C0178601|C0017710|C0028833|C3540777|C3540778|C2757007","[phsu]|[horm, orch]|[aapp, horm, phsu]|[horm, orch, phsu]|[orch, phsu]|[moft]","Dopamine Agonists|Glucocorticoids|Octreotide|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Dopamine Agonists [MoA]"
"Dopamine/Dopamine AgonistsGlucocorticoidsOctreotide","C0013030","[bacs, orch, phsu]","Dopamine"
"Doseadjustmentnotneeded","","",""
"Doseadjustmentnot needed","C0027552|C0686904","[qlco]|[ftcn]","Needs|Patient need for (contextual qualifier)"
"Doseadjustmentnotneeded","","",""
"Doseadjustmentnotneeded","","",""
"Dosing in adult patients: A dose adjustment of lopinavir/ritonavir to 500/125 mg tablets twice daily or 533/133 mg (6.5 mL) oral solution twice daily is recommended when used in combination with nevirapine. ","C0001675|C0030705|C1706450|C2826232|C0939237|C0026410|C0039225|C0585361|C0439269|C1960952|C2346927|C0442749|C0439526|C1705224|C3887665|C0991536|C0034866|C1273517|C0205195|C1947911|C3811910|C0132326","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapine"
"Dosing in adult patients: A dose adjustment of lopinavir/ritonavir to 500/125 mg tablets twice daily or 533/133 mg (6.5 mL) oral solution twice daily is recommended when used in combination with nevirapine. ","C0001675|C0030705|C1706450|C2826232|C0939237|C0026410|C0039225|C0585361|C0439269|C1960952|C2346927|C0442749|C0439526|C1705224|C3887665|C0991536|C0034866|C1273517|C0205195|C1947911|C3811910|C0132326","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapine""Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine. ","C0939237|C0039225|C0991536|C1521801|C0556983|C0205195|C1947911|C3811910|C0132326","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu][orch, phsu]|[bodm]|[bodm]|[ftcn]|[tmco]|[qlco]|[phob]|[fndg]|[orch, phsu]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapinelopinavir / Ritonavir|Tablet Dosage Form|Oral Solution|Having administered|Once daily|Combined|combination of objects|combination - answer to question|Nevirapine"
"Dosing in adult patients: A dose adjustment of lopinavir/ritonavir to 500/125 mg tablets twice daily or 533/133 mg (6.5 mL) oral solution twice daily is recommended when used in combination with nevirapine. ","C0001675|C0030705|C1706450|C2826232|C0939237|C0026410|C0039225|C0585361|C0439269|C1960952|C2346927|C0442749|C0439526|C1705224|C3887665|C0991536|C0034866|C1273517|C0205195|C1947911|C3811910|C0132326","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapine""Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine. ","C0939237|C0039225|C0991536|C1521801|C0556983|C0205195|C1947911|C3811910|C0132326","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu][orch, phsu]|[bodm]|[bodm]|[ftcn]|[tmco]|[qlco]|[phob]|[fndg]|[orch, phsu]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapinelopinavir / Ritonavir|Tablet Dosage Form|Oral Solution|Having administered|Once daily|Combined|combination of objects|combination - answer to question|Nevirapine""Dosing in pediatric patients: Please refer to the Kaletra prescribing information for dosing recommendations based on body surface area and body weight. ","C0030755|C0030705|C1521725|C0205543|C0939357|C0278329|C1533716|C0178602|C0034866|C0869039|C1114758|C1527178|C1705938|C0005902|C0005910|C1305866","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu][orch, phsu]|[bodm]|[bodm]|[ftcn]|[tmco]|[qlco]|[phob]|[fndg]|[orch, phsu][bmod]|[podg]|[qlco]|[ftcn]|[orch, phsu]|[hlca]|[idcn]|[qnco]|[idcn]|[qnco]|[clna]|[ftcn]|[idcn]|[orga]|[orga]|[diap]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapinelopinavir / Ritonavir|Tablet Dosage Form|Oral Solution|Having administered|Once daily|Combined|combination of objects|combination - answer to question|NevirapinePediatrics|Patients|Pediatric|Referring|Kaletra|prescribed|Information|Dosage|Recommendation|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Basis - conceptual entity|Base - General Qualifier|Body Surface Area|Body Weight|Weighing patient"
"Dosing in adult patients: A dose adjustment of lopinavir/ritonavir to 500/125 mg tablets twice daily or 533/133 mg (6.5 mL) oral solution twice daily is recommended when used in combination with nevirapine. ","C0001675|C0030705|C1706450|C2826232|C0939237|C0026410|C0039225|C0585361|C0439269|C1960952|C2346927|C0442749|C0439526|C1705224|C3887665|C0991536|C0034866|C1273517|C0205195|C1947911|C3811910|C0132326","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapine""Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine. ","C0939237|C0039225|C0991536|C1521801|C0556983|C0205195|C1947911|C3811910|C0132326","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu][orch, phsu]|[bodm]|[bodm]|[ftcn]|[tmco]|[qlco]|[phob]|[fndg]|[orch, phsu]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapinelopinavir / Ritonavir|Tablet Dosage Form|Oral Solution|Having administered|Once daily|Combined|combination of objects|combination - answer to question|Nevirapine""Dosing in pediatric patients: Please refer to the Kaletra prescribing information for dosing recommendations based on body surface area and body weight. ","C0030755|C0030705|C1521725|C0205543|C0939357|C0278329|C1533716|C0178602|C0034866|C0869039|C1114758|C1527178|C1705938|C0005902|C0005910|C1305866","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu][orch, phsu]|[bodm]|[bodm]|[ftcn]|[tmco]|[qlco]|[phob]|[fndg]|[orch, phsu][bmod]|[podg]|[qlco]|[ftcn]|[orch, phsu]|[hlca]|[idcn]|[qnco]|[idcn]|[qnco]|[clna]|[ftcn]|[idcn]|[orga]|[orga]|[diap]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapinelopinavir / Ritonavir|Tablet Dosage Form|Oral Solution|Having administered|Once daily|Combined|combination of objects|combination - answer to question|NevirapinePediatrics|Patients|Pediatric|Referring|Kaletra|prescribed|Information|Dosage|Recommendation|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Basis - conceptual entity|Base - General Qualifier|Body Surface Area|Body Weight|Weighing patient""Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine.","C0939237|C0039225|C0991536|C1521801|C0556983|C0205195|C1947911|C3811910|C0132326","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu][orch, phsu]|[bodm]|[bodm]|[ftcn]|[tmco]|[qlco]|[phob]|[fndg]|[orch, phsu][bmod]|[podg]|[qlco]|[ftcn]|[orch, phsu]|[hlca]|[idcn]|[qnco]|[idcn]|[qnco]|[clna]|[ftcn]|[idcn]|[orga]|[orga]|[diap][orch, phsu]|[bodm]|[bodm]|[ftcn]|[tmco]|[qlco]|[phob]|[fndg]|[orch, phsu]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapinelopinavir / Ritonavir|Tablet Dosage Form|Oral Solution|Having administered|Once daily|Combined|combination of objects|combination - answer to question|NevirapinePediatrics|Patients|Pediatric|Referring|Kaletra|prescribed|Information|Dosage|Recommendation|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Basis - conceptual entity|Base - General Qualifier|Body Surface Area|Body Weight|Weighing patientlopinavir / Ritonavir|Tablet Dosage Form|Oral Solution|Having administered|Once daily|Combined|combination of objects|combination - answer to question|Nevirapine"
"Dosing in adult patients:A dose adjustment of lopinavir/ritonavir to 500/125 mg tablets twice daily or 533/133 mg (6.5 mL) oral solution twice daily is recommended when used in combination with nevirapine. ","C0001675|C0030705|C1706450|C2826232|C0939237|C0026410|C0039225|C0585361|C0439269|C1960952|C2346927|C0442749|C0439526|C1705224|C3887665|C0991536|C0034866|C1273517|C0205195|C1947911|C3811910|C0132326","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapine"
"Dosing in adult patients:A dose adjustment of lopinavir/ritonavir to 500/125 mg tablets twice daily or 533/133 mg (6.5 mL) oral solution twice daily is recommended when used in combination with nevirapine. ","C0001675|C0030705|C1706450|C2826232|C0939237|C0026410|C0039225|C0585361|C0439269|C1960952|C2346927|C0442749|C0439526|C1705224|C3887665|C0991536|C0034866|C1273517|C0205195|C1947911|C3811910|C0132326","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapine""Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine.","C0939237|C0039225|C0991536|C1521801|C0556983|C0205195|C1947911|C3811910|C0132326","[aggp]|[podg]|[humn]|[hlca]|[orch, phsu]|[geoa]|[bodm]|[tmco]|[qnco]|[qnco]|[elii, phsu]|[fndg]|[qnco]|[gngm]|[aapp, bacs]|[bodm]|[idcn]|[fndg]|[qlco]|[phob]|[fndg]|[orch, phsu][orch, phsu]|[bodm]|[bodm]|[ftcn]|[tmco]|[qlco]|[phob]|[fndg]|[orch, phsu]","Adult|Patients|Legal Adult|Dose Adjustment|lopinavir / Ritonavir|Mongolia|Tablet Dosage Form|Twice a day|mg/dL|Milligram percent|Magnesium Cation|6/5|/mL|THPO wt Allele|Thrombopoietin, human|Oral Solution|Recommendation|Used by|Combined|combination of objects|combination - answer to question|Nevirapinelopinavir / Ritonavir|Tablet Dosage Form|Oral Solution|Having administered|Once daily|Combined|combination of objects|combination - answer to question|Nevirapine"
"Dosing in pediatric patients:Please refer to the Kaletra prescribing information for dosing recommendations based on body surface area and body weight.","C0030755|C0030705|C1521725|C0205543|C0939357|C0278329|C1533716|C0178602|C0034866|C0869039|C1114758|C1527178|C1705938|C0005902|C0005910|C1305866","[bmod]|[podg]|[qlco]|[ftcn]|[orch, phsu]|[hlca]|[idcn]|[qnco]|[idcn]|[qnco]|[clna]|[ftcn]|[idcn]|[orga]|[orga]|[diap]","Pediatrics|Patients|Pediatric|Referring|Kaletra|prescribed|Information|Dosage|Recommendation|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Basis - conceptual entity|Base - General Qualifier|Body Surface Area|Body Weight|Weighing patient"
"Dosing in pediatric patients:Please refer to the Kaletra prescribing information for dosing recommendations based on body surface area and body weight.","C0030755|C0030705|C1521725|C0205543|C0939357|C0278329|C1533716|C0178602|C0034866|C0869039|C1114758|C1527178|C1705938|C0005902|C0005910|C1305866","[bmod]|[podg]|[qlco]|[ftcn]|[orch, phsu]|[hlca]|[idcn]|[qnco]|[idcn]|[qnco]|[clna]|[ftcn]|[idcn]|[orga]|[orga]|[diap]","Pediatrics|Patients|Pediatric|Referring|Kaletra|prescribed|Information|Dosage|Recommendation|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Basis - conceptual entity|Base - General Qualifier|Body Surface Area|Body Weight|Weighing patient""Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine.","C0939237|C0039225|C0991536|C1521801|C0556983|C0205195|C1947911|C3811910|C0132326","[bmod]|[podg]|[qlco]|[ftcn]|[orch, phsu]|[hlca]|[idcn]|[qnco]|[idcn]|[qnco]|[clna]|[ftcn]|[idcn]|[orga]|[orga]|[diap][orch, phsu]|[bodm]|[bodm]|[ftcn]|[tmco]|[qlco]|[phob]|[fndg]|[orch, phsu]","Pediatrics|Patients|Pediatric|Referring|Kaletra|prescribed|Information|Dosage|Recommendation|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Basis - conceptual entity|Base - General Qualifier|Body Surface Area|Body Weight|Weighing patientlopinavir / Ritonavir|Tablet Dosage Form|Oral Solution|Having administered|Once daily|Combined|combination of objects|combination - answer to question|Nevirapine"
"Dosing of Vardenafil 5 mgand Alpha-BlockerSeparated by 6 Hours,Placebo-Subtracted","C0971579|C0439095|C2003941|C2350010|C1292428|C0032042|C1719767|C2348589|C1696465|C1706408","[orch, phsu]|[inpr]|[inpr]|[qlco]|[tmco]|[topp]|[inpr]|[phpr]|[bodm]|[resa]","vardenafil|Greek letter alpha (qualifier value)|Alpha|Alpha Value|6 Hours|Placebos|Subtract - dosing instruction fragment|Subtraction process|placebo|Placebo Control"
"Dosing of Vardenafil and Alpha-Blocker Separated by 6 Hours","C0971579|C0001641|C0086972|C0443299|C0687118|C1292428","[orch, phsu]|[phsu]|[fndg]|[qlco]|[ftcn]|[tmco]","vardenafil|Adrenergic alpha-Antagonists|Separated from cohabitee|Separate|Detached|6 Hours"
"Donotexceed10mgsimvastatindaily","","",""
"Donotexceed20mgsimvastatindaily","","",""
"Donotexceed8mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"Donotexceed8mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"Donotexceed8mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"Donotexceed8mg/day","C0332173|C0439228|C0439505","[tmco]|[tmco]|[tmco]","Daily|day|per day"
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.6, 5.1, 7, 12.3)","C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893","[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco]","Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5"
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis ( , , , )\2.6\5.1\7\12.3","C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410","[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]","Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis"
"Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.6, 5.1, 7, 12.3)","C0687133|C0332281|C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893","[moft]|[qlco]|[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco]","Drug Interactions|Associated with|Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5"
"Efavirenz*","C0674428","[orch, phsu]","efavirenz"
"Effect\Average effect on steady state theophylline concentration or other clinical effect for pharmacologic interactions. ","C1280500|C1510992|C2825518|C2348382|C0678587|C0039771|C0004268|C0086045|C1446561|C0205210|C0237412|C0497591|C1553058|C0031330|C1704675|C0205464","[qlco]|[qnco]|[qnco]|[qlco]|[npop]|[bacs, orch, phsu]|[menp]|[menp]|[qnco]|[qlco]|[prog]|[prog]|[prog]|[bmod]|[ftcn]|[ftcn]","Effect|Average|Average of Value Derivation Technique|Effect, Appearance|steady state|Theophylline|Attention|Mental concentration|Concentration measurement|Clinical|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Pharmacology|Interaction|pharmacological"
"Effect\Average effect on steady state theophylline concentration or other clinical effect for pharmacologic interactions. ","C1280500|C1510992|C2825518|C2348382|C0678587|C0039771|C0004268|C0086045|C1446561|C0205210|C0237412|C0497591|C1553058|C0031330|C1704675|C0205464","[qlco]|[qnco]|[qnco]|[qlco]|[npop]|[bacs, orch, phsu]|[menp]|[menp]|[qnco]|[qlco]|[prog]|[prog]|[prog]|[bmod]|[ftcn]|[ftcn]","Effect|Average|Average of Value Derivation Technique|Effect, Appearance|steady state|Theophylline|Attention|Mental concentration|Concentration measurement|Clinical|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Pharmacology|Interaction|pharmacological""Individual patients may experience larger changes in serum theophylline concentration than the value listed.","C0027361|C0030705|C0237401|C0237607|C0596545|C0549177|C0392747|C0443172|C1704243|C0683149|C0039771|C1522609|C0745732|C3272378","[qlco]|[qnco]|[qnco]|[qlco]|[npop]|[bacs, orch, phsu]|[menp]|[menp]|[qnco]|[qlco]|[prog]|[prog]|[prog]|[bmod]|[ftcn]|[ftcn][popg]|[podg]|[humn]|[menp]|[menp]|[qnco]|[ftcn]|[qnco]|[qnco]|[qnco]|[bacs, orch, phsu]|[qnco]|[cnce]|[inpr]","Effect|Average|Average of Value Derivation Technique|Effect, Appearance|steady state|Theophylline|Attention|Mental concentration|Concentration measurement|Clinical|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Pharmacology|Interaction|pharmacologicalPersons|Patients|Individual|Practice Experience|Experience|Large|Changing|Changed status|Greater|serum concentration|Theophylline|Numerical value|List|Sequence Data Type"
"EffectAverage effect on steady state theophylline concentration or other clinical effect for pharmacologic interactions. ","C1280500|C2348382|C0678587|C0039771|C0004268|C0086045|C1446561|C0205210|C0237412|C0497591|C1553058|C0031330|C1704675|C0205464","[qlco]|[qlco]|[npop]|[bacs, orch, phsu]|[menp]|[menp]|[qnco]|[qlco]|[prog]|[prog]|[prog]|[bmod]|[ftcn]|[ftcn]","Effect|Effect, Appearance|steady state|Theophylline|Attention|Mental concentration|Concentration measurement|Clinical|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Pharmacology|Interaction|pharmacological"
"EffectAverage effect on steady state theophylline concentration or other clinical effect for pharmacologic interactions. ","C1280500|C2348382|C0678587|C0039771|C0004268|C0086045|C1446561|C0205210|C0237412|C0497591|C1553058|C0031330|C1704675|C0205464","[qlco]|[qlco]|[npop]|[bacs, orch, phsu]|[menp]|[menp]|[qnco]|[qlco]|[prog]|[prog]|[prog]|[bmod]|[ftcn]|[ftcn]","Effect|Effect, Appearance|steady state|Theophylline|Attention|Mental concentration|Concentration measurement|Clinical|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Pharmacology|Interaction|pharmacological""Individual patients may experience larger changes in serum theophylline concentration than the value listed.","C0027361|C0030705|C0237401|C0237607|C0596545|C0549177|C0392747|C0443172|C1704243|C0683149|C0039771|C1522609|C0745732|C3272378","[qlco]|[qlco]|[npop]|[bacs, orch, phsu]|[menp]|[menp]|[qnco]|[qlco]|[prog]|[prog]|[prog]|[bmod]|[ftcn]|[ftcn][popg]|[podg]|[humn]|[menp]|[menp]|[qnco]|[ftcn]|[qnco]|[qnco]|[qnco]|[bacs, orch, phsu]|[qnco]|[cnce]|[inpr]","Effect|Effect, Appearance|steady state|Theophylline|Attention|Mental concentration|Concentration measurement|Clinical|Psychologist - Clinical|Social Worker - Clinical|Neuropsychologist - Clinical|Pharmacology|Interaction|pharmacologicalPersons|Patients|Individual|Practice Experience|Experience|Large|Changing|Changed status|Greater|serum concentration|Theophylline|Numerical value|List|Sequence Data Type"
"Ergot alkaloids: Ergotamine","C0014707|C3541393|C3541405|C3542459|C0014710","[bacs, orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[orch, phsu]","Ergot Alkaloids|Ergot alkaloids, antimigraine|Ergot alkaloid peripheral vasodilators|Ergot alkaloid oxytocics|Ergotamine"
"Estrogen-containing oral","C0014939|C0332256|C0442027|C2700400|C2936882","[horm, orch, phsu]|[ftcn]|[spco]|[acty]|[phsu]","Estrogens|Containing (qualifier)|Oral|Contain (action)|Estrogen [EPC]"
"Estrogens (oral)","C0014939|C3537250|C3541386|C3714615|C0442027","[horm, orch, phsu]|[horm, orch, phsu]|[horm, orch, phsu]|[phsu]|[spco]","Estrogens|ESTROGENS, SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM|Estrogens, endocrine therapy drugs|Estrogens Drug Class|Oral"
"Excessive use of thyroid hormones with growth hormones may accelerate epiphyseal closure.","C0442802|C0042153|C0457083|C1947944|C0040135|C0037663|C0521110|C0231577","[qlco]|[ftcn]|[ftcn]|[inpr]|[aapp, horm]|[aapp, horm, phsu]|[ftcn]|[ortf]","Excessive|utilization qualifier|Usage|Use - dosing instruction imperative|Thyroid Hormones|Growth Hormone|Accelerated|Epiphysis closure"
"Excessive use of thyroid hormones with growth hormones may accelerate epiphyseal closure.","C0442802|C0042153|C0457083|C1947944|C0040135|C0037663|C0521110|C0231577","[qlco]|[ftcn]|[ftcn]|[inpr]|[aapp, horm]|[aapp, horm, phsu]|[ftcn]|[ortf]","Excessive|utilization qualifier|Usage|Use - dosing instruction imperative|Thyroid Hormones|Growth Hormone|Accelerated|Epiphysis closure""However, untreated hypothyroidism may interfere with growth response to growth hormone.","C0332155|C0020676|C0521102|C0018270|C0871261|C1704632|C1706817|C2911692|C0220844|C1621966|C2911660|C0037663|C0169964|C3714500","[qlco]|[ftcn]|[ftcn]|[inpr]|[aapp, horm]|[aapp, horm, phsu]|[ftcn]|[ortf][fndg]|[dsyn]|[ftcn]|[orgf]|[orga]|[fndg]|[inpr]|[menp]|[phsf]|[ortf]|[acty]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm]","Excessive|utilization qualifier|Usage|Use - dosing instruction imperative|Thyroid Hormones|Growth Hormone|Accelerated|Epiphysis closureDid not receive therapy or drug for|Hypothyroidism|Interferes with|Growth|Response process|Disease Response|Response (statement)|Response (communication)|growth aspects|Tissue Growth|Growth action|Growth Hormone|Somatropin|Human Growth Hormone"
"Excessive use of thyroid hormones with growth hormones may accelerate epiphyseal closure. ","C0442802|C0042153|C0457083|C1947944|C0040135|C0037663|C0521110|C0231577","[qlco]|[ftcn]|[ftcn]|[inpr]|[aapp, horm]|[aapp, horm, phsu]|[ftcn]|[ortf]","Excessive|utilization qualifier|Usage|Use - dosing instruction imperative|Thyroid Hormones|Growth Hormone|Accelerated|Epiphysis closure"
"Excessive use of thyroid hormones with growth hormones may accelerate epiphyseal closure. ","C0442802|C0042153|C0457083|C1947944|C0040135|C0037663|C0521110|C0231577","[qlco]|[ftcn]|[ftcn]|[inpr]|[aapp, horm]|[aapp, horm, phsu]|[ftcn]|[ortf]","Excessive|utilization qualifier|Usage|Use - dosing instruction imperative|Thyroid Hormones|Growth Hormone|Accelerated|Epiphysis closure""However, untreated hypothyroidism may interfere with growth response to growth hormone.","C0332155|C0020676|C0521102|C0018270|C0871261|C1704632|C1706817|C2911692|C0220844|C1621966|C2911660|C0037663|C0169964|C3714500","[qlco]|[ftcn]|[ftcn]|[inpr]|[aapp, horm]|[aapp, horm, phsu]|[ftcn]|[ortf][fndg]|[dsyn]|[ftcn]|[orgf]|[orga]|[fndg]|[inpr]|[menp]|[phsf]|[ortf]|[acty]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm]","Excessive|utilization qualifier|Usage|Use - dosing instruction imperative|Thyroid Hormones|Growth Hormone|Accelerated|Epiphysis closureDid not receive therapy or drug for|Hypothyroidism|Interferes with|Growth|Response process|Disease Response|Response (statement)|Response (communication)|growth aspects|Tissue Growth|Growth action|Growth Hormone|Somatropin|Human Growth Hormone"
"ForpatientswithHoFH,donotexceed20mgsimvastatindaily*","","",""
"Fosamprenavir*","C1176315","[orch, phsu]","fosamprenavir"
"Fosamprenavir/ Ritonavir*","C1979439","[orch, phsu]","Fosamprenavir+Ritonavir"
"Furosemide ( > 80 mg IV)HeparinHydantoinsNon Steroidal Anti-lnflammatory Drugs- Fenamates- PhenylbutazoneSalicylates ( > 2 g/day)","C0016860|C3842583|C0026410|C0022326|C0439269|C1960952|C2346927|C0260264|C1955898|C3542931|C3843640|C0439267|C3843641|C0740116|C0439417|C2827735|C2981700|C3833492","[orch, phsu]|[fndg]|[geoa]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch]|[orch]|[orch, phsu]|[fndg]|[qnco]|[fndg]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Furosemide|80%|Mongolia|Ivory Coast|mg/dL|Milligram percent|Magnesium Cation|steroid drugs|Fenamates|Fenamates, antiinflammatory and antirheumatic drugs|> 2/day|Gram per Deciliter|2/day|+2|g/24h|2+ Score|2+ Score, WHO|2+"
"Furosemide ( > 80 mg IV)HeparinHydantoinsNon Steroidal Anti-lnflammatory Drugs- Fenamates- PhenylbutazoneSalicylates ( > 2 g/day)","C0016860|C3842583|C0026410|C0022326|C0439269|C1960952|C2346927|C0260264|C1955898|C3542931|C3843640|C0439267|C3843641|C0740116|C0439417|C2827735|C2981700|C3833492","[orch, phsu]|[fndg]|[geoa]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch]|[orch]|[orch, phsu]|[fndg]|[qnco]|[fndg]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Furosemide|80%|Mongolia|Ivory Coast|mg/dL|Milligram percent|Magnesium Cation|steroid drugs|Fenamates|Fenamates, antiinflammatory and antirheumatic drugs|> 2/day|Gram per Deciliter|2/day|+2|g/24h|2+ Score|2+ Score, WHO|2+"
"Furosemide ( > 80 mg IV) Heparin Hydantoins Non Steroidal Anti-lnflammatory Drugs - Fenamates - Phenylbutazone Salicylates ( > 2 g/day)","C0016860|C3842583|C0026410|C0022326|C0439269|C1960952|C2346927|C0019134|C0020209|C1518422|C0260264|C1955898|C0031463|C0036077|C3542931|C0770546|C3843640|C0439267|C3843641|C0740116|C0439417|C2827735|C2981700|C3833492","[orch, phsu]|[fndg]|[geoa]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[bacs, orch, phsu]|[orch, phsu]|[ftcn]|[orch]|[orch]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[bacs, orch, phsu]|[fndg]|[qnco]|[fndg]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Furosemide|80%|Mongolia|Ivory Coast|mg/dL|Milligram percent|Magnesium Cation|Heparin|Hydantoins|Negation|steroid drugs|Fenamates|Phenylbutazone|Salicylates|Fenamates, antiinflammatory and antirheumatic drugs|heparin, porcine|> 2/day|Gram per Deciliter|2/day|+2|g/24h|2+ Score|2+ Score, WHO|2+"
"Furosemide ( > 80 mg IV) Heparin Hydantoins Non Steroidal Anti-lnflammatory Drugs - Fenamates - Phenylbutazone Salicylates ( > 2 g/day)","C0016860|C3842583|C0026410|C0022326|C0439269|C1960952|C2346927|C0019134|C0020209|C1518422|C0260264|C1955898|C0031463|C0036077|C3542931|C0770546|C3843640|C0439267|C3843641|C0740116|C0439417|C2827735|C2981700|C3833492","[orch, phsu]|[fndg]|[geoa]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[bacs, orch, phsu]|[orch, phsu]|[ftcn]|[orch]|[orch]|[orch, phsu]|[orch, phsu]|[orch, phsu]|[bacs, orch, phsu]|[fndg]|[qnco]|[fndg]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Furosemide|80%|Mongolia|Ivory Coast|mg/dL|Milligram percent|Magnesium Cation|Heparin|Hydantoins|Negation|steroid drugs|Fenamates|Phenylbutazone|Salicylates|Fenamates, antiinflammatory and antirheumatic drugs|heparin, porcine|> 2/day|Gram per Deciliter|2/day|+2|g/24h|2+ Score|2+ Score, WHO|2+"
"Furosemide ( > 80 mg IV)HeparinHydantoinsNon Steroidal Anti-lnflammatory Drugs- Fenamates- PhenylbutazoneSalicylates ( > 2 g/day)","C0016860|C3842583|C0026410|C0022326|C0439269|C1960952|C2346927|C0260264|C1955898|C3542931|C3843640|C0439267|C3843641|C0740116|C0439417|C2827735|C2981700|C3833492","[orch, phsu]|[fndg]|[geoa]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch]|[orch]|[orch, phsu]|[fndg]|[qnco]|[fndg]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Furosemide|80%|Mongolia|Ivory Coast|mg/dL|Milligram percent|Magnesium Cation|steroid drugs|Fenamates|Fenamates, antiinflammatory and antirheumatic drugs|> 2/day|Gram per Deciliter|2/day|+2|g/24h|2+ Score|2+ Score, WHO|2+"
"Furosemide ( > 80 mg IV)HeparinHydantoinsNon SteroidalAnti-lnflammatory Drugs- Fenamates- PhenylbutazoneSalicylates ( > 2 g/day)","C0016860|C3842583|C0026410|C0022326|C0439269|C1960952|C2346927|C0013227|C1955898|C3542931|C3687832|C3843640|C0439267|C3843641|C0740116|C0439417|C2827735|C2981700|C3833492","[orch, phsu]|[fndg]|[geoa]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[phsu]|[orch]|[orch, phsu]|[topp]|[fndg]|[qnco]|[fndg]|[qnco]|[qnco]|[qnco]|[clas]|[fndg]","Furosemide|80%|Mongolia|Ivory Coast|mg/dL|Milligram percent|Magnesium Cation|Pharmaceutical Preparations|Fenamates|Fenamates, antiinflammatory and antirheumatic drugs|Drugs|> 2/day|Gram per Deciliter|2/day|+2|g/24h|2+ Score|2+ Score, WHO|2+"
"Growth Hormones- Somatrem- Somatropin","C0037663|C0143083|C0169964|C0384570|C3714500","[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm]","Growth Hormone|somatrem|Somatropin|Recombinant Human Growth Hormone|Human Growth Hormone"
"Growth Hormones- Somatrem- Somatropin","C0037663|C0143083|C0169964|C0384570|C3714500","[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm]","Growth Hormone|somatrem|Somatropin|Recombinant Human Growth Hormone|Human Growth Hormone"
"Growth Hormones - Somatrem - Somatropin","C0037663|C0143083|C0169964|C0384570|C3714500","[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm]","Growth Hormone|somatrem|Somatropin|Recombinant Human Growth Hormone|Human Growth Hormone"
"Growth Hormones- Somatrem- Somatropin","C0037663|C0143083|C0169964|C0384570|C3714500","[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[aapp, horm]","Growth Hormone|somatrem|Somatropin|Recombinant Human Growth Hormone|Human Growth Hormone"
"Heroin / Methadone","C0011892|C0025605|C1552533","[hops, orch, phsu]|[orch, phsu]|[hcro, mnob]","Heroin|Methadone|Methadone Clinic/Center"
"hyperthyroidism poor nutritional state steatorrhea vitamin K deficiency","C0020550|C0162429|C0038238|C0042880","[dsyn]|[dsyn]|[fndg]|[dsyn]","Hyperthyroidism|Malnutrition|Steatorrhea|Vitamin K Deficiency"
"hyperthyroidismpoor nutritional statesteatorrheavitamin K deficiency","C0162429|C0597277|C1708601|C1521739|C0020621|C0032827|C2707262","[dsyn]|[elii, phsu]|[qnco]|[qlco]|[fndg]|[dsyn]|[clna]","Malnutrition|Potassium Ion|K Prime|Nutritional|Hypokalemia|Potassium Deficiency|Nutritional:-:Point in time:^Patient:-"
"Hypoglycemia potentiated","C0020615","[dsyn]","Hypoglycemia"
"Hypoglycemia potentiated.","C0020615","[dsyn]","Hypoglycemia"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting""Monitor blood glucose when ciprofloxacin is co-administered with oral antidiabetic drugs. ","C1820407|C0008809|C3245499|C1521801|C0029167|C0935929|C0175795|C0304289|C0442027","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Ciprofloxacin|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|Oral"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting""Monitor blood glucose when ciprofloxacin is co-administered with oral antidiabetic drugs. ","C1820407|C0008809|C3245499|C1521801|C0029167|C0935929|C0175795|C0304289|C0442027","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Ciprofloxacin|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|Oral""[See Adverse Reactions (6.1).]","C0042789|C1947903|C0559546","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco][orgf]|[acty]|[patf]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Ciprofloxacin|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|OralVision|See|Adverse reactions"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting""Monitor blood glucose when ciprofloxacin is co-administered with oral antidiabetic drugs. ","C1820407|C0008809|C3245499|C1521801|C0029167|C0935929|C0175795|C0304289|C0442027","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Ciprofloxacin|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|Oral"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting""Monitor blood glucose when ciprofloxacin is co-administered with oral antidiabetic drugs. ","C1820407|C0008809|C3245499|C1521801|C0029167|C0935929|C0175795|C0304289|C0442027","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Ciprofloxacin|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|Oral""[See Adverse Reactions ( ).]\6.1","C0042789|C1947903|C0559546","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco][orgf]|[acty]|[patf]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Ciprofloxacin|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|OralVision|See|Adverse reactions"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting""Monitor blood glucose when ciprofloxacin is co-administered with oral antidiabetic drugs. ","C1820407|C0008809|C3245499|C1521801|C0029167|C0935929|C0175795|C0304289|C0442027","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Ciprofloxacin|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|Oral"
"Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. ","C0020615|C1998882|C0205082|C0684224|C0700287|C0008809|C0442027|C0935929|C0038766|C3653359|C1707959|C0017628|C0061323|C3245499|C1521801|C0441472|C3266814","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|Action""Fatalities have been reported. ","C1302234|C1705232|C0684224|C0700287","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|Reporting""Monitor blood glucose when ciprofloxacin is co-administered with oral antidiabetic drugs. ","C1820407|C0008809|C3245499|C1521801|C0029167|C0935929|C0175795|C0304289|C0442027","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Ciprofloxacin|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|Oral""[See Adverse Reactions (6.1).]","C0042789|C1947903|C0559546","[dsyn]|[tmco]|[qlco]|[inpr]|[hlca]|[orch, phsu]|[spco]|[phsu]|[orch, phsu]|[phsu]|[cnce]|[orch, phsu]|[orch, phsu]|[geoa]|[ftcn]|[ftcn]|[acty][qlco]|[fndg]|[inpr]|[hlca][fndg]|[orch, phsu]|[geoa]|[ftcn]|[bmod]|[phsu]|[topp]|[phsu]|[spco][orgf]|[acty]|[patf]","Hypoglycemia|Sometimes|Severe (severity modifier)|Report (document)|Reporting|Ciprofloxacin|Oral|Antidiabetics|Sulfonylurea Compounds|Sulfonylureas for blood glucose lowering|Example|Glyburide|glimepiride|Colombia|Having administered|Clinical action|ActionFatal|Death Related to Adverse Event|Report (document)|ReportingMonitors blood glucose|Ciprofloxacin|Colombia|Having administered|Oral Medicine|Antidiabetics|oral medication|Oral drug preparation|OralVision|See|Adverse reactions"
"hypothyroidism nephrotic syndrome","C0020676|C0027726","[dsyn]|[dsyn]","Hypothyroidism|Nephrotic Syndrome"
"hypothyroidismnephrotic syndrome","C0039082","[dsyn]","Syndrome"
"I. ","C0021966|C0221138","[inch]|[aapp, imft]","Iodides|Blood group antibody I"
"I. ","C0021966|C0221138","[inch]|[aapp, imft]","Iodides|Blood group antibody I""Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:","C0679932|C0036075|C0036077|C0013227|C3687832|C1145667|C1167622|C0036773|C0728877|C0231290|C0687133|C0332282|C1709305|C2745955","[inch]|[aapp, imft][socb]|[orch, phsu]|[orch, phsu]|[phsu]|[topp]|[acty]|[moft]|[aapp]|[lbtr]|[tmco]|[moft]|[tmco]|[acty]|[tmco]","Iodides|Blood group antibody Icompetition|salicylate|Salicylates|Pharmaceutical Preparations|Drugs|Binding action|Binding (Molecular Function)|Serum Albumin|Serum albumin level|Status post|Drug Interactions|Following|Occur (action)|Occurrence"
"If unavoidable, monitor for duloxetine toxicity","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0245561|C0040539|C0600688","[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[orch, phsu]|[qlco]|[inpo]","Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|duloxetine|Toxicity aspects|Toxic effect"
"Immunosuppressants: Cyclosporine, tacrolimus, sirolimus","C0021081|C0010592|C0010594|C0085149|C0072980","[imft, phsu]|[aapp, phsu]|[imft, phsu]|[orch, phsu]|[antb, orch]","Immunosuppressive Agents|Cyclosporine|Cyclosporins|Tacrolimus|Sirolimus"
"Increased exposure to eluxadoline when coadministered with cyclosporine [see Clinical Pharmacology (12.3)]","C0205217|C0274281|C0332157|C0442805|C3712232|C0010592|C0010594|C0042789|C1947903|C0031332|C1555729","[qnco]|[inpo]|[clna]|[ftcn]|[aapp, phsu]|[aapp, phsu]|[imft, phsu]|[orgf]|[acty]|[bmod]|[prog]","Increased|Injury due to exposure to external cause|Exposure to|Increase|eluxadoline|Cyclosporine|Cyclosporins|Vision|See|Clinical pharmacology discipline|Allopathic & Osteopathic Physicians - Clinical Pharmacology"
"Increased Risk of Myopathy/Rhabdomyolysis (2, 5.1, 7, 12.3)","C0205217|C0035647|C0442805|C0026848|C0035410|C0740116|C2827735|C2981700|C3833492|C0439084|C0728893","[qnco]|[idcn]|[ftcn]|[dsyn]|[patf]|[qnco]|[qnco]|[clas]|[fndg]|[qnco]|[qnco]","Increased|Risk|Increase|Myopathy|Rhabdomyolysis|+2|2+ Score|2+ Score, WHO|2+|>5|+5"
"Indinavir*","C0376637","[orch, phsu]","Indinavir"
"InteractionInteraction","","",""
"Iodide and drugs that contain pharmacologic amounts of iodide may cause hyperthyroidism in euthyroid patients with Grave's disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular goiter or hyper functioning thyroid adenoma). ","C0021966|C0013227|C3687832|C0332256|C2700400|C0031330|C1265611|C0205464|C0015127|C1524003|C0020550|C0117002|C0030705|C0018213|C1522326|C0040125|C0040132|C0085862|C3540038|C0342208|C0424295|C0205245|C0151468|C0542341","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|Function"
"Iodide and drugs that contain pharmacologic amounts of iodide may cause hyperthyroidism in euthyroid patients with Grave's disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular goiter or hyper functioning thyroid adenoma). ","C0021966|C0013227|C3687832|C0332256|C2700400|C0031330|C1265611|C0205464|C0015127|C1524003|C0020550|C0117002|C0030705|C0018213|C1522326|C0040125|C0040132|C0085862|C3540038|C0342208|C0424295|C0205245|C0151468|C0542341","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|Function""Hyperthyroidism may develop over several weeks and may persist for several months after therapy discontinuation. ","C0020550|C0205136|C0439230|C0347984|C0439064|C0439231|C0443302|C0039798|C0457454|C1444662|C0087111|C1363945","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn][dsyn]|[spco]|[tmco]|[tmco]|[qnco]|[tmco]|[qnco]|[ftcn]|[hlca]|[fndg]|[topp]|[fndg]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|FunctionHyperthyroidism|Over (spatial)|week|During|Numerous|month|Several|therapeutic aspects|Discontinuation (procedure)|Discontinued|Therapeutic procedure|Therapy Object (animal model)"
"Iodide and drugs that contain pharmacologic amounts of iodide may cause hyperthyroidism in euthyroid patients with Grave's disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular goiter or hyper functioning thyroid adenoma). ","C0021966|C0013227|C3687832|C0332256|C2700400|C0031330|C1265611|C0205464|C0015127|C1524003|C0020550|C0117002|C0030705|C0018213|C1522326|C0040125|C0040132|C0085862|C3540038|C0342208|C0424295|C0205245|C0151468|C0542341","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|Function""Hyperthyroidism may develop over several weeks and may persist for several months after therapy discontinuation. ","C0020550|C0205136|C0439230|C0347984|C0439064|C0439231|C0443302|C0039798|C0457454|C1444662|C0087111|C1363945","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn][dsyn]|[spco]|[tmco]|[tmco]|[qnco]|[tmco]|[qnco]|[ftcn]|[hlca]|[fndg]|[topp]|[fndg]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|FunctionHyperthyroidism|Over (spatial)|week|During|Numerous|month|Several|therapeutic aspects|Discontinuation (procedure)|Discontinued|Therapeutic procedure|Therapy Object (animal model)""Amiodarone may induce hyperthyroidism by causing thyroiditis.","C0002598|C0205263|C0020550|C0678227|C0040147","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[fndg]|[ftcn]|[neop]|[ftcn][dsyn]|[spco]|[tmco]|[tmco]|[qnco]|[tmco]|[qnco]|[ftcn]|[hlca]|[fndg]|[topp]|[fndg][orch, phsu]|[ftcn]|[dsyn]|[ftcn]|[dsyn]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Hyperactive behavior|Functional|Thyroid Gland Follicular Adenoma|FunctionHyperthyroidism|Over (spatial)|week|During|Numerous|month|Several|therapeutic aspects|Discontinuation (procedure)|Discontinued|Therapeutic procedure|Therapy Object (animal model)Amiodarone|Induce (action)|Hyperthyroidism|Causing|Thyroiditis"
"Iodide and drugs that contain pharmacological amounts of iodide may cause hyperthyroidism in euthyroid patients with Grave's disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular goiter or hyperfunctioning thyroid adenoma).","C0021966|C0013227|C3687832|C0332256|C2700400|C0031330|C1265611|C0205464|C0015127|C1524003|C0020550|C0117002|C0030705|C0018213|C1522326|C0040125|C0040132|C0085862|C3540038|C0342208|C1863960","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[neop]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Thyroid Adenoma, Hyperfunctioning"
"Iodide and drugs that contain pharmacological amounts of iodide may cause hyperthyroidism in euthyroid patients with Grave's disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular goiter or hyperfunctioning thyroid adenoma).","C0021966|C0013227|C3687832|C0332256|C2700400|C0031330|C1265611|C0205464|C0015127|C1524003|C0020550|C0117002|C0030705|C0018213|C1522326|C0040125|C0040132|C0085862|C3540038|C0342208|C1863960","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[neop]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Thyroid Adenoma, Hyperfunctioning""Hyperthyroidism may develop over several weeks and may persist for several months after therapy discontinuation.","C0020550|C0205136|C0439230|C0347984|C0439064|C0439231|C0443302|C0039798|C0457454|C1444662|C0087111|C1363945","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[neop][dsyn]|[spco]|[tmco]|[tmco]|[qnco]|[tmco]|[qnco]|[ftcn]|[hlca]|[fndg]|[topp]|[fndg]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Thyroid Adenoma, HyperfunctioningHyperthyroidism|Over (spatial)|week|During|Numerous|month|Several|therapeutic aspects|Discontinuation (procedure)|Discontinued|Therapeutic procedure|Therapy Object (animal model)"
"Iodide and drugs that contain pharmacological amounts of iodide may cause hyperthyroidism in euthyroid patients with Grave's disease previously treated with antithyroid drugs or in euthyroid patients with thyroid autonomy (e.g., multinodular goiter or hyperfunctioning thyroid adenoma).","C0021966|C0013227|C3687832|C0332256|C2700400|C0031330|C1265611|C0205464|C0015127|C1524003|C0020550|C0117002|C0030705|C0018213|C1522326|C0040125|C0040132|C0085862|C3540038|C0342208|C1863960","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[neop]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Thyroid Adenoma, Hyperfunctioning""Hyperthyroidism may develop over several weeks and may persist for several months after therapy discontinuation.","C0020550|C0205136|C0439230|C0347984|C0439064|C0439231|C0443302|C0039798|C0457454|C1444662|C0087111|C1363945","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[neop][dsyn]|[spco]|[tmco]|[tmco]|[qnco]|[tmco]|[qnco]|[ftcn]|[hlca]|[fndg]|[topp]|[fndg]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Thyroid Adenoma, HyperfunctioningHyperthyroidism|Over (spatial)|week|During|Numerous|month|Several|therapeutic aspects|Discontinuation (procedure)|Discontinued|Therapeutic procedure|Therapy Object (animal model)""Amiodarone may induce hyperthyroidism by causing thyroiditis.","C0002598|C0205263|C0020550|C0678227|C0040147","[inch]|[phsu]|[topp]|[ftcn]|[acty]|[bmod]|[qnco]|[ftcn]|[ftcn]|[cnce]|[dsyn]|[fndg]|[podg]|[dsyn]|[ftcn]|[horm, phsu]|[bpoc]|[idcn]|[irda]|[dsyn]|[neop][dsyn]|[spco]|[tmco]|[tmco]|[qnco]|[tmco]|[qnco]|[ftcn]|[hlca]|[fndg]|[topp]|[fndg][orch, phsu]|[ftcn]|[dsyn]|[ftcn]|[dsyn]","Iodides|Pharmaceutical Preparations|Drugs|Containing (qualifier)|Contain (action)|Pharmacology|Quantity|pharmacological|Etiology aspects|Science of Etiology|Hyperthyroidism|Euthyroid (finding)|Patients|Graves Disease|Treating|Antithyroid Agents|Thyroid Gland|Independence|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|Multinodular goiter|Thyroid Adenoma, HyperfunctioningHyperthyroidism|Over (spatial)|week|During|Numerous|month|Several|therapeutic aspects|Discontinuation (procedure)|Discontinued|Therapeutic procedure|Therapy Object (animal model)Amiodarone|Induce (action)|Hyperthyroidism|Causing|Thyroiditis"
"Itraconazole","C0064113","[orch, phsu]","Itraconazole"
"Ketamine","C0022614","[orch, phsu]","Ketamine"
"Ketoconazole*","C0022625","[orch, phsu]","Ketoconazole"
"lomefloxacinmebendazole","","",""
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients.The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism.","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589|C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]|[emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%|Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients.The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism.","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589|C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]|[emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%|Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents.","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]|[emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%|Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients.The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism.","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589|C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]|[emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%|Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents.","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]|[emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%|Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media""Long-term aminoglutethimide therapy may minimally decrease T4 and T3 levels and increase TSH, although all values remain within normal limits in most patients.","C0443252|C0002555|C0039798|C0087111|C1363945|C0392756|C0547047|C0446421|C0442805|C0042295|C0442816|C0030705","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]|[emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda][tmco]|[orch, phsu]|[ftcn]|[topp]|[fndg]|[qlco]|[qnco]|[blor]|[ftcn]|[qlco]|[qnco]|[podg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%|Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast mediaLong-term|Aminoglutethimide|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Reduced|Decrease|Level of the third thoracic vertebra|Increase|Values|Normal limits|Patients"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents. ","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents. ","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media""Long-term amino-glu-tethimide therapy may minimally decrease T4 and T3 levels and increase TSH, although all values remain within normal limits in most patients.","C0443252|C0061472|C0039798|C0087111|C1363945|C0220839|C0392756|C0547047|C0446421|C0442805|C0042295|C0442816|C0030705","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda][tmco]|[aapp, bacs, phsu]|[ftcn]|[topp]|[fndg]|[aapp, bacs]|[qlco]|[qnco]|[blor]|[ftcn]|[qlco]|[qnco]|[podg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast mediaLong-term|Glutamic Acid|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Glutamate|Reduced|Decrease|Level of the third thoracic vertebra|Increase|Values|Normal limits|Patients"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents. ","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents. ","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media""Long-term amino-glu-tethimide therapy may minimally decrease T4 and T3 levels and increase TSH, although all values remain within normal limits in most patients.","C0443252|C0061472|C0039798|C0087111|C1363945|C0220839|C0392756|C0547047|C0446421|C0442805|C0042295|C0442816|C0030705","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda][tmco]|[aapp, bacs, phsu]|[ftcn]|[topp]|[fndg]|[aapp, bacs]|[qlco]|[qnco]|[blor]|[ftcn]|[qlco]|[qnco]|[podg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast mediaLong-term|Glutamic Acid|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Glutamate|Reduced|Decrease|Level of the third thoracic vertebra|Increase|Values|Normal limits|Patients"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents. ","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents. ","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media""Long-term amino-glu-tethimide therapy may minimally decrease T and T levels and increase TSH, although all values remain within normal limits in most patients.\4\3","C0443252|C0061472|C0039798|C0087111|C1363945|C0220839|C0392756|C0547047|C2603360|C0441889|C0442805|C0042295|C0442816|C0030705","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda][tmco]|[aapp, bacs, phsu]|[ftcn]|[topp]|[fndg]|[aapp, bacs]|[qlco]|[qnco]|[clna]|[qlco]|[ftcn]|[qlco]|[qnco]|[podg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast mediaLong-term|Glutamic Acid|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Glutamate|Reduced|Decrease|T prime|Levels (qualifier value)|Increase|Values|Normal limits|Patients"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents. ","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media"
"Long-term lithium therapy can result in goiter in up to 50% of patients, and either subclinical or overt hypothyroidism, each in up to 20% of patients. ","C0443252|C0204592|C1274040|C1546471|C2825142|C0018021|C3842586|C3843766|C0030705|C0205211|C0020676|C3842589","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%""The fetus, neonate, elderly and euthyroid patients with underlying thyroid disease (e.g., Hashimoto's thyroiditis or with Grave's disease previously treated with radioiodine or surgery) are among those individuals who are particularly susceptible to iodine-induced hypothyroidism. ","C0015965|C0242291|C1305737|C0021289|C2239178|C2939425|C0001792|C1999167|C0117002|C0030705|C0040128|C0677607|C0018213|C1522326|C0038894|C0038895|C0543467|C1274039|C3853799|C0027361|C0237401|C0220898|C0231204|C2827758|C0154159|C0205263","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)""Oral cholecystographic agents and amiodarone are slowly excreted, producing more prolonged hypothyroidism than parenterally administered iodinated contrast agents. ","C0203079|C0450442|C1254351|C1521826|C0002598|C0439834|C1688651|C0205172|C0439590|C0020676|C1521801|C1960405","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast media""Long-term amino-glu-tethimide therapy may minimally decrease T4 and T3 levels and increase TSH, although all values remain within normal limits in most patients.","C0443252|C0061472|C0039798|C0087111|C1363945|C0220839|C0392756|C0547047|C0446421|C0442805|C0042295|C0442816|C0030705","[tmco]|[topp]|[ftcn]|[idcn]|[fndg]|[patf]|[fndg]|[fndg]|[podg]|[qlco]|[dsyn]|[fndg][emst]|[tisu]|[anst]|[aggp]|[fndg]|[tmco]|[popg]|[popg]|[fndg]|[podg]|[dsyn]|[dsyn]|[dsyn]|[ftcn]|[bmod]|[ftcn]|[hlca]|[bmod]|[prog]|[popg]|[humn]|[orga]|[ftcn]|[lbtr]|[dsyn]|[ftcn][diap]|[chvf]|[phsu]|[inpr]|[orch, phsu]|[qlco]|[qnco]|[ftcn]|[tmco]|[dsyn]|[ftcn]|[irda][tmco]|[aapp, bacs, phsu]|[ftcn]|[topp]|[fndg]|[aapp, bacs]|[qlco]|[qnco]|[blor]|[ftcn]|[qlco]|[qnco]|[podg]","Long-term|Lithium therapy|Result|What subject filter - Result|Experimental Result|Goiter|50%|<50|Patients|Subclinical|Hypothyroidism|20%Fetus|Fetal Tissue|Entire fetus|Infant, Newborn|Newborn (finding)|Neonatal (qualifier value)|Elderly (population group)|Old age|Euthyroid (finding)|Patients|Thyroid Diseases|Hashimoto Disease|Graves Disease|Treating|Surgery specialty|Surgical aspects|Operative Surgical Procedures|General surgery specialty|Allopathic & Osteopathic Physicians - Surgery|Persons|Individual|Predisposition|Susceptible|Antimicrobial Susceptibility Result|Iodine hypothyroidism|Induce (action)Oral contrast cholecystography|Agent|Pharmacologic Substance|Protocol Agent|Amiodarone|Slow|% excret|More|Prolonged|Hypothyroidism|Having administered|Iodinated contrast mediaLong-term|Glutamic Acid|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Glutamate|Reduced|Decrease|Level of the third thoracic vertebra|Increase|Values|Normal limits|Patients"
"Lopinavir/Ritonavir*","C0939237","[orch, phsu]","lopinavir / Ritonavir"
"Mean Ratio of\Co-administered Drug\Pharmacokinetic Parameters90% CI; ","C0444504|C0456603|C1547037|C2347634|C2348143|C3245499|C1521801|C0013227|C0201734|C0008107|C3259781|C1254351","[qnco]|[qnco]|[inpr]|[qnco]|[qnco]|[geoa]|[ftcn]|[phsu]|[resa]|[geoa]|[lbpr]|[phsu]","Statistical mean|Ratio|data type - ratio|Population Mean|Sample Mean|Colombia|Having administered|Pharmaceutical Preparations|Pharmacokinetic study|Chile|Coagulation Index Measurement|Pharmacologic Substance"
"Mean Ratio of\Co-administered Drug\Pharmacokinetic Parameters90% CI; ","C0444504|C0456603|C1547037|C2347634|C2348143|C3245499|C1521801|C0013227|C0201734|C0008107|C3259781|C1254351","[qnco]|[qnco]|[inpr]|[qnco]|[qnco]|[geoa]|[ftcn]|[phsu]|[resa]|[geoa]|[lbpr]|[phsu]","Statistical mean|Ratio|data type - ratio|Population Mean|Sample Mean|Colombia|Having administered|Pharmaceutical Preparations|Pharmacokinetic study|Chile|Coagulation Index Measurement|Pharmacologic Substance""No effect = 1.00","C1280500|C2348382|C2827734|C2981698|C3816745","[qnco]|[qnco]|[inpr]|[qnco]|[qnco]|[geoa]|[ftcn]|[phsu]|[resa]|[geoa]|[lbpr]|[phsu][qlco]|[qlco]|[qnco]|[clas]|[fndg]","Statistical mean|Ratio|data type - ratio|Population Mean|Sample Mean|Colombia|Having administered|Pharmaceutical Preparations|Pharmacokinetic study|Chile|Coagulation Index Measurement|Pharmacologic SubstanceEffect|Effect, Appearance|1+ Score|1+ Score, WHO|1+"
"Mean Ratio of Etravirine\Pharmacokinetic Parameters90% CI; ","C0444504|C0456603|C1547037|C2347634|C2348143|C1456409|C0201734|C0008107|C3259781","[qnco]|[qnco]|[inpr]|[qnco]|[qnco]|[orch, phsu]|[resa]|[geoa]|[lbpr]","Statistical mean|Ratio|data type - ratio|Population Mean|Sample Mean|etravirine|Pharmacokinetic study|Chile|Coagulation Index Measurement"
"Mean Ratio of Etravirine\Pharmacokinetic Parameters90% CI; ","C0444504|C0456603|C1547037|C2347634|C2348143|C1456409|C0201734|C0008107|C3259781","[qnco]|[qnco]|[inpr]|[qnco]|[qnco]|[orch, phsu]|[resa]|[geoa]|[lbpr]","Statistical mean|Ratio|data type - ratio|Population Mean|Sample Mean|etravirine|Pharmacokinetic study|Chile|Coagulation Index Measurement""No Effect = 1.00","C1280500|C2348382|C2827734|C2981698|C3816745","[qnco]|[qnco]|[inpr]|[qnco]|[qnco]|[orch, phsu]|[resa]|[geoa]|[lbpr][qlco]|[qlco]|[qnco]|[clas]|[fndg]","Statistical mean|Ratio|data type - ratio|Population Mean|Sample Mean|etravirine|Pharmacokinetic study|Chile|Coagulation Index MeasurementEffect|Effect, Appearance|1+ Score|1+ Score, WHO|1+"
"medroxyprogesterone","C0025147","[horm, orch, phsu]","Medroxyprogesterone"
"Methadone levels were decreased; ","C0025605|C0441889|C1552533|C0205216|C0392756|C0442797","[orch, phsu]|[qlco]|[hcro, mnob]|[qnco]|[qlco]|[qlco]","Methadone|Levels (qualifier value)|Methadone Clinic/Center|Decreased|Reduced|Decreasing"
"Methadone levels were decreased; ","C0025605|C0441889|C1552533|C0205216|C0392756|C0442797","[orch, phsu]|[qlco]|[hcro, mnob]|[qnco]|[qlco]|[qlco]","Methadone|Levels (qualifier value)|Methadone Clinic/Center|Decreased|Reduced|Decreasing""increased dosages may be required to prevent symptoms of opiate withdrawal. ","C0205217|C0178602|C0442805|C1514873|C0040363|C0041260|C1883351|C0309872|C0683368|C1457887|C0376196|C2349954|C2825032|C3812880","[orch, phsu]|[qlco]|[hcro, mnob]|[qnco]|[qlco]|[qlco][qnco]|[qnco]|[ftcn]|[ftcn]|[geoa]|[aapp, enzy]|[qlco]|[phsu]|[ftcn]|[sosy]|[hops, phsu]|[acty]|[mobd]|[fndg]","Methadone|Levels (qualifier value)|Methadone Clinic/Center|Decreased|Reduced|DecreasingIncreased|Dosage|Increase|Requirement|Togo|Tryptophanase|To|PREVENT (product)|Symptoms aspect|Symptoms|Opiates|Withdraw (activity)|Withdrawal (dysfunction)|Withdrawal - birth control"
"Methadone levels were decreased; ","C0025605|C0441889|C1552533|C0205216|C0392756|C0442797","[orch, phsu]|[qlco]|[hcro, mnob]|[qnco]|[qlco]|[qlco]","Methadone|Levels (qualifier value)|Methadone Clinic/Center|Decreased|Reduced|Decreasing""increased dosages may be required to prevent symptoms of opiate withdrawal. ","C0205217|C0178602|C0442805|C1514873|C0040363|C0041260|C1883351|C0309872|C0683368|C1457887|C0376196|C2349954|C2825032|C3812880","[orch, phsu]|[qlco]|[hcro, mnob]|[qnco]|[qlco]|[qlco][qnco]|[qnco]|[ftcn]|[ftcn]|[geoa]|[aapp, enzy]|[qlco]|[phsu]|[ftcn]|[sosy]|[hops, phsu]|[acty]|[mobd]|[fndg]","Methadone|Levels (qualifier value)|Methadone Clinic/Center|Decreased|Reduced|DecreasingIncreased|Dosage|Increase|Requirement|Togo|Tryptophanase|To|PREVENT (product)|Symptoms aspect|Symptoms|Opiates|Withdraw (activity)|Withdrawal (dysfunction)|Withdrawal - birth control""Methadone-maintained patients beginning nevirapine therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly.","C0025605|C1314677|C0030705|C1552533|C0439659|C0132326|C0039798|C0087111|C1363945|C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C3887511|C2349954|C2825032|C3812880|C0366544|C0456081","[orch, phsu]|[qlco]|[hcro, mnob]|[qnco]|[qlco]|[qlco][qnco]|[qnco]|[ftcn]|[ftcn]|[geoa]|[aapp, enzy]|[qlco]|[phsu]|[ftcn]|[sosy]|[hops, phsu]|[acty]|[mobd]|[fndg][orch, phsu]|[ftcn]|[podg]|[hcro, mnob]|[tmco]|[orch, phsu]|[ftcn]|[topp]|[fndg]|[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[idcn]|[acty]|[mobd]|[fndg]|[clna]|[ftcn]","Methadone|Levels (qualifier value)|Methadone Clinic/Center|Decreased|Reduced|DecreasingIncreased|Dosage|Increase|Requirement|Togo|Tryptophanase|To|PREVENT (product)|Symptoms aspect|Symptoms|Opiates|Withdraw (activity)|Withdrawal (dysfunction)|Withdrawal - birth controlMethadone|Maintaining (action)|Patients|Methadone Clinic/Center|Beginning|Nevirapine|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Evidence|Withdraw (activity)|Withdrawal (dysfunction)|Withdrawal - birth control|methadone dose|Adjustment Action"
"Methylxanthine Bronchodilators- (e.g., Theophylline)","C0066447|C0006280|C3536939|C0039771","[orch, phsu]|[phsu]|[phsu]|[bacs, orch, phsu]","methylxanthine|Bronchodilator Agents|Methylxanthine [EPC]|Theophylline"
"Methylxanthine Bronchodilators- (e.g., Theophylline)","C0066447|C0006280|C3536939|C0039771","[orch, phsu]|[phsu]|[phsu]|[bacs, orch, phsu]","methylxanthine|Bronchodilator Agents|Methylxanthine [EPC]|Theophylline"
"Methylxanthine Bronchodilators - (e.g., Theophylline)","C0066447|C0006280|C3536939|C0039771","[orch, phsu]|[phsu]|[phsu]|[bacs, orch, phsu]","methylxanthine|Bronchodilator Agents|Methylxanthine [EPC]|Theophylline"
"Methylxanthine Bronchodilators- (e.g., Theophylline)","C0066447|C0006280|C3536939|C0039771","[orch, phsu]|[phsu]|[phsu]|[bacs, orch, phsu]","methylxanthine|Bronchodilator Agents|Methylxanthine [EPC]|Theophylline"
"Mitotane","C0026256","[orch, phsu]","Mitotane"
"Monitor for sildenafil toxicity (see Pharmacokinetics12.3).","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0529793|C0040539|C0600688|C0042789|C1947903","[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[orch, phsu]|[qlco]|[inpo]|[orgf]|[acty]","Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|sildenafil|Toxicity aspects|Toxic effect|Vision|See"
"Monitor for sildenafil toxicity (see Pharmacokinetics12.3).","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0529793|C0040539|C0600688|C0042789|C1947903","[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[orch, phsu]|[qlco]|[inpo]|[orgf]|[acty]","Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|sildenafil|Toxicity aspects|Toxic effect|Vision|See"
"Monitor for sildenafil toxicity (see  ).\Pharmacokinetics\12.3","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0529793|C0040539|C0600688|C0042789|C0031327|C0031328|C1947903","[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[orch, phsu]|[qlco]|[inpo]|[orgf]|[phsf]|[ftcn]|[acty]","Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|sildenafil|Toxicity aspects|Toxic effect|Vision|Drug Kinetics|Pharmacokinetic aspects|See"
"Monitor renal function (in particular serum creatinine) when ciprofloxacin is co-administered with cyclosporine.","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0232804|C0201976|C0600061|C0008809|C3245499|C1521801|C0010592|C0010594","[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[ortf]|[lbpr]|[fndg]|[orch, phsu]|[geoa]|[ftcn]|[aapp, phsu]|[imft, phsu]","Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Renal function|Creatinine measurement, serum (procedure)|Serum creatinine level|Ciprofloxacin|Colombia|Having administered|Cyclosporine|Cyclosporins"
"Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with ciprofloxacin[see Warnings and Precautions (5.15)].","C0150369|C1283169|C1516647|C0244821|C0439849|C0559546|C0445223|C1548787|C2826232|C0034866|C0814472|C0008809|C0042789|C1947903|C0871599|C1882442|C0439084|C0728893","[hlca]|[hlca]|[resa]|[orch, phsu]|[qlco]|[patf]|[fndg]|[qlco]|[hlca]|[idcn]|[hlca]|[orch, phsu]|[orgf]|[acty]|[gora]|[cnce]|[qnco]|[qnco]","Preventive monitoring|Monitoring - action|Clinical Trials, Monitoring|ropinirole|Relationships|Adverse reactions|Related personal status|Appropriate|Dose Adjustment|Recommendation|co-treatment|Ciprofloxacin|Vision|See|Cautionary Warning|Precaution|>5|+5"
"Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with ciprofloxacin[see ( )].\Warnings and Precautions\5.15","C0150369|C1283169|C1516647|C0244821|C0439849|C0559546|C0445223|C1548787|C2826232|C0034866|C0814472|C0008809|C0042789|C0871599|C1947903|C1882442","[hlca]|[hlca]|[resa]|[orch, phsu]|[qlco]|[patf]|[fndg]|[qlco]|[hlca]|[idcn]|[hlca]|[orch, phsu]|[orgf]|[gora]|[acty]|[cnce]","Preventive monitoring|Monitoring - action|Clinical Trials, Monitoring|ropinirole|Relationships|Adverse reactions|Related personal status|Appropriate|Dose Adjustment|Recommendation|co-treatment|Ciprofloxacin|Vision|Cautionary Warning|See|Precaution"
"Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with ciprofloxacin[see Warnings and Precautions (5.15)].","C0150369|C1283169|C1516647|C0244821|C0439849|C0559546|C0445223|C1548787|C2826232|C0034866|C0814472|C0008809|C0042789|C1947903|C0871599|C1882442|C0439084|C0728893","[hlca]|[hlca]|[resa]|[orch, phsu]|[qlco]|[patf]|[fndg]|[qlco]|[hlca]|[idcn]|[hlca]|[orch, phsu]|[orgf]|[acty]|[gora]|[cnce]|[qnco]|[qnco]","Preventive monitoring|Monitoring - action|Clinical Trials, Monitoring|ropinirole|Relationships|Adverse reactions|Related personal status|Appropriate|Dose Adjustment|Recommendation|co-treatment|Ciprofloxacin|Vision|See|Cautionary Warning|Precaution|>5|+5"
"Motility agents: Cisapride","C0007608|C0450442|C1254351|C1521826|C0678835|C1510470|C0072916","[orgf]|[chvf]|[phsu]|[inpr]|[lbtr]|[orgf]|[orch, phsu]","cell motility|Agent|Pharmacologic Substance|Protocol Agent|Motility result|Motility|Cisapride"
"Nelfinavir*","C0525005","[orch, phsu]","Nelfinavir"
"Nevirapine and boceprevir should not be coadministered because decreases in boceprevir plasma concentrations may result in a reduction in efficacy.","C0132326|C1738934|C1518422|C0392756|C0442797|C0547047|C0683150|C1274040|C1546471|C2825142|C0301630|C0441610|C1280519|C1707887","[orch, phsu]|[aapp, phsu]|[ftcn]|[qlco]|[qlco]|[qnco]|[qnco]|[ftcn]|[idcn]|[fndg]|[npop]|[topp]|[qlco]|[resa]","Nevirapine|boceprevir|Negation|Reduced|Decreasing|Decrease|plasma concentration|Result|What subject filter - Result|Experimental Result|Reduction (chemical)|Reduction - action|Effectiveness|Efficacy Study"
"Nevirapine and itraconazole should not be administered concomitantly due to potentiadecreases in itraconazole plasma concentrations that may reduce efficacy of the drug.","C0132326|C0064113|C1518422|C1521801|C0683150|C1280519|C1707887|C0013227|C1254351","[orch, phsu]|[orch, phsu]|[ftcn]|[ftcn]|[qnco]|[qlco]|[resa]|[phsu]|[phsu]","Nevirapine|Itraconazole|Negation|Having administered|plasma concentration|Effectiveness|Efficacy Study|Pharmaceutical Preparations|Pharmacologic Substance"
"Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug.","C0132326|C0022625|C1518422|C1521801|C0392756|C0442797|C0547047|C0683150|C1280519|C1707887|C0013227|C1254351","[orch, phsu]|[orch, phsu]|[ftcn]|[ftcn]|[qlco]|[qlco]|[qnco]|[qnco]|[qlco]|[resa]|[phsu]|[phsu]","Nevirapine|Ketoconazole|Negation|Having administered|Reduced|Decreasing|Decrease|plasma concentration|Effectiveness|Efficacy Study|Pharmaceutical Preparations|Pharmacologic Substance"
"Nevirapine and rifampin should not be administered concomitantly because decreases in nevirapine plasma concentrations may reduce the efficacy of the drug. ","C0132326|C0035608|C1518422|C1521801|C0392756|C0442797|C0547047|C0683150|C1280519|C1707887|C0013227|C1254351","[orch, phsu]|[antb, orch]|[ftcn]|[ftcn]|[qlco]|[qlco]|[qnco]|[qnco]|[qlco]|[resa]|[phsu]|[phsu]","Nevirapine|Rifampin|Negation|Having administered|Reduced|Decreasing|Decrease|plasma concentration|Effectiveness|Efficacy Study|Pharmaceutical Preparations|Pharmacologic Substance"
"Nevirapine and rifampin should not be administered concomitantly because decreases in nevirapine plasma concentrations may reduce the efficacy of the drug. ","C0132326|C0035608|C1518422|C1521801|C0392756|C0442797|C0547047|C0683150|C1280519|C1707887|C0013227|C1254351","[orch, phsu]|[antb, orch]|[ftcn]|[ftcn]|[qlco]|[qlco]|[qnco]|[qnco]|[qlco]|[resa]|[phsu]|[phsu]","Nevirapine|Rifampin|Negation|Having administered|Reduced|Decreasing|Decrease|plasma concentration|Effectiveness|Efficacy Study|Pharmaceutical Preparations|Pharmacologic Substance""Physicians needing to treat patients co-infected with tuberculosis and using a nevirapine-containing regimen may use rifabutin instead.","C0031831|C0686904|C0040363|C0041260|C1883351|C0087111|C1292734|C1522326|C0030705|C3245499|C0439663|C0041296|C1524063|C0132326|C0332256|C0040808|C2945654|C2700400|C0042153|C0457083|C1947944|C0140575","[orch, phsu]|[antb, orch]|[ftcn]|[ftcn]|[qlco]|[qlco]|[qnco]|[qnco]|[qlco]|[resa]|[phsu]|[phsu][prog]|[ftcn]|[geoa]|[aapp, enzy]|[qlco]|[topp]|[ftcn]|[ftcn]|[podg]|[geoa]|[fndg]|[dsyn]|[ftcn]|[orch, phsu]|[ftcn]|[topp]|[inpr]|[acty]|[ftcn]|[ftcn]|[inpr]|[antb, orch]","Nevirapine|Rifampin|Negation|Having administered|Reduced|Decreasing|Decrease|plasma concentration|Effectiveness|Efficacy Study|Pharmaceutical Preparations|Pharmacologic SubstancePhysicians|Patient need for (contextual qualifier)|Togo|Tryptophanase|To|Therapeutic procedure|Treatment intent|Treating|Patients|Colombia|Infected|Tuberculosis|Use of|Nevirapine|Containing (qualifier)|Treatment Protocols|Regimen - CHV concept|Contain (action)|utilization qualifier|Usage|Use - dosing instruction imperative|Rifabutin"
"Nevirapine and telaprevir should not be coadministered because changes in plasma concentrations of nevirapine, telaprevir, or both may be may result in a reduction in telaprevir efficacy or an increase in nevirapine-associated adverse events.","C0132326|C1876229|C1518422|C0392747|C0443172|C1705241|C0683150|C1274040|C1546471|C2825142|C0301630|C0392756|C0441610|C1280519|C1707887|C0442805|C0332281|C0877248|C1705413","[orch, phsu]|[aapp, phsu]|[ftcn]|[ftcn]|[qnco]|[qnco]|[qnco]|[ftcn]|[idcn]|[fndg]|[npop]|[qlco]|[topp]|[qlco]|[resa]|[ftcn]|[qlco]|[patf]|[inpr]","Nevirapine|telaprevir|Negation|Changing|Changed status|Delta (difference)|plasma concentration|Result|What subject filter - Result|Experimental Result|Reduction (chemical)|Reduced|Reduction - action|Effectiveness|Efficacy Study|Increase|Associated with|Adverse event|Adverse Event Domain"
"No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily. ","C2826232|C1514873|C0132326|C3245499|C1521801|C3817553|C0026410|C0439269|C1960952|C2346927|C1979439|C0585361","[hlca]|[ftcn]|[orch, phsu]|[geoa]|[ftcn]|[qnco]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch, phsu]|[tmco]","Dose Adjustment|Requirement|Nevirapine|Colombia|Having administered|100%|Mongolia|mg/dL|Milligram percent|Magnesium Cation|Fosamprenavir+Ritonavir|Twice a day"
"No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily. ","C2826232|C1514873|C0132326|C3245499|C1521801|C3817553|C0026410|C0439269|C1960952|C2346927|C1979439|C0585361","[hlca]|[ftcn]|[orch, phsu]|[geoa]|[ftcn]|[qnco]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch, phsu]|[tmco]","Dose Adjustment|Requirement|Nevirapine|Colombia|Having administered|100%|Mongolia|mg/dL|Milligram percent|Magnesium Cation|Fosamprenavir+Ritonavir|Twice a day""The combination of nevirapine administered with fosamprenavir/ritonavir once daily has not been studied.","C0205195|C1947911|C3811910|C0132326|C1521801|C1979439|C0332173|C1518422|C0557651|C2603343","[hlca]|[ftcn]|[orch, phsu]|[geoa]|[ftcn]|[qnco]|[geoa]|[qnco]|[qnco]|[elii, phsu]|[orch, phsu]|[tmco][qlco]|[phob]|[fndg]|[orch, phsu]|[ftcn]|[orch, phsu]|[tmco]|[ftcn]|[mnob]|[resa]","Dose Adjustment|Requirement|Nevirapine|Colombia|Having administered|100%|Mongolia|mg/dL|Milligram percent|Magnesium Cation|Fosamprenavir+Ritonavir|Twice a dayCombined|combination of objects|combination - answer to question|Nevirapine|Having administered|Fosamprenavir+Ritonavir|Daily|Negation|Room of building - Study|Study"
"Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing.","C0003211|C1518422|C0004057|C0205195|C1947911|C3811910|C0442804|C0178602|C0034428|C1533693|C1547282|C0040363|C0041260|C1883351|C0036572|C1709630|C0947630|C0332152|C0008972|C0740175|C2257086|C3669034","[phsu]|[ftcn]|[orch, phsu]|[qlco]|[phob]|[fndg]|[fndg]|[qnco]|[orch]|[orch, phsu]|[anim]|[geoa]|[aapp, enzy]|[qlco]|[sosy]|[qlco]|[lbpr]|[tmco]|[resa]|[qlco]|[genf]|[mamm]","Anti-Inflammatory Agents, Non-Steroidal|Negation|Aspirin|Combined|combination of objects|combination - answer to question|Very high|Dosage|Quinolones|Quinolone Antibacterial Agents|Show|Togo|Tryptophanase|To|Seizures|Preclinical|Scientific Study|Before|Clinical Research|Before values|photoreactivating enzyme activity|Pure Spanish horse breed (organism)"
"Opiate agonists: Fentanyl","C0242402|C0015846","[hops, orch, phsu]|[orch, phsu]","Opioids|Fentanyl"
"Oral contraceptives and other hormonal methods of birth control should not be used as the sole method of contraception in women taking nevirapine, since nevirapine may lower the plasma levels of these medications. ","C0009905|C0458083|C0025663|C0025664|C0449851|C0700589|C1518422|C1273517|C0230463|C0871511|C0043210|C1515187|C0132326|C0441994|C1548802|C2003888|C0032105|C0441889|C1550098|C0013227|C0802604|C2598133","[phsu]|[qlco]|[inpr]|[inpr]|[ftcn]|[topp]|[ftcn]|[fndg]|[blor]|[lbpr]|[popg]|[hlca]|[orch, phsu]|[spco]|[blor]|[acty]|[bdsu]|[qlco]|[bdsu]|[phsu]|[clna]|[clna]","Contraceptives, Oral|Hormonal|Methods|Methods aspects|Techniques|Contraceptive methods|Negation|Used by|Sole of Foot|Test Method|Woman|Take|Nevirapine|Lower - spatial qualifier|Body Site Modifier - Lower|Lower (action)|Plasma|Levels (qualifier value)|Plasma, NOS (not otherwise specified)|Pharmaceutical Preparations|Medications:Presence or Identity:Duration of the study:^Patient:Nominal|Medications:-:Point in time:^Patient:-"
"Oral contraceptives and other hormonal methods of birth control should not be used as the sole method of contraception in women taking nevirapine, since nevirapine may lower the plasma levels of these medications. ","C0009905|C0458083|C0025663|C0025664|C0449851|C0700589|C1518422|C1273517|C0230463|C0871511|C0043210|C1515187|C0132326|C0441994|C1548802|C2003888|C0032105|C0441889|C1550098|C0013227|C0802604|C2598133","[phsu]|[qlco]|[inpr]|[inpr]|[ftcn]|[topp]|[ftcn]|[fndg]|[blor]|[lbpr]|[popg]|[hlca]|[orch, phsu]|[spco]|[blor]|[acty]|[bdsu]|[qlco]|[bdsu]|[phsu]|[clna]|[clna]","Contraceptives, Oral|Hormonal|Methods|Methods aspects|Techniques|Contraceptive methods|Negation|Used by|Sole of Foot|Test Method|Woman|Take|Nevirapine|Lower - spatial qualifier|Body Site Modifier - Lower|Lower (action)|Plasma|Levels (qualifier value)|Plasma, NOS (not otherwise specified)|Pharmaceutical Preparations|Medications:Presence or Identity:Duration of the study:^Patient:Nominal|Medications:-:Point in time:^Patient:-""An alternative or additional method of contraception is recommended.","C1523987|C1524062|C0025663|C0449851|C0871511|C0700589|C0034866","[phsu]|[qlco]|[inpr]|[inpr]|[ftcn]|[topp]|[ftcn]|[fndg]|[blor]|[lbpr]|[popg]|[hlca]|[orch, phsu]|[spco]|[blor]|[acty]|[bdsu]|[qlco]|[bdsu]|[phsu]|[clna]|[clna][cnce]|[ftcn]|[inpr]|[ftcn]|[lbpr]|[topp]|[idcn]","Contraceptives, Oral|Hormonal|Methods|Methods aspects|Techniques|Contraceptive methods|Negation|Used by|Sole of Foot|Test Method|Woman|Take|Nevirapine|Lower - spatial qualifier|Body Site Modifier - Lower|Lower (action)|Plasma|Levels (qualifier value)|Plasma, NOS (not otherwise specified)|Pharmaceutical Preparations|Medications:Presence or Identity:Duration of the study:^Patient:Nominal|Medications:-:Point in time:^Patient:-Alternative|Additional|Methods|Techniques|Test Method|Contraceptive methods|Recommendation"
"Oral contraceptives: Ethinyl estradiol and Norethindrone*","C0009905|C0015011|C0028356","[phsu]|[horm, orch, phsu]|[horm, orch, phsu]","Contraceptives, Oral|Ethinyl Estradiol|Norethindrone"
"PK","","",""
"Plasma concentrations may be altered. ","C0683150|C0392747","[qnco]|[ftcn]","plasma concentration|Changing"
"Plasma concentrations may be altered. ","C0683150|C0392747","[qnco]|[ftcn]","plasma concentration|Changing""Nevirapine should not be coadministered with another NNRTI as this combination has not been shown to be beneficial.","C0132326|C1518422|C3537104|C0205195|C1947911|C3811910|C1547282|C0040363|C0041260|C1883351","[qnco]|[ftcn][orch, phsu]|[ftcn]|[phsu]|[qlco]|[phob]|[fndg]|[anim]|[geoa]|[aapp, enzy]|[qlco]","plasma concentration|ChangingNevirapine|Negation|Non-nucleoside Reverse Transcriptase Inhibitor|Combined|combination of objects|combination - answer to question|Show|Togo|Tryptophanase|To"
"Plasma concentrations may be decreased.","C0683150|C0205216|C0392756|C0442797","[qnco]|[qnco]|[qlco]|[qlco]","plasma concentration|Decreased|Reduced|Decreasing"
"Plasma concentrations may be increased.","C0683150|C0205217|C0442805","[qnco]|[qnco]|[ftcn]","plasma concentration|Increased|Increase"
"Plasma concentrations of boceprevir may be decreased due to induction of CYP3A4/5 by nevirapine.","C0683150|C1738934|C0205216|C0392756|C0442797|C0205263|C0857127|C3714798|C0132326","[qnco]|[aapp, phsu]|[qnco]|[qlco]|[qlco]|[ftcn]|[topp]|[aapp, enzy]|[orch, phsu]","plasma concentration|boceprevir|Decreased|Reduced|Decreasing|Induce (action)|Induction procedure|Cytochrome P-450 CYP3A4|Nevirapine"
"Plasma concentrations of nevirapine and the anticonvulsant may be decreased.","C0683150|C0132326|C0003286|C0205216|C0392756|C0442797","[qnco]|[orch, phsu]|[phsu]|[qnco]|[qlco]|[qlco]","plasma concentration|Nevirapine|Anticonvulsants|Decreased|Reduced|Decreasing"
"Plasma concentrations of telaprevir may be decreased due to induction of CYP3A4 by nevirapine and plasma concentrations of nevirapine may be increased due to inhibition of CYP3A4 by telaprevir.","C0683150|C1876229|C0205216|C0392756|C0442797|C0205263|C0857127|C3714798|C0132326|C0205217|C0442805|C0021467|C0021469|C1628982|C3463820","[qnco]|[aapp, phsu]|[qnco]|[qlco]|[qlco]|[ftcn]|[topp]|[aapp, enzy]|[orch, phsu]|[qnco]|[ftcn]|[menp]|[moft]|[qnco]|[acty]","plasma concentration|telaprevir|Decreased|Reduced|Decreasing|Induce (action)|Induction procedure|Cytochrome P-450 CYP3A4|Nevirapine|Increased|Increase|Psychological inhibition|Metabolic Inhibition|Percent inhibition|Inhibition"
"Plasma concentrations of boceprevir may be decreased due to induction of CYP3A4/5 by nevirapine","C0683150|C1738934|C0205216|C0392756|C0442797|C0205263|C0857127|C3714798|C0132326","[qnco]|[aapp, phsu]|[qnco]|[qlco]|[qlco]|[ftcn]|[topp]|[aapp, enzy]|[orch, phsu]","plasma concentration|boceprevir|Decreased|Reduced|Decreasing|Induce (action)|Induction procedure|Cytochrome P-450 CYP3A4|Nevirapine"
"Potential effect on anticoagulation. ","C3245505|C1280500|C2348382|C0003281|C2917212|C2919015|C3537050","[qlco]|[qlco]|[qlco]|[topp]|[phsf]|[fndg]|[phsf]","potential|Effect|Effect, Appearance|Anticoagulation Therapy|Negative Regulation of Coagulation|ANTICOAGULATION (finding)|Decreased Coagulation Activity [PE]"
"Potential effect on anticoagulation. ","C3245505|C1280500|C2348382|C0003281|C2917212|C2919015|C3537050","[qlco]|[qlco]|[qlco]|[topp]|[phsf]|[fndg]|[phsf]","potential|Effect|Effect, Appearance|Anticoagulation Therapy|Negative Regulation of Coagulation|ANTICOAGULATION (finding)|Decreased Coagulation Activity [PE]""Monitoring of anticoagulation levels is recommended.","C0150369|C1283169|C1516647|C0003281|C0441889|C2917212|C2919015|C3537050|C0034866","[qlco]|[qlco]|[qlco]|[topp]|[phsf]|[fndg]|[phsf][hlca]|[hlca]|[resa]|[topp]|[qlco]|[phsf]|[fndg]|[phsf]|[idcn]","potential|Effect|Effect, Appearance|Anticoagulation Therapy|Negative Regulation of Coagulation|ANTICOAGULATION (finding)|Decreased Coagulation Activity [PE]Preventive monitoring|Monitoring - action|Clinical Trials, Monitoring|Anticoagulation Therapy|Levels (qualifier value)|Negative Regulation of Coagulation|ANTICOAGULATION (finding)|Decreased Coagulation Activity [PE]|Recommendation"
"Potential increase in the risk of methotrexate associated toxic reactions. ","C3245505|C0442805|C0035647|C0025677|C0332281|C0542243","[qlco]|[ftcn]|[idcn]|[orch, phsu]|[qlco]|[fndg]","potential|Increase|Risk|Methotrexate|Associated with|toxic reaction (non-specific)"
"Potential increase in the risk of methotrexate associated toxic reactions. ","C3245505|C0442805|C0035647|C0025677|C0332281|C0542243","[qlco]|[ftcn]|[idcn]|[orch, phsu]|[qlco]|[fndg]","potential|Increase|Risk|Methotrexate|Associated with|toxic reaction (non-specific)""Therefore, carefully monitor patients under methotrexate therapy when concomitant ciprofloxacin therapy is indicated.","C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0030705|C0025677|C0039798|C0087111|C1363945|C1707479|C0008809|C1444656","[qlco]|[ftcn]|[idcn]|[orch, phsu]|[qlco]|[fndg][hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[podg]|[orch, phsu]|[ftcn]|[topp]|[fndg]|[topp]|[orch, phsu]|[fndg]","potential|Increase|Risk|Methotrexate|Associated with|toxic reaction (non-specific)Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Patients|Methotrexate|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Concomitant Therapy|Ciprofloxacin|Indicated"
"Potentiation of ciprofloxacin toxicity may occur.","C0279023|C0008809|C0040539|C0600688|C1709305|C2745955","[topp]|[orch, phsu]|[qlco]|[inpo]|[acty]|[tmco]","chemosensitization/potentiation|Ciprofloxacin|Toxicity aspects|Toxic effect|Occur (action)|Occurrence"
"Potentiation of ciprofloxacin toxicity may occur.","C0279023|C0008809|C0040539|C0600688|C1709305|C2745955","[topp]|[orch, phsu]|[qlco]|[inpo]|[acty]|[tmco]","chemosensitization/potentiation|Ciprofloxacin|Toxicity aspects|Toxic effect|Occur (action)|Occurrence"
"Potentiation of ciprofloxacin toxicity may occur.","C0279023|C0008809|C0040539|C0600688|C1709305|C2745955","[topp]|[orch, phsu]|[qlco]|[inpo]|[acty]|[tmco]","chemosensitization/potentiation|Ciprofloxacin|Toxicity aspects|Toxic effect|Occur (action)|Occurrence"
"Probenecid","C0033209","[orch, phsu]","Probenecid"
"Probenecid","C0033209","[orch, phsu]","Probenecid"
"Probenecid","C0033209","[orch, phsu]","Probenecid"
"Re-evaluatedosing.","C0556581|C2986904","[qnco]|[idcn]","Retinol equivalents|Respiratory Domain"
"Re-evaluatedosing.","C0556581|C2986904","[qnco]|[idcn]","Retinol equivalents|Respiratory Domain"
"Re-evaluatedosing.","C0556581|C2986904","[qnco]|[idcn]","Retinol equivalents|Respiratory Domain"
"Re-evaluatedosing.","C0556581|C2986904","[qnco]|[idcn]","Retinol equivalents|Respiratory Domain"
"Re-evaluatedosing.","C0556581|C2986904","[qnco]|[idcn]","Retinol equivalents|Respiratory Domain"
"Re-evaluatedosing.Donotexceed8mg/day","C0556581|C0332173|C0439228|C0439505|C2986904","[qnco]|[tmco]|[tmco]|[tmco]|[idcn]","Retinol equivalents|Daily|day|per day|Respiratory Domain"
"Re-evaluatedosing.Donotexceed8mg/day","C0556581|C0332173|C0439228|C0439505|C2986904","[qnco]|[tmco]|[tmco]|[tmco]|[idcn]","Retinol equivalents|Daily|day|per day|Respiratory Domain"
"Re-evaluatedosing.Donotexceed8mg/day","C0556581|C0332173|C0439228|C0439505|C2986904","[qnco]|[tmco]|[tmco]|[tmco]|[idcn]","Retinol equivalents|Daily|day|per day|Respiratory Domain"
"Rifabutin and its metabolite concentrations were moderately increased. ","C0140575|C0870883|C0086045|C0205081|C1881878|C0205217|C0442805","[antb, orch]|[bacs]|[menp]|[qlco]|[qlco]|[qnco]|[ftcn]","Rifabutin|Metabolite|Mental concentration|Moderate (severity modifier)|Moderation|Increased|Increase"
"Rifabutin and its metabolite concentrations were moderately increased. ","C0140575|C0870883|C0086045|C0205081|C1881878|C0205217|C0442805","[antb, orch]|[bacs]|[menp]|[qlco]|[qlco]|[qnco]|[ftcn]","Rifabutin|Metabolite|Mental concentration|Moderate (severity modifier)|Moderation|Increased|Increase""Due to high intersubject variability, however, some patients may experience large increases in rifabutin exposure and may be at higher risk for rifabutin toxicity. ","C0205250|C2827666|C1299351|C2700149|C3887512|C3889660|C0030705|C0237607|C0596545|C0549177|C0205217|C0442805|C0140575|C0274281|C0332157|C0332167|C3272283|C0040539|C0600688","[antb, orch]|[bacs]|[menp]|[qlco]|[qlco]|[qnco]|[ftcn][qlco]|[cnce]|[qlco]|[inpr]|[idcn]|[qnco]|[podg]|[menp]|[menp]|[qnco]|[qnco]|[ftcn]|[antb, orch]|[inpo]|[clna]|[qlco]|[fndg]|[qlco]|[inpo]","Rifabutin|Metabolite|Mental concentration|Moderate (severity modifier)|Moderation|Increased|IncreaseHigh|Variability|Abnormally high|Value Above Reference Range|high - ActExposureLevelCode|High Mitosis-Karyorrhexis Index|Patients|Practice Experience|Experience|Large|Increased|Increase|Rifabutin|Injury due to exposure to external cause|Exposure to|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Toxicity aspects|Toxic effect"
"Rifabutin and its metabolite concentrations were moderately increased. ","C0140575|C0870883|C0086045|C0205081|C1881878|C0205217|C0442805","[antb, orch]|[bacs]|[menp]|[qlco]|[qlco]|[qnco]|[ftcn]","Rifabutin|Metabolite|Mental concentration|Moderate (severity modifier)|Moderation|Increased|Increase""Due to high intersubject variability, however, some patients may experience large increases in rifabutin exposure and may be at higher risk for rifabutin toxicity. ","C0205250|C2827666|C1299351|C2700149|C3887512|C3889660|C0030705|C0237607|C0596545|C0549177|C0205217|C0442805|C0140575|C0274281|C0332157|C0332167|C3272283|C0040539|C0600688","[antb, orch]|[bacs]|[menp]|[qlco]|[qlco]|[qnco]|[ftcn][qlco]|[cnce]|[qlco]|[inpr]|[idcn]|[qnco]|[podg]|[menp]|[menp]|[qnco]|[qnco]|[ftcn]|[antb, orch]|[inpo]|[clna]|[qlco]|[fndg]|[qlco]|[inpo]","Rifabutin|Metabolite|Mental concentration|Moderate (severity modifier)|Moderation|Increased|IncreaseHigh|Variability|Abnormally high|Value Above Reference Range|high - ActExposureLevelCode|High Mitosis-Karyorrhexis Index|Patients|Practice Experience|Experience|Large|Increased|Increase|Rifabutin|Injury due to exposure to external cause|Exposure to|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Toxicity aspects|Toxic effect""Therefore, caution should be used in concomitant administration.","C1273517|C0521115|C0001554|C1533734","[antb, orch]|[bacs]|[menp]|[qlco]|[qlco]|[qnco]|[ftcn][qlco]|[cnce]|[qlco]|[inpr]|[idcn]|[qnco]|[podg]|[menp]|[menp]|[qnco]|[qnco]|[ftcn]|[antb, orch]|[inpo]|[clna]|[qlco]|[fndg]|[qlco]|[inpo][fndg]|[tmco]|[ocac]|[topp]","Rifabutin|Metabolite|Mental concentration|Moderate (severity modifier)|Moderation|Increased|IncreaseHigh|Variability|Abnormally high|Value Above Reference Range|high - ActExposureLevelCode|High Mitosis-Karyorrhexis Index|Patients|Practice Experience|Experience|Large|Increased|Increase|Rifabutin|Injury due to exposure to external cause|Exposure to|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Toxicity aspects|Toxic effectUsed by|Simultaneous|Administration occupational activities|Administration procedure"
"Rifabutin*","C0140575","[antb, orch]","Rifabutin"
"Rifampin*","C0035608","[antb, orch]","Rifampin"
"Risperidone","C0073393","[orch, phsu]","Risperidone"
"Risperidone","C0073393","[orch, phsu]","Risperidone"
"Risperidone","C0073393","[orch, phsu]","Risperidone"
"Risperidone","C0073393","[orch, phsu]","Risperidone"
"Risperidone","C0073393","[orch, phsu]","Risperidone"
"Risperidone","C0073393","[orch, phsu]","Risperidone"
"Saquinavir/Ritonavir","C1977397","[antb, orch]","Saquinavir+Ritonavir"
"Serum digitalis glycoside levels may be reduced in hyperthyroidism or when the hypothyroid patient is converted to the euthyroid state.","C0229671|C0012253|C0441889|C1546774|C1550100|C0392756|C0020550|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[bdsu]|[orch, phsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[dsyn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Serum|Digitalis Glycosides|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Reduced|Hyperthyroidism|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State"
"Serum digitalis glycoside levels may be reduced in hyperthyroidism or when the hypothyroid patient is converted to the euthyroid state.","C0229671|C0012253|C0441889|C1546774|C1550100|C0392756|C0020550|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[bdsu]|[orch, phsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[dsyn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Serum|Digitalis Glycosides|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Reduced|Hyperthyroidism|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Therapeutic effect of digitalis glycosides may be reduced.","C1527144|C0012253|C0392756","[bdsu]|[orch, phsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[dsyn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][clna]|[orch, phsu]|[qlco]","Serum|Digitalis Glycosides|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Reduced|Hyperthyroidism|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US StateTherapeutic Effect|Digitalis Glycosides|Reduced"
"Serum digitalis glycoside levels may be reduced in hyperthyroidism or when the hypothyroid patient is converted to the euthyroid state. ","C0229671|C0012253|C0441889|C1546774|C1550100|C0392756|C0020550|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[bdsu]|[orch, phsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[dsyn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Serum|Digitalis Glycosides|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Reduced|Hyperthyroidism|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State"
"Serum digitalis glycoside levels may be reduced in hyperthyroidism or when the hypothyroid patient is converted to the euthyroid state. ","C0229671|C0012253|C0441889|C1546774|C1550100|C0392756|C0020550|C0020676|C0030705|C2360836|C2360838|C2360840|C0117002|C1301808|C1442792|C3148680","[bdsu]|[orch, phsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[dsyn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa]","Serum|Digitalis Glycosides|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Reduced|Hyperthyroidism|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US State""Therapeutic effect of digitalis glycosides may be reduced.","C1527144|C0012253|C0392756","[bdsu]|[orch, phsu]|[qlco]|[inpr]|[bdsu]|[qlco]|[dsyn]|[dsyn]|[podg]|[clna]|[clna]|[clna]|[fndg]|[geoa]|[ftcn]|[geoa][clna]|[orch, phsu]|[qlco]","Serum|Digitalis Glycosides|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Reduced|Hyperthyroidism|Hypothyroidism|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Euthyroid (finding)|Geographic state|State|US StateTherapeutic Effect|Digitalis Glycosides|Reduced"
"Simultaneous dosing of Vardenafil 5 mgand Alpha-Blocker,Placebo-Subtracted","C0205420|C0521115|C1548968|C0971579|C0001641|C0032042|C1719767|C2348589|C1696465|C1706408","[tmco]|[tmco]|[idcn]|[orch, phsu]|[phsu]|[topp]|[inpr]|[phpr]|[bodm]|[resa]","Concurrent|Simultaneous|Service Request Relationship - Simultaneous|vardenafil|Adrenergic alpha-Antagonists|Placebos|Subtract - dosing instruction fragment|Subtraction process|placebo|Placebo Control"
"Simultaneous dosing of Vardenafil and Alpha-Blocker","C0205420|C0521115|C1548968|C0971579|C0001641","[tmco]|[tmco]|[idcn]|[orch, phsu]|[phsu]","Concurrent|Simultaneous|Service Request Relationship - Simultaneous|vardenafil|Adrenergic alpha-Antagonists"
"Slow-Release Nicotinic Acid","C0439834|C0030685|C0027996|C0028049|C3536880|C3714626|C0391871|C0439180|C0680255|C1283071|C1963578","[qlco]|[hlca]|[orch, phsu, vita]|[orch, phsu, vita]|[phsu]|[phsu, vita]|[ftcn]|[qnco]|[hlca]|[ftcn]|[topp]","Slow|Patient Discharge|Niacin|Nicotinic Acids|Nicotinic Acid [EPC]|Nicotinic Acid Drug Class|Released (action)|% release (qualifier value)|Discharge (release)|Release - action (qualifier value)|Release (procedure)"
"St. ","C0036056|C3272372","[geoa]|[inpr]","Saint Lucia|Character String Data Type"
"St. ","C0036056|C3272372","[geoa]|[inpr]","Saint LuciaCharacter String Data Type""Johns Wort","","[geoa][inpr]","Saint LuciaCharacter String Data Type"
"Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased Ievothyroxine requirements. ","C1292856|C1948023|C0428321|C1979928|C0013227|C0205177|C0439167|C0441655|C1561536|C3668946|C1254351|C0205054|C0243102|C0015127|C1524003|C0205217|C0243125|C0699900|C0442805|C0040165|C1881373|C0678226|C0520917","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirement"
"Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased Ievothyroxine requirements. ","C1292856|C1948023|C0428321|C1979928|C0013227|C0205177|C0439167|C0441655|C1561536|C3668946|C1254351|C0205054|C0243102|C0015127|C1524003|C0205217|C0243125|C0699900|C0442805|C0040165|C1881373|C0678226|C0520917","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirement""Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total- and free-T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid.","C0031507|C0006949|C0682993|C0036825|C1145667|C1167622|C0229671|C0033618|C1546774|C1550100|C0040165|C1881373|C0439175|C0439810|C0202225|C0392756|C3842589|C0439509|C3842587|C0030705|C0205307|C1277938|C0439166|C2347086|C0117002","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf][orch, phsu]|[orch, phsu]|[orch]|[aapp, bacs]|[acty]|[moft]|[bdsu]|[moft]|[inpr]|[bdsu]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[qlco]|[lbpr]|[qlco]|[fndg]|[tmco]|[qnco]|[podg]|[qlco]|[lbpr]|[qnco]|[qnco]|[fndg]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirementPhenytoin|Carbamazepine|carbamazepin|Serum Proteins|Binding action|Binding (Molecular Function)|Serum|Protein Binding|Specimen Source Codes - Serum|Specimen Type - Serum|Thyroxine|Synthetic Levothyroxine|% of total|Total|T4 free measurement|Reduced|20%|/40|40%|Patients|Normal|Measurement of serum thyroid stimulating hormone|Percent normal|Mean Percent of Normal|Euthyroid (finding)"
"Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased Ievothyroxine requirements. ","C1292856|C1948023|C0428321|C1979928|C0013227|C0205177|C0439167|C0441655|C1561536|C3668946|C1254351|C0205054|C0243102|C0015127|C1524003|C0205217|C0243125|C0699900|C0442805|C0040165|C1881373|C0678226|C0520917","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirement"
"Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased Ievothyroxine requirements. ","C1292856|C1948023|C0428321|C1979928|C0013227|C0205177|C0439167|C0441655|C1561536|C3668946|C1254351|C0205054|C0243102|C0015127|C1524003|C0205217|C0243125|C0699900|C0442805|C0040165|C1881373|C0678226|C0520917","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirement""Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total- and free-T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid.","C0031507|C0006949|C0682993|C0036825|C1145667|C1167622|C0229671|C0033618|C1546774|C1550100|C0040165|C1881373|C0439175|C0439810|C0202225|C0392756|C3842589|C0439509|C3842587|C0030705|C0205307|C1277938|C0439166|C2347086|C0117002","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf][orch, phsu]|[orch, phsu]|[orch]|[aapp, bacs]|[acty]|[moft]|[bdsu]|[moft]|[inpr]|[bdsu]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[qlco]|[lbpr]|[qlco]|[fndg]|[tmco]|[qnco]|[podg]|[qlco]|[lbpr]|[qnco]|[qnco]|[fndg]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirementPhenytoin|Carbamazepine|carbamazepin|Serum Proteins|Binding action|Binding (Molecular Function)|Serum|Protein Binding|Specimen Source Codes - Serum|Specimen Type - Serum|Thyroxine|Synthetic Levothyroxine|% of total|Total|T4 free measurement|Reduced|20%|/40|40%|Patients|Normal|Measurement of serum thyroid stimulating hormone|Percent normal|Mean Percent of Normal|Euthyroid (finding)"
"Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased Ievothyroxine requirements. ","C1292856|C1948023|C0428321|C1979928|C0013227|C0205177|C0439167|C0441655|C1561536|C3668946|C1254351|C0205054|C0243102|C0015127|C1524003|C0205217|C0243125|C0699900|C0442805|C0040165|C1881373|C0678226|C0520917","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirement"
"Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased Ievothyroxine requirements. ","C1292856|C1948023|C0428321|C1979928|C0013227|C0205177|C0439167|C0441655|C1561536|C3668946|C1254351|C0205054|C0243102|C0015127|C1524003|C0205217|C0243125|C0699900|C0442805|C0040165|C1881373|C0678226|C0520917","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirement""Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total- and free-T may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid.\4","C0031507|C0006949|C0682993|C0036825|C1145667|C1167622|C0229671|C0033618|C1546774|C1550100|C0040165|C1881373|C0439175|C0439810|C0332296|C1880497|C1996904|C0392756|C3842589|C0439509|C3842587|C0030705|C0205307|C1277938|C0439166|C2347086|C0117002","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf][orch, phsu]|[orch, phsu]|[orch]|[aapp, bacs]|[acty]|[moft]|[bdsu]|[moft]|[inpr]|[bdsu]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[qlco]|[ftcn]|[qlco]|[qlco]|[qlco]|[fndg]|[tmco]|[qnco]|[podg]|[qlco]|[lbpr]|[qnco]|[qnco]|[fndg]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirementPhenytoin|Carbamazepine|carbamazepin|Serum Proteins|Binding action|Binding (Molecular Function)|Serum|Protein Binding|Specimen Source Codes - Serum|Specimen Type - Serum|Thyroxine|Synthetic Levothyroxine|% of total|Total|Free of (attribute)|Empty (qualifier)|Free (available (qualifier))|Reduced|20%|/40|40%|Patients|Normal|Measurement of serum thyroid stimulating hormone|Percent normal|Mean Percent of Normal|Euthyroid (finding)"
"Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased Ievothyroxine requirements. ","C1292856|C1948023|C0428321|C1979928|C0013227|C0205177|C0439167|C0441655|C1561536|C3668946|C1254351|C0205054|C0243102|C0015127|C1524003|C0205217|C0243125|C0699900|C0442805|C0040165|C1881373|C0678226|C0520917","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirement"
"Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased Ievothyroxine requirements. ","C1292856|C1948023|C0428321|C1979928|C0013227|C0205177|C0439167|C0441655|C1561536|C3668946|C1254351|C0205054|C0243102|C0015127|C1524003|C0205217|C0243125|C0699900|C0442805|C0040165|C1881373|C0678226|C0520917","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirement""Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total- and free-T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid.","C0031507|C0006949|C0682993|C0036825|C1145667|C1167622|C0229671|C0033618|C1546774|C1550100|C0040165|C1881373|C0439175|C0439810|C0202225|C0392756|C3842589|C0439509|C3842587|C0030705|C0205307|C1277938|C0439166|C2347086|C0117002","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf][orch, phsu]|[orch, phsu]|[orch]|[aapp, bacs]|[acty]|[moft]|[bdsu]|[moft]|[inpr]|[bdsu]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[qlco]|[lbpr]|[qlco]|[fndg]|[tmco]|[qnco]|[podg]|[qlco]|[lbpr]|[qnco]|[qnco]|[fndg]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirementPhenytoin|Carbamazepine|carbamazepin|Serum Proteins|Binding action|Binding (Molecular Function)|Serum|Protein Binding|Specimen Source Codes - Serum|Specimen Type - Serum|Thyroxine|Synthetic Levothyroxine|% of total|Total|T4 free measurement|Reduced|20%|/40|40%|Patients|Normal|Measurement of serum thyroid stimulating hormone|Percent normal|Mean Percent of Normal|Euthyroid (finding)"
"Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine requirements.","C1292856|C1948023|C0428321|C1979928|C0013227|C0205177|C0439167|C0441655|C1561536|C3668946|C1254351|C0205054|C0243102|C0015127|C1524003|C0205217|C0243125|C0699900|C0442805|C0040165|C1881373|C0678226|C0520917","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirement"
"Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine requirements.","C1292856|C1948023|C0428321|C1979928|C0013227|C0205177|C0439167|C0441655|C1561536|C3668946|C1254351|C0205054|C0243102|C0015127|C1524003|C0205217|C0243125|C0699900|C0442805|C0040165|C1881373|C0678226|C0520917","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirement""Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total- and free-T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid.","C0031507|C0006949|C0682993|C0036825|C1145667|C1167622|C0229671|C0033618|C1546774|C1550100|C0040165|C1881373|C0439175|C0439810|C0202225|C0392756|C3842589|C0439509|C3842587|C0030705|C0205307|C1277938|C0439166|C2347086|C0117002","[topp]|[npop]|[lbpr]|[qlco]|[phsu]|[ftcn]|[qnco]|[acty]|[idcn]|[fndg]|[phsu]|[blor]|[moft]|[ftcn]|[cnce]|[qnco]|[ftcn]|[orgf]|[ftcn]|[aapp, horm, phsu]|[orch, phsu]|[ftcn]|[patf][orch, phsu]|[orch, phsu]|[orch]|[aapp, bacs]|[acty]|[moft]|[bdsu]|[moft]|[inpr]|[bdsu]|[aapp, horm, phsu]|[orch, phsu]|[qnco]|[qlco]|[lbpr]|[qlco]|[fndg]|[tmco]|[qnco]|[podg]|[qlco]|[lbpr]|[qnco]|[qnco]|[fndg]","Stimulation procedure|Stimulation (motivation)|Measurement of liver enzyme|Microsomal|Pharmaceutical Preparations|Active|Percent Activity|Activities|*Activity (kind of quantity)|Activity (animal life circumstance)|Pharmacologic Substance|Hepatic|enzyme activity|Etiology aspects|Science of Etiology|Increased|degradation aspects|Catabolism|Increase|Thyroxine|Synthetic Levothyroxine|Due to|Increased metabolic requirementPhenytoin|Carbamazepine|carbamazepin|Serum Proteins|Binding action|Binding (Molecular Function)|Serum|Protein Binding|Specimen Source Codes - Serum|Specimen Type - Serum|Thyroxine|Synthetic Levothyroxine|% of total|Total|T4 free measurement|Reduced|20%|/40|40%|Patients|Normal|Measurement of serum thyroid stimulating hormone|Percent normal|Mean Percent of Normal|Euthyroid (finding)"
"Table 13. ","C0039224|C1706073|C1706074","[mnob]|[mnob]|[inpr]","Table - furniture|Table Device Component|Data Table"
"Table 13. ","C0039224|C1706073|C1706074","[mnob]|[mnob]|[inpr]","Table - furniture|Table Device Component|Data Table""Established and Other Potentially Significant Drug Interactions","C0443211|C1272684|C0237881|C0687133|C0750502|C1546944","[mnob]|[mnob]|[inpr][qlco]|[qlco]|[qnco]|[moft]|[idcn]|[qlco]","Table - furniture|Table Device Component|Data TableEstablished|Accepted|Statistical Significance|Drug Interactions|Significant|Event Seriousness - Significant"
"Tamoxifen","C0039286","[orch, phsu]","Tamoxifen"
"Telaprevir","C1876229","[aapp, phsu]","telaprevir"
"The appropriate doses of the combination of and nevirapine and saquinavir/ritonavir with respect to safety and efficacy have not been established.","C1548787|C0178602|C0205195|C1947911|C3811910|C0132326|C1977397|C0036043|C1705187|C1280519|C1707887|C1518422|C0443211|C1272684","[qlco]|[qnco]|[qlco]|[phob]|[fndg]|[orch, phsu]|[antb, orch]|[hcpp]|[resa]|[qlco]|[resa]|[ftcn]|[qlco]|[qlco]","Appropriate|Dosage|Combined|combination of objects|combination - answer to question|Nevirapine|Saquinavir+Ritonavir|Safety|Safety Study|Effectiveness|Efficacy Study|Negation|Established|Accepted"
"The appropriate doses of the combination of nevirapine and nelfinavir with respect to safety and efficacy have not been established.","C1548787|C0178602|C0205195|C1947911|C3811910|C0132326|C0525005|C0036043|C1705187|C1280519|C1707887|C1518422|C0443211|C1272684","[qlco]|[qnco]|[qlco]|[phob]|[fndg]|[orch, phsu]|[orch, phsu]|[hcpp]|[resa]|[qlco]|[resa]|[ftcn]|[qlco]|[qlco]","Appropriate|Dosage|Combined|combination of objects|combination - answer to question|Nevirapine|Nelfinavir|Safety|Safety Study|Effectiveness|Efficacy Study|Negation|Established|Accepted"
"The appropriate doses of the combination of nevirapine and saquinavir/ritonavir with respect to safety and efficacy have not been established.","C1548787|C0178602|C0205195|C1947911|C3811910|C0132326|C1977397|C0036043|C1705187|C1280519|C1707887|C1518422|C0443211|C1272684","[qlco]|[qnco]|[qlco]|[phob]|[fndg]|[orch, phsu]|[antb, orch]|[hcpp]|[resa]|[qlco]|[resa]|[ftcn]|[qlco]|[qlco]","Appropriate|Dosage|Combined|combination of objects|combination - answer to question|Nevirapine|Saquinavir+Ritonavir|Safety|Safety Study|Effectiveness|Efficacy Study|Negation|Established|Accepted"
"The appropriate doses of these combinations with respect to safety and efficacy have not been established.","C1548787|C0178602|C0453882|C3539181|C3539182|C3539954|C3539955|C3539956|C3539957|C3539958|C3539959|C3539960|C3539961|C3539962|C3539963|C3539964|C3539965|C3539966|C3539967|C3539968|C3539969|C3539970|C3539971|C3539972|C3539973|C3539974|C3539975|C3539976|C3539977|C3539978|C3539979|C3540026|C3540027|C3540028|C3540030|C3540031|C3540719|C3540720|C3540721|C3540722|C3540723|C3540724|C3540740|C3854036|C0036043|C1705187|C1280519|C1707887|C1518422|C0443211|C1272684","[qlco]|[qnco]|[mnob]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[phsu]|[hcpp]|[resa]|[qlco]|[resa]|[ftcn]|[qlco]|[qlco]","Appropriate|Dosage|Combinations (Undergarment)|Short-acting sulfonamide combinations|Salt solution combinations|topical antibiotic combinations|lung surfactant combinations|Magnesium antacid compound combinations|opium alkaloids and derivative combination cough suppressants|Imidazole and triazole derivative topical antifungal combinations|Long-acting sulfonamide combinations|Other intestinal adsorbent combinations in ATC|Platelet aggregation inhibitor combinations excl. heparin|vitamin D and analog combinations|Amide local anesthetic combinations|local opthalmologic anesthetic combinations|Local hemostatic combinations|insulins and analogs for injection combinations, long-acting|Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations|Enema combinations|Specific immunoglobulin combinations|combination drugs used in erectile dysfunction|otologic analgesic and anesthetic combinations|Combination solutions for parenteral nutrition|Other antifungal combinations for topical use in ATC|Insulins and analogs for injection, intermediate-acting combinations|Aluminium antacid compound combinations|Penicillins with extended spectrum combinations|Calcium antacid compound combinations|expectorant combinations excluding combinations with cough suppressants|Antiinfective irrigating solution combinations|Hepatitis vaccine combinations|Adrenergic and dopaminergic agents combinations|Other irrigating solution combinations in ATC|other cough suppressant combinations in ATC|gonadotropin combinations|Intermediate-acting sulfonamide combinations|Caries prophylactic agent combinations|other nasal preparation combinations in ATC|Beta-lactamase sensitive penicillin combinations|Insulins and analogs for injection, fast-acting combinations|expectorant combinations, excl. combinations with cough suppressants|Potassium supplement combinations|Other anti-dementia drug combinations in ATC|Safety|Safety Study|Effectiveness|Efficacy Study|Negation|Established|Accepted"
"The appropriate doses of these combinations with respect to safety and efficacy have not been established.","C1548787|C0178602|C0453882|C3539181|C3539182|C3539954|C3539955|C3539956|C3539957|C3539958|C3539959|C3539960|C3539961|C3539962|C3539963|C3539964|C3539965|C3539966|C3539967|C3539968|C3539969|C3539970|C3539971|C3539972|C3539973|C3539974|C3539975|C3539976|C3539977|C3539978|C3539979|C3540026|C3540027|C3540028|C3540030|C3540031|C3540719|C3540720|C3540721|C3540722|C3540723|C3540724|C3540740|C3854036|C0036043|C1705187|C1280519|C1707887|C1518422|C0443211|C1272684","[qlco]|[qnco]|[mnob]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[phsu]|[hcpp]|[resa]|[qlco]|[resa]|[ftcn]|[qlco]|[qlco]","Appropriate|Dosage|Combinations (Undergarment)|Short-acting sulfonamide combinations|Salt solution combinations|topical antibiotic combinations|lung surfactant combinations|Magnesium antacid compound combinations|opium alkaloids and derivative combination cough suppressants|Imidazole and triazole derivative topical antifungal combinations|Long-acting sulfonamide combinations|Other intestinal adsorbent combinations in ATC|Platelet aggregation inhibitor combinations excl. heparin|vitamin D and analog combinations|Amide local anesthetic combinations|local opthalmologic anesthetic combinations|Local hemostatic combinations|insulins and analogs for injection combinations, long-acting|Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations|Enema combinations|Specific immunoglobulin combinations|combination drugs used in erectile dysfunction|otologic analgesic and anesthetic combinations|Combination solutions for parenteral nutrition|Other antifungal combinations for topical use in ATC|Insulins and analogs for injection, intermediate-acting combinations|Aluminium antacid compound combinations|Penicillins with extended spectrum combinations|Calcium antacid compound combinations|expectorant combinations excluding combinations with cough suppressants|Antiinfective irrigating solution combinations|Hepatitis vaccine combinations|Adrenergic and dopaminergic agents combinations|Other irrigating solution combinations in ATC|other cough suppressant combinations in ATC|gonadotropin combinations|Intermediate-acting sulfonamide combinations|Caries prophylactic agent combinations|other nasal preparation combinations in ATC|Beta-lactamase sensitive penicillin combinations|Insulins and analogs for injection, fast-acting combinations|expectorant combinations, excl. combinations with cough suppressants|Potassium supplement combinations|Other anti-dementia drug combinations in ATC|Safety|Safety Study|Effectiveness|Efficacy Study|Negation|Established|Accepted"
"The appropriate doses of these combinations with respect to safety and efficacy have not been established.","C1548787|C0178602|C0453882|C3539181|C3539182|C3539954|C3539955|C3539956|C3539957|C3539958|C3539959|C3539960|C3539961|C3539962|C3539963|C3539964|C3539965|C3539966|C3539967|C3539968|C3539969|C3539970|C3539971|C3539972|C3539973|C3539974|C3539975|C3539976|C3539977|C3539978|C3539979|C3540026|C3540027|C3540028|C3540030|C3540031|C3540719|C3540720|C3540721|C3540722|C3540723|C3540724|C3540740|C3854036|C0036043|C1705187|C1280519|C1707887|C1518422|C0443211|C1272684","[qlco]|[qnco]|[mnob]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[phsu]|[hcpp]|[resa]|[qlco]|[resa]|[ftcn]|[qlco]|[qlco]","Appropriate|Dosage|Combinations (Undergarment)|Short-acting sulfonamide combinations|Salt solution combinations|topical antibiotic combinations|lung surfactant combinations|Magnesium antacid compound combinations|opium alkaloids and derivative combination cough suppressants|Imidazole and triazole derivative topical antifungal combinations|Long-acting sulfonamide combinations|Other intestinal adsorbent combinations in ATC|Platelet aggregation inhibitor combinations excl. heparin|vitamin D and analog combinations|Amide local anesthetic combinations|local opthalmologic anesthetic combinations|Local hemostatic combinations|insulins and analogs for injection combinations, long-acting|Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations|Enema combinations|Specific immunoglobulin combinations|combination drugs used in erectile dysfunction|otologic analgesic and anesthetic combinations|Combination solutions for parenteral nutrition|Other antifungal combinations for topical use in ATC|Insulins and analogs for injection, intermediate-acting combinations|Aluminium antacid compound combinations|Penicillins with extended spectrum combinations|Calcium antacid compound combinations|expectorant combinations excluding combinations with cough suppressants|Antiinfective irrigating solution combinations|Hepatitis vaccine combinations|Adrenergic and dopaminergic agents combinations|Other irrigating solution combinations in ATC|other cough suppressant combinations in ATC|gonadotropin combinations|Intermediate-acting sulfonamide combinations|Caries prophylactic agent combinations|other nasal preparation combinations in ATC|Beta-lactamase sensitive penicillin combinations|Insulins and analogs for injection, fast-acting combinations|expectorant combinations, excl. combinations with cough suppressants|Potassium supplement combinations|Other anti-dementia drug combinations in ATC|Safety|Safety Study|Effectiveness|Efficacy Study|Negation|Established|Accepted""Plasma concentrations may be altered.","C0683150|C0392747","[qlco]|[qnco]|[mnob]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[phsu]|[hcpp]|[resa]|[qlco]|[resa]|[ftcn]|[qlco]|[qlco][qnco]|[ftcn]","Appropriate|Dosage|Combinations (Undergarment)|Short-acting sulfonamide combinations|Salt solution combinations|topical antibiotic combinations|lung surfactant combinations|Magnesium antacid compound combinations|opium alkaloids and derivative combination cough suppressants|Imidazole and triazole derivative topical antifungal combinations|Long-acting sulfonamide combinations|Other intestinal adsorbent combinations in ATC|Platelet aggregation inhibitor combinations excl. heparin|vitamin D and analog combinations|Amide local anesthetic combinations|local opthalmologic anesthetic combinations|Local hemostatic combinations|insulins and analogs for injection combinations, long-acting|Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations|Enema combinations|Specific immunoglobulin combinations|combination drugs used in erectile dysfunction|otologic analgesic and anesthetic combinations|Combination solutions for parenteral nutrition|Other antifungal combinations for topical use in ATC|Insulins and analogs for injection, intermediate-acting combinations|Aluminium antacid compound combinations|Penicillins with extended spectrum combinations|Calcium antacid compound combinations|expectorant combinations excluding combinations with cough suppressants|Antiinfective irrigating solution combinations|Hepatitis vaccine combinations|Adrenergic and dopaminergic agents combinations|Other irrigating solution combinations in ATC|other cough suppressant combinations in ATC|gonadotropin combinations|Intermediate-acting sulfonamide combinations|Caries prophylactic agent combinations|other nasal preparation combinations in ATC|Beta-lactamase sensitive penicillin combinations|Insulins and analogs for injection, fast-acting combinations|expectorant combinations, excl. combinations with cough suppressants|Potassium supplement combinations|Other anti-dementia drug combinations in ATC|Safety|Safety Study|Effectiveness|Efficacy Study|Negation|Established|Acceptedplasma concentration|Changing"
"The appropriate doses of these combinations with respect to safety and efficacy have not been established.","C1548787|C0178602|C0453882|C3539181|C3539182|C3539954|C3539955|C3539956|C3539957|C3539958|C3539959|C3539960|C3539961|C3539962|C3539963|C3539964|C3539965|C3539966|C3539967|C3539968|C3539969|C3539970|C3539971|C3539972|C3539973|C3539974|C3539975|C3539976|C3539977|C3539978|C3539979|C3540026|C3540027|C3540028|C3540030|C3540031|C3540719|C3540720|C3540721|C3540722|C3540723|C3540724|C3540740|C3854036|C0036043|C1705187|C1280519|C1707887|C1518422|C0443211|C1272684","[qlco]|[qnco]|[mnob]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[phsu]|[hcpp]|[resa]|[qlco]|[resa]|[ftcn]|[qlco]|[qlco]","Appropriate|Dosage|Combinations (Undergarment)|Short-acting sulfonamide combinations|Salt solution combinations|topical antibiotic combinations|lung surfactant combinations|Magnesium antacid compound combinations|opium alkaloids and derivative combination cough suppressants|Imidazole and triazole derivative topical antifungal combinations|Long-acting sulfonamide combinations|Other intestinal adsorbent combinations in ATC|Platelet aggregation inhibitor combinations excl. heparin|vitamin D and analog combinations|Amide local anesthetic combinations|local opthalmologic anesthetic combinations|Local hemostatic combinations|insulins and analogs for injection combinations, long-acting|Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations|Enema combinations|Specific immunoglobulin combinations|combination drugs used in erectile dysfunction|otologic analgesic and anesthetic combinations|Combination solutions for parenteral nutrition|Other antifungal combinations for topical use in ATC|Insulins and analogs for injection, intermediate-acting combinations|Aluminium antacid compound combinations|Penicillins with extended spectrum combinations|Calcium antacid compound combinations|expectorant combinations excluding combinations with cough suppressants|Antiinfective irrigating solution combinations|Hepatitis vaccine combinations|Adrenergic and dopaminergic agents combinations|Other irrigating solution combinations in ATC|other cough suppressant combinations in ATC|gonadotropin combinations|Intermediate-acting sulfonamide combinations|Caries prophylactic agent combinations|other nasal preparation combinations in ATC|Beta-lactamase sensitive penicillin combinations|Insulins and analogs for injection, fast-acting combinations|expectorant combinations, excl. combinations with cough suppressants|Potassium supplement combinations|Other anti-dementia drug combinations in ATC|Safety|Safety Study|Effectiveness|Efficacy Study|Negation|Established|Accepted""Plasma concentrations may be altered.","C0683150|C0392747","[qlco]|[qnco]|[mnob]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[phsu]|[hcpp]|[resa]|[qlco]|[resa]|[ftcn]|[qlco]|[qlco][qnco]|[ftcn]","Appropriate|Dosage|Combinations (Undergarment)|Short-acting sulfonamide combinations|Salt solution combinations|topical antibiotic combinations|lung surfactant combinations|Magnesium antacid compound combinations|opium alkaloids and derivative combination cough suppressants|Imidazole and triazole derivative topical antifungal combinations|Long-acting sulfonamide combinations|Other intestinal adsorbent combinations in ATC|Platelet aggregation inhibitor combinations excl. heparin|vitamin D and analog combinations|Amide local anesthetic combinations|local opthalmologic anesthetic combinations|Local hemostatic combinations|insulins and analogs for injection combinations, long-acting|Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations|Enema combinations|Specific immunoglobulin combinations|combination drugs used in erectile dysfunction|otologic analgesic and anesthetic combinations|Combination solutions for parenteral nutrition|Other antifungal combinations for topical use in ATC|Insulins and analogs for injection, intermediate-acting combinations|Aluminium antacid compound combinations|Penicillins with extended spectrum combinations|Calcium antacid compound combinations|expectorant combinations excluding combinations with cough suppressants|Antiinfective irrigating solution combinations|Hepatitis vaccine combinations|Adrenergic and dopaminergic agents combinations|Other irrigating solution combinations in ATC|other cough suppressant combinations in ATC|gonadotropin combinations|Intermediate-acting sulfonamide combinations|Caries prophylactic agent combinations|other nasal preparation combinations in ATC|Beta-lactamase sensitive penicillin combinations|Insulins and analogs for injection, fast-acting combinations|expectorant combinations, excl. combinations with cough suppressants|Potassium supplement combinations|Other anti-dementia drug combinations in ATC|Safety|Safety Study|Effectiveness|Efficacy Study|Negation|Established|Acceptedplasma concentration|Changing""Nevirapine should not be coadministered with another NNRTI as this combination has not been shown to be beneficial.","C0132326|C1518422|C3537104|C0205195|C1947911|C3811910|C1547282|C0040363|C0041260|C1883351","[qlco]|[qnco]|[mnob]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[orch, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[aapp, imft, phsu]|[phsu]|[phsu]|[phsu]|[aapp, horm, phsu]|[orch, phsu]|[phsu]|[phsu]|[antb, orch]|[phsu]|[phsu]|[phsu]|[phsu]|[hcpp]|[resa]|[qlco]|[resa]|[ftcn]|[qlco]|[qlco][qnco]|[ftcn][orch, phsu]|[ftcn]|[phsu]|[qlco]|[phob]|[fndg]|[anim]|[geoa]|[aapp, enzy]|[qlco]","Appropriate|Dosage|Combinations (Undergarment)|Short-acting sulfonamide combinations|Salt solution combinations|topical antibiotic combinations|lung surfactant combinations|Magnesium antacid compound combinations|opium alkaloids and derivative combination cough suppressants|Imidazole and triazole derivative topical antifungal combinations|Long-acting sulfonamide combinations|Other intestinal adsorbent combinations in ATC|Platelet aggregation inhibitor combinations excl. heparin|vitamin D and analog combinations|Amide local anesthetic combinations|local opthalmologic anesthetic combinations|Local hemostatic combinations|insulins and analogs for injection combinations, long-acting|Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations|Enema combinations|Specific immunoglobulin combinations|combination drugs used in erectile dysfunction|otologic analgesic and anesthetic combinations|Combination solutions for parenteral nutrition|Other antifungal combinations for topical use in ATC|Insulins and analogs for injection, intermediate-acting combinations|Aluminium antacid compound combinations|Penicillins with extended spectrum combinations|Calcium antacid compound combinations|expectorant combinations excluding combinations with cough suppressants|Antiinfective irrigating solution combinations|Hepatitis vaccine combinations|Adrenergic and dopaminergic agents combinations|Other irrigating solution combinations in ATC|other cough suppressant combinations in ATC|gonadotropin combinations|Intermediate-acting sulfonamide combinations|Caries prophylactic agent combinations|other nasal preparation combinations in ATC|Beta-lactamase sensitive penicillin combinations|Insulins and analogs for injection, fast-acting combinations|expectorant combinations, excl. combinations with cough suppressants|Potassium supplement combinations|Other anti-dementia drug combinations in ATC|Safety|Safety Study|Effectiveness|Efficacy Study|Negation|Established|Acceptedplasma concentration|ChangingNevirapine|Negation|Non-nucleoside Reverse Transcriptase Inhibitor|Combined|combination of objects|combination - answer to question|Show|Togo|Tryptophanase|To"
"The appropriate doses of this combination of indinavir and nevirapine with respect to efficacy and safety have not been established.","C1548787|C0178602|C0205195|C1947911|C3811910|C0376637|C0132326|C1280519|C1707887|C0036043|C1705187|C1518422|C0443211|C1272684","[qlco]|[qnco]|[qlco]|[phob]|[fndg]|[orch, phsu]|[orch, phsu]|[qlco]|[resa]|[hcpp]|[resa]|[ftcn]|[qlco]|[qlco]","Appropriate|Dosage|Combined|combination of objects|combination - answer to question|Indinavir|Nevirapine|Effectiveness|Efficacy Study|Safety|Safety Study|Negation|Established|Accepted"
"The appropriate doses of this combination of indinavir and nevirapine with respect to efficacy and safety have not been established.","C1548787|C0178602|C0205195|C1947911|C3811910|C0376637|C0132326|C1280519|C1707887|C0036043|C1705187|C1518422|C0443211|C1272684","[qlco]|[qnco]|[qlco]|[phob]|[fndg]|[orch, phsu]|[orch, phsu]|[qlco]|[resa]|[hcpp]|[resa]|[ftcn]|[qlco]|[qlco]","Appropriate|Dosage|Combined|combination of objects|combination - answer to question|Indinavir|Nevirapine|Effectiveness|Efficacy Study|Safety|Safety Study|Negation|Established|Accepted"
"The concomitant use of beta-blockers and Glucagon for Injection may increase the risk of a temporary increase in heart rate and blood pressure.","C0521115|C0042153|C0457083|C1947944|C0001645|C0017687|C0876232|C0021485|C1272883|C1533685|C1828121|C0442805|C0035647|C0205374|C1548539|C3245481|C0018810|C0005823|C1271104|C1272641","[tmco]|[ftcn]|[ftcn]|[inpr]|[phsu]|[aapp, horm, phsu]|[aapp, horm, phsu]|[topp]|[bodm]|[topp]|[ftcn]|[ftcn]|[idcn]|[tmco]|[idcn]|[inpr]|[clna]|[orgf]|[fndg]|[fndg]","Simultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Adrenergic beta-Antagonists|Glucagon|glucagon (rDNA)|Injection of therapeutic agent|Injection product|Injection procedure|Injection Route of Drug Administration|Increase|Risk|Transitory|Job Status - Temporary|EntityNameUseR2 <temporary>|heart rate|Blood Pressure|Blood pressure finding|Systemic arterial pressure"
"The interaction between nevirapine and saquinavir/ritonavir has not been evaluated","C1704675|C0132326|C1977397|C1518422|C0220825","[ftcn]|[orch, phsu]|[antb, orch]|[ftcn]|[hlca]","Interaction|Nevirapine|Saquinavir+Ritonavir|Negation|Evaluation"
"The interaction between nevirapine saquinavir/ritonavir has not been evaluated","C1704675|C0132326|C1977397|C1518422|C0220825","[ftcn]|[orch, phsu]|[antb, orch]|[ftcn]|[hlca]","Interaction|Nevirapine|Saquinavir+Ritonavir|Negation|Evaluation"
"The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalized ratio) is difficult to assess. ","C0035647|C0749769|C0001779|C0947124|C0030705|C2360836|C2360838|C2360840|C0037640|C1880177|C0008809|C0442805|C0525032|C1704538|C0332218|C1299586|C0040363|C0041260|C1883351|C1516048","[idcn]|[dsyn]|[orga]|[fndg]|[podg]|[clna]|[clna]|[clna]|[geoa]|[acty]|[orch, phsu]|[ftcn]|[lbpr]|[topp]|[qlco]|[fndg]|[geoa]|[aapp, enzy]|[qlco]|[acty]","Risk|underlying infection|Age|General status|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Somalia|Contribution|Ciprofloxacin|Increase|International Normalized Ratio|Integrated Neuromusculoskeletal Release|Difficult (qualifier value)|Has difficulty doing (qualifier value)|Togo|Tryptophanase|To|Assessed"
"The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalized ratio) is difficult to assess. ","C0035647|C0749769|C0001779|C0947124|C0030705|C2360836|C2360838|C2360840|C0037640|C1880177|C0008809|C0442805|C0525032|C1704538|C0332218|C1299586|C0040363|C0041260|C1883351|C1516048","[idcn]|[dsyn]|[orga]|[fndg]|[podg]|[clna]|[clna]|[clna]|[geoa]|[acty]|[orch, phsu]|[ftcn]|[lbpr]|[topp]|[qlco]|[fndg]|[geoa]|[aapp, enzy]|[qlco]|[acty]","Risk|underlying infection|Age|General status|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Somalia|Contribution|Ciprofloxacin|Increase|International Normalized Ratio|Integrated Neuromusculoskeletal Release|Difficult (qualifier value)|Has difficulty doing (qualifier value)|Togo|Tryptophanase|To|Assessed""Monitor prothrombin time and INR frequently during and shortly after co-administration of ciprofloxacin with an oral anti-coagulant (for example, warfarin).","C0030695|C0033707|C0482694|C0150369|C0181904|C0596972|C1521743|C1704646|C0525032|C0332183|C1704538|C0814472|C0008809|C0442027|C0848112|C3536711|C1707959|C0043031","[idcn]|[dsyn]|[orga]|[fndg]|[podg]|[clna]|[clna]|[clna]|[geoa]|[acty]|[orch, phsu]|[ftcn]|[lbpr]|[topp]|[qlco]|[fndg]|[geoa]|[aapp, enzy]|[qlco]|[acty][hlca]|[lbpr]|[clna]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[lbpr]|[tmco]|[topp]|[hlca]|[orch, phsu]|[spco]|[topp]|[phsu]|[cnce]|[hops, orch, phsu]","Risk|underlying infection|Age|General status|Patients|Abortion consent:Finding:Point in time:^Patient:Document|Hysterectomy consent:Finding:Point in time:^Patient:Document|Sterilization consent:Finding:Point in time:^Patient:Document|Somalia|Contribution|Ciprofloxacin|Increase|International Normalized Ratio|Integrated Neuromusculoskeletal Release|Difficult (qualifier value)|Has difficulty doing (qualifier value)|Togo|Tryptophanase|To|AssessedPatient Monitoring|Prothrombin time assay|Coagulation tissue factor induced:Time:Pt:PPP:Qn:Coag|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|International Normalized Ratio|Frequent|Integrated Neuromusculoskeletal Release|co-treatment|Ciprofloxacin|Oral|on anti-coagulants|Anti-coagulant [EPC]|Example|Warfarin"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both.","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both.","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism""Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment.","C0030705|C0700384|C0039798|C0087111|C1522326|C1533734|C1705169|C3538994|C3887704|C0332167|C3272283|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunction"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both.","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism""Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment.","C0030705|C0700384|C0039798|C0087111|C1522326|C1533734|C1705169|C3538994|C3887704|C0332167|C3272283|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunction""Interleukin-2 has been associated with transient painless thyroiditis in 20% of patients.","C0021756|C0879590|C1522405|C0332281|C0040704|C0271814|C0205374|C3842589|C0030705","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|Patients"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both.","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism""Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment.","C0030705|C0700384|C0039798|C0087111|C1522326|C1533734|C1705169|C3538994|C3887704|C0332167|C3272283|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunction""Interleukin-2 has been associated with transient painless thyroiditis in 20% of patients.","C0021756|C0879590|C1522405|C0332281|C0040704|C0271814|C0205374|C3842589|C0030705","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|Patients""Interferon-? ","C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferon|Interferon"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both.","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism""Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment.","C0030705|C0700384|C0039798|C0087111|C1522326|C1533734|C1705169|C3538994|C3887704|C0332167|C3272283|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunction""Interleukin-2 has been associated with transient painless thyroiditis in 20% of patients.","C0021756|C0879590|C1522405|C0332281|C0040704|C0271814|C0205374|C3842589|C0030705","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|Patients""Interferon-? ","C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferonInterferon""and -? ","","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu][aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferonInterferon"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both.","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism""Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment.","C0030705|C0700384|C0039798|C0087111|C1522326|C1533734|C1705169|C3538994|C3887704|C0332167|C3272283|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunction""Interleukin-2 has been associated with transient painless thyroiditis in 20% of patients.","C0021756|C0879590|C1522405|C0332281|C0040704|C0271814|C0205374|C3842589|C0030705","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|Patients""Interferon-? ","C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferonInterferon""and -? ","","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu][aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferonInterferon""have not been reported to cause thyroid dysfunction.","C1518422|C0684224|C0700287|C0040363|C0041260|C1883351|C0015127|C1524003|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu][aapp, imft, phsu][ftcn]|[inpr]|[hlca]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[cnce]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferonInterferonNegation|Report (document)|Reporting|Togo|Tryptophanase|To|Etiology aspects|Science of Etiology|Thyroid dysfunction"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both. ","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both. ","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism""Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment. ","C0030705|C0700384|C0039798|C0087111|C1522326|C1533734|C1705169|C3538994|C3887704|C0332167|C3272283|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunction"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both. ","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism""Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment. ","C0030705|C0700384|C0039798|C0087111|C1522326|C1533734|C1705169|C3538994|C3887704|C0332167|C3272283|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunction""Interleukin-2 has been associated with transient painless thyroiditis in 20% of patients. ","C0021756|C0879590|C1522405|C0332281|C0040704|C0271814|C0205374|C3842589|C0030705","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|Patients"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both. ","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism""Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment. ","C0030705|C0700384|C0039798|C0087111|C1522326|C1533734|C1705169|C3538994|C3887704|C0332167|C3272283|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunction""Interleukin-2 has been associated with transient painless thyroiditis in 20% of patients. ","C0021756|C0879590|C1522405|C0332281|C0040704|C0271814|C0205374|C3842589|C0030705","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|Patients""Interferon-? ","C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferon|Interferon"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both. ","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism""Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment. ","C0030705|C0700384|C0039798|C0087111|C1522326|C1533734|C1705169|C3538994|C3887704|C0332167|C3272283|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunction""Interleukin-2 has been associated with transient painless thyroiditis in 20% of patients. ","C0021756|C0879590|C1522405|C0332281|C0040704|C0271814|C0205374|C3842589|C0030705","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|Patients""Interferon-? ","C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferonInterferon""and -? ","","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu][aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferonInterferon"
"Therapy with interferon-? ","C0039798|C0087111|C1363945|C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|Interferon""has been associated with the development of antithyroid microsomal antibodies in 20% of patients and some have transient hypothyroidism, hyperthyroidism, or both. ","C0332281|C0243107|C0678723|C1527148|C0700384|C1979928|C3842589|C0030705|C0271795|C0020550","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|Hyperthyroidism""Patients who have antithyroid antibodies before treatment are at higher risk for thyroid dysfunction during treatment. ","C0030705|C0700384|C0039798|C0087111|C1522326|C1533734|C1705169|C3538994|C3887704|C0332167|C3272283|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunction""Interleukin-2 has been associated with transient painless thyroiditis in 20% of patients. ","C0021756|C0879590|C1522405|C0332281|C0040704|C0271814|C0205374|C3842589|C0030705","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|Patients""Interferon-? ","C0021747|C0733470|C3652465","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferonInterferon""and -? ","","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu][aapp, imft, phsu]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferonInterferon""have not been reported to cause thyroid dysfunction.","C1518422|C0684224|C0700287|C0040363|C0041260|C1883351|C0015127|C1524003|C0348024","[ftcn]|[topp]|[fndg]|[aapp, imft, phsu]|[aapp, imft, phsu]|[aapp, imft, phsu][qlco]|[phsf]|[orgf]|[ftcn]|[aapp, imft]|[qlco]|[fndg]|[podg]|[dsyn]|[dsyn][podg]|[aapp, imft]|[ftcn]|[topp]|[ftcn]|[topp]|[cnce]|[resa]|[hlca]|[qlco]|[fndg]|[patf][aapp, imft]|[gngm]|[aapp, phsu]|[qlco]|[popg]|[dsyn]|[tmco]|[fndg]|[podg][aapp, imft, phsu]|[aapp, imft, phsu][aapp, imft, phsu][ftcn]|[inpr]|[hlca]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[cnce]|[patf]","therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Interferons|human leukocyte interferon|InterferonAssociated with|development aspects|Biologic Development|Development|Thyroid antibody|Microsomal|20%|Patients|Transient hypothyroidism|HyperthyroidismPatients|Thyroid antibody|therapeutic aspects|Therapeutic procedure|Treating|Administration procedure|Biomaterial Treatment|Treatment Epoch|treatment - ActInformationManagementReason|High risk of|American College of Cardiology/American Heart Association Lesion Complexity Score C|Thyroid dysfunctionInterleukin-2|IL2 gene|Recombinant Interleukin-2|Associated with|Transient Population Group|Silent thyroiditis|Transitory|20%|PatientsInterferons|human leukocyte interferonInterferonNegation|Report (document)|Reporting|Togo|Tryptophanase|To|Etiology aspects|Science of Etiology|Thyroid dysfunction"
"These agents have been associated with thyroid hormone and / or TSH level alterations by various mechanisms.","C0450442|C1254351|C1521826|C0332281|C0040135|C0202230|C1515926|C0440102|C0441712|C3540008|C3540761|C3540762|C3540763|C3540765|C3540766|C3540769","[chvf]|[phsu]|[inpr]|[qlco]|[aapp, horm]|[lbpr]|[idcn]|[irda]|[ftcn]|[phsu]|[phsu]|[phsu]|[phsu]|[imft, phsu]|[phsu]|[phsu]","Agent|Pharmacologic Substance|Protocol Agent|Associated with|Thyroid Hormones|Thyroid stimulating hormone measurement|Alteration|Various patch test substance|Mechanism (attribute)|various antiinfectives and antiseptics for local oral treatment|various other nasal preparations in ATC|various other agents for local oral treatment in ATC|VARIOUS DRUG CLASSES IN ATC|various allergen extracts|various antiseptic throat preparations|various other intestinal adsorbents in ATC"
"These agents have been associated with thyroid hormone and/or TSH level alterations by various mechanisms.","C0450442|C1254351|C1521826|C0332281|C0040135|C0202230|C1515926|C0440102|C0441712|C3540008|C3540761|C3540762|C3540763|C3540765|C3540766|C3540769","[chvf]|[phsu]|[inpr]|[qlco]|[aapp, horm]|[lbpr]|[idcn]|[irda]|[ftcn]|[phsu]|[phsu]|[phsu]|[phsu]|[imft, phsu]|[phsu]|[phsu]","Agent|Pharmacologic Substance|Protocol Agent|Associated with|Thyroid Hormones|Thyroid stimulating hormone measurement|Alteration|Various patch test substance|Mechanism (attribute)|various antiinfectives and antiseptics for local oral treatment|various other nasal preparations in ATC|various other agents for local oral treatment in ATC|VARIOUS DRUG CLASSES IN ATC|various allergen extracts|various antiseptic throat preparations|various other intestinal adsorbents in ATC"
"Thyroid hormones appear to increase the catabolism of vitamin K-dependent clotting factors, thereby increasing the anticoagulant activity of oral anticoagulants.","C0040135|C0700364|C0040363|C0041260|C1883351|C0442805|C0543484|C0699900|C1516314|C0042878|C0851827|C0005789|C1701901|C3244310|C2936884|C3541380|C3714648|C0442808|C1148561|C0354604","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulants"
"Thyroid hormones appear to increase the catabolism of vitamin K-dependent clotting factors, thereby increasing the anticoagulant activity of oral anticoagulants.","C0040135|C0700364|C0040363|C0041260|C1883351|C0442805|C0543484|C0699900|C1516314|C0042878|C0851827|C0005789|C1701901|C3244310|C2936884|C3541380|C3714648|C0442808|C1148561|C0354604","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulants""Concomitant use of these agents impairs the compensatory increases in clotting factor synthesis.","C0521115|C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C0231186|C0205217|C0442805|C0005789|C0220781|C1883254","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu][tmco]|[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[qnco]|[ftcn]|[aapp, bacs, phsu]|[biof]|[acty]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulantsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|compensatory|Increased|Increase|Blood Coagulation Factor|Anabolism|Synthesis"
"Thyroid hormones appear to increase the catabolism of vitamin K-dependent clotting factors, thereby increasing the anticoagulant activity of oral anticoagulants.","C0040135|C0700364|C0040363|C0041260|C1883351|C0442805|C0543484|C0699900|C1516314|C0042878|C0851827|C0005789|C1701901|C3244310|C2936884|C3541380|C3714648|C0442808|C1148561|C0354604","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulants""Concomitant use of these agents impairs the compensatory increases in clotting factor synthesis.","C0521115|C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C0231186|C0205217|C0442805|C0005789|C0220781|C1883254","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu][tmco]|[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[qnco]|[ftcn]|[aapp, bacs, phsu]|[biof]|[acty]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulantsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|compensatory|Increased|Increase|Blood Coagulation Factor|Anabolism|Synthesis""Prothrombin time should be carefully monitored in patients taking levothyroxine and oral anticoagulants and the dose of anticoagulant therapy adjusted accordingly.","C0033707|C0482694|C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0030705|C1515187|C0040165|C1881373|C0354604|C0178602|C0869039|C1114758|C0150457|C0456081","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu][tmco]|[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[qnco]|[ftcn]|[aapp, bacs, phsu]|[biof]|[acty][lbpr]|[clna]|[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[podg]|[hlca]|[aapp, horm, phsu]|[orch, phsu]|[orch, phsu]|[qnco]|[qnco]|[clna]|[topp]|[ftcn]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulantsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|compensatory|Increased|Increase|Blood Coagulation Factor|Anabolism|SynthesisProthrombin time assay|Coagulation tissue factor induced:Time:Pt:PPP:Qn:Coag|Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Patients|Take|Thyroxine|Synthetic Levothyroxine|oral anticoagulants|Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Anticoagulant therapy|Adjustment Action"
"Thyroid hormones appear to increase the catabolism of vitamin K-dependent clotting factors, thereby increasing the anticoagulant activity of oral anticoagulants. ","C0040135|C0700364|C0040363|C0041260|C1883351|C0442805|C0543484|C0699900|C1516314|C0042878|C0851827|C0005789|C1701901|C3244310|C2936884|C3541380|C3714648|C0442808|C1148561|C0354604","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulants"
"Thyroid hormones appear to increase the catabolism of vitamin K-dependent clotting factors, thereby increasing the anticoagulant activity of oral anticoagulants. ","C0040135|C0700364|C0040363|C0041260|C1883351|C0442805|C0543484|C0699900|C1516314|C0042878|C0851827|C0005789|C1701901|C3244310|C2936884|C3541380|C3714648|C0442808|C1148561|C0354604","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulants""Concomitant use of these agents impairs the compensatory increases in clotting factor synthesis. ","C0521115|C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C0231186|C0205217|C0442805|C0005789|C0220781|C1883254","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu][tmco]|[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[qnco]|[ftcn]|[aapp, bacs, phsu]|[biof]|[acty]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulantsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|compensatory|Increased|Increase|Blood Coagulation Factor|Anabolism|Synthesis"
"Thyroid hormones appear to increase the catabolism of vitamin K-dependent clotting factors, thereby increasing the anticoagulant activity of oral anticoagulants. ","C0040135|C0700364|C0040363|C0041260|C1883351|C0442805|C0543484|C0699900|C1516314|C0042878|C0851827|C0005789|C1701901|C3244310|C2936884|C3541380|C3714648|C0442808|C1148561|C0354604","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulants""Concomitant use of these agents impairs the compensatory increases in clotting factor synthesis. ","C0521115|C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C0231186|C0205217|C0442805|C0005789|C0220781|C1883254","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu][tmco]|[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[qnco]|[ftcn]|[aapp, bacs, phsu]|[biof]|[acty]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulantsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|compensatory|Increased|Increase|Blood Coagulation Factor|Anabolism|Synthesis""Prothrombin time should be carefully monitored in patients taking levothyroxine and oral anticoagulants and the dose of anticoagulant therapy adjusted accordingly.","C0033707|C0482694|C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0030705|C1515187|C0040165|C1881373|C0354604|C0178602|C0869039|C1114758|C0150457|C0456081","[aapp, horm]|[qlco]|[geoa]|[aapp, enzy]|[qlco]|[ftcn]|[ftcn]|[orgf]|[phsf]|[orch, vita]|[qlco]|[aapp, bacs, phsu]|[qlco]|[ftcn]|[phsu]|[orch, phsu, vita]|[phsu, vita]|[ftcn]|[moft]|[orch, phsu][tmco]|[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[qnco]|[ftcn]|[aapp, bacs, phsu]|[biof]|[acty][lbpr]|[clna]|[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[podg]|[hlca]|[aapp, horm, phsu]|[orch, phsu]|[orch, phsu]|[qnco]|[qnco]|[clna]|[topp]|[ftcn]","Thyroid Hormones|Appearance|Togo|Tryptophanase|To|Increase|catabolic aspects|Catabolism|Catabolic Process|Vitamin K|Dependent - ability|Blood Coagulation Factor|Conditional|dependent|Vitamin K [EPC]|Vitamin K containing hemostatics|Vitamin K Drug Class|Increasing|anticoagulant activity|oral anticoagulantsSimultaneous|utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|compensatory|Increased|Increase|Blood Coagulation Factor|Anabolism|SynthesisProthrombin time assay|Coagulation tissue factor induced:Time:Pt:PPP:Qn:Coag|Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Patients|Take|Thyroxine|Synthetic Levothyroxine|oral anticoagulants|Dosage|Unit dose|Dose number:Number:Point in time:^Patient:Quantitative|Anticoagulant therapy|Adjustment Action"
"Thyroid hormones may reduce the uptake of 123I, 131I, and 99mTc.","C0040135|C0243144|C0347980|C3888108","[aapp, horm]|[phsf]|[qnco]|[celf]","Thyroid Hormones|Uptake|percent uptake|Import into cell"
"Thyroid hormones may reduce the uptake of 123I, 131I, and 99mTc.","C0040135|C0243144|C0347980|C3888108","[aapp, horm]|[phsf]|[qnco]|[celf]","Thyroid Hormones|Uptake|percent uptake|Import into cell"
"Thyroid hormones may reduce the uptake of 123I, 131I, and 99mTc.","C0040135|C0243144|C0347980|C3888108","[aapp, horm]|[phsf]|[qnco]|[celf]","Thyroid Hormones|Uptake|percent uptake|Import into cell"
"Thyroid hormones may reduce the uptake of I, I, and Tc.\123\131\99m","C0040135|C0243144|C0347980|C3888108|C0021966|C0221138|C0303611","[aapp, horm]|[phsf]|[qnco]|[celf]|[inch]|[aapp, imft]|[irda]","Thyroid Hormones|Uptake|percent uptake|Import into cell|Iodides|Blood group antibody I|Technetium 99m"
"tipranavir/ritonavir\Drug Dose (Schedule)","C1977399|C0678766|C0086960","[antb, orch]|[qnco]|[inpr]","Tipranavir+Ritonavir|Drug dose|Schedule (document type)"
"tipranavir/ritonavir Drug Dose (Schedule)","C1977399|C0678766|C0086960","[antb, orch]|[qnco]|[inpr]","Tipranavir+Ritonavir|Drug dose|Schedule (document type)"
"Titratedoseupwards.","","",""
"Titratedoseupwards.","","","""Donotexceedtwicethepatientsusualdose","","",""
"Titratedoseupwards. ","","",""
"Titratedoseupwards. ","","","""Donotexceedtwicethepatientsusualdose","","",""
"Titratedoseupwards.","","",""
"Titratedoseupwards.","","","""Donotexceedtwicethepatientsusualdose","","",""
"Titratedoseupwards.","","",""
"Titratedoseupwards.","","","""Donotexceedtwicethepatientsusualdose","","",""
"To avoid the loss of seizure control associated with decreased phenytoin levels and to prevent phenytoin overdose-related adverse reactions upon ciprofloxacin discontinuation in patients receiving both agents, monitor phenytoin therapy, including phenytoin serum concentration during and shortly after co-administration of ciprofloxacin with phenytoin.","C0040363|C0041260|C1883351|C1517945|C0036572|C0243148|C1550141|C1882979|C2587213|C3274648|C1959629|C0332281|C0205216|C0702177|C0392756|C0442797|C0309872|C0413741|C0029944|C0439849|C0445223|C1546941|C4018909|C0008809|C0457454|C1444662|C0030705|C1514756|C0450442|C1254351|C1521826|C0030695|C0031507|C0039798|C0087111|C1363945|C0150369|C0181904|C0596972|C1521743|C1704646|C0332257|C0683149|C0814472","[geoa]|[aapp, enzy]|[qlco]|[qnco]|[sosy]|[qlco]|[sbst]|[cnce]|[ftcn]|[qlco]|[fndg]|[qlco]|[qnco]|[lbtr]|[qlco]|[qlco]|[phsu]|[inpo]|[inpo]|[qlco]|[fndg]|[idcn]|[fndg]|[orch, phsu]|[hlca]|[fndg]|[podg]|[qlco]|[chvf]|[phsu]|[inpr]|[hlca]|[orch, phsu]|[ftcn]|[topp]|[fndg]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[ftcn]|[qnco]|[hlca]","Togo|Tryptophanase|To|Loss|Seizures|control aspects|control substance|Scientific Control|Control function|True Control Status|Seizure Adverse Event|Associated with|Decreased|Phenytoin level - finding|Reduced|Decreasing|PREVENT (product)|Phenytoin adverse reaction|Drug Overdose|Relationships|Related personal status|Event Qualification - Overdose|Overdose|Ciprofloxacin|Discontinuation (procedure)|Discontinued|Patients|Receive|Agent|Pharmacologic Substance|Protocol Agent|Patient Monitoring|Phenytoin|therapeutic aspects|Therapeutic procedure|Therapy Object (animal model)|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|Including (qualifier)|serum concentration|co-treatment"
"Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: dopamine ( ? 1 mcg/kg/min); ","C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C1274040|C1546471|C2825142|C0040704|C0301630|C0392756|C0441610|C0205374|C2611225|C1521801|C0231290|C0178602|C0332282|C0013030|C2827734|C1300567|C2981698|C3816745","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+"
"Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: dopamine ( ? 1 mcg/kg/min); ","C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C1274040|C1546471|C2825142|C0040704|C0301630|C0392756|C0441610|C0205374|C2611225|C1521801|C0231290|C0178602|C0332282|C0013030|C2827734|C1300567|C2981698|C3816745","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+""Glucocorticoids (hydrocortisone ? 100 mg/day or equivalent); ","C0017710|C3540777|C3540778|C0020268|C3817553|C0439422|C0205163|C0439185","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg][horm, orch]|[horm, orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[qnco]|[qnco]|[qlco]|[qnco]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Hydrocortisone|100%|milligram/day|Equal|Equivalent Weight"
"Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: dopamine ( ? 1 mcg/kg/min); ","C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C1274040|C1546471|C2825142|C0040704|C0301630|C0392756|C0441610|C0205374|C2611225|C1521801|C0231290|C0178602|C0332282|C0013030|C2827734|C1300567|C2981698|C3816745","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+""Glucocorticoids (hydrocortisone ? 100 mg/day or equivalent); ","C0017710|C3540777|C3540778|C0020268|C3817553|C0439422|C0205163|C0439185","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg][horm, orch]|[horm, orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[qnco]|[qnco]|[qlco]|[qnco]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Hydrocortisone|100%|milligram/day|Equal|Equivalent Weight""Octreotide ( > 100 mcg/day).","C0028833|C3817553|C0439426","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg][horm, orch]|[horm, orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[qnco]|[qnco]|[qlco]|[qnco][aapp, horm, phsu]|[qnco]|[qnco]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|Microgram per Kilogram per Minute|1+ Score, WHO|1+Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Hydrocortisone|100%|milligram/day|Equal|Equivalent WeightOctreotide|100%|Microgram per Day"
"Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: Dopamine ( ? 1 g/kg/min); ","C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C1274040|C1546471|C2825142|C0040704|C0301630|C0392756|C0441610|C0205374|C2611225|C1521801|C0231290|C0178602|C0332282|C0013030|C2827734|C1320758|C2981698|C3816745","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|g/kg/min|1+ Score, WHO|1+"
"Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: Dopamine ( ? 1 g/kg/min); ","C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C1274040|C1546471|C2825142|C0040704|C0301630|C0392756|C0441610|C0205374|C2611225|C1521801|C0231290|C0178602|C0332282|C0013030|C2827734|C1320758|C2981698|C3816745","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|g/kg/min|1+ Score, WHO|1+""Glucocorticoids (hydrocortisone ? 100 mg/day or equivalent); ","C0017710|C3540777|C3540778|C0020268|C3817553|C0439422|C0205163|C0439185","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg][horm, orch]|[horm, orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[qnco]|[qnco]|[qlco]|[qnco]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|g/kg/min|1+ Score, WHO|1+Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Hydrocortisone|100%|milligram/day|Equal|Equivalent Weight"
"Use of these agents may result in a transient reduction in TSH secretion when administered at the following doses: Dopamine ( ? 1 g/kg/min); ","C0042153|C0457083|C1947944|C0450442|C1254351|C1521826|C1274040|C1546471|C2825142|C0040704|C0301630|C0392756|C0441610|C0205374|C2611225|C1521801|C0231290|C0178602|C0332282|C0013030|C2827734|C1320758|C2981698|C3816745","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|g/kg/min|1+ Score, WHO|1+""Glucocorticoids (hydrocortisone ? 100 mg/day or equivalent); ","C0017710|C3540777|C3540778|C0020268|C3817553|C0439422|C0205163|C0439185","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg][horm, orch]|[horm, orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[qnco]|[qnco]|[qlco]|[qnco]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|g/kg/min|1+ Score, WHO|1+Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Hydrocortisone|100%|milligram/day|Equal|Equivalent Weight""Octreotide ( > 100 g/day).","C0028833|C3817553|C0439417","[ftcn]|[ftcn]|[inpr]|[chvf]|[phsu]|[inpr]|[ftcn]|[idcn]|[fndg]|[popg]|[npop]|[qlco]|[topp]|[tmco]|[celf]|[ftcn]|[tmco]|[qnco]|[tmco]|[bacs, orch, phsu]|[qnco]|[qnco]|[clas]|[fndg][horm, orch]|[horm, orch, phsu]|[orch, phsu]|[horm, orch, phsu]|[qnco]|[qnco]|[qlco]|[qnco][aapp, horm, phsu]|[qnco]|[qnco]","utilization qualifier|Usage|Use - dosing instruction imperative|Agent|Pharmacologic Substance|Protocol Agent|Result|What subject filter - Result|Experimental Result|Transient Population Group|Reduction (chemical)|Reduced|Reduction - action|Transitory|thyroid-stimulating hormone secretion|Having administered|Status post|Dosage|Following|Dopamine|1+ Score|g/kg/min|1+ Score, WHO|1+Glucocorticoids|Glucocorticoids, Systemic|Glucocorticoid inhalants for obstructive airway disease|Hydrocortisone|100%|milligram/day|Equal|Equivalent WeightOctreotide|100%|g/24h"
"Use with caution","C0042153|C0457083|C1947944","[ftcn]|[ftcn]|[inpr]","utilization qualifier|Usage|Use - dosing instruction imperative"
"Use with caution (Increase in anticoagulant effect)","C0042153|C0457083|C1947944|C0442805|C0520996","[ftcn]|[ftcn]|[inpr]|[ftcn]|[ortf]","utilization qualifier|Usage|Use - dosing instruction imperative|Increase|Anticoagulant effect"
"Use with caution (interferes with renal tubular secretion of ciprofloxacin and increases ciprofloxacin serum levels)","C0042153|C0457083|C1947944|C0521102|C0678876|C0008809|C0205217|C0442805|C0229671|C0441889|C1546774|C1550100","[ftcn]|[ftcn]|[inpr]|[ftcn]|[ortf]|[orch, phsu]|[qnco]|[ftcn]|[bdsu]|[qlco]|[inpr]|[bdsu]","utilization qualifier|Usage|Use - dosing instruction imperative|Interferes with|renal tubular secretion|Ciprofloxacin|Increased|Increase|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum"
"Use with caution (interferes with renal tubular secretion of ciprofloxacin and increases ciprofloxacin serum levels)","C0042153|C0457083|C1947944|C0521102|C0678876|C0008809|C0205217|C0442805|C0229671|C0441889|C1546774|C1550100","[ftcn]|[ftcn]|[inpr]|[ftcn]|[ortf]|[orch, phsu]|[qnco]|[ftcn]|[bdsu]|[qlco]|[inpr]|[bdsu]","utilization qualifier|Usage|Use - dosing instruction imperative|Interferes with|renal tubular secretion|Ciprofloxacin|Increased|Increase|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum"
"Use with caution (interferes with renal tubular secretion of ciprofloxacin and increases ciprofloxacin serum levels)","C0042153|C0457083|C1947944|C0521102|C0678876|C0008809|C0205217|C0442805|C0229671|C0441889|C1546774|C1550100","[ftcn]|[ftcn]|[inpr]|[ftcn]|[ortf]|[orch, phsu]|[qnco]|[ftcn]|[bdsu]|[qlco]|[inpr]|[bdsu]","utilization qualifier|Usage|Use - dosing instruction imperative|Interferes with|renal tubular secretion|Ciprofloxacin|Increased|Increase|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum"
"Use with caution (transient elevations in serum creatinine)","C0042153|C0457083|C1947944|C0040704|C0702240|C0205374|C0201976|C0600061","[ftcn]|[ftcn]|[inpr]|[popg]|[spco]|[tmco]|[lbpr]|[fndg]","utilization qualifier|Usage|Use - dosing instruction imperative|Transient Population Group|Elevation|Transitory|Creatinine measurement, serum (procedure)|Serum creatinine level"
"Use with caution Altered serum levels of phenytoin (increased and decreased)","C0042153|C0457083|C1947944|C0392747|C0229671|C0441889|C1546774|C1550100|C0031507|C0205217|C0442805|C0205216|C0392756|C0442797","[ftcn]|[ftcn]|[inpr]|[ftcn]|[bdsu]|[qlco]|[inpr]|[bdsu]|[orch, phsu]|[qnco]|[ftcn]|[qnco]|[qlco]|[qlco]","utilization qualifier|Usage|Use - dosing instruction imperative|Changing|Serum|Levels (qualifier value)|Specimen Source Codes - Serum|Specimen Type - Serum|Phenytoin|Increased|Increase|Decreased|Reduced|Decreasing"
"Use with caution and monitor virologic response and levels of anticonvulsants.","C0042153|C0457083|C1947944|C0030695|C0150369|C0181904|C0596972|C1521743|C1704646|C0205466|C0871261|C1704632|C1706817|C2911692|C0441889|C0003286","[ftcn]|[ftcn]|[inpr]|[hlca]|[hlca]|[medd]|[medd]|[prog]|[mnob]|[ftcn]|[orga]|[fndg]|[inpr]|[menp]|[qlco]|[phsu]","utilization qualifier|Usage|Use - dosing instruction imperative|Patient Monitoring|Preventive monitoring|Biomedical Monitors|Monitoring Device|Monitor, occupation|Monitor Device Component|virologic|Response process|Disease Response|Response (statement)|Response (communication)|Levels (qualifier value)|Anticonvulsants"
"Use with caution Glucose-lowering effect potentiated","C0042153|C0457083|C1947944|C1158774|C0441994|C2003888","[ftcn]|[ftcn]|[inpr]|[genf]|[spco]|[acty]","utilization qualifier|Usage|Use - dosing instruction imperative|negative regulation of transcription by glucose|Lower - spatial qualifier|Lower (action)"
"Use with caution Inhibition of methotrexate renal tubular transport potentially leading to increased methotrexate plasma levels","C0042153|C0457083|C1947944|C0021467|C0021469|C1628982|C3463820|C0025677|C0597373|C0332152|C1522538|C0205217|C0202421|C0032105|C1550098|C0442805","[ftcn]|[ftcn]|[inpr]|[menp]|[moft]|[qnco]|[acty]|[orch, phsu]|[ortf]|[tmco]|[ftcn]|[qnco]|[lbpr]|[bdsu]|[bdsu]|[ftcn]","utilization qualifier|Usage|Use - dosing instruction imperative|Psychological inhibition|Metabolic Inhibition|Percent inhibition|Inhibition|Methotrexate|renal tubular transport|Before|Leading|Increased|Methotrexate measurement|Plasma|Plasma, NOS (not otherwise specified)|Increase"
"Use with caution Reduced clearance resulting in elevated levels and prolongation of serum half-life","C0042153|C0457083|C1947944|C0392756|C0449297|C1382187|C2825073|C0678226|C0205250|C0441889|C3163633|C0229671|C0018517|C1546774|C1550100","[ftcn]|[ftcn]|[inpr]|[qlco]|[qlco]|[clna]|[npop]|[ftcn]|[qlco]|[qlco]|[qlco]|[bdsu]|[tmco]|[inpr]|[bdsu]","utilization qualifier|Usage|Use - dosing instruction imperative|Reduced|Clearance|Clearance of substance|Clearance [PK]|Due to|High|Levels (qualifier value)|Elevated|Serum|Half-Life|Specimen Source Codes - Serum|Specimen Type - Serum"
"Use with caution Two-fold increase in exposure","C0042153|C0457083|C1947944|C0205448|C0332462|C0442805|C1880834|C0274281|C0332157","[ftcn]|[ftcn]|[inpr]|[qnco]|[spco]|[ftcn]|[phpr]|[inpo]|[clna]","utilization qualifier|Usage|Use - dosing instruction imperative|Two|Folded structure|Increase|Fold in Medical Device Material|Injury due to exposure to external cause|Exposure to"
"VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates.","C4026868|C0442805|C0274281|C0332157|C3245499|C1521801|C1420131|C3812257|C1332002|C1710236|C3891814|C1704927","[phsu]|[ftcn]|[inpo]|[clna]|[geoa]|[ftcn]|[gngm]|[gngm]|[gngm]|[mnob]|[sbst]|[gngm]","Viberzi|Increase|Injury due to exposure to external cause|Exposure to|Colombia|Having administered|SLCO1B1 gene|SLCO1B1 wt Allele|ABCG2 gene|Substrate Device Component|Substrate|ABCG2 wt Allele"
"VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates.","C4026868|C0442805|C0274281|C0332157|C3245499|C1521801|C1420131|C3812257|C1332002|C1710236|C3891814|C1704927","[phsu]|[ftcn]|[inpo]|[clna]|[geoa]|[ftcn]|[gngm]|[gngm]|[gngm]|[mnob]|[sbst]|[gngm]","Viberzi|Increase|Injury due to exposure to external cause|Exposure to|Colombia|Having administered|SLCO1B1 gene|SLCO1B1 wt Allele|ABCG2 gene|Substrate Device Component|Substrate|ABCG2 wt Allele""Increased exposure to rosuvastatin when co-administered with VIBERZI with a potential for increased risk of myopathy/rhabdomyolysis [see Clinical Pharmacology (12.3)]","C0205217|C0274281|C0332157|C0442805|C0965129|C3245499|C1521801|C4026868|C3245505|C0035647|C0026848|C0035410|C0042789|C1947903|C0031332|C1555729","[phsu]|[ftcn]|[inpo]|[clna]|[geoa]|[ftcn]|[gngm]|[gngm]|[gngm]|[mnob]|[sbst]|[gngm][qnco]|[inpo]|[clna]|[ftcn]|[orch, phsu]|[geoa]|[ftcn]|[phsu]|[qlco]|[idcn]|[dsyn]|[patf]|[orgf]|[acty]|[bmod]|[prog]","Viberzi|Increase|Injury due to exposure to external cause|Exposure to|Colombia|Having administered|SLCO1B1 gene|SLCO1B1 wt Allele|ABCG2 gene|Substrate Device Component|Substrate|ABCG2 wt AlleleIncreased|Injury due to exposure to external cause|Exposure to|Increase|rosuvastatin|Colombia|Having administered|Viberzi|potential|Risk|Myopathy|Rhabdomyolysis|Vision|See|Clinical pharmacology discipline|Allopathic & Osteopathic Physicians - Clinical Pharmacology"
"_Nevirapine","C0132326","[orch, phsu]","Nevirapine"
"_Rifabutin","C0140575","[antb, orch]","Rifabutin"
"Atazanavir _ Nevirapine","C1145759|C0132326","[orch, phsu]|[orch, phsu]","Atazanavir|Nevirapine"
"Efavirenz","C0674428","[orch, phsu]","efavirenz"
"Indinavir","C0376637","[orch, phsu]","Indinavir"
"Itraconazole","C0064113","[orch, phsu]","Itraconazole"
"Ketoconazole","C0022625","[orch, phsu]","Ketoconazole"
"Methadone","C0025605|C1552533","[orch, phsu]|[hcro, mnob]","Methadone|Methadone Clinic/Center"
"Nevirapine","C0132326","[orch, phsu]","Nevirapine"
"Amprenavir _Nevirapine","C0754188|C0132326","[orch, phsu]|[orch, phsu]","Amprenavir|Nevirapine"
"Amprenavir _Nevirapine","C0754188|C0132326","[orch, phsu]|[orch, phsu]","Amprenavir|Nevirapine"
"Ethinyl estradiol Norethindrone","C1260235","[horm, orch, phsu]","ethinyl estradiol and norethindrone"
"Lopinavir","C0674432","[orch, phsu]","lopinavir"
"Nelfinavir M8 MetaboliteNelfinavir Cmin","C1370173|C2827771","[orch, phsu]|[qnco]","M8-nelfinavir|Cmin"
"Antacids- Aluminum & Magnesium Hydroxides- SimethiconeBile Acid Sequestrants- Cholestyramine- ColestipolCalcium CarbonateCation Exchange Resins- KayexalateFerrous SulfateOrlistatSucralfate","C0003138|C2930042|C0001128|C0008402|C0678640|C4019011|C0202406","[phsu]|[phsu]|[chem]|[orch, phsu]|[socb]|[clna]|[lbpr]","Antacids|Aluminum Hydroxide / Magnesium Hydroxide|Acids|Cholestyramine Resin|degree of relationship - exchange|Exchange (clinical)|Lysergic acid diethylamide measurement"
"\Antacids- Aluminum & Magnesium Hydroxides- SimethiconeBile Acid Sequestrants- Cholestyramine- ColestipolCalcium CarbonateCation Exchange Resins- KayexalateFerrous SulfateOrlistatSucralfate","C0003138|C2930042|C0001128|C0008402|C0678640|C4019011|C0202406","[phsu]|[phsu]|[chem]|[orch, phsu]|[socb]|[clna]|[lbpr]","Antacids|Aluminum Hydroxide / Magnesium Hydroxide|Acids|Cholestyramine Resin|degree of relationship - exchange|Exchange (clinical)|Lysergic acid diethylamide measurement"
"\Antacids- Aluminum & Magnesium Hydroxides- SimethiconeBile Acid Sequestrants- Cholestyramine- ColestipolCalcium CarbonateCation Exchange Resins- KayexalateFerrous SulfateOrlistatSucralfate","C0003138|C2930042|C0001128|C0008402|C0678640|C4019011|C0202406","[phsu]|[phsu]|[chem]|[orch, phsu]|[socb]|[clna]|[lbpr]","Antacids|Aluminum Hydroxide / Magnesium Hydroxide|Acids|Cholestyramine Resin|degree of relationship - exchange|Exchange (clinical)|Lysergic acid diethylamide measurement"
"\Antacids- Aluminum & Magnesium Hydroxides- SimethiconeBile Acid Sequestrants- Cholestyramine- ColestipolCalcium CarbonateCation Exchange Resins- KayexalateFerrous SulfateOrlistatSucralfate\","C0003138|C2930042|C0001128|C0008402|C0678640|C4019011|C0202406","[phsu]|[phsu]|[chem]|[orch, phsu]|[socb]|[clna]|[lbpr]","Antacids|Aluminum Hydroxide / Magnesium Hydroxide|Acids|Cholestyramine Resin|degree of relationship - exchange|Exchange (clinical)|Lysergic acid diethylamide measurement"
"Antacids- Aluminum & Magnesium Hydroxides- SimethiconeBile Acid Sequestrants- Cholestyramine- ColestipolCalcium CarbonateCation Exchange Resins- KayexalateFerrous SulfateOrlistatSucralfate","C0003138|C2930042|C0001128|C0008402|C0678640|C4019011|C0202406","[phsu]|[phsu]|[chem]|[orch, phsu]|[socb]|[clna]|[lbpr]","Antacids|Aluminum Hydroxide / Magnesium Hydroxide|Acids|Cholestyramine Resin|degree of relationship - exchange|Exchange (clinical)|Lysergic acid diethylamide measurement"
"Antacids- Aluminum & Magnesium Hydroxides- SimethiconeBile Acid Sequestrants- Cholestyramine- ColestipolCalcium CarbonateCation Exchange Resins- KayexalateFerrous SulfateOrlistatSucralfate","C0003138|C2930042|C0001128|C0008402|C0678640|C4019011|C0202406","[phsu]|[phsu]|[chem]|[orch, phsu]|[socb]|[clna]|[lbpr]","Antacids|Aluminum Hydroxide / Magnesium Hydroxide|Acids|Cholestyramine Resin|degree of relationship - exchange|Exchange (clinical)|Lysergic acid diethylamide measurement"
"Antacids- Aluminum & Magnesium Hydroxides- SimethiconeBile Acid Sequestrants- Cholestyramine- ColestipolCalcium CarbonateCation Exchange Resins- KayexalateFerrous SulfateOrlistatSucralfate","C0003138|C2930042|C0001128|C0008402|C0678640|C4019011|C0202406","[phsu]|[phsu]|[chem]|[orch, phsu]|[socb]|[clna]|[lbpr]","Antacids|Aluminum Hydroxide / Magnesium Hydroxide|Acids|Cholestyramine Resin|degree of relationship - exchange|Exchange (clinical)|Lysergic acid diethylamide measurement"
"Antacids- Aluminum & Magnesium Hydroxides- SimethiconeBile Acid Sequestrants- Cholestyramine- ColestipolCalcium CarbonateCation Exchange Resins- KayexalateFerrous SulfateOrlistatSucralfate","C0003138|C2930042|C0001128|C0008402|C0678640|C4019011|C0202406","[phsu]|[phsu]|[chem]|[orch, phsu]|[socb]|[clna]|[lbpr]","Antacids|Aluminum Hydroxide / Magnesium Hydroxide|Acids|Cholestyramine Resin|degree of relationship - exchange|Exchange (clinical)|Lysergic acid diethylamide measurement"
